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Mind your thoughts, as they become words. 
Mind your words, as they become actions. 
Mind your actions, as they become habits. 
Mind your habits, as they define character. 
Mind your character, as it becomes destiny. 
 
 
 
 
 
 
Yorùbá Proverb 
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Summary 
It is increasingly recognised that chronic exposure to opioids has been associated 
with neuropsychological impairment during both active use and following a period 
of abstinence. The overall objective of this thesis was to review the relevant prior 
literature in a systematic manner and subsequently to describe the effects of 
chronic exposure to prescribed and illicit opioids using an ambispective cohort study 
design. 
 
A systematic literature review was conducted to identify if chronic (defined as a 
period for more than 3 months) exposure to opioids (prescribed and/or illicit) was 
associated with measurable neuropsychological deficits. This review was conducted 
accordingly to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) 
and the Preferred Reporting Items for Systematic reviews and Meta-Analysis 
(PRISMA) guidelines. The results were subsequently described within three 
cognitive domains of intelligence, executive function and memory and learning. Out 
of a total of 905 articles extracted between 1964 and 2009, 49 articles were 
considered appropriate for selection and review.   
 
Studies of current and abstinent chronic opioid users (illicit heroin users, patients 
prescribed methadone for illicit opioid dependence and patients taking opioids as 
part of the management of chronic pain) have identified performance deficits in 
measures of executive functioning and memory. These have included impairments 
within the domains of cognitive and motor impulsivity, strategic planning, cognitive 
flexibility, attention and memory. However other studies found no clear deficits 
when comparing the performance of healthy controls. The literature suggested that 
these neuropsychological deficits may be subject to at least partial recovery 
following initiation of methadone or total withdrawal from any opioids.This review 
also highlighted several methodological issues that affect the reliability, validity and 
clinical relevance of the results obtained.   
 
xv 
 
 
 
Subsequently a two year ambispective cohort design study was conducted which 
tested representative opioid exposed participants and healthy controls. Cohorts of 
participants with validated histories of illicit heroin use (HEROIN, n=24), stabilised 
methadone maintenance (METHADONE, n=29), chronic opioid prescriptions for pain 
(CHRONIC PAIN, n=28) and controls (HEALTHY CONTROL, n=28) were recruited. The 
study was designed to test neuropsychological performance in the HEALTHY 
CONTROL and CHRONIC PAIN groups on one occasion; and for the HEROIN and 
METHADONE groups on three and two occasions respectively. The intention was to 
describe neuropsychological performance in the HEROIN group under conditions of 
stable illicit heroin use, in controlled opioid withdrawal and when subsequently 
stabilised on methadone. For the METHADONE group, participants were tested 
twice, six months apart, to test for changes induced by chronic exposure to 
methadone. Eligible, screened and consented individuals were tested on nine tests 
from the CANTAB test battery. 
 
Data were analysed using univariate or repeated measures ANCOVA with a between 
subjects factor of GROUP. Further a priori subgroup analyses were conducted using 
(1) a two-group factor reflecting DEPENDENCE status and (2) a two-group factor 
reflecting INJECTING status separately as between subject factors. The homogeneity 
of variance across groups in repeated‐measures design ANCOVAs was assessed by 
the Mauchly Sphericity Test. NART, age in years, SIMD, total Fagerström score, years 
in education and past alcohol use in years were used as covariates. A significance 
level of p<0.01 was applied due to multiple testing, in addition to the post-hoc 
Bonferroni correction procedure. 
 
On the Cambridge Gambling Task (CGT), HEROIN users placed higher bets earlier 
and risked more. They also showed increased motor impulsivity, impaired strategic 
planning and visuospatial memory on the Affective Go-NoGo (AGN),  Stockings of 
Cambridge (SOC), and Delayed Matching to Sample(DMS) respectively.  
 
xvi 
 
 
 
METHADONE users deliberated longer and placed higher bets earlier on the CGT, 
but did not show a tendency to risk more. METHADONE users were also more 
inattentive and demonstrated poor strategic planning and visuospatial memory on 
the Spatial Span (SSP) task. The CHRONIC PAIN participants did not exhibit 
significant impairment in neuropsychological performance on all the CANTAB tasks. 
Participants from the HEROIN, METHADONE and CHRONIC PAIN groups did not 
present with impaired cognitive flexibility. 
 
Chronic opioid dependence is associated with neuropsychological impairment 
reflected in altered performance on measures of risk taking and strategic planning. 
These data support the hypothesis that these neuropsychological impairments 
reflect an underlying trait vulnerability to drug taking and/or dependence rather 
than an effect of chronic exposure to opioids. Notably, motor impulsivity and visuo-
spatial memory in HEROIN users improved after three weeks stability with 
methadone.  
 
Methadone use seems to confer improvement in some aspects of 
neuropsychological performance following cessation of heroin and sustains other 
deficits during long term stable methadone treatment. Dependence and injecting 
status do not contribute to the causation or deterioration of the identified 
neuropsychological impairments.  
 
Further long term longitudinal studies to help elucidate cognitive endophenotypes 
responsible for the components in the initiation, continuation and deterioration of 
neuropsychological deficits present in an opioid dependent population is necessary. 
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CHAPTER 1: Introduction-Chronic effects of opioids on human 
neuropsychological functioning: a systematic and narrative review 
 
This introductory Chapter will concentrate on addressing the question: What does 
the current literature tell us about the neuropsychological consequences of chronic 
opioid use if this was conducted as part of a systematic review?  
 
Answers to this complex question were required in order to set the scene for an 
in‐depth discussion in Chapter 2 on the methods used to plan an ambispective 
cohort study looking at the neuropsychological consequences of chronic heroin and 
methadone use in opioid dependent male individuals with subsequent experimental 
findings on these populations described in Chapters 3, 4, 5 and 6.  
 
Introduction 
Opiates (naturally occurring opioid receptor ligands, such as morphine and semi- 
synthetic ligands such as heroin) and opioids (synthetic ligands, such as fentanyl or 
methadone) have been associated with a number of neuropsychological 
impairments during both active use and after a period of abstinence (Verdejo-
Garcia et al., 2007).  
 
A large body of studies have examined the acute, subacute and chronic effects of 
opioids using a wide variety of cognitive measures sensitive to component aspects 
of attention, memory, learning and executive functioning (Chou et al., 2003; 
Fernandez-Serrano et al., 2010a; Ersche & Sahakian, 2007; Zacny, 1995; Miller, 
1985). However, the nature and extent of opioid-related impairments remains 
elusive. For instance, research on memory functions has resulted in a number of 
studies showing impairments in word/pattern recognition, learning and recall of 
words/figures, paired associate learning and retrieval (Amir & Bahiri, 1994; Darke 
et al., 2000, Ersche et al., 2006a; Fishbein et al., 2007a; Fishbein et al., 2007b). 
However, other studies did not find memory deficits in chronic, opioid dependent 
individuals (Davis et al., 2002; Mintzer et al., 2005). In addition to memory 
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function, studies on attention also showed mixed results. Studies either showed no 
impairments in attention (Davis et al., 2002; Soyka et al., 2005) or a significant 
reduction in attention span (Specka et al., 2000; Schindler et al., 2004). 
 
Neuropsychological studies of chronic opioid users identified deficits in executive 
function measures. These have included impairments in cognitive flexibility (Pirastu 
et al., 2006), in strategic planning (Ersche et al., 2006a; Ersche et al., 2006b), 
decision making (Verdejo-Garcia et al., 2007a; Verdejo-Garcia et al., 2007b) and 
inhibitory control (Mintzer et al., 2005). However other studies found no clear 
deficits when comparing the performance of healthy controls, with that of opioid 
abstinent, polysubstance users, head injury patients or patients with chronic pain 
(Rotterham-Fuller et al., 2004; Tassain et al., 2003). 
 
The accumulated literature tends to assume that neuropsychological function is 
commonly impaired as a consequence of chronic opioid use. It also specifically 
suggests that the impairments are different in chronic opioid use from those seen in 
acute and sub-acute users (Zacny, 1995).  
 
This uncertainty of the effects of neuropsychological consequences directly 
attributable to chronic opioid use is partly due to the lack of synthesising the 
literature available in a consistent, objective and comprehensively as possible 
(Verdejo-Garcia et al., 2007b; Verdejo-Garcia et al.,2007c). Traditional literature 
reviews frequently summarise highly unrepresentative and biased samples of 
studies in an unsystematic and uncritical fashion (Mulrow, 1994). 
 
Systematic reviews are literature reviews that adhere closely to a set of scientific 
methods that explicitly aim to limit systematic error (bias), mainly by attempting to 
identify, summarise, appraise and synthesis all relevant studies in order to answer a 
particular question (or set of questions) (Petticrew & Roberts, 2007). Intuitively 
systematic reviews are more ‘fit for purpose’ of answering specific questions and 
testing hypothesis than the traditional literature reviews (Knipschild, 1994; 
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Petticrew, 2001). Systematic reviews are less of a discussion of the literature and 
more of a scientific tool and therefore useful in when: 
 
 There is uncertainty in the direction of effects of particular behaviour such 
as chronic opioid use 
 There is a wide range of research on the subject but where the key 
questions remain unanswered such as questions on treatment, prevention, 
diagnosis or aetiology 
 A general overall picture of the evidence in the topic area is needed to direct 
future research or policy efforts 
 An accurate picture of past research and past methodological research is 
required to promote the development of new methodologies 
 
This dissertation revisited the literature available using a robust systematic review 
process and then, based on the evidence synthesised, conducted a cohort study to 
identify, if any, neuropsychological deficits in chronic opioid dependent users. 
 
Definitions 
An opioid is described as either a natural derivative of opium or a synthetic 
substance with agonist (heroin and methadone), partial agonist (buprenorphine), or 
mixed agonist and antagonist activity at opioid receptors (Trescot et al., 2008).  
 
An opiate is described as either a natural derivative or a semi-synthetic constituent 
of opium (Trescot et al., 2008). 
 
Table 1.1: Opioid Classification. 
Opioid Classification Examples 
Natural Agonist Opioids Opium, morphine, codeine 
Semi-synthetic  Agonist Opioids Heroin, oxycodone, hydrocodone, oxymorphone 
Synthetic Agonist Opioids Methadone, meperidine, fentanyl, tramadol 
Mixed Antagonists (Partial Agonists) Buprenorphine, nalbuphine, pentazocine 
Antagonists Naltrexone, naloxone, nalmifene 
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For the purpose of this thesis, the meanings of the terms 'opioid' and 'opiate' can be 
considered as largely synonymous, with ‘opioid’ being used, as it has a broader 
definition (Sweetman, 2005) (Table 1.1). 
 
Opioid receptors are a group of G protein-coupled receptors with opioids acting 
as ligands (Waldhoer et al., 2004).The endogenous opioids are dynorphins, 
enkephalins, endorphins, endomorphins and nociceptins. The opioid receptors are 
distributed widely in the brain but are also found in the spinal cord and digestive 
tract. There are four major subtypes of opioid peptide (OP) receptors; delta (δ) or 
OP1, kappa (κ) or OP2, mu (μ) or OP3 and nociceptin or OP4. 
 
Acute opioid effects or intoxication with agonist opioids have euphorogenic, 
analgesic, sedative, and respiratory depressant effects (Jaffe, 1990). Intravenous 
injection of opioids present with a faster and stronger euphorogenic effect than if 
smoked or snorted. This is described by users as a ‘rush’ (Leri, 2003). Acute 
sensitisation of the opioid receptor develops in minutes during opioid use and 
abates in minutes to hours following the exposure to the opioid (Leri, 2003).  
 
For the purpose of this thesis acute opioid intoxication will be considered as 
happening between 0 -3 hours after exposure to the opioid.  
 
Opioid withdrawal is defined as a maladaptive behavioural change, with 
physiological and cognitive concomitants that occur when blood or tissue 
concentrations of an opioid decline in an individual who had maintained prolonged 
heavy use of the opioid (Department of Health, 2007). Cessation of regular and 
frequent opioid use is associated with a dysphoric withdrawal syndrome. This 
withdrawal syndrome starts 6-8 hours after cessation of all opioids and is 
characterised by watering eyes, runny nose, yawning, sweating, restlessness, 
tremor, nausea, vomiting, diarrhoea, increased blood pressure and heart rate, chills, 
cramps and muscle aches, which can last 7–14 days (Figure 1.1) (Jasinski, 1981; 
Jaffe, 1990).  
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Figure 1.1: Opioid withdrawal for various types of opioids.Accessed from 
http://www.addictionsurvivors.org/. No permissions needed. 
 
Subacute or post acute withdrawal opioid effects are effects that linger on for more 
than fourteen days, usually as prolonged withdrawal symptoms, and subside after 
three months from the last opioid use (Lejeune et al., 1997). This protracted 
withdrawal can last months and can present with impaired cognition, insomnia, 
irritability, fatigue, drug craving, sweating, and dysphoria (Lejeune et al., 1997). 
Symptoms occur intermittently and are not always present. Symptoms are made 
worse through stress or other triggers and may arise at unexpected times and for 
no apparent reason. An outline for conceptualizing protracted opioid withdrawal 
has been presented by Satel et al (1993) in which these symptoms can be viewed as: 
(1) a global post acute syndrome, (2) attenuated opioid physiologic rebound, (3) 
opioid toxic residuals and (4) expression of pre-existing symptoms unmasked by 
cessation of use (Satel et al., 1993). 
 
For the purpose of this thesis subacute opioid effects include effects 1-3 months 
after the last use of opioid.  
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The term chronicity describes the repeated administration of opioid drugs with the 
adaptive mechanisms changing the functioning of opioid-sensitive neurons and 
neural networks perhaps in an irreversible manner (Weiss et al., 2001). Adaptation 
is particularly a consequence of sustained mu receptor stimulation by opioid drugs 
(Kieffer & Evans, 2002). 
 
Hallmarks of neuro-adaptations to chronic opioid use are: 
 Tolerance, defined as a reduced sensitivity to the opioid effects and 
generally referring to attenuation of analgesic efficacy  
 Drug craving  
 Physiological manifestations of opioid withdrawal.  
 
Adaptations following chronic opioid exposure extend well beyond reward circuits 
to other brain areas, notably those involved in learning and stress responses (Koob, 
2000). Important regions affected are the amygdala, hippocampus and cerebral 
cortex and their connections to the nucleus accumbens. All these areas express 
opioid receptors and peptides, and the overall distribution of opioid peptide-
expressing cells in neural circuits of dependence has been reviewed (Nestler, 2001; 
Koob & Nestler, 1997).  
 
For the purpose of this thesis chronic use of opioids will indicate use of more than 3 
months of daily and continuous opioid use. 
 
Dependence is described as a cluster of cognitive, behavioural, and physiological 
symptoms indicating that the individual continues to use the substance despite 
significant substance related problems (WHO, 1992). All opioids have dependence 
potential to varying degrees (Swadi et al., 1990). Of all the opioids, heroin has the 
greatest potential for dependency, especially when injected (Martin & Jasinski, 
1969; DH, 2007).Physical and psychological dependence can develop within a 
relatively short period of continuous use (NICE, 2007).The World Health 
Organization (WHO) and the American Psychiatric Association (APA) state that the 
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key elements of opioid dependence are (APA, 1994; WHO, UNODC and UNAIDS, 
2006): 
 A strong desire or sense of compulsion to take the substance 
 Difficulty in controlling use 
 A physiological withdrawal state 
 Tolerance 
 Neglect of alternative pleasures and interests 
 Persistence of use despite harm to oneself and others 
Cognition is defined as the process of knowing, including attending, remembering 
and reasoning as well as the content of these processes, such as concepts and 
memories (WHO, 2004). 
Neuropsychological deficits are  defined as a reduction or impairment of cognitive 
function closely linked to the function of particular areas, neural pathways, 
or cortical networks in the brain.This term is particularly used when physical 
changes can be seen to have occurred in the brain, such as after neurological illness, 
mental illness, drug use, or brain injury (Lezak, 1983; Lezak, 1984).  
The term neurotoxic is used to describe a substance that damages the nervous 
system and/or brain, usually by destroying neurons (Tilson, 1990). Structural 
neurotoxic effects are defined as neuroanatomical changes occurring at any level of 
nervous system organisation. Functional neurotoxic effects include adverse changes 
in somatic/autonomic, sensory, motor, and/or cognitive function. However the 
presence of neuropsychological deficits alone is not usually considered sufficient 
evidence of neurotoxicity, as many substances exist which may impair 
neuropsychological performance without resulting in the death or damage of 
neurons (behavioural toxicity) (Albert, 1973). This may be due to the direct action 
of the substance, with the impairment and neuropsychological deficits being 
temporary, and resolving when the substance is metabolised from the body. In 
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some cases the level or exposure-time may be critical, with some substances only 
becoming neurotoxic in certain doses or time periods (Tilson & Mitchell, 1983). 
Aim of the systematic review 
The aim of this systematic review was to identify if chronic (> 3 months) exposure to 
opioids (prescribed and/or illicit) was associated with measurable 
neuropsychological deficits. If deficits were present what would the pattern of 
these deficits be? The review did NOT address treatment or prevention issues with 
regards to chronic opioid use and subsequent dependence. 
 
Guidelines for data synthesis 
This systematic review was conducted according to the Meta-analysis of 
Observational Studies in Epidemiology (MOOSE) guidelines (Stroup et al., 2008) and 
the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) 
guidelines (Liberati et al., 2009). 
 
Inclusion criteria  
Articles selected satisfied the following criteria: 
 Participants were aged over 18 years old 
 International based literature studies on human cohort (i.e.not animal 
studies) 
 All English and other articles written in any other language 
 Chronicity of use and/or dependence to any opioids for more than three 
months 
 Diagnosis of opioid dependence syndrome or abuse in the cohort studied 
(according DSM III/III-R/IV and/or ICD-9/ICD-10) (APA, 1984; WHO, 1993)   
 Results reported separately for each neuropsychological task (i.e. not only 
composite scores) 
 If several articles dealt with the same population the article with the largest 
sample size was selected 
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 Sufficient data available to calculate the effect (e.g.mean and standard 
deviation (SD), F statistics) 
 If it was a follow up study, at least one month between test and re-test and 
with no specific training available to improve performance in the test used 
which might create practice effects 
 
All different trials in order of decreasing internal validity (study design hierearchy) 
were included in this sytematic review. These were grouped into (Petticrew & 
Roberts, 2007): 
 
1. Experimental studies (e.g. Randomised Controlled Trials with concealed 
allocation) 
2. Quasi-experimental studies (e.g. experimental study without randomisation) 
3. Controlled observational studies divided into cohort studies and case controlled 
studies 
4. Observational studies without control groups 
5. Expert opinion based on pathophysiology, bench research or consensus 
 
Search strategy and process 
The literature search was carried out in two stages: 
 
Stage 1: Literature search using electronic databases. The aim of this search was to 
provide an indication of the extent of available literature looking at the 
neuropsychological consequences of chronic opioid use between 1964 and 
December 2009 (45 years). 
 
PubMed was the main database used to identify relevant literature. This database 
was selected because it provided access to over 15 million citations for biomedical 
and life sciences journals. The largest component of PubMed, Medline, provided 
access to citations from 1950 onwards. However, PubMed also provided access to 
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citations that have not been incorporated in Medline via a service of the National 
Library of Medicine (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed). 
 
Project Cork database was selected to supplement citations identified through the 
PubMed search. Project Cork provided online access to 75,000 citations and 
literature on substance misuse for health professionals, educators, students and 
policy makers (http://www.projectcork.org/). 
 
Social Science Citation Indices is a database of abstracts from some 2474 journals in 
the field of sociology and behavioural sciences included books, book chapters, 
dissertations and conference papers dating back to 1974 
(http://thomsonreuters.com/products_services/science/science_products/a-
z/social_sciences_citation_index/). 
 
PsycINFO is a database produced by the American Psychological Association with a 
major emphasis on original research, while case studies, literature reviews, surveys 
and discussions are also covered. PsycINFO database provide extensive 
international coverage of the literature on psychology and allied fields from over 
1,300 journals. Allied fields included information on drug and behavioural therapy, 
treatment of disease, drug addiction, developmental psychology, and educational 
psychology, as well as the psychological aspects of such areas as linguistics, social 
processes, pharmacology, physiology, nursing, education, anthropology, business 
and law dating back to 1887 
(http://www.apa.org/pubs/databases/psycinfo/index.aspx). 
 
The Excerpta Medica database (EMBASE), produced by Elsevier, indexes over 3,500 
international journals in the fields of pharmacology, pharmaceutics, toxicology, 
clinical and experimental human medicine, health policy and management, public 
health, occupational health, environmental health, drug dependence and abuse, 
psychiatry, forensic medicine, and biomedical engineering. There was selective 
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coverage for nursing, dentistry, veterinary medicine, psychology, and alternative 
medicine (http://www.embase.com/). 
  
Relevant articles were identified by using the following search strings by utilising a 
PICO (Population, Intervention, Comparisons and Outcomes) technique (Booth & 
Fry-Smith, 2003):‘chronic and/or repeated drug use/abuse/misuse/dependence/ 
addiction and/or chronic opioid/opiate use/abuse/misuse/dependence/addiction 
AND neuropsychological deficits/impairments and/or neurocognitive 
deficits/impairments’. 
 
The term neuropsychological or neurocognitive was then replaced with a succession 
of terms describing the following neuropsychological tests ordered in standardised 
neuropsychological domains (Lezak, 1984).  
 
(1) Intelligence and Aptitude Tests (Anastasi & Urbina, 1997). 
 National Adult Reading (NART) (Nelson, 1982)  
 Raven’s Progressive Matrices (RPM) (Raven, 1976; Raven, 1998) 
 Shipley Institute to Living Scale (Shipley, 1940a)   
 Shipley – Hartford Retreat Scale (Shipley, 1940b) 
 Number Series Completion Test (Anderson, 1920) 
 Wechler Abbreviated Scale of Intelligence (WASI) (Psychological 
Corporation, 1999) 
 Grammatical Reasoning Test (GRT) (Baddeley, 1968) 
 Leistungs Pruf System (LPS) (Horn, 1962) 
 Weschler Test of Adult Reading (WTAR) (Lezak, 1983; Lezak, 1984) 
  
(2)  Executive Function Tests (Goldberg, 2001) which included strategic planning,               
reasoning and cognitive flexibility. 
 Wisconsin Card Sorting Test (WCST) (Kongs et al., 2000) 
 Porteus Mazes Test (PMT) (Porteus, 1933)  
 Grooved Pegboard (GP) (Kløve, 1963) 
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 Minnesota Paper Forms Board Test (MPFBT) (Likert & Quasha, 1948) 
 Tower of Hanoi and Tower of London (TOH and TOL) (Shallice, 1982)  
 Logan Stop Change task (SCT) (Logan & Burkell, 1986)  
 
 (3) Decision making which included risk taking and motor impulsivity tests. 
 Cambridge Risk Task or Rogers’ Decision Making Task (RDMT) Rogers et al., 
1999b)  
 Iowa Gambling Task (IGT) (Bechara et al., 1997) 
 Barratt Impulsivity Scale (BIS) (Patton et al., 1995)  
 Game and Dice Test (GDT) (Brand et al., 2002)  
 Bechara Card Test (BCT) (Bechara et al., 1994) 
 Delay Discounting Test (German DDT) (Forstmeier & Maercker, 2011)   
 
(4)  Verbal Fluency Tests (Goodglass & Kaplan, 1986). 
 Benton Verbal Fluency Test (Benton VFT) (Benton et al., 1978) 
 Controlled Oral Word Association Test and Phonological Fluency Test 
(COWAT/FAS) (Loonstra et al., 2001) 
 Regensburger Word Fluency Test (RWFT) (Aschenbrenner, 2000) 
 Ruff Figural Fluency Test (RFFT) (Ruff et al., 1987) 
 Verbal Fluency Test (VFT) (Lezak, 1984) 
  
(5)  Attention and Orientation Tests (Parasuraman & Greenwood, 1998). 
 Attention and Concentration Pauli Test (Arnold & Kohlmann, 1975)  
 Paced Auditory Serial Addition Task (PASAT) (Gronwall, 1977) 
 Test of Variables of Attention (TOVA) (Greenberg & Waldman, 1993) 
 Test of Everyday Attention (TEA) (Robertson et al., 1994)  
 Disturbed/Divided Attention Task (DAT) (Puglisi et al., 1988)  
 Toulouse–Pieron’s Concentration and Attention Test (Rainho, 1992)  
 Knox Cube (Arthur Performance Test) (Richardson, 2005) 
 Continuous Performance Test (Conners, 1992) 
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 Digit Symbol Substitution Test (DSST) (Lezak, 1995) 
 Five Digit Test (5DT) (Sedo´, 2005) 
 Adult Memory and Information Processing Battery (AMIPB) (Vlaar & Wade, 
2003) 
 Visual Search Task (VST) (Schneider & Shiffrin, 1977)   
 Stroop Word (Interference) Test (ST) (Golden , 1978)  
 Farbe-Wort-Interferenz Test (FWIT) (Bäumler, 1985)  
 
(6) Reaction Time Tests (Park et al., 1996). 
 Continuous Reaction Time (CRT) (Bruhn & Parsons, 1971) 
 Seriel Reaction Time (SRTT) and Simple Reaction Time (SRT) (Cleeremans & 
McClelland, 1991) 
  
(7) Verbal Memory Tests (Gazzaniga et al., 2002). 
 Verbal Memory (VM) Arnold Kohlmenn Tests (Arnold & Kohlmann, 1953)  
 California Verbal Learning Test (CVLT) (Delis et al., 1990)  
 Rey Auditory Verbal Learning Test (RAVLT) or Auditory Verbal Learning Test 
(AVLT) (Van Der Elst et al., 2005)  
 Hopkins Verbal Learning Test (HVLT) (Benedict et al., 1998)  
 Two–back Task (2BT) (Jaeggi et al., 2003)  
 Digit Forward and Digits Backward Test (DFDBT) (Lezak, 1994) 
 Word Recognition Memory (WRM) (Warrington, 1984) 
 
(8) Visuospatial Memory Tests (Banich, 2004). 
 Benton Visual Retention Test (BVRT) (Benton, 1974) 
 Memory for Names and Faces (MNF) (Faw, 1990) 
 Object Recognition Test (ORT) (Biederman, 1987)  
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(9) Long Term Memory Tests (Tulving, 1972). 
 Story Recall and Recognition Test or Auditory Comprehension Test (Adejumo, 
1980) 
 Williams Delayed Recall Test (WDRT) (Williams, 1965) 
 Rey Osterreith Complex Figure Test (RCFT) (Loring et al., 1990) 
 
(10) Other batteries of tests involving all or most of the above neuropsychological 
domains. 
 Act React Test Systems (ARTS and ART 2020) which included Labyrinth of 
Lines to Measure Visual Structuring Performance (LL5), Simple Choice 
Reaction (DR2), Attention under Monotonous Circumstances (Q1), Tracking 
Test (CORT), Tachistoscopic Perception and Visual Orientation (TT15), 
Multiple Choice Reaction under Stress (RST3), Matrices Test for Intelligence 
(MAT/M30) and Test for Attention Flexibility (FAT) (Bukasa et al., 1997). 
 Bexley Maudsley Automated Psychological Screening which included Spatial 
Little Men Test, Symbol Digit Test, Verbal Perceptual Analysis, Visuo-Spatial 
Recognition Memory and Bexley Maudsley Card Sorting Test (MCST) (Acker 
& Acker, 1982)  
 CANTAB Test which included Pattern Recognition Memory (PRM) Task, 
Spatial Recognition Memory (SRM) Task, Attentional Set Shifting Task, 
Spatial Working Memory (SWM) Task, One Touch Tower of London Task, 
Tower of London (TOL), Visuo-spatial Strategy Task, Intra/Extra –
Dimensional Set shifting Task (IED), Paired Associate Learning (PAL), , 
Cambridge Gambling Task (CGT), Continuous Performance Test (CPT), 
Information Sampling Task (IST) and Delayed Matching to Sample (DMS) 
Task (Robbins et al., 1998; Sahakian et al., 1988) 
 Halstead-Reitan Neuropsychological Test Battery and its components such as 
Tactual Performance Test (TPT), Finger Tapping (FTT) or Oscillation Test, 
Rhythm Test, Trail Making Test (TMT) and Category Test (Broshek & Jeffrey, 
2000; Reitan, 1955) 
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 Weschler Adult Intelligence Scale-3rd Edition (WAIS III) which included Pairs 
Associate Learning (PAL 1 +11), Letter Number Sequencing (LNC),  Semantic 
and Phonological Fluency (FAS), Logical Memory Test (LMT), Digit Symbol 
and Visual Reproduction (VR 1 + 11), Verbal and Performance IQ (Ryan & 
Lopez, 2001)  
 Weschler Memory Scale Revised (WMSR) which included Prose Recall Spatial 
Addition, Symbol Span, Design Memory, General Cognitive Screener, Logical 
Memory, Verbal Paired Associates, and Visual Reproduction (Wechsler, 
1945) 
 Rivermead Behavioural Memory Test (RBMT) (Wilson et al., 1985) 
 High Sensitivity Cognitive Screen (HSCT) (Faust & Fogel, 1989) 
 
Subsequently wild cards were also used including: ‘addict*’; ‘impair*’;’drug*’; 
‘neuro*’, ‘medic*’. 
 
Stage 2: Further literature search: This stage involved a more extensive collation of 
available literature identified through several sources and a preliminary review to 
inform the rationale for selection of articles. These included: 
 
(A) Snowballing Technique: The reference list of the identified articles was then 
screened to find other studies on the subject. 
 
(B) Hand Searching: Literature was further identified by hand searching the 
following 24 journals between 2003 and 2009.  
 
 Mental Health/Psychiatry Journals: The American Journal of Psychiatry; 
Archives of General Psychiatry; British Journal of Psychiatry; Journal of 
Nervous and Mental Disease; Psychiatry Research; Psychological Medicine.  
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 Neuropsychology/Psychopharmacology Journals: 
Psychopharmacology, Neuropsychology Review; 
Neuropsychopharmacology; Archives of Clinical Neuropsychology; 
Experimental and Clinical Psychopharmacology; Journal of Clinical 
Psychopharmacology; Journal of Psychopharmacology; Neuropsychologia; 
Human Psychopharmacology; Brain and Cognition; Neuroscience and 
Biobehavioral Review. 
 
 Addiction Journals: Drug and Alcohol Dependence; Addictive Behaviours; 
Addiction; American Journal on Addictions; Drug and Alcohol Review; 
European Addiction Research. 
 
 Pain Journals: Journal of Pain and Symptom Management; European Journal 
of Pain; Clinical Journal of Pain; Pain. 
 
 General: The Lancet; Nature; British Medical Journal; Journal of American 
Medical Association. 
 
(C) Experts in the field: Experts in the field of addiction and/or pain within various 
UK, European and other international academic and clinical centres were contacted 
for any relevant literature on neuropsychological consequences of chronic opioid 
use. They included centres in Norway, Denmark, Hungary, France, Spain, Italy, 
Malta, Poland, Bulgaria, Finland, Portugal, Germany, Greece and the United 
Kingdom (London, Keele, Glasgow, Stirling and Cambridge) from Europe and others 
from US and Australasia. 
 
Data extraction and recording 
Recorded variables 
For the purpose of this review it was necessary to develop a strategy for analysing 
the selected literature. From each selected study, variables describing the 
methodology used such as definition of the case, study setting, population studied 
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and sampling methods used, criteria and recruitment processes, diagnostic or 
screening instruments and neuropsychological tests used and biological 
confirmatory tests for substance misuse were extracted. We also extracted 
variables describing the statistical analysis, type and strength of findings such as 
potential confounders and bias (Table 1.2: Types of Bias) together with ethical and 
other research governance components (Appendix 1). 
 
Table 1.2: Types of bias. 
Type  Description Methods to minimise bias 
Selection (allocation) bias Systematic differences 
between comparison groups 
in prognosis or 
responsiveness to treatment  
Randomisation of large 
numbers of patients  
Concealment of their 
allocation to different 
groups 
Performance bias 
 
Systematic differences in care 
provided apart from the 
intervention being evaluated  
Standardisation of the care 
protocol and blinding of 
clinicians and participants 
Measurement bias 
(detection bias, 
ascertainment bias) 
 
Systematic differences 
between comparison groups 
in how outcomes were 
ascertained 
Blinding of study 
participants and outcome 
assessors 
 
Attrition bias (exclusion 
bias) 
 
Systematic differences 
between comparison groups 
in terms of withdrawals or 
exclusions of participants 
from the study sample 
Inclusion of such 
participants in the analysis 
(in combination with a 
sensitivity analysis) 
 
 
Establishing valid neuropsychological constructs 
In order to reliably group neuropsychological tests that provide similar results or 
have same concepts three workshops with leading neuropsychologists, health and 
clinical psychologists and neuropsychiatrists from Edinburgh, St Andrews and 
Stirling Universities were conducted. It was concluded that the ten 
neuropsychological domains described earlier in this chapter can be further 
collapsed into three broad domains as described by Ersche et al., (2007) and Potvin 
et al., (2005).The neuropsychological tests and results in Chapters 4,5,6 were 
subsequently described using the following three domains:  
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(1) Intelligence (aptitude) neuropsychological domain. 
(2) Executive Function neuropsychological domains which included: 
 Cognitive impulsivity (reflection impulsivity and risk taking) 
 Motor impulsivity (behavioural and cognitive inhibitions) 
 Non-planning impulsivity or lack of strategic planning (reasoning and 
problem solving and central executive of working memory) 
 Lack of cognitive flexibility or rigidity (reactive flexibility and spontaneous or 
verbal/non verbal fluency) 
 Attention (arousal, focused and selective attention, sustained attention, 
resistance to interference, mental manipulation, reaction time, visual or 
iconic and auditory or echoic memory) 
 
(3) Memory and learning neuropsychological domains which included: 
 Attention as above 
 Short term memory (immediate and working verbal or nonverbal or 
visuospatial) 
 Long term memory (explicit or declarative or episodic or semantic and 
Implicit or non declarative or procedural or priming) 
 
Intelligence (aptitude) 
The Cattell-Horn-Carroll (CHC) theory of intelligence suggests that it is composed of 
a number of different abilities that interact and work together to produce overall 
individual intelligence (McGrew, 1997; Wayne, 2003). The CHC theory represents 
the integration of the Cattell-Horn 'Fluid Intelligence (Gf)-Crystallised Intelligence 
(Gc)' theory (Horn & Noll, 1997; Horn & Cattell, 1967) and Carroll’s three-stratum 
theory (Carroll, 1993, 1997). This theory categorizes the intelligence function (g) 
according to the 10 overall cognitive factors:  
 Crystallised intelligence or comprehension/knowledge intelligence (Gc) is a 
broad ability that involves an individual’s breadth and depth of general and 
cultural knowledge, verbal communication and vocabulary, and ability to 
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reason using words and numbers with previously learned procedures. In 
other words what we have learned with language. This therefore improves 
with age. The Wechsler Adult Intelligence Scale- Revised (WAIS-R) measures 
crystallised intelligence on the verbal scale (Weschler, 1981). 
 Fluid intelligence or reasoning intelligence (Gf) refers to mental operations 
used primarily when individuals are faced with tasks that cannot be 
performed automatically. In short it is deﬁned as the ability to understand 
complex relationships and solve novel problems (Martinez, 2000) or logical 
thinking.  Fluid reasoning is further subdivided into inductive 
reasoning and deductive reasoning. Cognitive tests that do not rely on 
acquired knowledge are viewed as good measures of ﬂuid intelligence, such 
as Raven’s Progressive Matrices (Raven, 1998), Cattell’s Culture Fair Test 
(Cattell, 1973) and the performance subscale of the WAIS-R (Weschler, 
1981). It also correlates well with measures of abstract reasoning and puzzle 
solving (Ryan & Schnakenberg-Ott, 2003).  
 Short-term working memory (Gsm) is the ability to mentally hold information 
and then use this information within a few seconds (e.g.remembering a 
short message or a telephone number). 
 Long-term storage and retrieval (Glr) refers to the ability to memorise 
information and to retrieve it. 
 Processing speed (Gs) refers to the ability to quickly perform automatic, 
routine cognitive tasks.  
 Visual processing intelligence (Gv) is the ability to perceive and remember 
visual input. 
 Auditory processing intelligence (Ga) refers to the ability to analyse and 
synthesise auditory stimuli. 
 Others such as quantitative knowledge (Gq) and reading and writing (Grw). 
Researchers have been studying the relationship between working memory and 
ﬂuid intelligence for more than a decade but still have not reached agreement on 
the precise relationship between working memory and ﬂuid intelligence. Some have 
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argued that working memory is so highly correlated with ﬂuid intelligence that they 
could be deemed isomorphic (Engle, 2002; Jensen, 1998; Kyllonen, 2002; Stauffer 
et al., 1996), some have stated that these two constructs are barely linked to each 
other (Deary, 2000; Kline, 2000), while most have claimed that working memory 
and ﬂuid intelligence are closely related but not identical (Ackerman et al., 2005; 
Beier & Ackerman, 2005; Kane et al., 2004). 
 
It was agreed that this sytematic review would group crystallised and fliud 
intellligence as core component of the general intelligence cognitive domain (Table 
1.3), attention and processing speed as part of the decision making cognitive 
domain with the short term memory and long term storage and retrieval grouped 
within the learning and memory cognitive domains. 
 
Table 1.3: Intelligence (aptitude). 
Main Domain Subtypes Other names Definition Examples of test 
Premorbid or 
Crystallised 
Intelligence 
Verbal 
Intelligence 
Quotient (IQ) 
Indicated by a 
person's depth and 
breadth of general 
knowledge, 
vocabulary, and the 
ability 
to reason using 
words and numbers 
The ability to use 
skills, knowledge, 
and experience. It 
should not be 
equated with 
memory or 
knowledge, but it 
does rely on 
accessing 
information from 
long-term memory. 
School Reports, 
NART, WAT, 
WAIS-III (Verbal), 
SILS, MWT-B, 
WTAR 
General 
Intellectual 
Functioning or 
Fluid Intelligence 
Performance 
Intelligence 
Quotient (IQ) 
Fluid reasoning 
includes inductive 
and deductive 
reasoning 
The capacity to think 
logically and solve 
problems in novel 
situations, 
independent of 
acquired knowledge. 
Ability to analyze 
novel problems, 
identify patterns and 
relationships that 
underpin these 
problems and the 
extrapolation of 
these using logic.  
WAIS-III, 
(Performance), 
RPM, MMSE, 
WASI,SHRS, 
NSCT, SILS, LPS 
 
LPS= Leistungs Prufsystem(German intelligence test battery), MMSE=Mini Mental State Examination, 
MWT-B= MehrfachwahlWortschatz-Intelligenz-Test  (Multiple Choice Word Comprehension Test), 
NART=National Adult Reading Test, NSCT=Number Series Completion Test, RPM=Ravens Progressive 
Matrices , SHRS=Shipley–Hartford Retreat Scale, SILS=Shipley Institute to Living Scale, WAIS-
III=Weschler Adult Intelligence Scale Third Edition, WASI=Wechler Abbreviated Scale of Intelligence, 
WAT= Word Accentuation Test, WTAR= Weschler Test of Adult Reading. 
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Executive Function 
 
Modern concepts of executive functions are often traced to Luria (1966) who noted 
that patients with frontal-lobe damage frequently have their speech, motor 
abilities, and sensations intact yet are often unable to carry out complex, purposive, 
and goal directed actions. He also found that they could not accurately evaluate the 
success or failure of their behaviours and were unconcerned with their failures, and 
hesitant, indecisive, and indifferent to the loss of their critical self-awareness. Lezak 
(1983) also noted that frontal-lobe-damaged patients frequently lost their ability to 
be independent, constructive, creative, and socially productive and appropriate, 
despite their intact perceptual, language, and long term memory abilities. 
 
Pennington & Ozonoff (1996) defined executive functions as a unique domain of 
abilities that involves ‘organisation in space and time, selective inhibition, response 
preparation, goal-attainment, planning, and flexibility’. They viewed executive 
function as partially distinct yet overlapping with other neuropsychological domains 
such as sensation, perception, language, and long-term memory. Current 
neuropsychological assessment of executive function also invariably includes 
measures of planning, sequential memory, and temporal-order memory (Lezak 
1995). 
 
Impulsivity 
The term impulsivity is used widely within psychology to refer to behaviour that is 
performed with little or inadequate forethought (Evenden, 1999). The term has a 
long history in the study of individual differences, as a trait variable of human 
personality that is stable within an individual and varies normatively across the 
healthy population (Barratt, 1959; Patton et al., 1995). Within neuropsychology 
and cognitive neuroscience, impulsivity is often equated with the term 
‘disinhibition’, referring to the idea that top-down control mechanisms that 
ordinarily suppress automatic or reward-driven responses are not appropriate to 
the current demands (Aron, 2007). Impulsivity encompasses behaviours that are 
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rash, poorly planned, or focused on short-term outcomes despite potentially 
negative consequences in the long-term (Ainslie, 1975; Dawe & Loxton, 2004). It is 
a multiple component construct (Lane et al., 2003; Reynolds et al., 2006). For this 
thesis three constructs will be described: cognitive, motor and non-planning 
impulsivity. 
 
(1) Cognitive impulsivity involves making quick cognitive decisions. The choices or 
decisions of more impulsive individuals are influenced by the immediately available 
outcomes despite their long-term consequences putting them in a position to 
sustain excessive long-term costs in exchange for modest short-term gains 
(Baumeister & Scher, 1988; Cooper et al., 2003; Kirby et al., 1999).Cognitive 
impulsivity may be related to psychometric constructs such as sensation seeking 
and urgency in Whiteside & Lynam (2001) and delay-discounting (Ainslie, 1975; 
Mischel et al., 1989, Bickel & Marsch, 2001; Reynolds, 2006).  
 
One element of cognitive impulsivity is ‘reflection impulsivity’, which refers to the 
tendency to gather and evaluate information before making complex decisions 
(Kagan, 1966). Inadequate reflection at the pre-decisional stage will reduce the 
accuracy of the eventual decision (Evenden, 1999). This is also known as decision-
making under ambiguity when the outcomes are uncertain and the outcome 
probabilities are unknown or estimated (Ernst & Paulus, 2005; Hastie, 2001). 
The Iowa Gambling Task (IGT) (Bechara et al., 1994) is the most frequently used test 
to assess decisions under ambiguity. Other neuropsychological tests measuring 
reflection impulsivity include the Matching Familiar Figures Test (MFFT) (Kagan, 
1966) and the Information Sampling Test (Clark et al., 2006), 
 
Cognitive impulsivity may also contribute to abnormal decision-making on tasks 
where the subject may select between a conservative option and a more risky 
option that offers a ‘superficially seductive’ gain (Bechara & Martin, 2004; Knoch & 
Fehr, 2007). This is also known as decision making under risk where the outcomes 
are uncertain but the outcome probabilities are known (Camerer & Weber, 1992). 
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Some tests used to measure risk taking include the Risky Gains Procedure (Paulus et 
al., 2003); Games of Dice Test (GDT) (Brand et al., 2005; Brand et al., 2002);  Risky 
Gains Task (RGT) and Cambridge Gambling Task (CGT) (Rogers et al., 1999a; Rogers 
et al., 1999b) with the latter designed to investigate decision-making independently 
from learning. The last half of the IGT is thought to test both ambiguous and risky 
decision-making, so successful performance on this task is thought to require 
integrity of both the ventromedial and dorsolateral prefrontal brain areas (Bechara 
et al., 1994; Clark et al., 2006).  
 
(2) Motor Impulsivity (Response Inhibitory Control) (Olmstead, 2006; Barratt, 1985; 
Logan, 1994; Newman et al., 1987). It involves acting without thinking and when 
individuals have difficulty in suppressing reward-driven automatic behaviour or 
prepotent responses (Logan et al., 1997). Inhibitory control can be investigated in 
both the behavioural (motor) and cognitive domains. 
 
Behavioural (motor) response inhibition is defined as the process required to stop a 
planned movement (Aron et al., 2004; Chamberlain & Sahakian, 2007). Much of 
this work utilised Logan’s (1994) Stop Signal Task and the Go/NoGo Task (Newman 
et al., 1990). Meanwhile cognitive inhibition is frequently assessed by the Stroop 
Test (Stroop, 1992), which requires participants to suppress a salient but conflicting 
stimulus property while identifying a less salient one (e.g., reading the word ‘blue’ 
that is written in red ink requires more cognitive effort, so-called interference 
control, than reading the word ‘blue’ when written in blue ink).  
 
(3) Non-Planning Impulsivity (Strategic Planning or Problem Solving) is the ability to 
‘think ahead’ and actively search for an appropriate solution (Owen, 1997). Lack of 
planning and forethought has also been considered a component of impulsive 
behaviour (Dickman, 1990; Evenden, 1999). Non-planning impulsivity is 
synonymous with lack of premeditation (Whiteside & Lynam, 2001). 
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Baddeley and others (Baddeley & Logie, 1999; Miyake & Shah, 1999) view working 
memory as orchestrated by an executive component (Figure 1.2) which involves 
attention, decision making, planning, sequencing, temporal tagging, and also helps 
update and integrate the information generated from the three ‘slave systems’ 
(phonological loop, visuospatial sketchpad and episodic buffer). 
 
The Spatial Working Memory (SWM) Task and the Spatial Span Test (SST) from the 
CANTAB have been used to measure the executive aspect of working memory 
(CANTAB). This executive loop is considered as integral to non-planning impulsivity 
(Baddeley & Logie, 1999; Baddeley, 2000).  
 
Figure 1.2: Revised Baddeley’s working memory model (Baddeley, 2000). 
 
Cognitive Flexibility  
Cognitive flexibility has been defined as the ability for an individual to shift 
attention and to attend to environmental cues, and is considered as an important 
component in problem solving ability (Lezak et al., 2004). A lack of cognitive 
flexibility, or cognitive rigidity, appears to be a factor precluding individuals from 
discovering or employing alternative solutions to novel stimuli. McGuire (2001) 
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found that cognitive rigidity resulted in a lack of consideration of alternatives or 
consequences. Individuals tend to show difficulties in set shifting.  
 
(1) Reactive flexibility is the ability to shift cognition or behavior in response to 
changing tasks or situational demands (perseveration). This shifting occurs when 
either external task conditions or self initiated decision require an alternative to the 
current response be chosen and executed. Different tasks and situations require 
different type of reactive shifts and presumably different underlying cognitive 
processes (Grattan & Eslinger, 1989). Reactive flexibility is assessed with the 
Intra/Extra-Dimensional Set Shifting (IED) Task, originally developed from the 
Wisconsin Card Sorting Test (WCST). This paradigm examines different components 
of attentional flexibility, including reversal learning (i.e. the ability to adapt 
behaviour after negative feedback) and the ability to inhibit and shift attention 
between stimulus dimensions (extra-dimensional shift) as observed in animal (Dias 
et al., 1996) and human (Downes et al., 1989; Owen et al., 1991) studies. To assess 
psychomotor speed and cognitive flexibility the Trail Making Test (TMT) (Armitage, 
1945) is another tasks used. Trails Part A (TMT-A) is a more direct measure of 
psychomotor speed, whereas Trails Part B (TMT-B), with its set-switching demands, 
also reflects reactive flexibility (Zinn et al., 2004) 
 
(2) Spontaneous Flexibility (Fluency) represents the ability to produce diverse ideas, 
consider response alternatives and modify plans. Verbal flexibility (verbal fluency) is 
often described as divergent thinking which emphasizes variety, quantity and 
relevance of information. Naming something quickly and accurately is an essential 
part of efficient spoken language (Grattan & Eslinger, 1989).This requires the rapid 
production of variations on a theme (words beginning with the same letter or line 
patterns connecting dots) while avoiding repetition. The Controlled Oral Word 
Association Test (COWAT) (Borkowski et al., 1967; Loonstra et al., 2001) assesses 
verbal fluency.The Ruff Figural Fluency Test (RFFT) (Ruff et al. 1987, 1994) assesses 
non-verbal fluency. Two subtests from the WAIS-III are used to assess concrete 
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thinking or lack of abstract reasoning which is another measure of cognitive 
flexibility (Wechsler, 1997). 
 
Table 1.4 categorises the different components described in this chapter and 
grouped as executive function neuropsychological domain. 
 
 
 
  
Table 1.4: Executive function. 
Main Domain Subtypes Other names Definition Tests 
Cognitive Impulsivity   Delay discounting or urgency Ability to opt for larger delayed rewards over smaller 
more immediate rewards 
 
 (a) Reflection Impulsivity  Decision-making under ambiguity IGT, MFFT, BIS, DDT 
 (b) Risk taking  Decision-making under risk CGT, IGT, , GDT 
Motor Impulsivity  Inhibitory Control Ability to suppress emotional, cognitive and 
behavioural responses 
 
 (a) Behavioural Inhibition Motor Response Inhibition Process requires to stop a planned movement AGN, SS,,Go/NoGo  
 (b) Cognitive Inhibition Focused Attention Process required to suppress a salient but conflicting 
stimulus while identifying  less salient ones 
ST 
Non-planning 
Impulsivity  
Reasoning and Problem Solving Central Executive in working memory model 
Lack of pre-meditation 
Ability to think ahead and actively search for an 
appropriate solution  
TOL, SOC, ROCFT, PMT, TOH 
WAIS –III (Block Design, Matrix 
Reasoning), SSP, SWM 
Cognitive Flexibility  Rigidity Ability to shift avenues of thought and action in order 
to perceive process and respond to situations in 
different ways  
 
 (a) Reactive Flexibility  Perseveration or shifting of perceptual set Ability to realign a behavioural predisposition to 
altered contingencies 
WCST, ST, IED,  
TMT, SCT, MCST 
 (b) Spontaneous Flexibility or 
fluency 
Verbal and non verbal fluency Requires the intrinsic generation of responses or 
alternatives 
COWAT, FAS, VFT, RFFT, WAIS 
III (Similarities), RWT 
Attention (a) Deployment  (a) Arousal  Observation 
  (b) Focused and Selected Attention Ability to reject irrelevant information while attending 
to relevant input  
WAIS –III (Digit Span), TMT, 
TEA, ST, AGN 
  (c) Sustained Attention Readiness to detect rarely and unpredictable occurring 
signals over prolonged periods of time 
PASAT, TOVA, TEA, CFT 
 (b)Capacity/Encoding or Data 
Processing  
 Ability for individuals to hold information in mind and 
process OR need to process tasks simultaneously 
 
  (a) Attention Span   CVLT, RAVLT 
  (b) Reaction Time or information processing 
speed 
 DSST,WAIS (Digit Symbol) 
AGN= Affective Go-NoGo (CANTAB , BIS= Barratt Impulsivity Scale , BLC= Big Little Circle, CGT= Cambridge Gambling Task (CANTAB), CFT= Continuous Performance Test, COWAT= Controlled Oral Word Association 
Test, CVLT =California Verbal Learning Test , DDT= Delay Discounting Test, DSST= Digit Symbol Substitution Test.,FAS= Phonological Fluency Test , FFT= Finger Tapping Test, GDT= Game and Dice Test, IED= 
Intra/Extra-Dimensional Set Shifting Task (CANTAB), IST= Information Sampling Test, IGT= Iowa Gambling Task, MFFT= Matching Familiar Figures, MCST= Maudsley Card Sorting Test, PASAT= Paced Auditory Serial 
AdditionTask , PMT= Proteus Maze Test, RAVLT= Rey Auditory Verbal Learning Test , ROCFT= Rey-Osterreith Complex Figure Test, RT= Reaction Time,RWT= Regensburger Word Fluency Test,  SCT= Logan Stop Change 
Task, SOC= Stockings of Cambridge (CANTAB), SSP= Spatial Span (CANTAB), SS= Stop Signal ,SWM= Spatial Working Memory (CANTAB), ST= Stroop Test , TEA= Test of Everyday Attention, TMT= Trail Making Test , 
TOH= Tower of Hanoi, TOL=Tower of London (CANTAB), TOVA= Test of Variables of Attention, VFT= Benton Verbal Fluency Test, WCST= Wisconsin Card Sorting Test, WAIS-III= Weschler Adult Intelligence Scale Third 
Edition. 
  
(3) Memory and Learning 
To evaluate the effects of opioids, or any other drug, on memory and learning, one 
must first identify a model of memory formation and storage to use as a reference. 
One classic, often cited model, initially proposed by Atkinson & Shiffrin (1968), 
described memory formation and storage as taking place in several stages, 
proceeding from sensory memory (which lasts up to a few seconds) to short–term 
memory (which lasts from seconds to minutes depending upon whether the 
information is rehearsed) to long–term memory storage. This model is often 
referred to as the Atkinson–Shiffrin Modal Model of Memory (Figure 1.3).  
 
Figure 1.3: A general model of memory formation, storage, and retrieval based on 
the modal model of memory originally proposed by Atkinson and Shiffrin (1968). The 
likelihood that information will be transferred from short–term to long–term storage, or 
be encoded into long–term memory, was once thought to depend primarily on how long 
the person keeps the information active in short–term memory via rehearsal. 
 
In this model, memory is transferred from a sensory memory to a short term 
memory store. The likelihood that information will be transferred from short term 
to long term memory storage, or be encoded into long term memory, was once 
thought to depend primarily on how long the person keeps the information active 
in short term memory via rehearsal. Although rehearsal clearly influences the 
transfer of information into long term memory storage, other factors, such as the 
depth of processing (i.e., the level of true understanding and manipulation of the 
information), attention, motivation, and arousal also play important roles (Craik & 
Lockhart, 1972; Otten et al., 2001; Eichenbaum, 2002). 
Sensory 
Memory 
Transfer 
(encoding) 
Short Term 
Memory 
Transfer 
(encoding) 
Long Term 
Memory 
Rehearsal  
Sensory 
Input 
       Retrieval 
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Baddeley & Hitch (1974) expanded upon this concept and proposed a tripartite 
working memory model that includes a central executive and two ‘slave systems’; 
the phonological loop and the visuospatial sketchpad or store (Figure 1.2). 
 
The phonological loop contains two elements; (1) short-term phonological storage 
of sounds and (2) an articulatory loop that maintains and rehearses information 
either vocally or subvocally. Baddeley and colleagues (1974) viewed its primary 
purpose as evolving for language acquisition and comprehension (Baddeley et al., 
1998). In the laboratory, phonological storage has been traditionally measured by 
the Digit-Span Task, a subtest of the Wechsler Adult Intelligence Scale (WAIS) and 
the Ray Auditory Verbal Learning Task (RAVLT) amongst others (Table 1.5). 
 
The visuospatial sketchpad or store was hypothesized to involve the maintenance 
and integration of visual ('what' information, like objects) and spatial ('where' 
information, like location in space) elements and a means of refreshing it by 
rehearsal (Baddeley & Logie, 1999).In laboratory conditions, this has been 
measured by the Rey Osterreith Complex Figure Test (RCFT), Spatial Span from the 
CANTAB tests and the Weschler Memory Scale Revised (WMRS) amongst others 
(Table 1.5). 
 
There are many different models describing variations of the long-term memory 
domain. The two major subdivisions used are explicit and implicit long term 
memory. Although understanding these differences is helpful, the divisions are fluid 
(i.e. different forms of memory often mix and mingle) (Coolidge & Wynn, 2005). 
Whether short term working memory stores constitute a separate anatomical and 
functional system from long term memory or whether they are activated parts of 
long term-memory is debatable (Miyake & Shah, 1999; Ruchkin et al., 2003). 
Nevertheless, long-term memory storage and retrieval is an integral part of working 
memory (O'Reilly et al., 1999). 
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(1) Explicit or declarative memory requires conscious thought (e.g. such as recalling 
who came to dinner last night) and it is what most people have in mind when they 
think of ‘memory’. This is further divided into episodic and semantic memory.  
 
Episodic or autobiographical memory provides us with a crucial record of our 
personal or autobiographical experiences. Semantic memory accounts for our 
‘textbook learning’ or general knowledge about the world. As with episodic 
memory, semantic memory ranges from strong (recall) to weak (familiarity) but 
unlike episodic memory, semantic memory is better sustained over time.  
 
(2) Implicit or procedural memory (non-declarative memory) doesn’t require 
conscious thought and allows you to do things automatically. This is also further 
divided into motor skill training and priming. 
 
Motor skill acquisition enables us to carry out commonly learned tasks without 
consciously thinking about them. It’s our ‘how to’ knowledge and examples include 
riding a bike and tying a shoe. Even what we think of as ‘natural’ tasks, such as 
walking, also require this type of procedural memory. Priming or conditioning 
occurs as a result of ones own personal experiences; if you have heard something 
very recently, or many more times than another thing, you are primed to recall it 
more quickly. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1.5: Memory and learning 
Main Domain Subtypes Other names Definition Examples of test 
Directed 
Attention or 
Registration  
(1-2 
seconds) 
Sensory 
Peripheral Store 
(Sensory 
Memory) 
(1) Visual or Iconic  Memory Retains large amount of information (see 
Table 1.4) 
 
(2) Auditory or Echoic Memory 
Short Term 
Memory 
(1-20 
minutes) 
Immediate 
Memory 
 
(1) Verbal Memory 
 
 
 
(2) Visuospatial (non verbal) 
Memory 
Reproduction, recognition or recall of 
information directly or some time after 
presentation 
 
Allow information to be evaluated and 
perhaps stored longer through rehearsal 
and coding 
LMT, RAVLT, CVLT,WAIS-III, VRM, 
WMSR , WRM, GNT, DFDBT, TBT 
 
SWM, SSP. DMS, PRM, PAL, BVRT, 
PAL, SRM,.WMSR, RCFT, PASAT, 
WAIS-III 
 
 
 
 
 
 
Long Term 
Memory 
 
 
Explicit 
(Declarative) 
Memory 
(1) Auobiographical, Episodic or 
Event Memory 
 
Records details salient to individuals life 
Needs conscious thinking 
‘Knowing that’ 
 
Meaning of words and concepts or 
propositional knowledge (facts) 
PRM,SRM, 
CVLT, RAVLT, PAL, RCFT,  WMSR 
WAIS-III (Vocabulary) 
(2) Semantic Memory 
 
 
RCFT, 
COWAT, GNT , WMSR, RBMT 
 
Implicit (Non 
Declarative) or 
Procedural 
Memory 
(1)  Motor skill training  
Does not need conscious thinking 
‘Knowing how’ 
                                                           
(2) Priming or classical 
conditioning  
 
BVRT=Benton Visual Retention Test, COWAT= Controlled Oral Word Association Test, CVLT= California Verbal Learning Test, DFDBT= Digit Forward and Digit Backwards Test, DMS=Delayed 
Matching to Sample (CANTAB), GNT=Graded Name Test (CANTAB), LMT= Logical memory Test, SRM=Spatial Recognition Memory (CANTAB), PAL= Paired Associate Learning (CANTAB), 
PASAT= Paced Auditory Seriel Addition Task, PRM= Pattern Recognition Memory (CANTAB), RAVLT= Rey Auditory Verbal Learning Test, RBMT= Rivermead  Behavioural Memory Test, RCFT= 
Rey Complex Figure Test, SWM=Spatial Working Memory (CANTAB), SSP=Spatial Span (CANTAB), TBT= Two Back Test ,VRM= Verbal Recognition Memory (CANTAB), WAIS-III= Weschler Adult 
Intelligence Scale Third Edition, WMSR= Weschler Memory Scale Revised, WRM= Word Recognition Memory. 
 
  
Quality and Validity assessment 
For all review questions, data were extracted by one reviewer and checked by a 
second reviewer. Discrepancies were resolved by referral to the original studies. If 
necessary, arbitration was by a third reviewer. Duplicate publications were actively 
screened for and the latest or most complete report used for further analysis. The 
quality assessment checklist used was sourced from the Effective Public Health 
Practice Project, McMaster University (EPHPP) (Appendix 2). 
 
Results 
Included and Excluded Studies 
The literature search identified a number of articles relevant to chronic opioid use 
and neuropsychological consequences. The abstracts identified through the 
electronic and further searching were subjected to a ‘selection and classification 
stage’. All abstracts extracted were merged together with the aim of excluding 
duplication of citations. Nine hundred and five (905) articles were then further 
analysed to identify relevant articles that satisfied the inclusion criteria. A total of 
ninety five (95) abstracts were then selected (Figure 1.4). 
 
From the total number of abstracts (95), only seventy  (70) studies could be used for 
the systematic review which also included four articles that could not be 
located.From these seventy studies eligible for this systematic review there were 
eight (8) articles that had reports published in different journals but using the same 
cohorts and instruments. A further nine (9) studied a polydrug population, one (1) 
study looked at the acute effects of methadone and three (3) other studies looked 
at subacute effects of opioid use on neuropsychological performance (Appendix 3).  
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Figure 1.4: Neuropsychological consequences of chronic opioid use: Quality of reporting of 
meta-analysis (QUOROM).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   All identified using study selection keywords:  
N= 510    
Relevant articles using study selection keywords, 
reference lists and manual search of journals: 
                              N=510+395 = 905   
 Animal studies: N=219 
Studies not relavant to search (pregnancy, theoretical 
concepts): N=371 
Conceptual/theoretical reviews rather than empirical 
studies: N=108 
Studies examined for inclusion/exclusion 
criteria: N= 207   Studies on individuals < 18 yrs old: N=13 
 Withdrawal effect studies: N= 13 
 Acute/subacuate effects studies (less than 3 
months):  N=86 
Studies on adult patients with chronic opioid 
use/dependence & neuropsychological deficits 
as in inclusion criteria:  N= 95 
 Not enough data available to calculate effect 
size: N=17 
 Articles did not perform neuropsychological 
tests: N=4 
 Articles could not be located: N=4 
        Studies included:  N=70    
 
Final studies included:                            
N= 49    
 Successive reports from the same studies. N=8 
 Polydrug population: N=9 
 Acute effects of methadone: N=1 
 Subacute effects of opioids: N=3 
 Opioid dependent population studies: N=29 
 Chronic pain population studies: N=10 
 Driving population studies: N=10 
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The remaining forty nine (49) studies were categorized into three distinct 
population groups (Table 1.6): 
(1) Opioid dependent population studies (N=29).  
(2) Chronic malignant and non malignant pain population studies (N=10).  
(3) Driving population studies (n=10). 
 
Table 1.6: Number and type of cohort and controls used in the 49 selected studies.      
                                  
Cohort Substance Misuse 
Studies N= 29  
Chronic Pain Studies  
N= 10 
Driving Related 
Studies N= 10  
TOTAL 
Methadone Maintained 
Programme (MMP) 
14 0 5 19 
Heroin users 4 1 0 5 
Abstinent previously opioid 
users 
6 0 0 6 
Methadone and Buprenorphine 2 0 1 3 
Buprenorphine only 1 0 0 1 
Morphine or Fentanyl users 0 8 3 11 
Mixture of heroin, 
buprenorphine, fentanyl, 
oxycodone and/or methadone 
users 
2 1 1 4 
                    Controls*     
Healthy 21 4 6 31 
Abstinent opioid users 9 1 0 10 
Heroin users 1 0 0 1 
Methadone Maintained 
Programme (MMP) 
2 0 0 2 
Buprenorphine users 0 0 2 2 
Alcohol users 2 0 0 2 
Amphetamine users 5 0 0 5 
Chronic pain 1 3 0 4 
Psychiatric 0 0 0 0 
DLM-PFC/ Low Tryptophan/ 2 0 0 2 
Head Injury/Epilepsy 1 0 1 2 
None 2 2 1 5 
*= Some studies used more than one type of control, DLM-PFC= Patients with focal lesions of Dorsolateral and Medial 
Prefrontal Cortex.
  
Quality threshold 
Out of the forty nine studies identified twenty eight (28) studies met moderate level 
in quality threshold and twenty one (21) studies were judged to be of weak quality. 
There were no strong quality studies. The twenty one studies judged to be of weak 
quality were excluded in the subsequent review analysis (Tables 1.7a, b &c; Appendix 
3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1.7a: Quality threshold of the selected studies in the substance using population (N=29). 
Study Selection Bias Study Design Confounders Blinding Data Collection 
Methods 
Withdrawal  
Dropouts 
Global Rating 
Mintzer et al (2005) Moderate Moderate Strong Moderate Strong Moderate MODERATE 
Lombardo et al (1976) Moderate Moderate Moderate Moderate Strong Weak MODERATE 
Gritz et al (1975) Weak Moderate Strong Weak Strong Weak WEAK 
Darke et al  (2000) Moderate Moderate Strong Weak Strong Strong MODERATE 
Rotherhan-Fuller et al 
(2004) 
Moderate Moderate Strong Weak Strong Strong MODERATE 
Guerra et al  (1987) Strong Moderate Weak Weak Strong Strong WEAK 
Rounsaville et al (1982) Strong Moderate Strong Moderate Strong Strong MODERATE 
Davis et al  (2002) Weak Moderate Strong Weak Strong Strong WEAK 
Gruber et al  (2006a) Strong Moderate Strong Weak Weak Weak WEAK 
Prosser et al (2006) Strong Moderate Strong Weak Strong Strong MODERATE 
Pirastu et al (2006) Strong Moderate Strong Weak Strong Strong MODERATE 
Hill & Mikhael  (1979) Moderate Moderate Strong Strong Strong Strong MODERATE 
Strang & Gurling (1989) Strong Moderate Weak Weak Strong Strong WEAK 
Kelley et al  (1978) Weak Strong Strong Strong Strong Weak WEAK 
Soyka et al (2008) Strong Moderate Strong Weak Strong Moderate MODERATE 
Brand et al  (2008) Strong Moderate Strong Weak Strong Strong MODERATE 
Passetti et al (2008) Strong Moderate Moderate Moderate Moderate Strong MODERATE 
Petry et al  (1998) Strong Moderate Strong Weak Strong Weak WEAK 
Stevens et al (2007) Moderate Moderate Strong Moderate Strong Strong MODERATE 
Gordon (1970) Weak Moderate Weak Weak Weak Weak WEAK 
Fishbein et al (2005a) Strong Moderate Strong Weak Strong Strong MODERATE 
Fishbein et al (2007) Strong Moderate Strong Weak Strong Strong MODERATE 
Verdejo et al (2007a) Moderate Moderate Strong Moderate Strong Weak MODERATE 
Verdejo et al (2007b) Moderate Moderate Strong Moderate Strong Weak MODERATE 
Ornstein et al (2000) Strong Moderate Strong Moderate Strong Strong MODERATE 
Rogers et al  (1999a) Strong Moderate Strong Moderate Strong Strong MODERATE 
Clark et al  (2006) Strong Moderate Strong Moderate Strong Strong MODERATE 
Ersche et al  (2005a) Strong Moderate Strong Moderate Strong Strong MODERATE 
Ersche et al  (2006a) Strong Moderate Strong Moderate Strong Strong MODERATE 
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Table 1.7b: Quality threshold of the selected studies in the chronic pain population (N=10). 
Study Selection Bias Study 
Design 
Confounders Blinding Data Collection 
Methods 
Withdrawal  
Dropouts 
Global Rating 
Sjogren et al 
(2005) 
Moderate Moderate Moderate Moderate Strong Strong MODERATE 
Sjogren et al  (2000a) Strong Moderate Moderate Weak Strong Weak WEAK 
Sjogren et al (2000b) Strong Moderate Moderate Weak Strong Moderate WEAK 
Banning & Sjogren 
(1990) 
Weak Moderate Weak Weak Strong Weak WEAK 
Clemons et al (1996) Weak Moderate Moderate Weak Strong Weak WEAK 
Wood et al (1998) Weak Moderate Moderate Weak Moderate Moderate WEAK 
McNairy et al (1984) Moderate Moderate Moderate Moderate Strong Strong MODERATE 
Jamison et al  (2003) Moderate Moderate Strong Weak Strong Strong MODERATE 
Haythornthwaite et al 
(1998) 
Weak Moderate Moderate Weak Moderate Weak WEAK 
Tassain et al  (2003) Moderate Moderate Moderate Weak Strong Strong MODERATE 
 
 
Table 1.7c: Quality threshold of the selected studies in the driving population (N=10). 
Study Selection Bias Study 
Design 
Confounders Blinding Data Collection 
Methods 
Withdrawal  
Dropouts 
Global Rating 
Soyka et al  (2005) Weak Strong Strong Weak Strong Moderate WEAK 
Soyka et al  (2001) Weak Moderate Weak Weak Strong Weak WEAK 
Vainio et al (1995) Strong Moderate Moderate Weak Strong Moderate MODERATE 
Byas-Smith et al (2005) Weak Moderate Weak Moderate Weak Moderate WEAK 
Galski et al  (2000) Strong Moderate Moderate Weak Weak Weak WEAK 
Schindler et al  (2004) Weak Moderate Strong Moderate Strong Weak MODERATE 
Specka et al (2000) Strong Moderate Strong Weak Strong Strong MODERATE 
Staak et al  (1993) Weak Moderate Weak Weak Strong Weak WEAK 
Hornung et al  (1996) Strong Moderate Weak Weak Strong Weak WEAK 
Bukasa et al  (2006) Weak Moderate Weak Weak Strong Weak WEAK 
  
Background information of selected studies (N=28) 
Tables 1.8 and 1.9 describe the participants, measures and procedures employed by 
each of the twenty eight identified and selected studies. There were a mean number 
of 39.2 cohorts and 563.9 healthy controls per study. The studies were all conducted 
in an urbanized setting. Eighteen (68%) studies were conducted in Europe, 
predominantly in the UK, nine (29%) studies in the USA and one (3.2%) in Australia. 
All the studies were published in English speaking journals (Tables 1.8 a&b; Tables 1.9 
a&b). There was a wide variation in the period of data collection and most were case 
controlled studies attending a drug dependence clinical setting. Most of the cohorts 
were considered as dependent on opioids with the exception of four studies where 
the cohort had a diagnosis of non malignant chronic pain prescribed opioids but not 
dependent.The studies were biased towards the male gender with an average ratio of 
2 males to 1 females (n=28). The mean age of the cohorts was 33.9 years (n=27) with 
a mean educational attainment of 11.1 years (n=19). 
 
Mean duration of chronic opioid use was 8.5 years (n=22) with a mean morphine 
equivalent daily dosage available only in seventeen studies. For the thirteen (13) 
studies with a history of drug dependence the mean dose was 588.62mg daily and for 
the four studies looking at the chronic pain population the morphine equivalent dose 
was 95.58mg daily.  Chronic opioid use spanned between 15 and 0.26  years . 
 
Neuropsychological tests and outcomes from these selected studies were grouped 
into the composite neuropsychological domains as discussed earlier in this chapter 
(Table 1.10). 
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Table 1.8a: Generic guidelines in substance using population (N=21).  
Study Country of 
study 
Period of 
data 
collection 
(months) 
Study design 
hierarchy 
Cohort (N) Control (N) and 
type 
Mintzer et al (2005) USA 36 3b 18 20 Healthy 
Lombardo et al (1976) USA n/a 4 20 Methadone 
80mg 
18 Methadone 
50mg 
Darke et al 
(2000) 
Australia n/a 3b 30 30 Healthy 
Rotherham Fuller et al 
(2004) 
USA n/a 3b 18 19 Healthy 
Rounsaville et al 
(1982) 
USA n/a 3b 72 29 Healthy 
Prosser et al (2006) USA n/a 3b 29 56 Abstinent 
Pirastu et al (2006) 
 
Italy n/a 3b 30 Meth, 18 
Bup 
21 Healthy 
Hill & Mikhael (1979) USA n/a 3b 15 15 Alcohol  
15 Healthy 
Soyka et al (2008) Germany n/a 1 24 Meth, 22 
Bup  
24 Healthy 
Brand et al (2008) Germany n/a 3b 18 18 Healthy 
Passetti et al (2008) UK n/a 3b 10 27 Healthy 
Stevens et al (2007) Germany n/a 3b 25 26 Abstinent  
26 Healthy 
Fishbein et al (2005a) USA n/a 3b 13 14 healthy 
Fishbein et al (2007) Russia 24 3b 100 102 Alcohol  
60 Alcohol & Opiate  
160 Healthy 
Verdejo Garcia et al 
(2007a) 
Spain n/a 3b 81 37 Healthy 
Verdejo Garcia et al 
(2007b) 
Spain  n/a 3b 64 30 Healthy 
Ornstein et al (2000) UK 12 3b 22 23 Amp  
25 Healthy 
Rodgers et al (1999a) UK 12   3b 13 18 Amp 
10 ORB-PFCPFC 
10 DLM –PFC 
26 Healthy 
Clark et al (2006) UK n/a 3b 40 24 Amp 
24 Abstinent  
26 Healthy 
Ersche et al (2005a) UK n/a 3b 27 Heroin, 12  
Bup 
24 Amp  
26 Abstinent  
27 Healthy  
Ersche et al  (2006a) UK n/a  3b 42  25 Amp  
27 Healthy  
26 Abstinent  
1= Experimental studies, 2=Quasi-experimental studies (e.g. experimental study without randomisation), 
3a=Cohort studies, 3b=Case control studies, 4=Observational studies without control groups, Amp=Amphetamines, 
Bup= Buprenorphine, DLM-PFC=Dorsolateral/Medial Prefrontal Cortex , Meth=Methadone, ORB-PFC= Orbital 
Prefrontal Cortex, , n/a =information not available, N= Number, USA= United States of America, UK= United 
Kingdom. 
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Table 1.8b: Generic guidelines in chronic pain and driving populations (N=7).  
Study Country 
of study 
Period of data 
extraction 
(months) 
Study 
design 
hierarchy 
Cohort 
(N) 
Control (N) and type 
Chronic Pain Population Studies (N=4) 
Sjogren et al (2005) Denmark 12 3a 91 64 Healthy 
McNairy et al 
(1984) 
USA n/a 3b 33 14 Healthy 
Jamieson et al 
(2003) 
USA n/a 1 114 Cross over trial  
Tassain et al (2003) France  n/a 3b 18 10 Healthy 
Driving Population Studies (N=3) 
Vainio et al (1995) Finland  n/a  3b 24 25  Healthy 
Schindler et al 
(2004) 
Austria  n/a  3b 15 14500  Healthy 
Specka et al (2000) Germany  n/a  3b 54  54  Healthy 
1= Experimental studies, 2=Quasi-experimental studies (e.g. experimental study without randomisation), 
3a=Cohort studies, 3b=Case control studies, 4=Observational studies without control groups, Amp=Amphetamines, 
Bup= Buprenorphine, DLM-PFC=Dorsolateral/Medial Prefrontal Cortex, Meth=Methadone, ORB-PFC= Orbital 
Prefrontal Cortex, n/a =information not available, N= Number, USA= United States of America, UK= United 
Kingdom. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1.9a: Specific guidelines in substance using population (N= 21). 
Study Age 
(yrs) 
M:F Ethnic R:L Education 
(yrs) 
Opioid 
Use (yrs) 
Dosage (morph 
equivalent) 
Types of opioids Service Diagnosis Measures (Psych/Depend/Pain) 
Mintzer et al  (2005) 37.6 2:1 28% n/a 11.8  15.3  670mg Meth CDT OD n/a 
Lombardo et al (1976) 32.1 1:0 n/a n/a 11.4  n/a 800mg Meth 
 
CDT OD DSM IV(D) 
Darke et al (2000) 35.8 3:2 n/a n/a 11.2  n/a 786mg Meth CDT OD CIDI(D), DSM IV(D)  
Rotherham- Fuller et al  
(2004) 
41.7 n/a 22% n/a 11.8  n/a 680mg Meth Smokers  Inpatient OD DSM IV (D),BDI (S),SCID R(D), 
ADHD (S),ASI (D) 
Rounsaville et al (1982) 27.9 2:1 58% 9:1 11.5  8.2  n/a Meth Inpatient OD MMPI (S),ICD9(D), SCL-90 (S), BDI (S)  
Prosser et al (2006) 38.0 4:1 38% n/a 13  21  730mg Her and Meth Inpatient  
& Rehab 
OD DSM III (D), SUI (S) 
Pirastu et al (2006) 34.0 2 F n/a n/a 8.27  n/a n/a Meth  and Bup CDT OD DSM III (D)  
Hill & Mikhael (1979) 29.2 n/a 0% n/a 11.5 8.6 n/a Her  CDT OD FC (D) 
Soyka et al (2008) n/a n/a n/a n/a n/a n/a n/a Meth and Bup CDT OD  
Brand et al (2008) 31.1 7:2 n/a n/a 9.3 11.6  n/a Abst Her Rehab OD DSM IV SCI (D), FPI (S)  
Passetti et al (2008) 37.7 7:3 n/a n/a n/a 10.2  400mg Meth CDT OD DSM IV SCI(D),YMRS(S),BDI(S),BPRS 
(S),MAP(S) 
Stevens et al (2007) 30.4 1:0 n/a 1:0 11.3 9.5  476mg Her  CDT and 
Rehab  
OD BDI (S), TAF (S),  
STAI (S), SHAPS (S) 
Fishbein et al (2005a) 27.3 7:6 39% 1:0 n/a 9.4  n/a Abst Her Rehab OD DI (D), PCL-R (S), SCL-9R (S), ASI, (D) 
Fishbein et al (2007) 25.6 2:1 100%  n.a 11  6.3  n/a Abst Her Rehab OD DSM IV-SCI (D), ASI (D), BPRS (S),16PF  
Verdejo-Garcia et al (2007a) 30.9 76:5 100%  n/a 9.8 9.2  n/a Abst Her Rehab OD  
Verdejo-Garcia et al (2007b) 29.8 n/a 100% n/a 9.42 n/a n/a Abst Her Rehab OD  
Ornstein et al (2000) 33.3 1:0 100%  n/a 11.9  11.6  n/a Her and Meth CDT OD  
Rodgers et al (1999a) 34.5 1:0  100%  n/a n/a 13.9  395mg Her and Meth CDT OD  
Clark et al (2006) 34.0 4:1 100%  n/a n/a 11  428mg Meth CDT OD BDI (S) 
Ersche et al (2005a) 33 4:1 100%  9:1 n/a 9.2 450mg Meth and Her CDT OD BDI (S) 
Ersche et al (2006a) 33.8 4:1 100%  9:1 n/a 10.8 450mg Her,Meth,Bup CDT  OD BDI (S) 
Abst Her= Abstinent Heroin, bup=buprenorphine , CDT= Community Drug Team , D= Diagnostic , Ethnic= Ethnicity, , F/up= Follow up period when neuropsychological outcomes measured after baseline, her= heroin ,M:F= Male: Female, m/meth= 
methadone, morph= morphine , n/a= not available, OD= opioid dependence , other= dihydrocodeine, tramadol and/or oxycodone, R:L= Right:Left Handendeness, S= Screening, rehab= rehabilitation, yrs= years. 
ADHD= Attention Deficit Hyperactivity Disorder Scale , BDI=Beck Depression Inventory , BPRS= Brief Psychiatric Rating Scale, Cattell 16PF= Cattell 16 Personality Factor Assessment , CIDI =Composite International Diagnostic Index , 
DI=Dysregulation Inventory ,DSM IV/III = Diagnostic and Statistical Manual of Mental Disorders 4th/3rd Edition, Euro ASI= European version of Addiction Severity Index , Fager= Fagerstrom Test of Nicotine Dependence , FC= Feighner Criteria , FPI= 
Freiburg Personality Inventory , HDRS=Hamilton Depression Rating Scale , ICD-9= International Classification of Disorders 9th Edition, MAACL= Multiple Affect Adjective Check List , MAP= Maudlsey Addiction Profile , McGill=Melzack's McGill Pain 
Questionnaire ,MMPI= Minnesota Multiphasic Personality Inventory ,MMSE=Mini Mental State Examination , PCL-R=Psychopathy Checklist-Revised ,PVAS=Pain Visual Analogue Scale ,SCID R III =Structured Clinical Inventory –Revised for DSM-III, 
SCL-90R= Symptom Checlist-90-Revised, SHAPS = Snaith-Hamilton Pleasure Scale , STAI =State-Trait-Anxiety Inventory ,SUI= Substance Use Inventory,TAF= Tῧbingen Anhedonia Questionnaire, Wang Scale= Opiate withdrawal scale, WURS = Wender 
Utah Rating Scale ,W-VAS= Visual Analogue Mood Scale, YMRS=Young Mania Rating Scale.
  
 
 
 
Table 1.9b: Specific guidelines in chronic pain and driving populations (N= 7). 
 
Study Age 
(yrs) 
M:F Ethnic R:L Education 
(yrs) 
Opioid 
Use 
(yrs) 
Dosage 
(morph 
equivalent) 
Types of 
opioids 
Service Diagnosis Measures (Psych/Depend/Pain) 
Sjogren et al (2005) 44.4 1:1 100%  n/a 13.2  7  n/a Morph 
 
Pain  Non malignant 
chronic pain  
MMSE (S), PVAS (S) 
McNairy et al (1984) 46.0 5:4 n/a n/a n/a 9  25.5mg Her Pain   OD  with        
chronic pain 
MMPI (S), PVAS (S) 
ICD-9 (D) 
Jamieson et al (2003) 46.3 2:1 90% n/a 11          
0.49 
75.85mg Oxycodone 
& Fentanyl 
 
Pain  Non malignant 
chronic pain 
BDI (S) , PVAS (S) 
Tassain et al (2003) 46.0 5:4 n/a n/a 12.0 1  72mg Morph 
 
Pain  Non malignant 
chronic pain 
BDI (S), HDRS (S) PVAS 
STAI (S), W-VAS (S) McGill. (S) 
Vainio et al (1990) 53 1:1 n/a n/a 11  0.26 
 
209mg Morph Oncology  Chronic malignant 
pain 
MAACL (S) ICD-9 (D) 
Schindler et al (2004) 25.8 3:2 n/a n/a n/a 5.8 457mg Meth & 
Bup 
CDT OD Euro ASI (D), Wang Scale (S) 
Specka et al (2000) 29.0 2:1 n/a n/a 11  8  930mg Meth CDT  & 
Psychiatric  
 
OD FPI (S) 
Vainio et al (1990) 53 1:1 n/a n/a 11  0.26 
 
209mg Morph Oncology  Chronic malignant 
pain 
MAACL (S) ICD-9 (D) 
Abst Her= Abstinent Heroin, bup=buprenorphine , CDT= Community Drug Team , D= Diagnostic , Ethnic= Ethnicity, , F/up= Follow up period when neuropsychological outcomes measured after baseline, her= heroin, 
M:F= Male: Female, m/meth= methadone, morph= morphine , n/a= not available, OD= opioid dependence , other= dihydrocodeine, tramadol and/or oxycodone, R:L= Right:Left Handendeness, S= Screening, rehab= 
rehabilitation, yrs= years.ADHD= Attention Deficit Hyperactivity Disorder Scale , BDI=Beck Depression Inventory , BPRS= Brief Psychiatric Rating Scale, Cattell 16PF= Cattell 16 Personality Factor Assessment , CIDI 
=Composite International Diagnostic Index , DI=Dysregulation Inventory ,DSM IV/III = Diagnostic and Statistical Manual of Mental Disorders 4th/3rd Edition, Euro ASI= European version of Addiction Severity Index , 
Fager= Fagerstrom Test of Nicotine Dependence , FC= Feighner Criteria , FPI= Freiburg Personality Inventory , HDRS=Hamilton Depression Rating Scale , ICD-9= International Classification of Disorders 9th Edition, 
MAACL= Multiple Affect Adjective Check List , MAP= Maudlsey Addiction Profile , McGill=Melzack's McGill Pain Questionnaire ,MMPI= Minnesota Multiphasic Personality Inventory ,MMSE=Mini Mental State 
Examination , PCL-R=Psychopathy Checklist-Revised ,PVAS=Pain Visual Analogue Scale ,SCID R III =Structured Clinical Inventory –Revised for DSM-III, SCL-90R= Symptom Checlist-90-Revised, SHAPS = Snaith-Hamilton 
Pleasure Scale , STAI =State-Trait-Anxiety Inventory ,SUI= Substance Use Inventory,TAF= Tῧbingen Anhedonia Questionnaire, Wang Scale= Opiate withdrawal scale, WURS = Wender Utah Rating Scale ,W-VAS= Visual 
Analogue Mood Scale, YMRS=Young Mania Rating Scale.
  
Table 1.10: Neuropsychological outcomes. 
Study Short Term  Memory  
 
Long Term 
Memory  
Cognitive Flexibility  
 
Attention  
 
Intelligence  Motor 
Impulsivity 
Non-Planning 
Impulsivity 
Cognitive 
Impulsivity  
Substance Misuse Population 
Mintzer et al (2005) 2BT   ↓  n/a              TMT↓       DSST↓                      SILS↔ n/a              n/a IGT ↓          
Lombardo et al (1976) n/a n/a n/a WAIS II↔ 
 
WAIS II↔ n/a n/a n/a 
Darke et al (2000) WMSR,CVLT,RCFT↓ n/a COWAT, WCST↓ WAIS II↓ 
 
WAIS II↓ n/a n/a n/a 
Rotherham-Fuller et al (2004) n/a n/a WCST↔ n/a SILS↔ n/a n/a IGT↓ 
Rounsaville et al (1982) n/a n/a TMT↔ DSST↔ WAIS II ↔ GP↔ n/a n/a 
Prosser et al (2006) BVRT↓ n/a COWAT↔,ST↓ n/a WAIS III↓ n/a n/a n/a 
Pirastu et al (2006) BVRT↓ n/a WCST↓ n/a WAIS III↓ n/a n/a IGT↓ 
Hill & Mikhael (1979) n/a n/a CT↔,TMT↓ n/a 
 
SILS↔ n/a n/a n/a 
Soyka et al (2008) AVLT↓ n/a  RWT,TMT↓ DR2↓ n/a n/a n/a n/a 
Brand et al (2008) n/a n/a FAS ↔,MCST↓ n/a LPS↓ FWIT↓ TOH ↔ GDT↓ 
              Passetti et al(2008) n/a n/a n/a n/a WTAR↔ Go-NoGo 
     
TOL↔ CGT,IGT,IST↓, 
DDT↔ 
Stevens et al (2007) WMSR,DMS↔ WMSR↔ TMT↓ SRTT↓ MWT-B↔ n/a n/a n/a 
Gordon et al (1970) n/a n/a n/a SRT↑ WAIS III↔ n/a n/a n/a 
Fishbein et al (2005a) n/a n/a n/a n/a  SILS↓ n/a n/a RDMT↓ 
 
Fishbein et al (2007) PAL, DMS↓ PAL↓ SCT, ST↓ n/a RPM ↓ n/a  SOC↓ RDMT↓ 
Verdejo Garcia et al (2007a) WMSR,WAIS III,CBT↓ n/a FAS,RFFT,WCST, ST, 
CT↓ 
WAISIII,5DT↓ 
 
WAIS III↔ Go-NoGo↓ n/a IGT ↓ 
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Verdejo Garcia  et al (2007b) n/a n/a ST↓ 5DT↔ WAT↔ Go-NoGo↓ n/a IGT↓  
Ornstein et al (2000) SRM ↔,SWM↓ PRM ↔ VFT, IED↓ n/a NART↔ n/a TOL↓ n/a 
Rodgers et al (1999a) n/a n/a n/a n/a NART↔ n/a n/a CGT ↓ 
Clark et al (2006) n/a n/a n/a n/a NART↔ n/a n/a IST,BIS↓ 
Ersche et al (2005a) n/a n/a n/a n/a NART↔ n/a n/a CGT,BIS↓ 
Ersche et al (2006a) PAL, PRM↓ PAL,PRM↓ IED↓ n/a NART↔           n/a SOC↓ n/a 
Chronic Pain Population 
Sjogren et al (2005) n/a n/a n/a CRT,PASAT↓ n/a FTT↓ n/a n/a 
McNairy et al (1984) AVLT↔ n/a TMT↔ WAIS II↔ WAIS II↔ FTT↓ n/a n/a 
Jamieson et al (2003) n/a n/a TMT↑  WAISIII,DSST↔  n/a n/a n/a n/a 
Tassain et al (2003) CVLT,WAIS III↔ CVLT↔ VFT, ST, TMT↔ WAIS III,SRT↔ n/a n/a n/a n/a 
Driving population 
Vainio et al (1995) n/a n/a n/a Q1↔ M30↔ RST3↔ LL5↔ n/a 
Schindler et al (2004) n/a n/a FAT↔ DR2,Q1↓ MAT↔ RST3↔ LL5↔ n/a 
Specka et al (2000) n/a n/a n/a DR2,Q↔ n/a RST3↓ LL5↔ n/a 
 
n/a= not applicable, ↓= sig. deficits present, ↔= no sig.deficits present, ↑= sig.improvement observed at p<0.05. 
 
AVLT= Auditory Verbal Learning Test ,BIS= Barrats Impulsivity Scale , BVRT= Benton Visual Retention Test, CBT=Cognitive Bias Test, COWAT/FAS= Controlled Oral Word Association Test/Phonological Fluency Test,CRT=Continuous Reaction Time, 
CVLT=California Verbal Learning Test, DDT= Delay Discounting Task, DSST=Digital Symbol Substitution Test ,FWIT= Farbe-Wort-Interferenz-Test (Word-Color-Interference Test), 5DT= Five Digit Test, GDT=Game and Dice Test, Go-NoGo=Go-NoGo 
Test, GP= Grooved Pegboad ,IGT= Iowa Gambling Task, IST=Information Sampling Task, LPS= Leistungs Prufsystem(German intelligence test battery), MWT-B= MehrfachwahlWortschatz-Intelligenz-Test  (Multiple Choice Word Comprehension Test) 
MCST=Maudlsey Card Sorting Test,NART= National Adult Reading Test ,PASAT= Paced Auditory Serial Addition Task, RPM= Raven’s Progressive Matrices, RCFT=Rey Osterreith Complex Figure Test, RWT= Regensburger Word Fluency Test, 
SILS=Shipley Institute to Living Scale,  ST=Stroop Test , TOH= Tower of Hanoi, 2BT= Two Back Task,RAVLT=Rey Auditory Verbal Learning Test, RFFT= Ruff Figural Fluency Test, SCT= (Logan) Stop Change Task ,SRTT=Seriel Reaction Time Task, SRT=  
Simple Reaction Time, VFT= Verbal Fluency Test, WAIS III/II= Weschler Adult Intelligence Scale 3
rd
/2
nd
  Edition,  WCST= Wisconsin Card Sorting Test ,WMSR= Weschler Memory Scale Revised,WTAR= Weschler Test of Adult Reading, WAT= Word 
Accentuation Test. 
 
CANTAB: DMS= Delayed Matching to Sample, PAL= Paired Associate Learning Task, PRM= Pattern Recognition Memory,  SRM= Spatial Recognition Memory, SWM= Spatial Working Memory, SOC = Stockings of Cambridge, IED= Intra/Extra-
Dimensional Set Shifting Task, CGT/RDMT= Cambridge Gambling Task/Roger’s Decision Making Test, SST= Stop Signal Task, AGN= Affective Go-NoGo Test.Halstead Reitan Neuropsychological Test Battery: FTT= Finger Tapping Test, TMT= Trail 
Making Test, CT= Category Test. Act React Test Systems (ART 90/2020): FAT= Test of Attentional Flexibility, DR2=Simple Choice Reaction, Q1= Attention under Monotonous Circumstances, MAT/M30=Matrices for Intelligence Test, RST3=Multiple 
Choice under Stress, LL5=Labyrinth of Lines to Measure Visual Structuring Performance 
  
Descriptive summary of findings 
A large number of studies have been conducted which examine the effects of opioid 
use on a variety of neuropsychological skills and abilities. The population studied 
were either from the opioid dependent or chronic pain clinical settings. Most studies 
have attempted to target one opioid such as prescribed methadone or illicit heroin 
use. In addition to the literature on the chronic effects of heroin and methadone, 
some studies have examined neuropsychological functioning in the more general 
group of ‘opioid addicts’ by combining participants with current methadone, heroin 
and/or other opioid use. The progress in each of these areas will be examined in turn.  
 
Intelligence in opioid dependent and using population 
The first published study to examine the effects on intelligence in chronic methadone 
users was conducted by Isbell et al., (1948). This study examined ‘general 
intelligence’ in methadone users and concluded that ‘methadone may have a 
detrimental impact on intellectual functioning’. Gordon (1970) reported that they had 
found no irregularities in the performance of methadone maintenance patients on 
the Wechsler Adult Intelligence Scale (WAIS).  
 
Gordon & Lispet (1976) followed up an initial cohort approximately 112 months after 
their initial assessment. They repeated the WAIS assessment with thirty of these 
participants who were still receiving prescribed methadone and found that all 
participants’ intellectual functioning remained in the average range. 
 
Darke et al., (2000) and Prosser et al., (2006) both found low IQ and reduced verbal 
function in methadone users. While limited inference can be drawn from these cross-
sectional studies of such a small number of participants, the results may suggest 
problems in achieving recovery within methadone maintenance for this group. 
 
Several studies have suggested the existence of neuropsychological alterations prior 
to drug use that could act as causal or vulnerability factors (Verheul, 2001). This 
systematic review has described studies who have either adjusted for possible 
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differences between opioid users and controls, on intelligence and educational level 
(Ersche et al., 2005a & 2006a; Darke et al., 2000; Rotherham–Fuller et al., 2004) or 
not (Prosser et al., 2006).  
 
Overall studies  show coflicting evidence on the effects ofintellectual function in 
participants with a history of opioid use and dependence either still on illicit heroin, 
treated with methadone, following a period of abstinence or using opioids for 
analgesic purposes. Table 1.11 summarises the evidence presented in this review for 
an association between chronic opioid use and intellectual impairment. 
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Table 1.11: Summary of previous research regarding chronic opioid use and intelligence.  
 
Studies Intelligence tests and 
results* 
Cohen’s  d 
Brand et al (2008) LPS:↓ 0.99 
Clark et al (2006) Verbal IQ (WAIS):↔ 0.28 
Darke et al (2000) Verbal IQ (WAIS):   ↓ 0.13 
Ersche et al (2005a) Verbal IQ (WAIS):↔ 0.19 (Meth) & 
0.23 (Heroin) 
Ersche et al (2006a) Verbal IQ (WAIS):↔ 0.23 (Opioid) & 
0.13 (Abstinent) 
Fishbein et al (2005a) SILS:↓ 0.54 
Fishbein et al (2007) RPM:↓ 0.75 
Gordon (1970) Verbal IQ (WAIS):  ↔ 0.43 
Hill & Mikhael (1979) SILS:↔ 0.73 
Lombardo et al (1976) Verbal IQ (WAIS):  ↔ 0.43 
Mintzer et al (2005) SILS:         ↔ 2.40 (Meth)& 
1.70 (Abstinent) 
McNairy et al (1984) Verbal IQ (WAIS):↔ 0.00 
Ornstein et al (2000) NART:↔ 0.44 
Passetti et al (2008) Verbal IQ (WTAR): ↔ 0.95 (Meth vs Meth + Heroin) 
Pirastu et al (2006) Verbal IQ (WAIS):↓ 6.97(Meth) & 4.30(Bup) 
Prosser et al (2006) Verbal IQ (WAIS): ↓ 1.43 (Meth) & 1.09 
(Abstinent) 
Rogers et al (1999a) NART:↔ 3.09 
Rotherham-Fuller et al 
(2004) 
SILS:  ↔ 0.72 (Meth smoker) & 
0.56 (Meth non smoker) 
Rounsaville et al (1982) Verbal IQ (WAIS): ↔ 0.93 
Schindler et al (2004)  MAT: ↔ n/c 
Stevens et al (2007) Verbal IQ (MWT-B): ↔ 0.09 (Abstinent) 
Vainio et al (1995) M30: ↔ 0.33 
Verdejo-Garcia et al 
(2007a) 
(2007b) 
 
WAT:↔ 
WAT:↔ 
 
0.42 
0.40 
 
Meth= Methadone, Bup=Buprenorphine, n/c= controls not healthy controls or not enough information to calculate 
effect size ↓= Deficits present, ↔= no deficits present, ↑= improvement observed at *p<0.05 when compared 
with healthy controls. 
LPS= Leistungs Prufsystem(German intelligence test battery), MAT/M30=Matrices for Intelligence Test (Part of Act 
React Test Systems: ART 90/2020), MWT-B= MehrfachwahlWortschatz-Intelligenz-Test (Multiple Choice Verbal 
ComprehensionTest), NART= National Adult Reading Test, RPM= Raven’s Progressive Matrices, SILS=Shipley 
Institute to Living Scale, WAIS = Weschler Adult Intelligence Scale, WTAR= Weschler Test of Adult Reading, WAT= 
Word Accentuation Test (similar to NART in Spanish). 
 
 
 
Neuropsychological functioning in opioid dependent and using population 
The results of such studies are difficult to interpret as these groups often contain 
individuals who abuse various different opioids, and it is therefore not possible to 
attribute observed deficits to the effects of any specific type of opioid. However as 
many individuals in this population will use a variety of different opioids in their 
48 
 
 
 
lifetime, these studies may help to examine whether there is a neuropsychological 
profile characteristic of this population. 
 
An early example of this type of research was conducted by Rounsaville et al., (1982) 
who assessed a group of 72 opioid addicts upon entering treatment, using a brief 
neuropsychological battery. This group consisted of individuals who were still using 
illicit heroin, those who had recently commenced on a prescribed methadone dose, 
and those who had recently been detoxified from all opioids. Many of these 
individuals could be classified as poly-drug users, reporting regular use of other 
substances including amphetamines, cocaine, sedatives, cannabis and alcohol. The 
group varied widely in terms of the length and nature of their drug abuse.  
 
The authors found that although the opioid group’s intellectual functioning scores 
was in the normal range, their performance in a number of areas of 
neuropsychological functioning was at the mildly impaired range. These included 
tasks of attention, cognitive flexibility and motor impulsivity. When the opioid group 
were compared to a control group of non substance using participants matched for 
sociodemographic variables, the former did not perform significantly below the latter 
group on any of the measures included. Six months after the initial assessment, the 
authors noted that the improvements observed could not be attributed to the effects 
of detoxification from opioids as more than half of the sample provided urine samples 
which tested positive for opioids. Instead it was suggested that these improvements 
are related to an overall change in clinical status of this group when compared to 
their initial presentation.  
 
Although this study failed to find any significant differences between opioid users and 
non substance using controls, it did show that following a period of relative stability 
in treatment improvements were seen in some areas of functioning. This suggested 
that on entering treatment, opioid dependent individuals were performing at a level 
below their actual optimal ability on several indices of neuropsychological 
functioning.  
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Ersche et al., (2006a & 2005a) compared a group of opioid dependent individuals 
with a group of amphetamine dependent individuals across a number of 
neuropsychological domains. The opioid dependent group consisted largely of 
methadone maintenance patients and current illicit heroin users, as well as 
participants receiving prescribed buprenorphine, dihydrocodeine, diamorphine and 
morphine sulphate. Urine analysis showed recent use of other substances in around 
half of the opioid group. Control groups included drug free controls, drug free 
(abstinent) ex-opioid users and drug-free (abstinent) ex-amphetamine users. All 
participants were assessed using three measures of executive functioning 
(impulsivity, planning and cognitive flexibility tests) and two measures of visual 
memory. On the planning task, both the current and former drug users performed 
significantly worse than the non substance use healthy controls. Amphetamine users’ 
performance was poorer than opioid users and there was no difference between 
current and former susbtance users. Performance on cognitive flexibility (attentional 
set-shift task) was comparable for all groups. On both the tests of visual memory, 
current and former susbtance users performed at a level that was significantly poorer 
than controls.  
 
These results contradicted those of a number of previous and subsequent studies as 
it failed to find any difference between current and former heroin users. Instead 
these results supported the notion that the neuropsychological deficits observed in 
chronic opioid users were not a direct result of the opioid itself, but rather were a 
consequence of the factors associated with long-term drug abuse (Darke et al., 
2000). This is in contrast with more recent evidence which had provided evidence for 
impairments in current opioid users above and beyond those observed in abstinent 
ex-opioid addicts (e.g. Mintzer et al., 2005; Verdejo-Garcia et al., 2005a, 2005b). 
However there were a number of limitations to the Ersche et al., (2006a & 2005a) 
study, the most obvious of these being the heterogeneous nature of the opioid group 
in terms of the type of opioid used, whether opioid use was illicit or prescribed 
opioid, and whether other illicit drugs were used concurrently. In addition, the former 
amphetamine and opioid users were combined into one group for comparison, with 
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some reporting a history of previous amphetamine use or previous opioid use and 
others reporting a history of both amphetamine and opioid use. Given these 
limitation, the results of this study should be treated with caution. 
 
Ornstein et al., (2000) conducted a study which aimed to clarify the notion that there 
exists a distinct profile of neuropsychological impairment which is common to heroin 
dependent individuals. In this study, a group of participants whose primary drug of 
abuse was heroin and most also treated with methadone were compared to a group 
who primarily used amphetamine. A third group of susbstance-free participantswas 
matched to the other two groups for age and pre-morbid intellectual functioning. The 
assessment consisted of a number of subtests chosen from the CANTAB 
computerised test battery (Sahakian et al., 1988), as well as an orally administered 
test of verbal fluency. These tests included measures of visual and visuospatial 
recognition memory, spatial working memory, attentional rule-shifting, and spatial 
planning, . This study found that, relative to controls, the heroin group generated 
fewer words (but not significantly) on the verbal fluency task, and showed no 
improvement following practice trials on the test of visuospatial strategy. In addition, 
significant impairments were found in visual and visuospatial recognition memory, 
attentional set-shifting and spatial planning. These results pointed to the existence of 
a diverse pattern of neuropsychological impairment in heroin dependent individuals 
who were still using heroin.   
 
Opioid users have been reported to show impairments on delay discounting tasks, 
where there was a steeper discounting of both hypothetical and real delayed 
monetary rewards (Kirby & Petry, 2004; Bickel & Marsch, 2001). Rogers et al., 
(1999a) compared the decision making behaviour of the same sample of chronic 
amphetamine and opioid users in Ornstein’s et al., (2000) and compared to either 
healthy normal controls or a cohort with focal lesions of the orbital, dorsolateral or 
medial prefrontal cortex. The opioid users deliberated for significantly longer before 
making their decision compared to the other experimental groups who in addition 
also made suboptimal decisions. 
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Table 1.12 summarises the evidence presented in this review for an association 
between chronic and dependent opioid use and neuropsychological impairment. 
 
 
Table 1.12: Summary of previous research regarding dependent opioid use and neuropsychological 
functioning..  
Neuropsychological 
domain 
Chronic opioid dependence 
studies* 
Standardised Effect size d 
(neuropsychological test) 
Cognitive Impulsivity 
(reflection Impulsivity ) 
Clark et al (2006)↓ 0.78 (IGT) 
0.68 (BIS) 
Cognitive Impulsivity (risk 
taking) 
Rogers et al (1999a)↓ 
Ersche et al (2005a) ↔ 
0.46 (CGT) 
0.31 (CGT) 
Motor Impulsivity 
(behavioural or motor 
response inhibition) 
 
 
 
Motor Impulsivity 
(cognitive inhibition) 
  
 
Non-Planning Impulsivity  Ersche et al (2006a)↓ 
Ornstein et al (2000)↓ 
Clark et al (2006)↓ 
0.95 (TOL) 
1.18 (TOL) 
0.78 (IGT) 
 Cognitive Flexibility 
(ability to shift attentional 
set) 
Ersche et al (2006a)↔ 
Ornstein et al (2000)↓ 
0.18 (IED) 
0.55 (IED) 
 Cognitive Flexibility 
(verbal fluency) 
Ornstein et al (2000)↓ 0.55 (VFT) 
Sustained Attention   
Short Term  Memory Ersche et al (2006a)↓ 
Ornstein et al (2000)↓ 
0.89 (PAL) & 0.64 (PRM) 
0.87 (SRM) & 0.53 (SWM) 
Long Term Memory Ersche et al (2006a)↓ 
Ornstein et al (2000)↓ 
0.98 (PRM) 
0.80 (PRM) 
*= p<0.05; ↔= no sig. difference in neuropsychological performance; ↓= sig. neuropsychological 
deficits present; ↑= sig.improvement in neuropsychological performance when compared to healthy 
controls, d= Cohen’s effect size defined as the differrence between two means divided by a standard 
deviation for the data.Standardised effect sizes are reported regardless of the statistical significance (p-
value) of the results reported in the original studies. 
IGT= Iowa Gambling Task, BIS= Barrets Impulsivity Scale, VFT= Verbal Fluency Test, CANTAB: 
DMS=Delayed Matching to Sample Test, PAL= Paired Associate Learning Task, PRM= Pattern 
Recognition Memory,  SRM= Spatial Recognition Memory, SWM= Spatial Working Memory, TOL = 
Tower of London, IED= Intra/Extra-Dimensional Set Shifting Task, CGT= Cambridge Gambling Task. 
 
Neuropsychological functioning and dependent heroin use 
Heroin (diamorphine/diacetylmorphine) is a semi-synthetic opioid which is derived 
from morphine. It is most often used medically as an analgesic or illicitly for 
recreation. Illicit heroin users will often start by ‘smoking’ this substance (burning the 
heroin and inhaling the fumes), but many will quickly progress to intravenous use. 
Injecting heroin allows it to pass quickly through the blood-brain barrier where it is 
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broken down into mono-acetylmorphine and morphine. These bind to mu-opioid 
receptors and result in intense analgesic, euphoric and anxiolytic effects (Jaffe, 1990).  
 
Research into the effects of heroin on neuropsychological functioning is notably 
scarcer than the equivalent research which examines the impact of methadone. This 
may be because those individuals who are either currently using heroin or are 
completely abstinent following prior heroin dependence are less likely to be known to 
health services or to be currently receiving treatment. As a result they tend to be a 
less accessible population. However several studies have made progress in this area.  
 
A review by Lundqvist (2005) discussed the research evidence for neuropsychological 
impairments as a result of different types of substance use. This paper concluded that 
‘There is a consensus that all drugs cause a disharmony in the neuropsychological 
network, causing a decrease in activity in areas responsible for short term memory, 
attention and executive functioning, with the possible exception of heroin’. However, 
the literature described in this section paints a different picture. Although some 
studies have failed to find any evidence for significant neuropsychological decline 
associated with heroin abuse, others have shown that individuals with current heroin 
use displayed impairments in a variety of neuropsychological domains. However the 
evidence did not support a link between the amount of heroin used and/or duration 
of heroin use and level of impairment (Prosser et al., 2006). 
 
In Stevens et al (2007) tests assessing various executive functions, memory and 
learning were administered to 25 male heroin dependent individuals and compared 
to 26 polydrug abusers abstinent for more than 3 months and another 26 non 
subtance using healthy male controls. There was significant (p<0.05) impairment in 
cognitive flexibility, working memory and sustained attention in the heroin group 
(Stevens et al., 2007). 
 
The heroin dependent group attending a chronic pain clinic in McNairy et al., (1984) 
were significantly (p<0.05) impaired in verbal learning but not in memory, cognitive 
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flexibility and sustained attention. The study suggested that the neuropsychological 
impairment could have been caused by the chronic use of opioids and compounded 
by the ‘slowed, disorganised or inappropriate responses to environmental demands 
for adaptive and stressful behaviour such as chronic pain and the iatrogenic 
prescription of opioids’. 
 
Neuropsychological functioning in abstinent former heroin dependent populations 
A number of the studies of methadone use and neuropsychological functioning 
included a control group of abstinent ex-heroin users (Mintzer et al., 2005; Prosser et 
al., 2006; Clark et al., 2006), and these have generally indicated that this group may 
be impaired in some areas relative to controls with no history of opioid use, but may 
be less impaired than current methadone users. Several further studies which 
focused on abstinent ex-heroin users contributed to the research in this area.   
 
Two studies by Verdejo-Garcia et al., (2007a; 2007b) focused on the effects of 
substance misuse on executive functions. Specifically, these studies set out to 
examine executive function in abstinent polysubstance users whose primary 
addiction was heroin and in those whose primary addiction was cocaine. A third 
group of healthy, substance free controls was also included in the study. All 
participants in the heroin and cocaine groups had been abstinent for a minimum of 
two weeks and none of the participants in any of the three groups had a history of 
mood disorder, head injury or neurological disorder. The results showed that the 
heroin polysubstance users displayed significant (p<0.05) impairment in motor 
impulsivity, cognitive impulsivity and cognitive flexibility relative to controls. 
  
Fishbein et al., (2007) contrasted the cognitive performance of four groups of 
participants; pure users of heroin, co-users of heroin and alcohol, pure alcohol users 
and non users, on measures of visual memory and different components of executive 
functions including, non-planning impulsivity, cognitive flexibility and cognitive 
impulsivity. Substance users were evaluated after three weeks of abstinence. The 
data suggested that heroin users had significant (p<0.05) impaired performance on 
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cognitive impulsivity and cognitive flexibility taking more risk even though they had 
more time to make a decision. However performance on visual memory and problem 
solving tasks (non-planning impulsivity) by heroin users did better than the other two 
cohorts suggesting that these tasks were more closely linked to chronic alcohol rather 
than heroin use. 
 
The results of this study therefore lended further support to the idea that long term 
heroin use cause deficits in at least some areas of executive functioning. However, 
because the participants included in this study were polysubstance users, it was 
difficult to attribute the neuropsychological impairments which were highlighted to 
the effects of one substance alone. It is a clinical fact that many heroin users will 
concurrently use a number of other substances either consistently or occasionally. 
This may be for a number of reasons, such as an inability to afford or obtain their 
drug of choice, an attempt to attenuate or alter the effect of one drug with the use of 
another, or because of co-existing dependencies. This prevalence of polysubstance 
misuse can make it difficult to identify a group of heroin users for the purposes of 
research. However it could be argued that including poly-substance users in this type 
of research will provide results which can be more easily generalised to the substance 
using population (Brand et al., 2008).  
 
A similar study by the same author (Fishbein et al., 2005a) observed similar 
impairments in decision making with a group of heroin users who have been 
abstinent for more than 12 weeks. This heroin group selected significantly more risky 
choices particularly riskiest scenarios despite repeated penalties incurred (i.e. they 
were less likely to employ a more cautious strategy in response to improbable 
options). The group’s choice did not appear to be due to motor impulsivity since they 
had ample time to think about their next move and could have been a willingness to 
accept the likelihood of negative consequences even in unfavourable circumstances. 
Such significant (p<0.05) reduced cognitive impulsivity in heroin dependent 
individuals was suggested as a cognitive marker of substance dependence that does 
not recover with prolonged abstinence (Clark et al., 2006). 
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In Brand et al., (2008) eighteen inpatients from an addiction unit were tested after a 
two week opioid detoxification period from heroin. These opioid dependent 
individuals significantly (p<0.05) chose the risky alternatives more frequently than the 
control group and had struggled to shift from one perceptual set to another but 
performing no different in non-planning impulsivity and problem solving from the 
healthy non substance user control group.   
 
Although the research in this area was limited, it seemed to point to a general 
improvement in at least some areas of neuropsychological functioning following at 
least after two week abstinence from heroin use. This suggested that some of the 
deficits observed in the active opioid users were either transient effects from the 
acute intoxication of the drug itself or that the residual impairments may be (a) 
permanent and a direct result of chronic opioid abuse and/or (b) factors associated 
with opioid abuse, and/or (c) if deficits are present they may resolve with sustained 
abstinence. It is therfore important to test, if there is an effect in neuropsychological 
performance, the same individuals prospectively at different stages of duration of 
abstinence. 
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Table 1.13: Summary of previous research regarding dependent heroin use and 
neuropsychological functioning.  
Neuropsychological 
domain 
Illicit chronic 
heroin use * 
Standardised 
effect size d 
(neuropsycho
logical test) 
Abstinent ex-heroin use* Standardised 
effect size d 
(neuropsycho
logical test) 
Chronic 
opioid 
dependence* 
Cognitive 
Impulsivity 
(reflection 
Impulsivity) 
  Mintzer et al (2005)↓ 
Verdejo-Garcia et al (2007 
a)↓ 
0.30 (IGT) 
0.54 (IGT) 
 
Clark et al 
(2006)↓ 
Cognitive 
Impulsivity (risk 
taking) 
Ersche et al 
(2005a)↔ 
0.31 (CGT) Fishbein et al (2007a)↓ 
Fishbein et al (2005a)↓ 
Clark et al (2006)↓ 
0.38 (RDMT) 
1.00 (RDMT) 
0.68 (BIS) 
Rogers et al 
(1999a)↓ 
Ersche et al 
(2005a) ↔ 
Motor Impulsivity 
(Behavioural 
response 
inhibition) 
 n/c Verdejo-Garcia et al 
(2007a)↔ 
Verdejo-Garcia et al 
(2007b)↓ 
0.66 
(Go-NoGo) 
0.87  
(Go-NoGo) 
 
 
Motor Impulsivity 
(cognitive 
Inhibition) 
     
Non-Planning 
Impulsivity 
 
 
 Fishbein et al (2007)↔ 
Brand et al (2008)↔ 
1.05 (SOC) 
0.19 (TOH) 
Ersche et al 
(2006a)↓ 
Ornstein et al 
(2000)↓ 
Cognitive Flexibility 
(ability to shift 
attentional set) 
Hill & Mikhael 
(1979)↓ 
Stevens et al 
(2007)↓ 
McNairy et al 
(1984)↔ 
0.44 (CT)  
 
0.40 (TMT) 
 
0.18 (TMT) 
Verdejo-Garcia et al 
(2007a)↓ 
Fishbein et al (2007a)↓ 
Brand et al (2008)↓ 
0.67 (ST) & 
0.29 (WCST) 
0.27 (ST) 
1.42 (MCST) 
Ersche et al 
(2006a)↓ 
Ornstein et al 
(2000)↓ 
Cognitive Flexibility 
(verbal fluency) 
 
 
 Prosser et al (2006)↔ 
Verdejo-Garcia et al 
(2007a)↓ 
Brand et al (2008)↔ 
0.33(COWAT) 
0.82 (FAS) & 
1.10 (RFFT) 
0.52 (FAS) 
Ornstein et al 
(2000)↓ 
Sustained 
Attention 
McNairy et al 
(1984)↔ 
Stevens et al 
(2007)↓ 
0.20 (WAIS II) 
 
0.32 (SRTT) 
Verdejo-Garcia et al 
(2007a)↓ 
Mintzer et al (2005)↓ 
0.34 (5DT) 
 
0.52 (DSST) 
 
Short Term 
Memory 
 
McNairy et al 
(1984)↔ 
Stevens et al 
(2007)↔ 
0.21 (AVLT) 
 
0.39 (DMS) 
Verdejo-Garcia et al 
(2007a)↓ 
Fishbein et al (2007a)↔ 
0.81 (CBT) 
 
0.59 (PAL) 
Ersche et al 
(2006a)↓ 
Ornstein et al 
(2000)↔ 
Long Term Memory Stevens et al 
(2007)↔ 
 
0.22 (WMSR)   Ersche et al 
(2006a)↓ 
Ornstein et al 
(2000)↔ 
*= p<0.05; ↔= no difference in neuropsychological performance; ↓= neuropsychological deficits present; ↑= 
improvement in neuropsychological performance when compared to healthy controls, d= Cohen’s effect size 
defined as the differrence between two means divided by a standard deviation for the data.Standardised effect 
sizes are reported regardless of the statistical significance (p-value) of the results reported in the original studies, 
n/c= controls not healthy controls or not enough information to calculate effect size. 
AVLT= Auditory Verbal Learning Test, BIS= Barrets Impulsivity Scale , CBT=Cognitive Bias Test, COWAT/FAS= 
Controlled Oral Word Association Test/Phonological Fluency Test, DSST=Digital Symbol Substitution Test, 5DT= Five 
Digit Test, Go-NoGo=Go-NoGo Test, IGT= Iowa Gambling Task, MCST=Maudlsey Card Sorting Test, ST=Stroop Test , 
TOH= Tower of Hanoi, , RFFT= Ruff Figural Fluency Test, SRTT=Seriall Reaction Time Task,WAIS II=Weschler Adult 
Intelligence Scale Second Edition, WCST= Wisconsin Card Sorting Test ,WMSR= Weschler Memory Scale Revised. 
CANTAB: DMS=Delayed Matching to Sample Test, PAL=Paired Associate Learning Task, TOL/SOC =Tower of 
London/Stockings of Cambridge, CGT/RDMT=Cambridge Gambling Task/Roger’s Decision Making Test,  
Halstead Reitan Neuropsychological Test Battery: TMT=Trail Making Test, CT=Category Test. 
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Table 1.13 summarises the evidence presented in this review for an association 
between illicit and dependent heroin use and neuropsychological impairment at two 
stages of opioid receptor occupancy (use and abstinent). Overall the literature 
suggested limited but significant deficits in attention and cognitive flexibility in the 
heroin dependent population and significant deficits in attention, impulsivity and 
cognitive flexibility in the abstinent heroin cohorts (Fernandez-Serrano et al., 2010a, 
2010b). 
 
Neuropsychological functioning and methadone use 
Lombardo et al., (1976) failed to demonstrate any difference in neuropsychological 
functioning as measured by the WAIS between participants maintained on 50mg and 
others on 80mg of methadone daily. Gordon (1970) and Gorden & Appel (1995) 
found no deterioration in the reaction time of methadone treated participants when 
compared to substance free ex-heroin users or opioid-naïve controls, even after 24 
hours of methadone abstinence. Other early studies which showed minimal 
impairments in methadone maintenance patients (Appel, 1982; Rothenberg et al., 
1977) have been criticised for using a limited range of assessment measures (Mintzer 
& Stitzer, 2002; Zacny, 1995).  
 
A review of these earlier studies by Gordon & Appel (1995) concluded that ‘there 
should be considerable confidence that maintenance on methadone at appropriate 
dosage levels, as part of treatment for heroin addiction, has little if any effect on 
ability to function in any capacity for which the maintained person is otherwise 
qualified’. However, more recent studies have in fact pointed to a wide range of 
possible neuropsychological deficits in methadone users.  
 
Darke et al., (2000) compared neuropsychological performance in methadone 
maintained individuals with opioid free controls matched for age, gender and 
education. This study examined a number of areas of neuropsychological functioning, 
including information processing, attention, short and long term verbal and non-
verbal memory and cognitive flexibility. The authors reported that despite being 
58 
 
 
 
matched to the control group in terms of their pre-morbid level of intellectual 
functioning, the methadone maintenance groups’ performance was significantly 
poorer than the control group in all domains tested. There was no significant effect of 
methadone dose on performance in any of the domains. However the authors 
pointed out that the methadone maintained group reported a significantly (p<0.05) 
higher incidence of alcohol dependence and non-fatal overdose, both of which were 
found to be independent predictors of poorer performance in each 
neuropsychological domain. The methadone maintenance group also had a 
significantly (p<0.05) higher prevalence of head injury than the control group, 
another common cause of neuropsychological impairment. This study demonstrated 
the potential difficulties in identifying neuropsychological impairment which can 
unequivocally be attributed to opioid abuse rather than to the range of conditions 
which are frequently comorbid with opioid dependency.  In addition, the results of 
this study are limited by the fact that the methadone maintenance group reported a 
high incidence of other substance use, and recent illicit substance use was not 
objectively verified using urine analysis. The authors suggested that the 
neuropsychological impairments seen in opioid users are likely to be a consequence 
of factors associated with substance abuse lifestyle, rather than the direct effects of 
the opioids or other substance.  
 
In the same year, a study by Specka et al., (2000) also compared methadone 
maintained participants with matched substance free controls on a number of 
measures of neuropsychological functions relevant specifically to driving ability. The 
methadone maintained group in this study demonstrated significant (p<0.05) 
impairments in attention and tachistoscopic perception, they were faster but less 
accurate on a response time task (motor impulsivity deficits), and they were more 
accurate than controls but slower on a visual tracking test (reduced reaction time). 
Although this study had implications in further understanding the association 
between methadone and neuropsychological skills relative to driving, it was limited 
by the fact that participants who tested positive for other substances in their urine 
were not excluded.  
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In 2004, Rotheram-Fuller et al. compared methadone maintained patients with 
substance free controls matched for pre-morbid intellectual functioning on cognitive 
impulsivity (risk taking) and cognitive flexibility (perseveration). In addition, the 
authors divided both groups into smokers and non-smokers in order to determine 
whether smoking had any impact on performance of these tasks. This study showed 
that the methadone maintained group who smoked displayed significant (p<0.05) 
impairments in cognitive impulsivity relative to controls and the non-smoking 
methadone maintained group. There were no differences between groups in 
cognitive flexibility. These results suggest that in addition to the numerous other risk 
factors for neuropsychological impairment associated with substance use, smoking 
may be related to impairment in cognitive impulsivity, and possibly in other 
neuropsychological domains.  
 
Research conducted by Mintzer & Stitzer (2002), provided evidence for the presence 
of impaired neuropsychological functioning as a result of methadone maintenance 
therapy. Their initial study in 2002 compared the performance of a group of 
methadone maintained participants with matched drug-free controls across a range 
of neuropsychological domains. Urine testing prior to assessment provided objective 
evidence of recent abstinence from other substances. The authors suggested that the 
methadone maintenance group showed significant (p<0.05) impairments relative to 
controls in the areas of psychomotor speed, short term memory, and cognitive 
flexibility.   
 
In 2005, Mintzer et al. developed their earlier study by comparing the results of a 
new group of opioid free ex-heroin users on the same battery of neuropsychological 
tests retrospectively with their initial two groups. The new group was matched to the 
earlier two groups demographically, and matched to the methadone maintenance 
group in terms of history of substance use. The authors found that in general the new 
group’s scores fell between that of the methadone maintenance group and the 
controls on most tests, although they only performed significantly better than the 
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methadone group on a test of cognitive flexibility, and significantly below the control 
group on the task of psychomotor speed. The results of this study lended further 
support to the notion that the significant (p<0.05) impairments seen in methadone 
maintained patients may be related to the direct effects of opioids rather than factors 
other than those associated with substance abuse (e.g. history of head injury 
overdose etc), as it suggested that some recovery of function may occur with 
detoxification from all opioids.  
 
In a similar study, Prosser et al., (2006) compared methadone maintained ex-heroin 
dependent group with a group of abstinent heroin dependent group who had been 
detoxified from methadone. Both groups were matched for substance using history. A 
group of healthy non substance using controls was also included in this study. The 
authors hypothesised that abstinent heroin dependent individuals should perform 
better than methadone maintened participants on tests of various 
neuropsychological skills. However, the results of this study showed that both 
methadone maintenance and abstinent heroin dependent groups performed 
significantly (p<0.05) worse than controls but, at a similar level to one another, on 
attention and cognitive flexibility (perseveration). The only significant difference 
between methadone maintenance and abstinent heroin dependent groups was on a 
test of visuospatial memory, with abstinent heroin group performing more poorly. No 
effect of length or level of prior heroin use on neuropsychological functioning was 
found.  
 
Although this study is useful as it compared the effects of current methadone use 
with the possible residual effects of long-term opioid use, caution should be used in 
comparing the results of the two heroin dependent groups with the non substance 
using healthy control group. This is because both the former groups had fewer years 
of formal education than controls, and their scores on a test of verbal functioning was 
lower than the controls. As the authors explained, this measure is often used as an 
estimate of an individual’s pre-morbid level of intellectual functioning, suggesting 
that the two heroin groups had lower levels of pre-morbid intellectual functioning 
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than the control group. If this is the case, then it would be expected that their 
performance on other measures of neuropsychological functioning would also be 
lower, consistent with their estimated pre-morbid level of functioning. It therefore 
does not make sense to compare the two ex-heroin user groups with the control 
group in terms of test performance in order to identify impairments in the former 
two groups.  
 
As the authors did not provide actual scores, it was unclear whether the two heroin 
dependent groups’ performances were lower than would be predicted by their 
estimated pre-morbid intellectual functioning or at a similar level. This highlights the 
importance of matching controls to experimental participants in terms of estimated 
pre-morbid level of functioning if meaningful between-group comparisons are to be 
made.  
 
Finally Passetti et al., (2008) tested thirty seven opioid dependent heroin users six 
weeks after starting a community methadone treatment programme and 
subsequently followed up three months after. They were tested on measures of non-
planning impulsivity, motor impulsivity and cognitive impulsivity (risk taking). Three 
months after initiation of methadone treatment, ten individuals had become 
abstinent for heroin while another twenty four were taking at least heroin on a 
weekly basis on top of their methadone medication. The study stated that 
performance on cognitive impulsivity (Cambridge Gambling Task and Iowa Gambling 
Task) at baseline could predict clinical outcome.There were no significant deficits 
observed in strategic planning and motor impulsivity. 
 
Table 1.14 summarises the evidence presented in this review for an association 
between illicit methadone use and neuropsychological impairment. 
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Table 1.14: Summary of previous research regarding methadone use and 
neuropsychological functioning.  
 
*= p<0.05; ↔= no difference in neuropsychological performance; ↓= neuropsychological deficits present; ↑= 
improvement inneuropsychological performance when compared to healthy controls, d= Cohen’s effect size 
defined as the differrence between two means divided by a standard deviation for the data.Standardised effect 
sizes are reported regardless of the statistical significance (p-value) of the results reported in the original studies., 
n/c= controls not healthy controls or not enough information to calculate effect size. 
AVLT= Auditory Verbal Learning Test, BVRT= Benton Visual Retention Test, COWAT/FAS= Controlled Oral Word 
Association Test/Phonological Fluency Test, DSST=Digital Symbol Substitution Test ,IGT= Iowa Gambling Task, , 
RCFT=Rey Osterreith Complex Figure Test, RWT= Regensburger Word Fluency Test, ST=Stroop Test,  2BT= Two Back 
Task, WAIS II=Weschler Adult Intelligence Scale Second Edition, WCST= Wisconsin Card Sorting Test ,WMSR= 
Weschler Memory Scale Revised,CANTAB: TOL = Tower of London,Halstead Reitan Neuropsychological Test 
Battery: TMT= Trail Making Test, Act React Test Systems (ART 90/2020): DR2=Simple Choice Reaction, Q1= 
Attention under Monotonous Circumstances. 
Neuropsychological 
domain 
Methadone use * Cohen’s d 
(neuropsychological 
test) 
Chronic opioid 
dependent use * 
Cognitive Impulsivity 
(reflection Impulsivity 
) 
Pirastu et al (2006)↓ 
Rotheram-Fuller et al (2004)↓ 
 
3.02 (IGT) 
0.89 (IGT) 
Clark et al (2006)↓ 
Cognitive Impulsivity 
(risk taking) 
Passetti et al (2008)↓ n/c Rogers et al (1999a)↓ 
Ersche et al (2005a) ↔ 
Motor Impulsivity 
(Behavioural  
response inhibition) 
 
Passetti et al (2008)↔ 
Specka et al (2000) ↓ 
 
 
n/c 
0.78 
 
 
Motor Impulsivity 
(Cognitive Inhibition) 
Prosser et al (2008)↔ 
 
  
Non-Planning 
Impulsivity  
Passetti et al (2008)↔ 
 
0.98 (TOL) Ersche et al (2006a)↓ 
Ornstein et al (2000)↓ 
Cognitive Flexibility 
(perseveration and 
attentional set 
shifting) 
 
Darke et al (2000)↓ 
Mintzer et al (2005)↓ 
Rotheram-Fuller et al 
(2004)↔ 
Pirastu et al (2006)↓ 
Prosser et al (2006)↓ 
 
Soyka et al (2008)↓ 
0.65 (WCST) 
0.87 (TMT) 
0.61 (WCST) 
 
7.27 (WCST) 
0.65 (ST) 
0.81 (TMT) 
 
Ersche et al (2006a)↓ 
Ornstein et al (2000)↓ 
Cognitive Flexibility 
(verbal fluency) 
Darke et al (2000)↓ 
Soyka et al (2008)↓ 
Prosser et al (2006)↔ 
0.57 (COWAT) 
0.54 (RWT) 
0.20 (COWAT) 
Ornstein et al (2000)↓ 
Sustained Attention Darke et al (2000)↓ 
Specka et al (2000)↓ 
Mintzer et al (2005)↓ 
 
Soyka et al (2008)↓ 
0.76 (WAIS II) 
0.45 (DR2)& 0.64 (Q1) 
1.00 (DSST) 
 
0.77 (DR2)  
 
Short Term Memory 
 
Darke et al (2000)↓ 
 
Mintzer et al (2005)↓ 
Prosser et al (2006)↓ 
Pirastu et al (2006)↓ 
Soyka et al (2008)↓ 
0.80 (WMSR) & 0.55 
(RCFT) 
0.70 (2BT) 
0.97 (BVRT) 
7.82 (BVRT) 
0.83 (AVLT) 
Ersche et al (2006a)↓ 
Ornstein et al 
(2000)↔ 
Long Term Memory Darke et al (2000)↓ 
 
1.40 (WMSR) Ersche et al (2006a)↓ 
Ornstein et al 
(2000)↔ 
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From the range of studies that have examined the impact of methadone on 
neuropsychological functioning there seems to be an evidence base describing 
impairment in methadone users in a number of neuropsychological domains. There is 
conflicting evidence regarding the possible impact of the dose of methadone on level 
of impairment with some research pointing to no effect of dose on performance, and 
some research reporting a dose related impact on the specific domains of delayed 
verbal memory and reaction time. Furthermore, other studies suggested that some 
recovery of functioning takes places with time in methadone maintained ex-heroin 
users. Finally, those studies which have compared methadone users with abstinent 
ex-heroin dependent and substance free healthy controls have indicated that the 
abstinent ex-heroin dependent group performed at a superior level to methadone 
users but below the level of substance free and healthy controls.  
 
This suggested that the neuropsychological deficits observed in opioid users may be 
subject to at least partial recovery with total withdrawal from opioids.. However, 
interpretation of these results must be be done with caution, as there were a number 
of possible causes of neuropsychological dysfunction at work in this population. 
These include the effects of the drug itself, as well as the effects of any other illicit or 
prescribed substances, alcohol abuse, the effects of previous head injury, overdose, 
psychiatric disorders or psychological distress. Unfortunately each confounding 
variable mentioned is prolific in the opioid dependent population. It is therefore likely 
that factors other than the direct effects of methadone account for at least some of 
the wide range of deficits observed in the research literature.  
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Neuropsychological functioning and use of other opioids. 
Buprenorphine 
Buprenorphine is a partial mu-receptor agonist and kappa receptor antagonist which 
has increasingly been used as an alternative to methadone in the treatment of opiate 
dependency (British National Formulary 55, 2008).  
 
Soyka et al., (2008) assessed the neuropsychological functioning after at least two 
weeks of stable substitution treatment with buprenorphine or methadone and then 
followed up using a repeated cognitive assessment after 8-10 weeks of stable 
substitution treatment. In their study, the neuropsychological battery measured 
attention, reaction time, verbal memory, and cognitive flexibility. Participants in both 
treatment modalities performed equally well at baseline in all neuropsychological 
domains compared to the substance free healthy control group. At follow up however 
there was significant (p<0.05) impairment in both experimental groups in cognitive 
flexibility and memory when compared to the healthy control group. 
 
In 2006, Pirastu et al. published a study which compared a group of methadone 
maintained and another group of buprenorphine treated opioid dependent 
individuals after twelve months of treatment, with a group of substance free healthy 
controls. Each of the three groups included in this study were assessed using tests of 
cognitive flexibility, cognitive impulsivity, and verbal memory, with the aim of 
identifying any differences in the neuropsychological profiles of patients receiving 
methadone versus patients receiving buprenorphine. Participants were excluded if 
they had any other major risk factors for neuropsychological impairment, such as 
DSM-IV diagnoses of psychiatric disorder(s) (other than substance misuse disorder), 
serious head injury, neurological disease, psychosis, HIV, epilepsy or primary 
neuropsychological deficit. The results of their study showed that the buprenorphine 
group performed significantly better than those participants maintained on 
methadone and the control group in the cognitive impulsivity tasks. But both the 
methadone and buprenorphine groups struggled markedly on tasks measuring 
cognitive flexibility and memory when compared to the control groups.  
65 
 
 
 
 
Schindler et al., (2004) assessed the influence of fifteen months of either methadone 
or buprenorphine maintenance treatment on the driving abilities of opioid dependent 
individuals. Using the ART 2020 Standard Test (Bukasa et al., 1997) both 
experimental groups showed significant (p<0.05) impairment in Attention under 
Monotonous Circumastances Test (ACT) when compared with healthy controls. The 
authors postulated that this could be as a result of both experimental groups making 
errors to complete the task quicker, at the expense of accuracy. There were no 
significant differences in non-planning impulsivity, cognitive flexibility and motor 
impulsivity in the two groups when compared with non substance using healthy 
control group. 
 
Morphine 
In a long-term prospective study, Tassain et al., (2003) evaluated the 
neuropsychological impact of oral sustained release morphine in participants with 
chronic non malignant pain. A battery of neuropsychological tests to explore 
attention, psychomotor speed, cognitive flexibility (verbal fluency) and memory was 
administered. The effects of morphine on pain, quality of life, mood, and side-effects 
were also investigated. Evaluations were performed at baseline to participants free 
from opioids and then followed up after 3, 6 and 12 months. Twenty-eight patients 
were included. Eighteen received oral sustained morphine (range 40–140 mg/day), 
ten patients stopped morphine prematurely because of side-effects or insufficient 
pain relief and were followed as a control group.  
 
There was no impairment of any neuropsychological variable over time in the 
morphine treated group in comparison with the control. Measures of cognitive 
flexibility (Stroop Test) and information processing speed (Digit Symbol Test) 
improved at 6 and 12 months with significant (p<0.05) correlations with the pain 
relief and improvement of mood. The authors concluded that this study 
demonstrated that twelve months treatment with oral morphine does not disrupt 
cognitive functioning in patients with chronic non-maligant pain and instead results in 
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moderate improvement of some aspects of cognitive functioning. The authors 
continue by concluding that any neuropsychological imporvement present was more 
a consequence of the pain relief and concomitant improvement of well-being and 
mood. 
 
Vainio et al., (1995) studied twenty four chronic morphine (mean dose of 209 mg 
daily) participants treated for chronic malignant pain. This cohort did not experience 
impairment in intelligence, motor impulsivity, cognitive flexibility (verbal fluency) and 
attention.  The control group was an equal number of participants with malignancy 
who did not require opioid analgesia. Therefore this study was not tested with a 
substance free or healthy control group. 
 
Combination of opioids (morphine, tramadol, fentanyl, oxycodone, buprenorphine 
and/or methadone) 
Sjogren et al., (2005) investigated the influence of pain, sedation, pain medication 
and sociodemographic characteristics on cognitive functioning of nineteen 
participants with chronic non-malignant pain prescribed morphine, tramadol, 
buprenorphine and/or methadone compared to sixty four healthy controls. The 
opioid medicated individuals identified significant (p<0.05) deficits in motor 
impulsivity but not in memory. The authors suggested that impaired sustained 
attention and reduced psychomotor speed in this cohort could be a consequence of 
high pain scores in the cohort group. 
 
Jamison et al., (2003) investigated the psychomotor effects of long-term opioid use in 
144 patients with chronic non-malignant low back pain. All participants were 
administered the Digit Symbol and Trail Making Test-B before being prescribed 
opioids for pain. Tests were re-administered at 90-day and 180-day intervals. Test 
scores significantly (p<0.05) improved while participants were taking opioids for pain, 
which suggested that long-term opioids do not significantly impair cognitive ability or 
psychomotor function.Between 16% and 25% of these participants demonstrated 
declining performance on the individual neuropsychological tests while on opioids.In 
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general, those who were older and had lower pain intensity scores at their first 
measurement were most predisposed to poor test scores. Some participants’ scores 
may also have changed due to situational or chance factors, variability in test 
administration, or concomitant treatments unrelated to opioid use or patient 
characteristics. The authors speculated why psychomotor performance would 
improve in those patients with high pain intensity. The impaired cognition in this 
study group compared with published standardised neuropsychological test results 
may be attributable to chronic pain conditions and is consistent with other findings of 
neuropsychological impairment in those with chronic pain (Lorenz et al., 1997; 
Sjogren et al., 2000a, 2000b; Vainio et al., 1995; Crombez et al., 1996). 
 
Given that high pain intensity at baseline was most predictive of improvement on 
neuropsychological tests, it can be inferred that improvement in performance in this 
population was attributable to the ameliorating effects of opioids on pain rather than 
properties of the opioids per se. This was supported by the overall decrease in 
average pain intensity scores and SF-36 bodily pain scores between baseline and 
follow-up. 
 
A number of limitations of this study deserve mention. Firstly, testing was performed 
in multiple sites by researchers who were not licensed psychological examiners. Thus, 
despite the fact that each examiner was given specific instruction on how to 
administer the tests and had to perform five practice test protocols, the reliability of 
the examiner technique was not established. Secondly, the practice effect of test 
taking for patients may account for some improvement in scores. The literature 
suggests that a 5% improvement is possible after a 3-week interval, (Lezak, 1995).  
Although this effect cannot be ruled out most participants, however, showed a better 
than 5% improvement on their scores. Thirdly, this study did not include a control 
group of patients who were not taking opioids. We do not know whether such a 
group followed for 6 months would also show improvement. Fourthly, approximately 
30% of the participants were not followed for the full 180 days. Although no 
differences were found between those patients who completed the study and those 
who did not, it is possible that the dropouts may have biased the results. Finally, the 
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patients in this study were not opioid naıve. They may have accommodated less to 
the opioids and shown more cognitive impairment had they been given opioids for 
the first time. 
 
Table 1.15 summarises the evidence presented in this review for an association 
between other opioid use and neuropsychological functioning 
 
Table 1.15: Summary of previous research regarding other opioid (buprenorphine, morphine, 
oxycodone and tramadol) use and neuropsychological functioning.  
 
*= p<0.05; ↔= no difference in neuropsychological performance; ↓=neuropsychological deficits present; ↑= 
improvement in neuropsychological performance when compared to healthy controls, d=Cohen’s effect size 
defined as the differrence between two means divided by a standard deviation for the data.Standardised effect 
sizes are reported regardless of the statistical significance (p-value) of the results reported in the original studies, 
n/c= controls not healthy controls or not enough information to calculate effect size. 
AVLT=Auditory Verbal Learning Test, BVRT=Benton Visual Retention Test, IGT=Iowa Gambling Task, PASAT=Paced 
Auditory Serial Addition Task, RWT=Regensburger Word Fluency Test, WCST=Wisconsin Card Sorting Test, Halstead 
Reitan Neuropsychological Test Battery: TMT=Trail Making Test, Act React Test Systems (ART 90/2020): 
DR2=Simple Choice Reaction, Q1=Attention under Monotonous Circumstances.  
Neuropsychological 
domain 
Other opioid use * Standardised effect 
size d  
Chronic opioid dependent use * 
Cognitive Impulsivity 
reflection impulsivity 
Pirastu et al (2006)↑ 1.94 (IGT) Clark et al (2006)↓ 
Cognitive Impulsivity 
(risk taking) 
  Rogers et al (1999a)↓ 
Ersche et al (2005a) ↔ 
Motor Impulsivity 
(Behavioural or motor 
response inhibition) 
Sjogren et al (2005)↓ 
Vainio et al (1995)↔ 
Schindler et al (2004)↔ 
n/c 
n/c 
n/c 
 
 
Motor Impulsivity 
(cognitive inhibition) 
   
Non-Planning 
Impulsivity  
Vainio et al (1995)↔ 
Schindler et al (2004)↔ 
n/c 
n/c 
Ersche et al (2006a)↓ 
Ornstein et al (2000)↓ 
Cognitive Flexibility  
(perseveration and 
attentional set 
shifting) 
 
Pirastu et al (2006)↓ 
Soyka et al (2008)↓ 
Jamieson et al (2003)↑ 
Tassain et al (2003)↔ 
Schindler et al (2004)↔ 
5.10 (WCST) 
0.78 (TMT) 
n/c 
n/c 
n/c 
Ersche et al (2006a)↓ 
Ornstein et al (2000)↓ 
Cognitive Flexibility 
(verbal fluency) 
Soyka et al (2008)↓ 0.52 (RWT) Ornstein et al (2000)↓ 
Sustained Attention Soyka et al (2008)↓ 
Sjogren et al (2005)↓ 
Jamieson et al (2003)↔ 
Tassain et al (2003)↔ 
Vainio et al (1995)↔ 
Schindler et al (2004)↓ 
0.93 (D2) 
0.36 (PASAT) 
n/c 
n/c 
n/c 
0.57 (D2) & 0.66 
(Q1) 
 
Short Term  Memory 
 
Pirastu et al (2006)↓ 
Soyka et al (2008)↓ 
Tassain et al (2003)↔ 
6.16 (BVRT) 
3.91 (AVLT) 
n/c 
Ersche et al (2006a)↓ 
Ornstein et al (2000)↔ 
Long Term Memory Tassain et al (2003)↔ n/c Ersche et al (2006a)↓ 
Ornstein et al (2000)↔ 
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Methodological issues related with the study of the neuropsychological correlates 
of chronic opioid use, abuse and dependence 
 
This systematic review exploring the neuropsychological impairments associated with 
the chronic use of opioids highlights the need to ensure rigorous control over a 
number of methodological variables that may affect the reliability, validity and clinical 
relevance of the results obtained.  
 
The lack of sufficient methodological rigour could be partly responsible for the lack of 
consistency in the results of different studies and the marked interindividual and 
temporal variability noted in the available literature in the field. Both the large 
number of variables that must be controlled, as well as the difficulties involved in 
their control in this type of population, present great obstacles that are difficult to 
surmount in the context of clinical research. In spite of the difficulties, the detection 
of neuropsychological impairments closely associated with substance abuse requires 
extreme methodological rigour and the control of the variables that have most often 
been associated with the discrepancies in results characteristic of research in this 
field (Verdejo-Garcia et al., 2004). Among the variables that must be considered 
would be context, study population, substance misuse and dependence, data 
gathering and analysis. 
  
Context 
Considerable confusion and misleading information has arisen from many studies 
because of loose definitions of the terms chronicity, neuropsychology and opioids.  
Confusion has also arisen because many research groups, for example, only vaguely 
describe specific diagnostic algorithms and the degree to which they consider 
diagnostic exclusion rules. This is relevant whether none, some or all of the diagnostic 
exclusions and hierarchies have been considered.  Complex sets of symptom, 
syndrome, and diagnostic exclusions (as employed by DSM-III-R, DSM-IV, ICD-9 and  
ICD-10) might all affect the result as well as their interpretation (Wittchen, 1996). 
 
70 
 
 
 
Further problems with defining the populations is that historically mental health, 
psychology and substance misuse services have evolved in their own way, using 
different language and models to inform their service policies and objectives (Todd et 
al., 2004).   
 
The method(s) of assessment and diagnosis may change within a country or scientific 
community. The settings where studies take place differ and even, if apparently 
similar, may not be so.  Studies in one region or location may not reflect the situation 
in another, especially in the international context.   
 
For studies looking at treatment seeking opioid populations it is necessary to 
distinguish between general psychiatric, pain and addiction services.  For example, in 
general psychiatric services, alcohol and cannabis are more likely to be encountered 
as the comorbid dimension, whereas in pain and addiction services depressive, 
anxiety and personality disorders are going to be the additional problems most 
commonly reported together with opioids and cannabis being the main substance 
use.  
 
The population studied 
Recruitment 
Recruitment related methodological problems depend largely on the type of 
substance abused by the target population and an important challenge in sampling is 
that of tracking the so-called ‘hidden’ population (Heckathorn, 1997, Heckathorn, 
2002). For example, dihydrocodeine abuse has been traditionally restricted to private 
and erratic consumption patterns within a gainfully occupied population that rarely 
generate admission to treatment centres (Shewan & Dalgarno, 2005).  
 
Therefore, studies tend to use the ‘snowball technique’, originally described by 
Solowij et al., (1992), in which subjects agreeing to participate in the study contact 
other acquaintances who are asked to contact other users (Fox et al., 2002; Morgan 
et al., 2001).  
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However, some other strategies have been described to recruit this population, 
including advertisements over the internet, in local newspapers and music magazines 
(McKetin & Mattick, 1998; Thomasius et al., 2003), flyers and posters in the areas 
surrounding schools and universities (Morgan, 1999; Simon & Mattick, 2002), 
through word of mouth, or directly ‘in vivo’ on the rave scene (Gouzoulis-Mayfrank 
et al., 2003). These tracking procedures introduce a methodological bias, because the 
subjects recruited may not be representative of the whole population of ecstasy 
(MDMA) users. 
 
In contrast, opioid and cocaine users are often recruited as they join inpatient or 
outpatient treatment programmes (Ornstein et al., 2000; Van Gorp et al., 1999), or 
among the incarcerated population (Selby & Azrin, 1998).  
 
Therefore, an opposite (Berkson) bias emerges, because most of the studies are 
unable to access those users who are not in treatment (Berkson, 1946). Furthermore, 
opioid treatment programmes may include agonist maintenance treatment with 
methadone and buprenorphine, introducing additional confounding factors in the 
detection of possible long-term effects of opioid abuse. 
 
Therefore, different recruitment strategies would be advisable, with special emphasis 
on accessing the ‘hidden’ population of abusers to help obtain a more representative 
population. 
 
Sample size 
Another frequent methodological problem is that of sample size. Participants need to 
be matched on a series of variables (duration of abstinence, chronicity and severity of 
use, type of substances used), which are sometimes very difficult to control if strict 
methodological rigour is not observed (Del Boca & Darkes, 2007).  
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Probably for these reasons the majority of the studies that attempted to relate 
chronic opioid use with significant neuropsychological impairments have used small 
samples. 
 
The main problem associated with using small sample sizes is the low 
representativity. Sample size is closely interrelated with methodological problems as 
a result of weak statistical power. The statistical power of a study depends on three 
variables: the level of significance established for the alpha level (or p value), the 
sample size, and the size of the effect that must be detected (Zakzanis, 2001).  
 
A reduced sample size can be appropriate for detecting an average effect, but 
inappropriate for capturing small effects. Therefore, if the effects detected in the 
study of the neuropsychological correlates of chronic opioid use are of a medium size, 
small samples may be enough to capture them. But if, on the other hand, what we 
are looking for are small effects, the sample sizes that have been used would be 
inappropriate for their verification. 
 
Up until now, there have been very few studies in the field that have incorporated 
estimations of the size of the effect. Among those that have such as Verdejo-Garcia 
et al., (2007a), Brand et al., (2008) and Fishbein et al., (2007) used Cohen’s arbitrary 
method of differentiating low, medium and strong effect size (Cohen, 1977). The 
systematic review in this chapter calculated the effect sizes of most identified studies 
showing a broad range of variation. Overall there has been a medium effect size (at 
least 0.45) in methadone and opioid studies but not in the heroin studies which had 
an overall low effect size (Fernandez-Serrano et al., 2011). 
 
However, Bezeau & Graves, (2001) considered that this effect size is probably too 
small to be applied to research in clinical neuropsychology. These authors considered 
that, to assume the clinical usefulness of the study, it would be necessary for both 
populations (in this case, opioid users or dependent and controls) to be separated by 
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at least 0.80 typical deviations in the variable measured (Verdejo-Garcia et al., 2004; 
Fernandez-Serrano et al., 2011). 
 
Substance misuse and dependence 
Effects of polysubstance use 
The majority of opioid-dependent participants are not users of only one substance, 
but rather a wide spectrum of them, so that the potentially detected 
neuropsychological impairments cannot really be attributed to the specific effect of 
the drug used. Instead, they are caused by the global effect of the group of drugs 
consumed (Rounsaville et al., 1982, Hay et al., 2007). 
 
Neuropsychological research has shown that alcohol consumption is an important 
confounding variable in the study of the neuropsychological consequences of chronic 
opioid use (Fishbein et al., 2007; Darke et al., 2000). The interpretation of the 
neuropsychological impairments identified in chronic opioid users also seem to be 
frequently complicated by the high incidence of treatments with other opioids such 
as methadone, buprenorphine, naloxone, naltrexone, and anitdepressant, sedative 
and sometimes antipsychotic medications (Ornstein et al., 2000). 
 
In general, the studies that discriminate between the cognitive impairments 
attributable to the use of one isolated substance and those that are derived from 
effects of polysubstance use have detected a greater number of impaired functions 
and an increase in the magnitude of the damage among polysubstance (including 
nicotine dependence) user participants as well as a reduced capacity to recover these 
functions (Specka et al., 2000; Passetti et al., 2008, Fernández-Serrano et al., 2011). 
However studies are too few and far between to make any conclusive remarks. 
 
Chronicity and severity of use 
The control of the chronicity and severity of the use of diverse drugs is another 
methodological challenge faced when studying the neuropsychological impairments 
associated with chronic opioid use. Some studies directly correlated both variables 
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with the magnitude of the neuropsychological deterioration in opioid users (Grant et 
al., 1978; Hill & Mikhael, 1979; Ornstein et al., 2000) whilst others have pointed out 
the lack of consistent relationships between the severity and chronicity of the use 
and the performance registered on the neuropsychological tests (Prosser et al., 
2006). 
 
This lack of consistency probably reflects the low reliability of the self-report 
measures that are usually used for control and the lack of objective measurements of 
drug taking in the opioid users. Opioid dependent participants tend to underestimate 
their own levels of use (Mensch & Kandel, 1988) so that the data provided can skew 
possible correlational analyses regarding the amount of neuropsychological 
impairment with the levels of chronicity and severity of opioid use.  
 
The option of carrying out toxicological urine analyses is not conclusive either. In spite 
of the fact that these analyses allow us to confirm the presence of a certain substance 
in the participants at a particular moment in time, these measures cannot be 
appropriate. A large quantity of information is lost about the frequency of use, the 
amount consumed, how recent the use was or the pattern the use has followed over 
a long period of time, and the results of the analyses present low correlations with 
the self-report measures (Easton & Bauer, 1996). 
 
This could be minimised either through serial analyses of drug metabolites or utilising 
newer technology such as a hair analysis which have been shown to provide more 
definitive information about patterns of use (Fraser et al., 2002). However these 
methods tend to be either not practical or prohibitively expensive. 
 
Time window (moment of evaluation) 
The moment in time of the neuropsychological evaluation is of utmost importance for 
an adequate detection of the impairments. If the evaluation takes place between 24 
and 72 hours after the use, what we may be detecting are impairments produced by 
the acute (Ersek et al., 2004; Heishman et al., 1996) or withdrawal effects of the drug 
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(Lyvers & Yakimoff, 2003; Serper et al., 2000). If evaluation takes place during the 
first three months of abstinence, impairments might be related to the residual effects 
of the drug on the participant (Ersek et al., 2004; Berry et al., 1993; O’Malley & 
Gawin, 1990).  
 
If evaluated from the third month of abstinence onwards, the neuropsychological 
impairments might be associated with lasting alterations of the central nervous 
system that might be more stable in time and that might not revert with abstinence 
(Strang & Gurling, 1989; Roselli & Ardila, 1996).  
 
It was suggested that the neuropsychological impairments resulting from substance 
use are partially reversible (Davis et al., 2002) and that this reversibility depends on 
the duration of the abstinence period (Bauer, 2001; Selby et al., 1995). 
 
This systematic review shows that abstinent heroin users experience impairment in 
performance in decision making but it is not clear the number of functions damaged, 
and the magnitude of the impairments or if it is related to the length of the 
abstinence period; (i.e. the more prolonged the abstinence, the greater the level of 
recovery of these functions might be) (Pezawas et al., 1998; Selby & Azrin, 1998).  
 
Although no cut off point has been defined from which the prolongment of the 
abstinence  is not relevant for the continuation to recover,it has been suggested that 
most of the neuropsychological recovery in substance misuse takes place during the 
first month (Goldman, 1983; Solowij et al., 1995) but that superior functions or 
abilities like abstract reasoning or problem solving take much longer to recover, and 
in many cases, might never return to their premorbid levels (Ellenberg et al., 1980; 
Gottschalk et al., 2001). There is no literature to suggest that this is the same for 
opioid users.  
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Other relevant factors 
Exposure to adulterants, prevalence of particular patterns of polysubstance abuse 
and the impact of the route of administration (e.g. injecting behaviour) all contribute 
to the uncertainties of attributing any observed impairment to chronic opioid use 
under consideration (Carlin & Trupin, 1977; Gruber et al., 2007; Lyers & Yakimoff, 
2003). 
 
One possible solution to reduce these methodological confounders is by planning an 
experimental design in which:  
(a) Control groups of pure users or polydrug users who do not use the target 
substance, are included (Verdejo-Garcia et al., 2007a)  
(b) Using non-substance using populations such as those with a diagnosis of chronic 
non- malignant pain and prescribed opioids for analgesia (Tassain et al., 2003; Vainio 
et al., 1995).  
 
Data gathering (diagnostic and screening instruments) 
Type of neuropsychological tests 
The selection of the neuropsychological tests used should take into consideration the 
type of functions there is of interest in measuring, as well, as the sensitivity of these 
tests in detecting specific impairments in these same functions (Lezak, 1995). 
 
While some studies focused on the evaluation of specific functions, mainly sustained 
attention and memory (Darke et al., 2000; Mintzer et al., 2005; Soyka et al., 2008) 
and executive functioning (Ornstein et al., 2000; Rogers et al., 1999a), others carried 
out a more exhaustive neuropsychological evaluation (Ersche et al., 2006a, 2006b; 
Fishbein et al., 2007; Verdejo-Garcia et al., 2007a). However, in this systematic 
review one finds that few studies are using the same tests, therefore making it 
difficult to compare the results, even when identical functions are being measured. 
For example in executive functioning, various authors (Bechara et al., 2000; Ornstein 
et al., 2000; Rogers et al., 1999a) have detected impairments in cognitive flexibility 
and decision making in amphetamine and opiate users by using three different 
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instruments: Iowa Gambling Task (IGT) (Bechara & Martin, 1994), the CANTAB 
Battery (Robbins et al., 1994), and the Rogers Decision-Making Task (RDMT) (Rogers 
et al., 1999a), respectively. Further research should be conducted in order to 
determine the exact relationship and significance between such tests (Monterosso et 
al., 2001). 
 
On the other hand, the ecological validity of these ‘classical’ neuropsychological tests 
(their ability to detect impairments in functions that are adaptively relevant for the 
participant in their everyday endeavors), has been questioned by various authors 
(Fals-Stewart et al., 1994; Goldberg & Podell, 2000; Sbordone & Long, 1996; 
Verdejo-Garcia et al., 2007c), when measuring performance in decision-making, 
memory and attentional functions. By using these ecologically friendly paradigms, 
studies showed that the neuropsychological function in substance users tend to 
improve (Verdejo-Garcia et al., 2007c, 2007d; Yuille et al., 1998). 
 
Beatty & Borrell (2000) showed that a group of drug users could perform better than 
a control group on a memory task in which the content of the items was adapted to 
the circumstances that characterized the lifestyle of the subjects. They suggested that 
some of the impairments detected by the ‘classical’ neuropsychological tests and 
attributed to prolonged substance use could be explained by the limited 
opportunities for knowledge acquisition imposed by their lifestyle. 
 
Finally, one needs to be careful not to assume that tests have the predictive validity 
to determine who will recover from impaired neuropsychological functions and/or 
enhance a successful recovery process (Passetti et al., 2008; Fals-Stewart et al., 
(1994). 
 
Other factors to consider include the time taken to complete the tests, the order of 
the test presentation and the practice effects if the same tests are repeated over time 
(Lowe & Rabbitt, 1998; Lezak, 1995). All these factors, if not either standardised or 
taken into account, will influence the results. 
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Other potential methodological issues include the use of battery assessments instead 
of a succession of individual tests and deciding on the pros and cons of using 
computerised neuropsychological assessments instead of pen and paper assessments 
(Levaux et al., 2007; Ellinwood & Lee, 1997). Some of these issues arise as a result of 
unstandardized presentation of stimuli and recording of responses, inefficient, 
inaccurate, lack of comparable collection of detailed data and lack of ecological 
validity between the ‘classic’ neuropsychological tests and computerised tests 
amongst others.  
 
Defining the population 
The assessment instrument used can also affect results.  For example, a comparison 
of ICD-10 and the Composite International Diagnostic Interview (CIDI) suggests that 
two or three times as many psychiatric diagnoses as the clinician would assign in 
routine diagnostic assessment are revealed by standardised instruments (Baldacchino 
& Crome, 2010).  This is particularly true for substance use disorders.  Although it is 
not clear which of the diagnoses are really valid, it can at least be assumed that the 
higher comorbidity rates of the CIDI cannot be fully explained as artefactual or invalid 
(Baldacchino & Crome, 2010).  There is some evidence that in the mid-1990s 
clinicians focused more on the current circumstances of a patient rather than the 
prior history of minor mental disorders since it was more likely to employ implicit 
hierarchies.  Since most clinicians were trained at that time in traditional nosological 
concepts and ICD-9, they were therefore more likely to include in their diagnosis 
features that might justify a separate diagnosis (Wittchen, 1996).   
 
Francis et al., (1990) suggest that semi-structured diagnostic instruments might be 
more susceptible to 'halo effect' than standardised instruments. The 'halo effect' is 
where one characteristic or quality of an individual overshadows all other attributes 
(i.e. the extension of an overall impression of one particular outstanding trait to 
influence the total judgement and assessment of that person by an observer). Kessler 
et al., (1995) demonstrated that technical modifications can significantly impact 
symptom reports as well as the accuracy of dating lifetime episodes of mental 
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disorders. Such modifications can include changes to the order in which disorders are 
assessed and the use of stem questions. 
 
When conducting diagnostic interviews, reliable and consistent information is crucial. 
The accuracy of data provided by the patient and the stability of presenting 
symptoms need to be taken into account.  In order to distinguish between 
chronologically primary and secondary disorders; age of onset, duration of symptoms  
as well as periods of remission and symptom offset are fundamental building blocks 
into which further information can be added and a fuller picture constructed.  It is 
imperative to obtain collateral detailed information from the referring agencies, case 
records and significant others.  This will lessen the distortion caused by intoxication, 
insufficient periods of abstinence on the part of participant, impaired memory, 
inconsistent answers, or deliberately falsified information.  
 
Data Analysis 
Most studies have been concerned with minimising Type 1 error by adjusting alpha 
level for multiple tests of significance (e.g. Bonferroni adjustment) (Westfall et al., 
1997). Most studies reviewed are either underpowered with no adjustment for 
attrition present (Del Boca & Darkes, 2007). Others fail to take into consideration the 
level and significance of the p value when multiple comparisions, such as using a 
family of neuropsychological tests or when multiple outcomes, are analysed 
(Ioannidis, 2005). This is further compounded by the lack of a clear hypothesis driven 
cohort experimental design (Sterne and Smith, 2001).  
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Conclusion 
Most of the data reviewed are designed as cross-sectional studies and therefore do 
not allow determination whether neuropsychological impairments observed precede 
drug use, or, if they occur as a consequence of the effects of continued opioid use. A 
growing line of evidence from human studies indicates that pre-existing executive 
dysfunction, especially in cognitive impulsivity, may predate the onset of drug use 
and constitute vulnerability markers for liability to addiction (Redish et al., 2008).  
 
Previous literature has highlighted that illicit heroin use, methadone treatment and 
chronic use of other opioids could determine neuropsychological impairment in all 
the cognitive domains when compared with healthy non- substance using control 
groups. These impairments seem to improve following abstinence from opioids for at 
least between two and four weeks or more. 
 
The previous literature has not only highlighted the current knowledge base on this 
subject but also identified methodological limitations and subsequent difficulties in 
interpretation what is essentially a heterogenous and non- comparable set of data.  
 
Nevertheless the evidence from this existing literature has helped to form the basis of 
the hypotheses which will be examined as part of the present study in the 
subsequent chapters of this thesis.  
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Chapter 2: Methods-Chronic opioid use and neuropsychological 
consequences 
 
Participants 
This study employed an ambispective cohort design testing opioid exposed 
participants (illicit and non-illicit) and healthy non-substance using controls over a 
period of 24 months. Cohorts of participants with validated histories of illicit heroin 
use (HEROIN), stabilised methadone maintenance (METHADONE), chronic opioid 
prescriptions for pain (CHRONIC PAIN) and healthy controls (HEALTHY CONTROL) 
were recruited.  
 
Heroin group (HEROIN) 
The onset of action, peak effects, and duration of action vary with the different 
administration of heroin use. Patients experience heroin's effect within one or two 
minutes when injected intravenously and within fifteen to thirty minutes when 
injected intramuscularly. Heroin's peak therapeutic and toxic effects are generally 
reached within ten minutes when injected intravenously, within thirty minutes when 
injected intramuscularly or when snorted, and within ninety minutes when injected 
subcutaneously. Analgesic effects generally last between three and five hours (Borg & 
Kreek, 1998). 
 
Intravenously injected heroin creates a ‘rush’ or a sensation of intense pleasure that 
begins within one minute of the injection. This ‘rush’ is followed by a period of 
sedation that lasts about an hour. The initial ‘rush’ is likely due to heroin's high lipid 
solubility and rapid penetration to the brain (Leri, 2003). The half-life of heroin is 
between fifteen and thirty minutes (Borg & Kreek, 1998). 
 
The presence of impurities and additives also limits heroin absorption through 
mucous membranes, thus limiting its ‘rush’ and ‘high’ when it is sniffed or snorted. It 
will also influence the neuropsychological performance of individuals taking additives 
that are neurotoxic and/or psychotropic (Schwartz, 1998). 
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During the study period the mean percentage purity of illicit heroin was 40% of the 
total amount of the substance seized in Scotland (EMCDDA, 2008) and analysis of 
heroin seized in 2007-8 in Fife and Tayside revealed that caffeine and paracetamol 
were the most common added substances used to dilute the illicit heroin (Scottish 
Crime Drug Enforcement Agency, 2009). Other pharmaceutical products such as 
benzocaine, diazepam and phenacetin were also found in a minority of seized and 
analysed samples from the South East Scotland region in 2008 (Baldacchino et al., 
2009). 
 
When heroin is discontinued, the user generally experiences physical withdrawal 
symptoms. Withdrawal starts within 6-8 hours of the last administration. Withdrawal 
symptoms include: restlessness, insomnia, diarrhoea, vomiting, cold flashes with 
goose bumps, kicking movements and muscle and bone pains. Major withdrawal 
symptoms peak between 48 and 72 hours after the last dose and subside after about 
a week (DH, 2007).  
 
Only male participants aged between 18 and 30 years entering for the first time a 
structured methadone maintenance treatment programme and attending Tayside 
and Fife Addiction Services between January 2007 and December 2009 were 
considered for inclusion in this study. The potential participants had confirmed 
histories of more than three years of regular, daily illicit opioid (usually heroin) use 
and met diagnostic criteria for opioid dependence syndrome according to DSM-IV 
(American Psychiatric Association, 1994; Appendix 4).  
 
Participants were taking between 0.4 g and 1.5g of heroin intravenously daily or 
smoked heroin with an equivalent daily methadone dose of 40-120mg (Preston, 
1996) and Table 2.1. They were also naïve to methadone and other types of 
prescribed opioids. The information on the participant’s drug history was subjective 
and there were no attempts to objectively validate the extent and magnitude of the 
participant’s drug exposure by measuring serum levels of the opioids taken. 
83 
 
 
 
Measuring serum heroin and methadone levels was considered as not possible in the 
belief that it will increase the likelihood of attrition from the study and would have 
been practically be very difficult, in terms of venous access, to obtain the required 
two blood specimens. Also, any serum results obtained would not necessarily have 
provided a more accurate assessment of the optimal dosage of methadone (Bell et 
al., 1988). 
Table 2.1: Illicit heroin conversion chart *. 
 
Daily spend on 
heroin 
Amount used in 
grams 
Route Heroin 
taken 
Methadone dose - 
stabilised 
£10 1/8th Smoked 5-25mg 
IV 5-25mg 
£25 0.25g Smoked 10-40mg 
IV 15-45mg 
£40 0.5g Smoked 20-50mg 
IV 30-65mg 
£50 0.75g Smoked 30-70mg 
IV 35-75mg 
£80 1.0g Smoked 35-85mg 
IV 35-100mg 
£100 1.5mg Smoked 45-120mg 
IV 45-130mg 
£150 2.0g Smoked 50-130mg 
IV 50-130mg 
*Material adapted with permission from Preston, 1996. It is not possible to accurately predict 
equivalent doses in most cases. This is especially true for street drugs where purity is notoriously 
variable. It is also problematic to convert from one drug to another when the half lives are not 
equivalent. Therefore this table is not intended to show absolute figures but possible range of dosages. 
 
To standardise the pharmacological status of this HEROIN group and determine 
consistent stages of ‘withdrawal’ and optimal opioid dose a well established clinical 
tolerance testing procedure was used (Appendix 5). Tolerance testing was a single-
blinded procedure that permitted the objective observation of individuals during 
stages of acute intoxication, withdrawal and subsequent stabilisation on a fixed dose 
methadone within a period of 7-14 days. Tolerance testing ensured that each 
participant took the dose that was considered optimal for them. Severity and quality 
of the opioid withdrawal symptoms were measured using the Clinical Opiate 
Withdrawal Scale (COWS) (Tompkins et al., 2009; Appendix 6).  
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The participants were assessed on entry to tolerance testing which was between 3-5 
hours after their last illicit dose so as to prevent any confounding results due to 
heroin intoxication. Then the same participants in the HEROIN group were invited to 
be retested in a state of opioid withdrawal and subsequently following a specified 
period of stabilisation with methadone. This assessment process took place within a 4 
week period. This offered an opportunity to perform repeated neuropsychological 
testing during periods when illicit heroin is either present, absent or replaced by an 
alternative opioid (methadone) from the participant’s system. This approach also 
determined whether any deficits present represented a stable phenomenon or could 
be modified by different degrees of opioid receptor occupancy.  
 
During the study period there were a total of 635 new treatment seeking individuals 
aged between 18 and 30 years old. Three hundred and seventy nine individuals were 
males and 295 of these cases presented with an opioid dependence syndrome. Eighty 
seven individuals were excluded due to presence of co-morbid severe mental health 
and/or physical conditions and a further one hundred and thirty six individuals were 
excluded due to co-occurring alcohol and/or benzodiazepine dependence. Another 
thirty eight individuals refused to participate leaving thirty six individuals that met the 
study criteria and who were invited to participate in this study. In summary half of all 
eligible cases who attended the Dundee and Fife Addiction Services in the two year 
study period were approached to participate in this study. 
 
Twenty eight (50%) of these participants consented and were tested during illicit 
heroin use as the HEROIN group. Twenty six of these twenty eight participants were 
tested after their last intake of illicit heroin and subsequently  retested more than 
twelve hours after their last intake of illicit heroin or any other opioids (in opioid 
withdrawal). Twenty four of the original twenty eight participants were tested after 
their last intake of illicit heroin, tested again in opioid withdrawal and then finally 
retested three weeks after stabilised on a daily methadone dose following tolerance 
testing (Appendix 7.1). One individual died just after initiating the methadone 
stabilisation stage. 
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Methadone group (METHADONE) 
Methadone is itself addictive and is only clinically prescribed for those who are 
clinically exhibiting physical opioid dependence especially withdrawal symptoms (DH, 
2007). Methadone is dispensed as an oral solution (1 mg/ml) and the dose is adjusted 
according to the severity of the opioid dependence (Ward et al., 1999).  
 
When administered at a therapeutic level to opioid dependent individuals, 
methadone produces no obvious psychotropic effects such as euphoria or sedation. 
Methadone is well absorbed when taken orally and reaches a peak plasma 
concentration 2-4 hours after ingestion. Methadone has a plasma elimination half life 
of between 18-36 hours and, for this reason, a once a daily dose of methadone is 
thought to induce a steady state (Curran et al., 2001).  
 
All male opioid dependent individuals aged between 18 and 30 years on methadone 
maintenance programme for more than 6 months, who showed retrospective and 
regular objective confirmation of the absence of illicit drug through weekly urine drug 
screen analysis and attending Fife Addiction Services between January 2007 and 
December 2009 were considered for inclusion in this study. 
 
The potential participants had confirmed histories of more than three years of 
regular, daily illicit opioid (usually heroin) use and met a diagnosis of opioid 
dependence syndrome according to DSM-IV (APA, 1994). The participants have been 
taking between 0.4 g and 1.5 g of heroin intravenously daily or to have smoked heroin 
such that they have achieved a similar degree of drug exposure and clinically 
translating itself to an equivalent daily methadone dose of 40-120mg (Preston, 1996). 
During the study period there were 2344 treatment seeking individuals who 
presented with opioid dependence and were prescribed methadone in Fife. One 
thousand five hundred and thirty four individuals were males with 524 of these 
individuals aged between 18 and 30 years old. Two hundred and ninety four 
individuals resided in Central Fife which included the Kirkaldy and Levenmouth areas. 
One hundred and seventy four of these opioid dependent individuals were excluded 
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due to the presence of co-morbid severe mental health and/or physical conditions 
and co-occurring alcohol and/or benzodiazepine dependence. Another seventy eight 
individuals were excluded since they did not show stability as stipulated by the study 
protocol. Overall forty two individuals fitted the inclusion criteria for the 
METHADONE group and were approached to participate in this study. Twenty nine 
(69%) agreed to participate and consented (Appendix 7.2). 
 
Throughout the study period, participants were asked to take their prescribed dose of 
methadone in the morning (8-10am) so that this allowed testing to happen about 
four hours afterwards (2-5pm). This created a standardised approach to the timing of 
methadone intake and neuropsychological testing. The mean daily dose of 
methadone varied but was within the 40-120 mg range with a morphine equivalent 
mean of 147.41 (+/- 59.33) mg daily if we assume that the heroin purity of the 
samples used by the participants was 40%. 
 
In order to determine that the results obtained were not time specific to the episode 
of treatment, eighteen out of the twenty nine participants were evaluated 
prospectively six months after their baseline neuropsychological test session.  
 
Chronic pain group (CHRONIC PAIN) 
All male non- opioid dependent individuals aged between 18 and 40 years with a 
history of more than three years of continuous prescribed opioids and attending the 
Tayside Pain Clinic between January 2007 and December 2009 were considered for 
inclusion in this study. 
 
The potential participants had no history of ‘illicit’ opioid (e.g. heroin) use or 
methadone treatment and would not have met the criteria for a diagnosis of opioid 
dependence syndrome according to DSM-IV (APA, 1994). 
 
During the study period there were a total of 303 treatment seeking individuals aged 
between 18 and 40 years who were referred to the Tayside Chronic Pain Clinic based 
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at Ninewells Hospital and Medical School in Dundee. Forty one individuals who had a 
history of opioid medication for more than three years due to chronic non--malignant 
pain were approached to participate in this study. On further assessment three of 
these cases did not fit the eligibility criteria due to (a) one case having a recent 
diagnosis of malignancy, (b) one case leaving the catchment area and (c) another 
stopping his opioid medication due to an improvement in his chronic painful 
condition. In total twenty eight (72%) eligible individuals were approached and they 
all consented to participate (Appendix 7.3). 
 
Normal control group (HEALTHY CONTROL) 
The control group consisted of twenty eight healthy males matched for age and sex, 
with no history of chronic pain and/or illicit drug use or a lifetime continuous/regular 
prescription of opioids. This group were recruited from the general population 
residing in Fife and aged between 18 and 40 years. 
 
General study design 
The study design created an experimental model within which individuals either 
experienced different degrees of opioid receptor occupancy (HEROIN) or were receipt 
of chronic and stable prescribed opioids (METHADONE and CHRONIC PAIN). 
 
Further, by including a cohort of non-heroin abusing individuals (CHRONIC PAIN) 
recruited from a pain clinic, one was able to identify the possible effects of drug 
adulterants and/or the ‘drug addict lifestyle’. By including a cohort of stable 
methadone maintained individuals (METHADONE) one was also able to 
retrospectively identify the possible contamination effect of previous illicit heroin use 
and prospectively test for deterioration and/or improvement. 
 
The HEROIN group performed the neuropsychological tasks between three and five 
hours after smoking or injecting illicit heroin (baseline). They were then re-tested 
when experiencing opioid withdrawals ten to fifteen hours after stopping any opioid 
use as part of a tolerance testing procedure. This cohort was again re-tested between 
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two and four weeks after the tolerance testing procedure when this cohort was 
adequately stabilised on a daily dose of methadone. They were therefore tested on 
three occasions.  
 
The METHADONE group performed the neuropsychological tasks between 4-6 hours 
of taking their last stable dose of methadone (baseline). They were re-tested again six 
months after their initial baseline test period. They were therefore tested on two 
occasions.  
 
The CHRONIC PAIN group performed the neuropsychological tasks between 4-6 hours 
after taking their chronic stable dose of opioid medication. They were therefore only 
tested at baseline.  
 
The HEALTHY CONTROL group was tested once at baseline (Table 2.2). 
 
Table 2.2:  Study procedures. 
Testing  
Sessions 
Illicit or licit  
opioids 
Opioid 
withdrawal 
2-4 weeks 
on 
methadone 
6 months on 
methadone 
HEROIN         † † † — 
CHRONIC PAIN         †  — — — 
METHADONE         † — — † 
HEALTHY CONTROL        — — — — 
        †= tested; —= not tested 
 
A two staged screening and assessment process was used. The identified individuals 
were approached by their keyworkers in order to seek interest in participation to this 
study. Informed written consent to participate in the study was obtained from this 
group in accordance with the guidelines from the Tayside Committee on Medical 
Research Ethics. Consent was subsequently obtained after the first meeting with the 
researcher (Appendices 8 & 9). 
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Inclusion and exclusion criteria 
Criteria for inclusion and exclusion to this study was based on the methodological 
limitations and confounding factors identified in Chapter 1.  
 
The inclusion criteria were: 
 Male gender 
 Males older than 18 years and younger than 30 years. In the CHRONIC PAIN 
and HEALTHY CONTROL groups the age limit was increased to 40 years. 
 Presenting with opioid dependence syndrome in the drug using population 
(HEROIN and METHADONE groups) and not in the CHRONIC PAIN group, 
 More than three years of daily opioid use. 
 
All individuals who presented with the following conditions were excluded. They 
were: 
 Female gender. 
 Males younger than 18 years and older than 30 years in the METHADONE and 
HEROIN groups only. 
 Intoxication due to drug and/or alcohol use. 
 Co-occurring severe physical problems with acute confusional state.  
 Presenting with opioid dependence syndrome in the chronic pain group. 
 Co-occurring benzodiazepine, psycho-stimulant and alcohol dependence. 
 History of Acquired Immunodeficiency Syndrome (AIDS) or associated HIV 
infection. 
 Post Trauma Amnesia. 
 Recent and past overdose episodes needing Cardio Pulmonary Resuscitation 
(CPR). 
 Bipolar or severe depressive mood disorder.  
 Schizophrenia. 
 Post Traumatic Stress Disorder (PTSD).  
 Attention Deficit Hyperactivity Disorder (ADHD) (Adult and Childhood).  
 History of confirmed epilepsy.  
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 Neurological (sensory and motor) impairment.  
 Previously determined learning disability (Intelligence Quotient (IQ) lower 
than 80). 
 Inability to understand English. 
 
Screening clinical instruments 
Eligible and consented individuals were then screened using a battery of validated 
instruments and their psychiatric, addiction and general practice case records 
accessed.  
 
The screening clinical instruments included the Mini International Neuropsychiatric 
Interview (MINI) (Sheehan et al., 1998) and Post Trauma Questionnaire (PTQ) 
(McMillan et al., 1996) (Appendices 10 & 11).  
 
A drug urine analysis screen was also conducted to validate a three or four day 
history of opioid (usually heroin) intake and also absence of any other illicit drugs 
such as amphetamine, cocaine, benzodiazepine and cannabis (Quantum Diagnostics 
Ltd) as part of the screening process. 
 
Assessing and screening for mental health related problems/illnesses: Mini 
International Neuropsychiatric Instrument (MINI) version 5.0 
The M.I.N.I. is a brief structured diagnostic and screening interview for the major Axis 
I psychiatric disorders in DSM-IV and ICD-10 (Sheehan et al., 1998). Validation and 
reliability studies have been done comparing the M.I.N.I. to the Structured Clinical 
Interview for DSM III-R Patients (SCID-P) and the Composite International Diagnostic 
Interview (CIDI) with results showing that the M.I.N.I. has acceptably high validity and 
reliability scores (Sheehan et al., 1997). 
 
It elicits all the symptoms listed in the symptom criteria for DSM-IV and ICD-10 for 15 
major Axis 1 diagnostic categories, one Axis II disorder. It uses a decision tree logic 
which is consistent with DSM-IV and ICD-10 diagnostic algorithms. The MINI includes 
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a psychiatric assessment of current diagnoses of PTSD, panic disorder, generalized 
anxiety disorder, social phobia, major depression, psychotic disorders, substance 
(drug and alcohol) abuse or dependence, ADHD, antisocial personality, somatisation 
and adjustment disorders (Sheehan et al., 1998).  
 
With an administration time of approximately 15 minutes, the M.I.N.I. is the 
structured psychiatric interview of choice for psychiatric evaluation and outcome 
tracking in clinical psychopharmacology trials and epidemiological studies. 
Participants’ views of MINI were also positive (Amorin et al., 1998). It was considered 
comprehensive enough to cover all patient symptoms and at the same time not being 
unduly lengthy.  
 
Assessing and screening for episodes of head injury and other cerebral insults: Post 
Traumatic Amnesia Questionnaire (PTQ) 
Post-Traumatic Amnesia Questionnaire was considered to be the best single indicator 
of the severity of closed head injury (Russell & Smith, 1961).The duration of post-
traumatic amnesia was taken to be the interval between injury and the patient 
regaining continuous memory for day to day events. The interview was structured by 
using notes in case records and dates of special events (Appendix 11) to establish 
landmarks in the acute stage after the head injury (McMillan et al., 1996). 
 
Objective measurement of substance misuse: urine analysis drug screening method 
Recent substance use may result in symptoms that are indistinguishable from 
psychiatric symptoms. Accurate interpretation of the screening tests within a clinical 
setting, alongside other relevant information, remains the key to the usefulness of 
any test (Simpson et al., 1997; Neale & Robertson, 2003). 
 
Quantitative accuracy usually demands the collection of a blood, hair or saliva 
samples. The advantage of hair sampling is its reflection of weeks/months rather than 
hours of recent use (Wolff et al., 1999).All the above tests are expensive and analysis 
of urine is currently the biological tool of choice for qualitative detection of illicit drug 
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use, becoming a common objective adjunct in the validation and reliability of 
substance misuse and mental health screening and/or diagnostic instruments (Wolff 
et al., 1999). The significant advantage of urine for drug testing is that biologically 
urine is generally available in sufficient quantity and the drugs or their metabolites 
tend to be present in relatively high concentrations (Moffat et al., 1986).  
 
The procedure used in this study was for analysis for drugs of misuse undergoing an 
initial screening test using self-contained drug testing kits for on-site testing 
(Armbruster & Krolak, 1992; Jenkins et al., 1995). The kit testing for cannabis, 
opioids, benzodiazepine, amphetamine and cocaine onsite was used for this study 
(Quantum Diagnostics Ltd and Illustration below). 
 
The same urine sample were then sent to the laboratory for 
another screening process using an automated Enzyme-
Mediated Immunoassay (EMIT) or Enzyme Linked 
Immunosorbent Assay (ELISA) to classify the type of drug (i.e. 
opioid, benzodiazepine, etc.) (Wilson et al., 1994). In the event 
of a positive finding a thin-layer (TLC), gas (GC) or liquid (LC) 
chromatography would be used for confirmation of a specific 
drug in the sample (i.e. morphine, codeine etc) (Braithwaite et al., 1995; Simpson et 
al., 1997). 
 
Diagnostic clinical instruments 
The diagnostic clinical instruments used for this study include the MINI (Sheehan et 
al., 1998), the Maudsley Addiction Profile (MAP) (Marsden et al., 1998a & 1998b), 
and the Fagerström Test for Nicotine Dependence (FTND) (Fagerström & Schneider, 
1989) (Appendices 12 & 13). Drug urine samples to confirm a recent history of opioid 
(heroin) intake and absence of any other illicit drugs. (Quantum Diagnostics Ltd) were 
analysed throughout the study period from all cohorts participating including the 
HEALTHY CONTROL group. The Clinical Opiate Withdrawal Scale (COWS) quantified 
the level of opioid withdrawal in the HEROIN group. 
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Assessing diagnosis of opioid dependence syndrome: Mini International 
Neuropsychiatric Instrument (MINI) version 5.0 
The MINI is a brief structured diagnostic and screening interview for the major Axis I 
psychiatric disorders in DSM-IV and ICD-10 (Sheehan et al., 1998). Description of the 
MINI is provided in the previous section. Diagnosis of opioid dependence, use and 
abuse (lifetime and current) was possible using the MINI (Section L) (Appendix 10). 
 
Assessing diagnosis of substance misuse problems: Maudsley Addiction Profile (MAP) 
The MAP is a brief, multi-dimensional tool designed for assessing treatment outcome 
(Marsden et al., 1998a, 1998b).The MAP was developed from the interview 
instrument used in the National Treatment Outcome Research Study (NTORS) 
(Gossop et al., 1997). It was originally designed as a core research instrument to be 
used by treatment services wishing to undertake outcome studies.  
 
The MAP employs a simple scoring system in each of the four domains incorporating 
continuous measures or ‘Likert’ type severity of symptom/condition. It covers four 
main domains: substance use, health risk behaviour, physical and psychological 
health and personal/social functioning of the last 30 day period. It is interviewer 
administered and has 60 items in these four domains and takes about 15 minutes to 
complete.  
 
The positive features include that it is quick and easy to complete, has good 
evaluation data and records the participants’ views/opinions. A validation study 
showed that the content of MAP was acceptable to participants (Marsden et al., 
1998a, 1998b). Further, internal reliability and feasible concurrent validity 
assessments of the scales and items were highly satisfactory. Test-retest reliability 
was good, average intra-class correlation coefficients across eight substances were 
0.94 and 0.81 across health risk, health problems, relationship conflict, employment 
and crime measures (Marsden et al., 1998a, 1998b).   
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Assessing diagnosis of nicotine dependence: Fagerström Test for Nicotine 
Dependence (FTND) 
The Fagerström Tolerance Questionnaire (FTQ), developed in 1978 (Fagerström, 
1978), was widely used in smoking research (Fagerström & Schneider, 1989) but  
revealed unacceptable internal consistency (Pomerleau et al., 1994 & Swan et al., 
1991). In response to this, Heatherton et al. (1991) revised the FTQ and developed a 
scale called Fagerström Test for Nicotine Dependence (FTND) (Appendix 13).  
 
Since 1991, the FTND is one of the most widely accepted evaluative instruments to 
establish and quantify nicotine dependence and also has been found to be reliable 
and valid in several different contexts (Dijkstra & Tromp, 2002; Etter, 2005). Studies 
have also evaluated the factor structure of the FTND among different types of 
population (Radzius et al., 2003; Vink et al., 2005; Haddock et al., 1999).  
 
The Fagerström Test for Nicotine Dependence (FTND) consists of six items from 
original FTQ, has a score range from 0 to 10 with an internal consistency of = 0.61 
(Heatherton et al.,1991). It is a self reporting tool that conceptualizes dependence 
through physiological and behavioural symptoms. It requires a few minutes to 
complete. 
 
All participants were tested approximately one hour after their last nicotine intake 
and were encouraged to smoke again if the neuropsychological testing lasted more 
than two hours in order to prevent changes in nicotine levels influencing the test 
outcomes. 
 
Assessing diagnosis of opiate withdrawal: Clinical Opiate Withdrawal Scale (COWS) 
The COWS is a clinician-administered, pen and paper instrument that rates eleven 
common opiate withdrawal signs or symptoms (Appendix 6). A total score of 5 to 12 
is indicative of mild withdrawal; 13 to 24, moderate withdrawal; 25 to 36, moderately 
severe withdrawal; and > 36, severe withdrawal. The summed score of these eleven 
items can be used to assess a patient's level of opiate withdrawal and to make 
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inferences about their level of physical dependence on opioids (Wesson & Ling, 
2003).  The COWS can be administered serially to identify changes in the severity of 
the signs and symptoms of opiate withdrawal.  
 
COWS has shown strong discriminant and concurrent validation and reliability 
(α=0.78) when compared to the Clinical Institute Narcotic Assessment (CINA) scale 
and Visual Analogue Scale (VAS) (Tompkins et al., 2009). 
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Table 2.3: Summary of screening and diagnostic clinical instruments and their 
measures/domains. 
Screening Tests Measures/Domains 
Mini International Neuropsychiatric 
Instrument (MINI) v5.0. 
Diagnosis of 15 Axis 1 and 1 Axis 2 DSM-4 
psychiatric illnesses and substance 
misuse/dependence presented in 24 
modules. 
Case records from addiction, psychiatric and 
General Practitioner’s Services.  
Identification of non fatal overdose episodes 
Confirming a history or not of epilepsy and 
other neurological phenomenon including 
learning disabilities. 
Confirming a diagnosis of Hepatitis B, C and 
HIV 
Validating medical and psychiatric histories 
Validating substance misuse career and 
current drug and alcohol use. 
Scottish Index of Multiple Deprivation (SIMD). 
Post Trauma Amnesia Questionnaire v1.0. Information on head and other cerebral 
insults and consequential post trauma 
amnesia. 
Urine analysis for drug screen. Using self contained on site drug test kits for 
presence of amphetamine, cannabinoids, 
opioids, benzodiazepine and cocaine. 
Subsequent lab investigations used ELISA  
followed up by TLC methodologies. 
Diagnostic Tests Measures/Domains 
Mini International Neuropsychiatric 
Instrument (MINI) (Section L) v5.0. 
Diagnosis of opioid misuse/dependence 
(lifetime and current). 
Maudsley Addiction Profile (MAP) v1.0. Information on substance misuse history, 
health risk behaviour, physical and 
psychological health, personal and social 
functioning in the last 30 days. 
Fagerström Test for Nicotine Dependence 
(FTND) v1.0. 
6 items with a diagnostic score ranging from 
0 (no nicotine dependence) to 10 (very 
severe nicotine dependence). 
Clinical Opiate Withdrawal Scale (COWS) 
v1.0. 
11 objective and subjective symptoms of 
opioid withdrawal. Scores ranged from 0-48. 
Urine analysis for drug screen. Using self contained on site drug test kit for 
presence of amphetamine, cannabinoids, 
opioids, benzodiazepine and cocaine. 
Subsequent lab investigations used ELISA  
followed up by TLC methodologies. 
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In summary the decision to choose the above screening and diagnostic clinical 
instruments were made due to a combination of: 
 It took a maximum of 45-60 minutes to complete all the questionnaires 
 The questionnaires used were valid and reliable instruments within the 
population tested 
 All the questionnaires used were free with no need for specialised training 
 The questionnaires were user friendly and easy to administer 
 The questionnaires helped differentiate co-morbid situations quickly 
 The scoring methods were easy to use and interpret 
 The questionnaires provided feedback to the participants on their 
performance 
 
Diagnostic neuropsychological tests 
Testing pre-morbid intelligence 
The National Adult Reading Test (NART) (Nelson & O’Connell, 1978; Nelson, 1982) 
was used to estimate general intellectual ability for all three experimental groups and 
control participants. The NART assesses pre-morbid crystallised intelligence and was 
chosen for its ease of administration and ability to be used with individuals 
experiencing organic conditions including substance misuse related problems 
(Crawford et al., 1988a). The NART score correlates significantly with education 
(r=.51) and social class (r=.36) (Crawford et al., 1988b) with no gender effects 
(Schlosser & Ivison, 1989).It consists of 50 phonetically irregular English words whose 
proper reading depends on the previous knowledge of the subject rather than on 
phonological decoding skills. 
 
CANTAB neuropsychological tasks  
The neuropsychological tasks were selected from the Cambridge Neuropsychological 
Test Automated Battery (CANTAB) (Morris et al., 1987). CANTAB is a computer-
administered, non-verbal (visually presented) set of tasks developed to examine 
specific components of cognition, particularly those associated with frontal and 
medial temporal regions of the brain (Robbins et al., 1994; Robbins et al., 1998). The 
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particular strength of the CANTAB battery was that it incorporates a wide variety of 
executive and memory tasks selected on the basis of adaptations for use with 
humans on paradigms developed from animal models with damage to specific brain 
areas (Lowe & Rabbit, 1998). CANTAB has been used with a wide variety of 
populations including substance misusers and psychiatric patients, with varying levels 
in ability, intellect and age (Rogers et al., 1999a; Ornstein et al., 2000; Fox et al., 
2002; Elliot et al., 1998; Goodwin & Clark, 2002). The graded nature of the tasks 
reduced the likelihood of floor and ceiling effects (Fray & Robbins, 1996). Critics of 
CANTAB argued that its strength centred on being exclusively non- verbal in its 
response requirement and in the nature of the stimulus presentation which could 
limit conclusions that can be drawn about the participant’s verbal functioning 
(Luciana, 2003).In addition the ecological validity of CANTAB needed further 
investigation in order to establish the value of CANTAB tests outcomes as predictors 
of community functioning and levels of morbidities within the population studied 
(Levaux et al., 2007). The CANTAB tests were considered siutable for this study since 
they tested all neuropsychological domains identified as important in the population 
to be studied allowing adequate comparison with results and conclusions from 
previous literature. 
 
At the beginning of the testing session participants were shown a line marked on the 
table to which they were instructed to keep their ‘pointing’ finger on at the beginning 
of each test and between trials. This line was measured as 12 inches from the centre 
of the screen. The instructions given for each task originated from manuals provided 
by CENES (Cambridge Cognition), the company responsible for commercial 
development and marketing of the CANTAB tests. The product used for this study was 
CANTAB eclipse version 3. 
 
Nine tests (and two screening tests) from three out of the four CANTAB battery 
neuropsychological domains were used in this study. These were: (1) executive 
function; (2) decision making and response control; (3) visual memory,  These tests 
were presented on a high‐resolution colour monitor with a touch sensitive screen and 
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run on standard Windows based PC systems. The neuropsychological tests were 
grouped in the same domains established in Chapter 1: 
(1) Induction stage: Motor Screening Test (MOT) and Big/Little Circle (BLC). 
(2) Cognitive Impulsivity: Cambridge Gambling Task (CGT). 
(3) Motor Impulsivity: Affective Go-NoGo (AGN);  
(4) Non-planning Impulsivity (Strategic Planning): Stockings of Cambridge (SOC); 
Spatial Span (SSP); Spatial Working Memory (SWM). 
(5) Cognitive Flexibility: Intra/Extra-Dimensional Set Shifting (IED).  
(6) Memory and Learning: Delayed Matching to Sample (DMS); Paired Associates 
Learning (PAL); Pattern Recognition Memory (PRM); Spatial Recognition 
Memory (SRM). 
 
Induction (screening) stage 
Motor Screening Test (MOT) 
This simple reaction time test measured psychomotor speed and accuracy and was 
designed to screen for psychomotor impairments, which would interfere with later 
task performance. On each of ten trials, a large ‘X’ appeared at a random location on 
the computer screen. Participants had to touch the centre of the ‘X’ as quickly but as 
accurately as possible. Accuracy of touch and response latency was recorded. All 
participants were deemed to understand this task. Hence, data from this task were 
not analysed in any detail and are not discussed further. 
 
Big/Little Circle (BLC) 
The purpose of this simple discrimination task was to ensure participants can reliably 
choose between two stimuli according to a simple rule before progressing to a more 
complex task which was the IED. Participants were presented with two filled, yellow 
circles displayed in boxes. One circle was small (described during the task as ‘little’) in 
size and one big in size. In the first twenty trials, subjects were instructed to touch the 
‘little’ circle each time, and in a second set the ‘big’ circle each time (Figure 2.1). The 
task took three minutes to complete.  Accuracy of response and speed of response 
was recorded as outcome measures. All participants were deemed to understand this 
100 
 
 
 
task after the second twenty trials. Hence, data from this task were not analysed in 
any detail and are not discussed further. 
 
Figure 2.1: CANTAB and Big Little Circle (BLC). In the first 20 trials, subjects were instructed 
to touch the ‘little’ circle each time. 
 
Cognitive Impulsivity 
Cambridge Gambling Task (CGT) 
The Cambridge Gambling Task (CGT) is a computerized measure of risky decision 
making but with less emphasis on strategy and working memory than the Iowa 
Gambling Task (IGT) (Rogers et al., 1999a & 1999b). Unlike other 'gambling' tasks, 
CGT was developed to permit the separation of components that underlie cognitive 
impulsivity, i.e. sensitivity to consequences and risk taking outside a learning context 
(Manes et al., 2002). Relevant information was presented to the participant 'up-front' 
and there was no need to learn or retrieve information over consecutive trials.  
 
Brain injury, alcoholism and drug abuse were all conditions sensitive to this test. 
Previous studies have shown performance of individuals with a drug addiction to be 
characterised by sub-optimal decisions and/or slower speed of decision-making 
(Rogers & Robbins, 2001).The likely neural substrate for this task was the orbito-
frontal prefrontal cortex (OF-PFC) (Ersche et al., 2011). 
 
On each trial, the participant was presented with a row of ten boxes across the top of 
the screen, some of which were red and some of which were blue (Figure 2.2). At the 
bottom of the screen were rectangles containing the words ‘Red’ and ‘Blue’. The 
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participant was asked to guess whether a yellow token was hidden in a red box or a 
blue box.  
 
In the gambling stages, participants started with a number of points, displayed on the 
screen, and selected a proportion of these points (displayed in either rising or falling 
order) in a second box on the screen, to gamble on their confidence in this 
judgement. A stake box on the screen displayed the current amount of the bet 
(Figure 2.2). The participants were asked try to accumulate as many points as 
possible.  
 
 
Figure 2.2: CANTAB and CGT: a typical display from the decision-making task. 
 
The ratio of coloured boxes varied across trials. This helped examine a participant’s 
decision-making behaviour over a variety of differentially weighted contingencies 
(difficulty levels). On each trial, the participant was asked to guess which colour 
concealed a token, and then wager a proportion of his/her total points on his/her 
colour decision. Thus, a participant’s choice of contingency, speed of choice, and size 
of bet were expected to differ as a function of the ratio of red/blue boxes. 
 
Wagers were offered in ascending (5%, 25%, 50%, 75%, and 95% of current points) or 
descending (95%, 75%, 50%, 25%, 5% of current points) sequences presented for 2.5 
seconds each. This afforded the possibility of isolating merely impulsive behaviour 
from genuine risk seeking. In both ascending and descending conditions, each bet was 
presented with a short tone whose pitch corresponded to the size of bet: higher 
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tones accompanied larger bets and lower tones accompanied small bets. If the 
participant failed to select a bet by the end of a sequence, the last bet was chosen 
automatically. 
 
Immediately following such a selection, one of the red or blue boxes opened to reveal 
the location of the token, accompanied by either a ‘You win!’ message and a short 
rising musical scale, or a  ‘You lose!’ message and a low tone. If the participant chose 
the correct colour, the bet placed was added to the total points score; if the 
participant chose the wrong colour, the bet was subtracted.  
 
On 80% of trials the probabilities were unequal and the large reward was always 
associated with the least likely outcome. Participants then had to decide whether to 
play safe and choose the likely option, which was associated with a small reward, or 
whether to take a risk and select the unlikely option, which was associated with a 
large reward. However, playing safe did not imply the participant was guaranteed to 
receive reward, since on 1/4 of trials the likely small reward option did result in loss. 
This assessed participant’s willingness to place already-accumulated reinforcement at 
risk in the hope of acquiring more reward. For example, one might suppose that a 
ratio of 9 red : 1 blue represented an opportunity to bet more points on a red 
decision in order to gain more reward, while a ratio of 6 blue : 4 red represented a 
situation in which more conservative behaviour might be appropriate. 
 
These bet options were presented sequentially in either ascending or descending 
order; in half of the games the ascending condition was used, and in half the 
descending condition. Participants played eight games each consisting of nine trials. 
The participant was instructed to treat the points as being valuable and to 
accumulate as many as possible during the test. However, no monetary significance 
was attached to the total points accumulated by the end of the task.  
 
Participants simply won or lost the amount of points they chose to bet on each trial. 
Thus, consistently choosing the least likely outcome in this task indicated poor quality 
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of decision-making. Previous literature have determined a cut off score that appeared 
to discriminate between substance dependent individuals and individuals without 
dependency (Bechara & Damasio, 2002). A quality of decision making score of 89.7% 
for the CGT (Rogers et al., 1999a) is usually used as the cut of point for the CGT. 
 
Risk taking (or overall proportion bet) on this task was characterized by choosing the 
least likely choice in pursuit of a greater reward even in the face of a more likely 
penalty. 
 
Other outcome measures covered were deliberation time or latency needed to make 
the colour choice (Deakin et al., 2004a, 2004b), delay aversion or insensitivity to cues 
when the participant is unwilling to wait, betting larger amounts when the possible 
bet amounts were presented in descending order than they do when the amounts 
were presented in ascending order and risk adjustment or lack of risk insight when 
the participant has a tendency to bet a higher proportion of their points on a trial if 
the odds were strongly on one’s favour. 
 
Motor Impulsivity 
Affective Go-NoGo (AGN) 
This task was modelled on the ‘set-shifting’ paradigm of Dias et al., (1996), and the 
‘modified affective shifting’ task developed by Murphy et al., (1999). It is an 
adaptation of the classic Go-NoGo paradigm that has been used for decades to test 
behavioural inhibition in both animals (Mishkin & Pribram, 1955) and humans 
(Costantini & Hoving, 1973).The emotional Go-NoGo task yields the same measure of 
inhibition, but the substitution of affective stimuli instead of the letters or pictorial 
stimuli used as Go and NoGo cues also permitted analysis of performance in response 
to cues of different emotional valences (e.g. happy versus sad). Therefore, the task 
not only provided a measure of behavioural inhibition, but also of the emotional 
modulation of this inhibition (Drevets & Raichle, 1998). 
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Neuroimaging studies with this task implicated the subgenual and rostral anterior 
regions of the cingulate gyrus in these emotional response biases (Elliott et al.,2000; 
Elliott et al., 2002 & Elliott et al.,2004). These studies also found activation of lateral 
orbitofrontal cortex when inhibiting responses to NoGo cues of any valence. Another 
study of healthy adults that used a Go-NoGo task with affective facial expressions as 
cues found slowed responses to fearful expressions that were associated with 
amygdala activation and difficulty inhibiting responses to happy faces that was 
inversely related to caudate nucleus activity (Hare et al., 2005). This study also noted 
consistent activation of a prefrontal region near the lateral orbitofrontal cortex during 
the inhibition of responses to NoGo cues regardless of emotional valence. 
 
In the Affective Go-NoGo task, words were rapidly presented one by one in the centre 
of a 12-inch black screen.Words were shown as 8-mm white letters (Figure 2.3). 
Participants responded to targets by pressing the space bar with their dominant hand 
as quickly as possible and not responding when ‘distractors’ appear. 
 
 
Figure 2.3: CANTAB and AGN. A happy valenced word presented.  
 
The task consisted of ten word blocks, each containing 18 affectively valenced words 
(nine happy, nine sad), each of which presented a series of words from two of three 
different affective categories: In this task positive/happy (H) (e.g. joyful), and 
negative/sad (S) (e.g. hopeless) but not neutral (N) (e.g. element) words were chosen.  
 
The participant was instructed initially to press the space bar when they saw a happy 
word (e.g. hopeful, serene) but not for sad words (e.g., glum, mistake). After two 18-
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word blocks requiring responses to happy words, the participant was then instructed 
to respond (press space bar) when he/she saw a sad word (e.g. glum). The 
presentation of valenced words alternated every two blocks and continued for ten 
18-word blocks. Conditions alternated in an HHSSHHSS pattern that created shift and 
non-shift response blocks. The participant was then given a target category, and was 
asked to press the press pad when they saw a word matching this category.  
 
Each word was presented for 300 milliseconds (msec), followed by a 900-msec inter-
stimulus interval. The first two word blocks were practice and therefore excluded 
from the analysis. A 500-msec/450-Hz tone sounded for each false alarm, but not for 
omissions. False alarms constituted responses to distracter stimuli while omissions 
were failure to respond to target stimuli. The task took around 10 minutes depending 
on the level of participant’s cognitive impairment.  
 
Outcome measures included: 
 Total commissions or distractor (commission) errors (e.g., responding to happy 
words during sad word blocks) during happy and sad word blocks, during shift 
and non-shift blocks 
 Total omissions or target (omission) errors (e.g., failing to respond to sad 
words during sad word blocks) during shift and non-shift blocks 
 Reaction times or mean correct latency 
 
Non-Planning Impulsivity  
(1) Stockings of Cambridge (SOC) 
This task was derived from the Tower of Hanoi (TOH) task and measured non- 
planning impulsivity (Shallice, 1982). A study using Positron Emission Tomography 
(PET) demonstrated activation in the parietal lobes bilaterally, as well as the left 
dorsolateral prefrontal cortex (DL-PFPFC) and left caudate nucleus in the dorsal 
striatum (Baker et al., 1996; Morris et al., 1993; Owen et al., 1996).  
The participant was shown two displays containing three coloured balls (one green, 
one blue and one red). The displays were presented in such a way that they can easily 
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be perceived as stacks of coloured balls held in stockings or socks suspended from a 
beam. This arrangement made the 3-D concepts involved apparent to the participants 
and fitted with the verbal instructions (Figure 2.4). 
 
 
Figure 2.4: CANTAB and Stockings of Cambridge (SOC). 
 
In this task, two sets of three coloured balls were presented, each arranged in three 
hanging pockets. Participants were asked to move the balls in the arrangement in the 
lower half of the screen according to specified rules, to match the upper or ‘goal’ 
arrangement. The balls were moved one at a time by touching the required ball then 
touching the position to which it should be moved. The participants were told the 
minimum number of moves necessary to match the goal configuration and were 
instructed to use as few moves as possible. This demanded planning and execution of 
an optimal set of moves that transformed the initial ball configuration to the goal 
configuration. 
 
Problems could be solved in a certain minimum number of moves (two, three, four or 
five moves) and participants were instructed to work out the solution prior to moving 
any balls. The maximum moves allowed corresponded to twice the minimum number 
possible plus one, or plus two in the case of ‘five move’ problems. If the maximum 
number of moves were exceeded the computer indicated ‘too many moves’ before 
beginning the next trial. Initial and subsequent ‘thinking’ latencies during trials were 
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recorded to provide estimates of cognitive speed during the preparatory and 
execution phases of task performance. 
 
For each trial, a controlled condition was also executed. During these ‘following’ 
trials, participants were instructed to execute a sequence of single moves as quickly 
as possible. The ‘following trials’ were exact reproductions of the participant’s earlier 
planning moves. Initial and subsequent movement latencies in these ‘following’ trials 
provided estimates of motor speed. These ‘movement times’ were subtracted from 
the test condition times, which included both ‘thinking times and ‘movement times’ 
in order to provide an estimate of cognitive deliberation and planning times in the 
test conditions. 
 
Therefore the SOC had four outcome measures:  
 Problems solved in minimum moves 
 Mean moves for 2, 3, 4 and 5-move problems  
 Mean initial thinking time for 2, 3, 4 and 5-move problems  
 Subsequent thinking time for 2, 3, 4 and 5 move problems 
 
(2) Spatial Working Memory (SWM) 
Spatial Working Memory (SWM) is a test of the participant’s ability to retain spatial 
information and to manipulate remembered items (Baddeley & Logie, 1999; Owen et 
al., 1990; Owen et al., 1995). It is a self-ordered searching task (Petrides & Milner, 
1982). Positron Emission Tomography (PET) imaging studies have indicated that this 
task preferentially activated neural circuitry, which included the dorsal and ventral 
(DV-PFPFC) prefrontal regions (Mehta et al., 2000; Owen et al., 1996; Robbins et al., 
1998). 
 
The test began with a number of coloured squares (boxes) being shown on the 
screen. The aim of this test was that, by touching the boxes and using a process of 
elimination, the participant found one blue ‘token’ in each of a number of boxes and 
used them to fill up an empty column on the right hand side of the screen while not 
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returning to boxes where a blue token had been previously found (Figure 2.5).The 
number of boxes was gradually increased from three to eight boxes. The number of 
tokens always equaled the number of boxes. The colour and position of the boxes used 
were changed from trial to trial which discouraged the use of stereotyped search 
strategies. The task took around 8 minutes, depending on level of impairment.  
 
Figure 2.5: CANTAB and SWM. Figure illustrating one blue ‘token’ in one of the four boxes 
with two other blue tokens already found and placed in the column on the right hand side 
of the screen. 
 
Consequently, four types of search errors were possible:  
(1) Between‐search error (BSE): When participants returned to a box where a token 
had already been found.  
(2) Within-search error (WSE): When participants returned to a box that was already 
opened and shown to be empty earlier in the same search sequence.  
(3) Double-search errors (DSE): Occasions where the particpant had committed an 
error that could be categorised as both a within and a between error.  
(4) Total search errors (TSE): The number of times a box selected that is certain not to 
contain a blue token and therefore should not have been visited by the particpant 
(i.e. between errors+ within errors – double errors). 
 
A strategy score was also derived from this task. A common strategy employed in the 
performance of this task was to follow a predetermined sequence, beginning with 
one box and returning to start each new search with that box after a token has been 
found (repetitive search strategy). Such strategies, when applied to self ordered 
search tasks of this type, served to reduce the load on active working memory and 
would, presumably, enhance performance at all levels of task difficulty. The strategy 
109 
 
 
 
score was calculated by counting the number of different boxes initially opened at 
each trial, hence, the lower the strategy score, the more efficient was the participant. 
 
Other SWM outcome measures include: 
 Mean time to first and last response  
 Mean token search preparation time 
 
(3) Spatial Span (SSP) 
Spatial Span Task is a visuo-spatial analogue of the Digit Span Test and a 
computerized version of the Corsi Blocks Tapping Task (Milner, 1971). This task 
assessed the participant’s ability to remember the spatial locations of a sequence of 
white boxes on a computer screen and was believed to preferentially activate neural 
circuitry that included the right ventrolateral prefrontal cortex and the parietal cortex 
(Owen et al., 1990; Robbins et al., 1994). It is predominantly a measure of short term 
memory but also involved in the executive component of working memory 
(Baddeley, 2003). 
 
On each individual trial, an array of nine white boxes was displayed on the screen. 
Participants watched while each white box changed colour before being asked to 
reproduce this sequence. The length of the sequence presented began with two 
boxes and increased steadily up to a maximum of nine (Figure 2.6).  
 
Figure 2.6: CANTAB and SSP. Participants watching while 2 of the 9 white boxes changed 
colour before being asking him/her to reproduce this sequence. 
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A participant’s spatial span was defined as the longest sequence that they can 
reproduce correctly within three attempts.  
 
Therefore outcome measures for this task included: 
 Span length 
 Total usage errors 
 Mean time to first and last response (latency)  
 Number of attempts 
 
Cognitive Flexibility  
Intra/Extra-Dimensional Set Shift (IED)  
Intra/Extra-Dimensional Set Shift (IED) is a test of rule acquisition and reversal. This 
task, previously described by Downes et al. (1989), examines the ability to attend to 
specific attributes which include visual discrimination, attentional set formation 
maintenance, shifting and flexibility of attention (Robbins & Roberts, 2007). This test 
is a computerised analogue of the Wisconsin Card Sorting Test (WCST) and is sensitive 
to changes to the DL-PFC and VL-PFC areas of the brain (Elliott et al., 1995; Downes 
et al., 1989; Durstewitz et al., 2000). The IED took seven minutes to complete 
depending on the level of cognitive impairment. 
 
This task assessed a participant’s ability to first focus attention on specific attributes 
of compound stimuli (intra‐dimensional stages) and then to shift attention, when 
required, to a previously irrelevant stimulus dimension (extra‐dimensional stages). 
Here ‘dimension’ refers to the attributes of an object such as different shapes and 
colours. In this study the two artificial dimensions used were colour-filled shapes and 
white lines. Simple stimuli were made up of just one of these dimensions, whereas 
compound stimuli were made up of both, namely white lines overlying colour-filled 
shapes. The participant started by seeing two simple colour-filled shapes, and must 
learn which one was correct by touching it (Figure 2.7). 
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Figure 2.7: CANTAB and IED Task. Participant asked to chose between two artificial 
dimensions (compound stimuli). 
 
Feedback helped the participant to understand which stimulus was correct, and after 
six correct responses, the stimuli and/or rules were changed. At this point distracting 
stimuli (lines) were added in order to provide compound discrimination stages (CD1 
and CD2). These shifts were initially intra-dimensional (e.g. colour filled shapes 
remained the only relevant dimension). After this stage has been learnt, there was an 
Intra-Dimensional Shift (IDS), where new exemplars of the two dimensions ‘line’ and 
‘shape’ were introduced, but the relevant dimension was unchanged (e.g. colour-
filled shapes remained the only relevant dimension). After an Intra-Dimensional 
Reversal (IDR), there followed an Extra-Dimensional Shift (EDS), when for example 
white lines became the relevant dimension followed by a final reversal stage (EDR) 
(Figure 2.8). 
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Figure 2.8: Schematic of the IED Task. The correct choice for each stage was marked with a 
green box. 
 
Therefore the task proceeded through a series of stages, each with a different 
contingency (up to a maximum of 9 stages) (Figure 2.8): 
 
(1) Simple Discrimination (SD): between two pink shapes or white lines. 
(2) Simple Reversal (SDR): using the same stimuli but with the contingencies reversed.  
(3) Compound Discrimination (C_D or CD1): the contingencies were the same, but 
now there was the addition of a new pattern of either lines or shapes (‘distracters’) 
which were kept separate and the two patterns on the screen do not overlap. The 
pairings of the lines and shapes was pseudo random, with no more than three 
consecutive trials with the same pairings.  
(4) Compound discrimination (CD or CD2): with stimuli overlapping, with 
contingencies kept the same, except for the overlap of the two patterns.  
(5) Compound Reversal (CDR): the contingencies were reversed but the correct 
response was within the same dimension.  
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During the above stages 1–5 (known as the discrimination and learning phases) 
participants could learn through trial and error to select one specific shape while 
ignoring the other shape and lines. The computer gave the participant feedback 
(‘correct’ in the colour green or ‘wrong’ in the colour red). The participants could 
learn a rule to follow to assure that one continued to make correct choices. The type 
of shapes or lines presented in stages 1–5 remained the same. 
(6) Intra-Dimensional Shift (IDS): This is the intra-dimensional shift stage, wherein a 
new set of exemplars was presented and success depended upon continuing to sort 
according to lines or shapes.  
(7) Intra-Dimensional Reversal (IDR): the contingencies within the same stimulus 
dimension were now reversed.  
(8) Extra-Dimensional Shift (EDS): The previously ignored dimension, the ‘distractor’, 
was now the correct dimension by which to sort. That is, if shapes were previously 
correct, now the subject needed to sort according to the lines that were reinforced 
randomly. Stage 8 is analogous to a change in category in the Wisconsin Card Sorting 
Test and requires conceptual flexibility (Owen et al., 1991; Rogers et al., 2000). Set-
shifting represents the ability to switch attention from one aspect of a stimulus to 
another in an ongoing task, as a result of changing reinforcement contingencies 
(Birrell & Brown, 2000). 
 
At this point, the participant was expected to incur an additional challenge because 
they were required to make a substantial shift away from the dimension that had 
been salient for the previous seven tasks, which required only perceptual flexibility 
(Luciana & Nelson, 1998).  
 
(9) Extra-Dimensional Reversal (EDR): Here, the contingencies were reversed within 
the new stimulus dimension.  
 
The task involved nine stages with participants proceeding to the next stage when 
they attain a criterion of six consecutive correct responses. Failure to achieve this 
criterion within 50 trials resulted in the premature discontinuation of the test.  
114 
 
 
 
The main outcome measures of the IED included: 
 Numbers of trials and stages successfully completed 
 Errors (i.e. instances when participant failed to select the stimulus that was 
compatible with the current rule) at each stage, up to the extradimensional 
shift (pre-EDS errors) and at the extradimensional shift (EDS errors). 
 Attrition rate (inability to complete the test resulting in termination of the 
actual tests). Since this has not occurred to any of the four study groups data 
from this part of the task were not analysed in any detail and were not 
discussed further. 
 
Memory and Learning 
(1) Delayed Matching to Sample (DMS) 
Delayed Matching to Sample (DMS) Task assessed forced choice recognition memory 
for novel non-verbalisable (visual) complex and abstract patterns by testing both 
visual matching ability and delayed visual recognition memory. The problem of 
control of a stimulus that has disappeared has long been studied in experimental 
psychology (Hunter, 1913). The delayed matching-to-sample procedure was used in a 
classical experiment by Blough (1959) and has often been used to study 
'remembering' in non-human animals (Sargisson & White, 2001; Urcuioli & Zentall, 
1986).Lesion studies suggest that this task was sensitive to temporal lobe or 
amygdale‐hippocampal damage (Owen et al., 1995).  
 
At the beginning of each trial, a complex, visual and multicoloured pattern consisting 
of four quadrants (stimulus) appeared in the centre of the screen in a box for a 
presentation period of 4.5 seconds (Figure 2.9). 
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Figure 2.9: CANTAB and DMS showing simultaneous matching.  
 
After presentation of the stimulus, the participant choose the identical pattern from a 
set of four stimuli (one correct and three ‘distractors’) after variable periods of 0 or 
immediately, 4 and 12 second delay (also known as delayed matching) or during a 
simultaneous matching condition in which the target and four choices appeared 
together (Figure 2.9).  
 
Only one of the choice patterns is identical to the target. One of the other choice 
patterns is a novel distracter, differing in both colour and form from the target. The 
remaining two choice patterns are ‘partial distracters’ in that one has the colours of 
the target but the form of the novel ‘distracter’, whilst the other has the form of the 
target but the colours of the novel ‘distracter’. In addition, each of the four choice 
patterns has one (random) quadrant in common to discourage mnemonic strategies 
based on remembering the colour and form of a single quadrant.  
 
The participant’s response elicits an auditory tone and visual feedback in the form of 
green ticks and red crosses. If the participant made an incorrect response they were 
required to continue to choose until the target stimulus was chosen. 
 
Following one practice trial (simultaneous, 0 second and 12 second delays), a total of 
four sets of 10 trials were presented with each of the four conditions presented in a 
pseudorandom order. The task took about 15 minutes to complete all trails. 
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The primary outcome measures in this task included: 
 Speed of response 
 Total number of correct targets chosen at each of the simultaneous and delay 
conditions. The difference between simultanoeus and delay conditions gave a 
good overall impression of visual memory ability.  
 
(2) Paired Associate Learning (PAL) 
Paired Associate Learning (PAL) Task assesses visual working memory and visuo-
spatial associative learning (explicit memory). The task contains aspects of both a 
delayed response and conditional learning procedures. The explicit memory 
component of this task is considered as part of fronto-temporal function (Potvin et 
al., 2005). 
 
In the initial (presentation) stage the six boxes were displayed on the screen and 
opened in a pseudo-random order, one at a time for three seconds to reveal a 
different pattern (complex stimuli) inside. One or more of these boxes contained a 
pattern. After a brief delay the patterns were then displayed in the middle of the 
screen (recall stage), one at a time. The participant was then asked to touch the box 
where the pattern was originally located. If the participant made an error, the 
patterns were re-presented to remind the participant of his/her locations so that the 
participant had another opportunity to indicate the correct locations (Figure 2.10). 
 
Figure 2.10: CANTAB and PAL. The participant was asked to touch the box and successfully 
identify where the pattern was originally located.  
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The test began at a very easy level with a single pattern in one of the boxes. Then 
gradually the test became more difficult with two and three pattern sets before tests 
with six and finally eight items (eight boxes on the screen) were finally reached. This 
ensured that the tests were suitable for varying level of neuropsychological 
impairment. Feedback was not provided after each participant response, but if all 
choices were correct the words ‘all correct’ appeared on the screen and the computer 
progressed to the next sequence. If the choice were incorrect, the boxes reopened 
for a further two seconds each, and the participant was given further attempts (up to 
a maximum of 10 trials in total, at which point the programme terminated) until 
he/she choose all correct locations. The task took about 10 minutes to complete all 
trials. 
 
The main outcome measures in this task included:  
 Total number errors made 
 Number of trials required to locate the pattern(s) correctly 
 Stages completed 
 Memory scores.  
 
(3) Pattern Recognition Memory (PRM) 
The Pattern Recognition Memory (PRM) Test is a two-choice forced discrimination 
paradigm and assesses the participant’s ability to recognise a previously presented 
abstract pattern from two adjacent stimuli. This test was often used, in conjunction 
with  Spatial Recognition Memory (SRM) , before the Paired Associates Learning (PAL) 
task as both these tests helped to train the subject for PAL. PRM and SRM contained 
different elements of PAL and the results considered together help to decide on the 
exact nature of the neuropsychological deficit being considered (Sahakian et al., 
1988). Lesion studies suggested that this task was sensitive to either temporal lobe or 
amygdale‐hippocampal, but not to frontal lobe excision (Owen et al., 1995).  
 
This task was presented in two phases. Initially the participant was presented with a 
series of twelve simple but abstract, coloured visual patterns, appearing one at a 
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time, inside a white box located in the centre of the screen (presentation phase). 
These patterns were designed so that they cannot easily be given verbal labels and no 
encouragement was given to the participant to use verbal labels. Each of these 
‘target’ patterns was presented for 3 seconds, the screen was then cleared and the 
next pattern appeared. 
 
Following a 5 second delay in the second recognition phase, the participant choose 
between a pattern he/she has already seen or a novel (distracter) pattern that 
differed in form but not in colour from the target (Figure 2.11). The participant then 
made a ‘forced-choice’ discrimination by touching the pattern he/she has seen 
previously. In this phase, the test patterns were presented in the reverse order to the 
original order of presentation. The participant was then required to respond to each 
pair by touching the pattern they had already seen during the presentation phase. 
Each response was accompanied by an auditory tone and visual feedback was 
automatically provided by the computer in the form of green ticks (for correct 
responses) and red crosses (for incorrect responses). 
 
 
Figure 2.11: CANTAB and PRM during the recognition stage. 
 
This procedure was then repeated with 12 new patterns in each set.  The task took 
about 5 minutes to complete all trials.The primary outcome measures in this task 
included: 
 Mean response latency 
 Number of correct locations chosen across the two trials  
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(4) Spatial Recognition Memory (SRM) 
The Spatial Recognition Memory (SRM) Test is a two-choice forced discrimination 
paradigm and assessed the participant’s ability to recognise and remember the 
spatial locations of target stimuli. This test was often used, in conjunction with 
Pattern Recognition Memory (PRM) , before the Paired Associates Learning (PAL) task 
as both these tests helped to train the subject for PAL. A study using PET scanning has 
shown that this task activates the dorso-lateral prefrontal cortex (Goldberg et al. 
1996), and lesion studies suggested that it was sensitive to frontal but not temporal 
or amygdale‐hippocampal lesions (Owen et al, 1995).  
 
The participant weas presented with a series of five (one‐inch) white squares, 
appearing, one at a time, in sequence at five different locations on the screen 
(presentation phase). Each square was presented for three seconds before the screen 
was cleared and the next square appeared. The participant was instructed to 
remember the location of the five boxes presented. 
 
In the recognition or discrimination phase, the participant saw a series of five pairs of 
squares, one of which was in a place previously seen in the presentation phase (target 
location) (Figure 2.12). The other square (distracter square) was in a location not seen 
in the presentation phase (novel location). The participant was then asked to select 
which of the two locations had been shown earlier.  
 
Figure 2.12: CANTAB and SRM with correctly identified target location paired with a novel 
location. 
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Locations were tested in the reverse of the presentation order. This sub-test was 
repeated four more times, each time with five new locations giving a maximum 
possible score of 20. Again, each response was accompanied by an auditory tone and 
visual feedback in the form of green ticks for correct responses and red crosses for 
incorrect responses. The task took about 5 minutes to complete all trials. 
 
The primary outcome measures in this task included: 
 Mean response latency 
 Number of correct locations chosen across the four trials 
 
Table 2.4: Summary of neuropsychological tasks used in the study and their key outcome 
measures. 
Test Measure 
National Adult Reading Test (NART) v2.0. WAIS-R Full Scale (IQ=70-131), Verbal Scale 
(IQ=72-127) and Performance Scale (IQ=74-128). 
CANTABeclipse v3.0.  
Motor Screening and Big Little Circle (BLC). Not measured.  
Cambridge Gambling Task (CGT). Quality of Decision Making.  
Risk Taking and Overall Proportion Bet 
Deliberation Time or Latency. 
Delay Aversion and Risk Adjustment. 
Affective Go-NoGo (AGN). Total Commissions/Distractor Errors.  
Total Omissions/Target Errors.  
Correct Mean Latency or Reaction Times.  
Stockings of Cambridge (SOC). Initial Thinking Times (at each stage). 
Subsequent Thinking Times (at each stage). 
Problems solved in minimum number of moves. 
Spatial Working Memory (SWM). Total Search Errors (mean,4, 6, 8 move problems). 
Between, Within and Double Search Errors 
(mean, 4, 6, 8 move problems). 
Strategy Score.  
Mean Time to First and Last Response. 
Mean Token Search Preparation Time. 
Spatial Span (SST). Span Length and Total Errors. 
Total Usage Errors and Total Number of Attempts. 
Mean Time to First and Last Response. 
Intra/Extra-Dimensional Set Shifting (IED). Number of Trials and Stages Completed.  
Total Number of Errors. 
Pre-EDs Errors and IDS Errors 
Delayed Matching to Sample (DMS). Mean Correct Latency or speed of response.  
Total Correct Responses(0,4,12 & simultaneous). 
Paired Associate Learning (PAL). Mean Total Number of Errors and Trails. 
Stages Completed and on 1
st
 Trial.  
Memory Score. 
Pattern Recognition Memory (PRM). Mean Correct Latency and Total Number of Trials. 
Spatial Recognition Memory (SRM). Mean Correct Latency and Total number of Trials. 
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Parallel batteries 
The CANTAB tests presented in this thesis referred to the standard tests selected 
from the batteries used at baseline testing (i.e. the clinical version). Parallel versions 
of the tests were used when the same participant was tested more than once. 
Parallel versions for Delayed Matching to Sample (DMS), Intra-Extra/Dimensional Set 
Shifting Task (IED), Paired Associate Learning (PAL), Pattern Recognition Memory 
(PRM), Spatial Recognition Memory (SRM), were available and used. 
 
The parallel versions differ in three key aspects:  
(1) The parallel batteries presented the participant with different patterns and 
locations to be remembered. Specifically, the tasks involved different patterns in each 
battery. (Pattern Recognition, Delayed Matching to Sample, Paired Associate 
Learning). The Spatial Recognition Memory task varied the locations of the boxes to 
be remembered.  
 
(2) Some of these tests (e.g. Paired Associate Learning) were shorter in duration due 
to a reduction in practice trials.  
 
(3) The Big/Little Circle, Stockings of Cambridge, Cambridge Gambling, Spatial Span 
and Affective Go-NoGo tasks were not presented within parallel versions and so 
participants performed these tasks using the clinical version during repeated testing. 
 
Statistical analysis 
General considerations 
This study tested several hypotheses using potentially a large number of outcome 
variables. When a significant difference in scale was recorded between groups one 
needed to be careful that the difference was also meaningful. Difference was 
measured in adjusted p-values (and effect size if significance reached). All data 
analysed were either continuously distributed measurements or dichotomised 
responses. All analyses were conducted using SPSS for Windows V.12 (SPSS Inc. 
Chicago Ill.).  
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Power calculations 
The power calculation for the numbers of participants required to reliably detect 
differences between the HEROIN and METHADONE groups in this study was 
hampered by the lack of comparable data.  
 
The power calculations were therefore based on the data reported by Ornstein et al. 
(2000) and Rogers et al. (1999a) .To detect a difference of three on the strategy score 
for the Spatial Working Memory Task (estimated to represent a conservative measure 
of a ‘real-world’ functional impairment in executive functioning) and to obtain a 
power of 0.8 (with alpha=0.01, two-tailed) the study required 17 completing 
participants in the HEALTHY CONTROL and in the three experimental groups. To 
detect a difference of 1 in the number of perservative responses made during the 
simple discrimination reversal stage of the IED task and to obtain a power of 0.9 (with 
alpha=0.01) the study required 15 completing participants. To accommodate a likely 
attrition rate of 40%, we attempted to recruit 28 participants in each of the four 
groups. 
 
Homogeneity of distribution and standard deviation 
Initial descriptive analyses were conducted to determine whether data met normal 
distribution. 
 
This was tested by:  
(1) Visually displayed a normal curve on a histogram and determine its ‘fit’ with the 
sample data. 
(2) Quantile-Quantile (Q-Q) or Probability-Probability (P-P) Plots using z-scores (Field, 
2009). If the data was normally distributed the observed data ‘fit’ exactly along the 
straight line of the plots. 
(3) Evaluating the skewness (‘asymmetry’ of distribution) and kurtosis (‘pointedness’ 
of the shape of the distribution) of the data analysed. So a normal distribution would 
have a skewness of 0 and a kurtosis of 0. A departure from symmetry was taken to 
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exist if absolute value of skewness and/or kurtosis was more than 1.96 times the 
Standard Error (SE).  
(4) Kologorov-Smirnov (K-S) Test (Field, 2009). A significant value of p<0.05 indicated 
deviation from normality. 
 
Although the assumption of normality of distribution was made in the derivation of 
many significance tests, its importance in the analysis of a data set remains 
controversial (Tabachnich & Fidell, 1996). For example, sample size effects the 
degree to which deviation from normality (non-normality) may affect robustness – 
the larger the sample size the smaller the effect non-normality is likely to have on 
both power and significance level (Pearson, 1929). The relatively small sample size in 
the present study was likely to have increased the effects of non-normality on 
robustness. The majority of theorists in this field argue that violation of the normality 
assumption should be of little concern for most parametric tests (Pearson, 1931; 
Rider, 1929; Tabachnich & Fidell, 1996). Games & Lucas (1966) reported that the 
effect of non‐normality on power of Analysis of Variance (ANOVA) was only 
significant when the non‐normal populations were extremely skewed or leptokurtic. 
Moderate departures from normality had minimal impact on the power or sensitivity 
of tests. However, the literature on robustness of significance testing and the degree 
to which assumptions can be violated is far from conclusive.  
 
The CGT, AGN, SRM, SWM, DMS and SSP tests met assumptions of normality and 
homogeneity of variance were analysed using ANOVA as a between subject factor. 
 
Homogeneity of variance 
Levene’s Test (F) tested the null hypothesis that the variances in the four 
independent groups studied were equal. If Levene’s Test was significant at p<0.05 
then we concluded that the null hypothesis was incorrect and that there was 
heterogeneity of variance. 
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The robustness of ANOVA to violation of homogeneity of variance has been 
intensively studied. Guidelines (Glass et al., 1972) have become more stringent than 
the earlier, more cavalier ones (Box, 1953). The effects of violating both normality 
and homogeneity of variance assumptions were regarded as compounding the impact 
on power and significance of the F‐test. 
 
Dealing with non-normality and unequal variances: transformation of data 
For some non‐normal distributions a transformation can be found, which brings the 
data more closely in line with the normal distribution (Tabachnich & Fidell, 1996). 
This depended on the relationship between the variances and the group means 
(Tukey, 1977).Where necessary, to stabilise variance and to diminish skewness and 
kurtosis, data were subjected to either square root (SQRT) or logarithmic 
transformation (log10) (Fields, 2009). Parametric statistics using ANOVA were 
subsequently conducted. The IED, PRM and SOC outcomes were SQRT transformed 
and PAL outcomes were subjected to log10 transformation. 
 
When transformation was either not possible or the data failed to meet the 
homogeneity of variance assumption, analyses were conducted using non‐parametric 
statistics using Kruskal-Wallis one‐way analysis of variance. No outcomes were 
analysed using non-parametric test. In addition non- parametric tests were also used 
in order to determine whether results from the analysis with transformed data could 
be replicated (Rasmussen & Dunlap, 1991).  
 
Levels of difficulty in neuropsychological tests: repeated measures analysis 
In cases where the tasks included incremental levels of difficulty within the testing 
session it was not possible to use simple ANOVA due to the need to include a second 
within‐subject variable difficulty levels, e.g. Cambridge Gambling Task (ratio of 
coloured boxes), Stockings of Cambridge (2, 3, 4 or 5 problem moves), Spatial 
Working Memory (between/within search errors), Spatial Span (span length between 
1-9), Delayed Matching to Sample (0, 4 and 12 second delays), and Paired Associate 
Learning (1,2,3,6,or 8 shapes).In the CGT one also conducted another within–subject 
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variable direction (descending and ascending orders) level analysis. In all these 
situations, a repeated‐measures ANOVA was conducted. 
 
The homogeneity of variance across groups in repeated‐measures design ANOVAs 
was assessed by the Mauchly Sphericity Test (Mauchly, 1940). Where data sets 
significantly (p<0.05) violated this requirement for a repeated‐measures design 
ANOVA, the Greenhouse Geisser Epsilon (^ε) correction parameter for degrees of 
freedom (Greenhouse & Geisser 1959; Winer et al., 1991) was used to calculate a 
more conservative p value for each F ratio. 
 
Comparison (a priori and post hoc contrasts) of data 
The F-ratio informs only whether the model fitted to the data accounted for more 
variation than extraneous factors, but it does not inform where the differences 
between groups lie. It was therefore necessary after conducting an ANOVA to carry 
out further analysis to find out which out of the four experimental independent 
groups differed (or not). This has been done using both a planned (a priori) and a post 
hoc (Field, 2009) comparison or contrast. A priori comparisons implied that the 
difference might exists but to be completely sure a post-hoc tests were always 
conducted throughout the analysis.  
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Figure 2.13 illustrates the planned contrasts used based upon the hypothesis being 
tested. 
 
Figure 2.13: Planned Comparisons/Contrasts (a priori) based upon the hypotheses being 
tested in this study. 
 
Post-hoc tests consisted of pairwise comparisons, which controlled for family wise 
error by correcting the level of significance, such that the overall Type 1 error rate (α) 
across all comparisons remained at 0.05. The trade off to this procedure is that it 
created a loss in Type 2 (β) error due to loss of statistical power. In this study 
conservative tests where used to control Type 1 error due to the small number in 
experimental groups and large number of neuropsychological variables present. The 
post hoc test used in this study was the Bonferroni correction (Fields, 2007). 
 
Multiple testing 
Since the number of families of neuropsychological tests in this study was five, as 
described in Chapters 1 and 2, the 5% significance level needed to be adjusted. The 
significance level was divided by the number of tests so that only statistical 
significance with p<0.01 will be considered (Sainani, 2009; Ioannidis, 2005). This 
minimised effects due to multiple comparisions,subgroup analyses and/or repeated 
measures when one was considering a family of statistical inferences simultaneously. 
Contrast 1 
• HEROIN + METHADONE + CHRONIC PAIN + HEALTHY 
CONTROL groups 
Contrast 2 
• (HEROIN + METHADONE) groups vs (CHRONIC PAIN + HEALTHY 
CONTROL) groups. Comparing opioid dependent cohort from cohorts 
who are non-opioid dependent 
Conrast 3 
• (HEROIN vs METHADONE vs HEALTHY CONTROL) or (HEROIN vs 
METHADONE vs CHRONIC PAIN). Comparing the two different opioid 
dependent groups with each other and with one of the two different 
control groups 
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Even though all multiple comparisons were post hoc Bonferroni corrected, this 
process helped in applying caution in the interpretation of the results obtained in this 
study (Sainani, 2009). 
 
Significance levels 
If a test gives a p-value lower than the significance level α, the null hypothesis is 
rejected. Smaller levels of α increases confidence in the determination of significance, 
but run an increased risk of failing to reject a false null hypothesis (Type II error) and 
so have less statistical power. The selection of the level α thus inevitably involves a 
compromise between significance and power, and consequently between the Type I 
error and the Type II error. More powerful studies can obviate this choice to an 
arbitrary degree (Fields, 2007). 
 
Results below a p level of 0.01 were described in this thesis as significant.They were 
then  qualified as achieving p<0.01, p<0.005 or p<0.001 levels accordingly. Outcome 
data between p<0.05 and p>0.01 were described in this thesis as having a non-
significant trend if they were considered relevant to substantiate the interpretation of 
the significant results. 
 
Effect size calculations 
Effect sizes were calculated when appropriate and when results were significant. An 
effect size is a measure of the magnitude or strength of a relationship between two 
variables or the degree to which the null hypothesis is false (Borenstein et al., 2009).  
 
The calculation of effect sizes standardised the magnitude of the difference between 
groups such that a 1‐point difference indicated that the groups differed by 1 standard 
deviation on a particular outcome measure. There were several different techniques 
for calculating effect sizes. In this study Cohen’s d which was defined as the difference 
between two means divided by the pooled standard deviation for those means was 
used (Cohen, 1992).  
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Cohen’s d was calculated using the formula: 
  
             
              
 
 
SD = Standard Deviation.  
 
Cohen suggested that an effect size (d) of ≤ 0.2 should be considered small, 0.5 – 0.79 
medium and more than 0.8 as large (Cohen, 1992). 
 
Specific statistical considerations relevant to the neuropsychological assessments 
The Cambridge Gambling Task (CGT) had six outcome measures, each of which had 
one or two options applied to it. The options were categorised into gamble type  
(ascending or descending orders) expressed as direction and ratio (5:5; 4:6; 3:7; 2:8; 
1:9) chosen expressed as difficulty. Therefore analysis on quality of decision making, 
deliberation time, risk taking and risk adjustment were conducted together for 
direction and difficulty and then separately (Passetti et al., 2008; Fishbein et al., 
2007; Ersche et al., 2005a, 2005b).  
 
For analysis of performance on the Affective Go-NoGo (AGN) task, trials were divided 
into two options. Option 1 was shift or non- shift and Option 2 tested the negative or 
positive valence target types. Therefore analysis on commissions, omissions, and 
latency data were conducted separately for option 1 and 2. 
 
In the Stockings of Cambridge (SOC) task comprised mean moves during a 2, 3, 4 and 
5-move problems (difficulty levels), and mean initial and subsequent thinking times. 
Therefore analyses of data were conducted separately for all above four move 
problem scenario. This method of analyses was used in other studies using this task 
(Ornstein et al., 2000; Fishbein et al., 2007a; Ersche et al., 2005a, 2005b). 
 
The Spatial Working Memory (SWM) task comprised of  between, within, double and 
total errors during a 4, 6, 8-box problems (difficulty levels). Analyses of data were 
conducted separately for all above three move problem scenario. 
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The Intra/Extra-Dimensional (IED) Set Shifting task had been analysed in studies using 
the CANTAB tests in a variety of ways (Ersche et al., 2006b). Measures analysed in 
this study were the total number of stages the participant completed successfully, 
total number of trials completed on all attempted stages and errors at every stage. 
This included analysis of data reaching ID Shift and Reversal (Stages 6 & 7 or also 
known as Pre-EDS stage), ED Shift and ED Reversal stages (Stages 8 and 9). Analysis 
was conducted in accordance with other studies using this task in opioid dependent 
individuals (Ornstein et al., 2000).  
 
The Delayed Matching to Sample (DMS) task composed of a simultaneous condition 
and three delay (0, 4, & 12 second) conditions. Unlike the simultaneous condition, 
where the target stimulus remained on the screen, the delay conditions assessed the 
participant’s ability to recognise the target pattern from memory. Therefore analyses 
on percentage correct and latency data were conducted separately for simultaneous 
and delay conditions. This method of analyses was used in other studies using this 
task (Owen et al., 1995). 
 
For the Pattern and Spatial Recognition Memory (PRM & SRM) tasks data from 
outcomes measuring number of trials and latency were analysed as a total of all the 
blocks tested.  
 
Specific statistical considerations relevant to the hypothesis driven analysis 
Specific statistical considerations relevant to the analyses presented were described 
at the beginning of Chapters 4, 5 & 6. 
 
Ethical and research governance 
Dr Alex Baldacchino was the registered Chief Investigator for this study with Professor 
Keith Matthews and Professor David Balfour as co-investigators. 
 
The study was approved by the Tayside Committee on Medical Research Ethics (A) 
administered by the East of Scotland Research Ethics Service. The REC reference 
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number is 06/S1401/32 and the study was approved on the 5th May 2006. The study 
also had favourable ethical approval from the University of St Andrews Ethics 
Committee on the 9th January 2008. 
 
Site Specific Assessment (SSA) approvals were given to all study sites (SSA reference 
numbers: 06/S0501/33; 34; & 35) and subsequently NHS Fife and NHS Tayside 
Management Approvals were issued. 
 
The University of Dundee accepted to be the sponsor to this study under the 
Research Governance Framework (RGF) for Health and Community Care (Ref: 
EB/LM/LET201/18184). 
 
The study was also registered on the NHS Fife Information Services Database Register 
in order to comply with the Data Protection Act 1998. The study was then audited by 
NHS Fife Research and Development Department on the 11th November 2008 and the 
17th November 2010 on both occasions giving a favourable opinion. 
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Chapter 3: Results-Descriptive Data 
 
The aims of this study were to determine if: 
1. Chronic exposure to opioids (prescribed and/or illicit) is associated with 
measurable neuropsychological deficits. Specifically it was predicted that 
these deficits were greatest on measures of so-called ‘executive 
neuropsychological functioning’- the abilities to plan, to organise and to 
sequence behaviour. 
2. The deficits identified depend upon the nature of the opioid (long acting 
opioids compared with short acting opioids) or the context (prescribed opioids 
compared with illicit opioids) or status (opioid dependence compared to non –
opiod dependence and injecting compared to non-injecting opioid dependent) 
in which it was used. 
 
The hypotheses to be tested are: 
1. Is chronic opioid dependence associated with neuropsychological impairment 
reflected in altered performance on measures of impulsivity, cognitive 
flexibility and memory?  
2. In patients with chronic opioid dependence, is injection status associated with 
neuropsychological impairment as reflected in altered performance on 
measures of impulsivity, cognitive flexibility and memory?  
3. In patients with chronic opioid dependent is the degree of acute opioid 
exposure (acute intoxication, withdrawal or stable initial exposure to 
methadone), or duration of opioid exposure (period of methadone 
maintenance) associated with neuropsychological impairment as reflected in 
altered performance on measures of impulsivity, cognitive flexibility and 
memory?  
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Statistical considerations 
Basic statistical considerations have been described in Chapter 2 of this thesis. 
 
Baseline demographic characteristics of cohorts and control populations  
Full details of the recruitment and assessment process were described in Chapter 2 of 
this thesis .To summarise: 
 
1. HEROIN Group: Twenty four male participants were recruited aged between 
18 and 30 years old entering a structured methadone maintenance treatment 
programme and attending Tayside and Fife NHS Addiction Services. The 
participants had confirmed histories of more than three years of regular, daily 
illicit opioid (heroin) use and met criteria for a diagnosis of opioid dependence 
syndrome according to DSM-IV. To merit inclusion, they were required to be 
taking between 0.4 g and 1.5g of heroin intravenously daily, or to have 
smoked heroin such that they have achieved a similar degree of drug 
exposure leading to an estimated equivalent daily methadone dose of 40-
120mg. They were naïve to methadone and other types of prescribed opioids. 
These participants were assessed on entry to, and following stabilisation with, 
methadone within the treatment programme.  
 
2. METHADONE group: Twenty nine opioid dependent males aged between 18 
and 30 years old were recruited. They have been stable on methadone for 
more than six months with retrospective objective confirmation of the 
absence of illicit drug use (including heroin) during this period. Eighteen of 
these participants where followed up after a further six months and re-
evaluated to identify changes in cognitive functioning. 
 
3. CHRONIC PAIN Group: Twenty eight males were recruited from the NHS 
Tayside Chronic Pain Clinic, aged between 18 and 40 years, who had a history 
of more than three years of continuous prescribed opioids, with no past or 
current history of illicit drug (e.g. heroin) use and/or methadone treatment. 
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4. HEALTHY CONTROL group: Twenty eight healthy control males aged between 
18 and 40 years old were recruited. They had no past or current history of 
chronic pain and/or illicit substance use, or a lifetime continuous/regular 
prescription of opioids. 
 
The cohort of non-heroin abusing individuals (CHRONIC PAIN) recruited from the 
Chronic Pain Clinic, helped identify the possible effects of drug adulterants and other 
potential confounders present in a ‘drug addict lifestyle’. The cohort of methadone 
maintained and stable individuals (METHADONE) helped to retrospectively identify 
the possible contamination effect of previous illicit heroin use in the HEROIN group 
and prospectively test for deterioration or improvement.  
 
Representativeness of the recruited opioid dependent groups (HEROIN and 
METHADONE groups) 
The demographic characteristics of the recruited cohort who completed the study 
testing  were compared with those of (a) the total opioid dependent population on a 
national and regional level, (b) the local drug-treatment seeking population who did 
not want to participate (non-participants) and (c) participants who did not complete 
the study (non- completers).  
 
For estimates of problem drug use in the United Kingdom information was collected 
from those in contact with general practitioners, outpatients or community based 
drug services and inpatient services using either capture-recapture or multiple 
indicator methodologies (Frischer et al, 2004;EMCDDA, 2008). This provided the 
opportunity to compare the demographic characteristics of the UK drug taking 
population with that of the characteristics of the HEROIN and METHADONE groups in 
this study. 
 
Other sources of comparison included information obtained from the (a) National 
Treatment Outcome Research Study (NTORS) (Gossop et al., 1997), (b) National Drug 
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Treatment Monitoring System (NDTMS) (Hay & Bauld, 2008) and related Drug 
Treatment Outcome Research Study (DTORS) (Jones et al., 2007) for England and the 
(c) Drug Misuse Prevalence Study (Hay et al., 2005) through the Information Services 
Division (ISD) for Scotland. All these databases were based on systematic recording of 
national datasets on patients seen at a broad range of services and held information 
on demographic and behavioural characteristics of patients attending treatment 
services. 
 
Table 3.1: Comparison of the sociodemographic characteristics of study participants with histories of 
opioid dependence (HEROIN and METHADONE groups) and those reported in earlier population 
studies and estimates provided by ISD. 
 
       
     N 
Mean 
age 
(yrs) 
Male 
(%) 
SIMD  Ethnicity 
% white 
Unemp 
(%) 
Stable 
housing 
Status 
(%) 
Education 
(%) 
Daily 
heroin 
use  
(gms) 
Inject 
(%) 
Heroin 
use  
(yrs) 
NTORS  1075 29.3 74 n/a 91 88 80 n/a 0.75 62 9 
NDTMS/DTORS  77849 29.5 73 n/a 89 85 78 49 0.75 50 9 
ISD (Scotland) 7047 30 67 n/a 96 84 83 n/a 0.75 56 >5 
ISD (Fife & 
Tayside) 
1441 29 65 n/a 96 86 82 n/a n/a 58 n/a 
Combined 
HEROIN and 
METHADONE 
group 
53 26.7 100 3.52 100 87.4 90 54 0.59 75.7 7.5 
DTORS=Drug Treatment Outcome Research Study, ISD=Information Services Division or Drug Misuse 
Prevalence Study, NTORS=National Treatment Outcome Research Study, NDTMS=National Drug 
Treatment Monitoring System, SIMD=Scottish Index of Multiple Deprivation,  
%= Percentage, gms=grams in weight; Inject= lifetime injecting, yrs=years, education= completed 12 
years of education, Unemp= unemployment, n/a= information not available, n= number of patients, >= 
more than. Completed 12 years of education Completed 12 years of education ompleted 12 years of education 
 
 
When the combined HEROIN and METHADONE groups recruited were compared to 
the population studies mentioned above, they did not differ significantly with respect 
to completing primary and secondary school education (p=.23), , daily heroin use 
(p=.48) and chronicity of heroin use (p=.69). There was a significant difference in 
housing with more individuals in the experimental group having a stable 
accommodation (p<0.005), as well as a younger age group (p=.02),more 
unemployment (p=.04) and more lifetime injecting (p=.02) in the experimental group 
(Table 3.1). 
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Table 3.2: Sociodemographic characteristics of the non-completers, non-participants and 
participants of the HEROIN and METHADONE groups. 
 
 N Mean 
age 
(yrs) 
Male 
(%) 
SIMD 
 
Ethnic 
(% 
white) 
Unem 
(%) 
Stable 
house 
(%) 
Edu 
(%) 
 
Daily 
heroin 
use  
(gms) 
Injec 
(%) 
Injecting 
in last 
30 days 
Her
oin 
use  
(yrs) 
HEROIN 
group 
identified 
36 25.8 100 3.8 100 90.3 87 53 0.60 62.5 n/a 6.8 
HEROIN 
group 
recruited 
28 26.3 100 3.6 100 88.5 89 50 0.60 60.7 12 6.3 
HEROIN 
group  
completed 
24 26 100 3.6 100 88.5 87 50 0.60 62.5 12 6.1 
METHADO
NE group 
identified 
42 26.6 100 3.5 100 86.4 95 67 0.59 86 0 8.5 
METHADO
NE group 
recruited 
29 27.3 100 3.4 100 86.2 93 58 0.58 89 0 8.8 
SIMD=Scottish Index of Multiple Deprivation, Ethnic= ethnicity, Injec= lifetime injecting, %= 
Percentage, yrs=years, gms=grams in weight, N= patient numbers involved, n/a= information 
not available, edu= completed 12 years of education, unem= unemployment. 
 
The recruited individuals for both the HEROIN and the METHADONE groups were 
young with a mean age of 26.7 years, all ethnically white Scottish and living in 
moderately deprived areas (median SIMD score of 3.5) of Fife or Tayside. Only 54% 
completed full time primary and secondary education with only 12.7 % employed at 
the time of the recruitment stage of this study. Most (90%) were living in stable 
accommodation. The average daily heroin dose was 0.59g which would be a 
morphine equivalent of 200mg if one is assuming that the heroin was 100% pure with 
no adulterants present (Vieweg et al.,2005; Hallenbeck, 2003).  Eighty nine percent 
of the METHADONE group significantly but subjectively described a lifetime history of 
injecting heroin (p<0.001) when compared to 62.5% of the HEROIN group. There was 
also a significant difference in the chronicity of heroin use between the HEROIN group 
(6.1 years) and the METHADONE group (8.8 years) prior to accessing treatment to 
start methadone stabilisation (p<0.001).This information was again not confirmed 
objectively (Table 3.2). There were no significant differences between non- 
participants, non-completers and cohort participants in all of the sociodemographic 
characteristics. 
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Comparison of sociodemographic and clinical characteristics of experimental and 
control groups 
Preliminary analysis of all the experimental and control groups separately indicate 
that the samples did not come from normally distributed populations with the same 
standard deviation. A planned (a priori) contrasts analysis was therefore run to test 
for significant differences between the four independent study groups.  
 
A Kruskal-Wallis Test compared the three experimental groups and the healthy 
control group with each other (describing this process as ‘HEROIN vs METHADONE vs 
CHRONIC PAIN vs HEALTHY CONTROL groups’). The result showed that the four 
groups differed with respect to: 
 
(A) NART, age in years, employment, years in education, SIMD, and Fagerström total 
score from the sociodemographic characteristics. 
 
(B) Age when first used alcohol from the drug and alcohol use histories. 
 
To test the null hypothesis of no differences between the four groups a Mann 
Whitney U test was subsequently done with collapsed groupings using the same 
above demographic variables in order to determine where these differences lie 
(Tables 3.3 & 3.4). The collapsed groupings included:  
 HEROIN vs METHADONE groups. 
 CHRONIC PAIN vs HEALTHY CONTROL groups. 
 HEROIN vs CHRONIC PAIN groups. 
 METHADONE vs CHRONIC PAIN groups. 
 HEROIN vs HEALTHY CONTROL groups. 
 METHADONE vs HEALTHY CONTROL groups.  
 (a) The HEROIN and METHADONE groups did not differ significantly. These groups 
had a similar (homogenous) drug use history, morphine equivalent dosages, and drug 
use history 30 days prior to the baseline neuropsychological testing (except the fact 
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that the HEROIN group where NOT on methadone and the METHADONE group were 
stable on methadone and so did not take either illicit methadone or heroin) (Tables 
3.3 & 3.4).  
 
Table 3.3: Comparison of sociodemographic and clinical characteristics of experimental and 
control groups*  
 HEROIN  METHADONE  
 
CHRONIC 
PAIN 
HEALTHY 
CONTROLS 
Sig¹. 
HEROIN vs 
METHADONE 
 
Sig.¹ 
HEROIN 
vs P/C  
Sig.¹ 
METHADONE  
vs  P/C 
N 24 29 28 28 n/a n/a n/a 
Ethnicity (% 
white) 
100 100 100 100 n/a n/a n/a 
Age (yrs) 26.3 
(3.45) 
27.3 (2.34) 33.97 
(4.35) 
24.12 
(3.56) 
p=.38 H >P= 
p<0.001 
 
M >P/C = 
p<0.005 
R:L 23:1 28:1 27:2 28:0 n/a n/a n/a 
SIMD 3.6(1.9) 3.41 (1.4) 4.6(2.00) 5.9 (2.5) p=.72 H >C = 
p<0.001 
M >P p<0.01,  
M>C  = 
p<0.001 
Unemployed 
(%) 
87.5 86.2 50 0 p=.86 P<0.001 p<0.001 
Stable 
accommodation 
(%)² 
87 
 
93 100 92.8 p=.67  M >P = 
p<0.005 
 
Education (yrs) 10.8(1.5) 10.6 (2.3) 11.18 
(1.22) 
15.4 (2.1) p=.57 H >C = 
p<0.001 
H>C = 
p<0.001 
Fagerström 
total score 
5.2 (2.7) 4.5 (2.7) 1.3(1.9) 0.04 (0.2) p=.41 p<0.001 p<0.001 
NART (IQ) 106.1 
(12.2) 
108.9 (7.6) 115.9 
(4.9) 
118.3 (5.1) p=.92 p<0.001 
 
C>M = 
p<0.001 
P>M= 
p<0.01) 
 
Sig ¹= significance at p<0.01 two tailed, ²Stable accommodation = own house + rented 
accommodation + living with parents (excluded hostel, student and homeless), *=mean total 
scores (+/- standard deviation), P=CHRONIC PAIN Group, C=HEALTHY CONTROL Group, H= 
HEROIN Group, M= METHADONE Group, n/a =not applicable, yrs=years; R:L= Right: Left 
Handedness, SIMD= Scottish Index of Multiple Deprivation, NART= National Adult Reading 
Test, IQ= Intelligence Quotient, %= percentage, ns=not significant, N=Total number in group. 
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Table 3.4: Comparative drug and alcohol use histories (self reported) in experimental and control 
groups.* 
 HEROIN 
 
METHADONE 
 
CHRONIC 
PAIN 
 
HEALTHY 
CONTROLS 
 
Sig.¹ 
HEROIN VS 
METHADONE 
Sig.¹ 
HEROIN 
vs P/C 
Sig.¹ 
M vs P/C 
Daily  intake 
expressed as 
morphine 
equivalent dose 
(mg)*¹ 
184.5 
(82.1) 
(n=24) 
 147.4 (59.3) 
(n=29) 
59.1(46.8) 
(n=28) 
       n/a p=.09 H >P = 
p<0.001 
M>P = 
p<0.001 
Age when first used 
heroin (yrs) 
19.4 (4.1) 
(n=24) 
17.9  
(2.6) 
(n=29) 
      n/a        n/a p=.46 n/a n/a 
Age when using 
opioids regularly 
(yrs) 
20.2 
(3.7) 
(n=24) 
19.5 (2.8) 
(n=29) 
      n/a         n/a P=.63 n/a n/a 
 
Age when 
dependent on 
opioids 
20.9 (3.9) 
(n=24) 
19.9(2.8) 
(n=29) 
      n/a        n/a p=.49 n/a n/a 
Age when injecting 
opioids  
20.5 (4.0) 
(n=17) 
19.1 (6.0) 
(n=29) 
      n/a        n/a p=.02 n/a n/a 
Years of opioid use 6.1 (2.9) 
(n=24) 
 8.8 (2.8) 
(n=29) 
5.0 (2.3) 
(n=28) 
        n/a M>H = 
p<0.001 
p=.21 M>P = 
p<0.001 
Stable methadone 
use (years) 
   n/a 1.3 (0.5) 
(n=29) 
       n/a         n/a n/a n/a n/a 
Days of illicit 
methadone in last 
30 days 
1.8(3.7) 
(n=10) 
    n/a        n/a         n/a n/a n/a n/a 
Days of heroin use 
in last 30 days 
29.5(2.7) 
(n=24) 
 0.8 (3.9) 
(n=3) 
        n/a         n/a n/a n/a n/a 
Age when first used 
benzodiazepine 
(years) 
16.82(3.3) 
(n=17) 
16.2 (3.5) 
(n=17) 
       n/a         n/a p=.18 n/a n/a 
Days of 
benzodiazepine use 
in the last 30 days 
3.0(4.6) 
(n=12) 
3.2 (0.8) 
(n=4) 
0.1 (0.8) 
(n=1) 
        n/a       p=.88 H>P = 
p<0.001 
p=.19 
Age when first used 
Cocaine (years) 
17.7 (2.3)  
(n=10)        
18.1 (2.5) 
(n=9) 
      n/a         n/a p=.49 n/a n/a 
Days of cocaine use 
in last 30 days 
      n/a      n/a      n/a         n/a n/a n/a n/a 
Age when first used 
cannabis (years) 
12.83(1.6) 
(n=23) 
12.9 (1.4) 
(n=29) 
26.0(10.3) 
(n=5) 
        n/a p=.49 H >P  = 
p<0.001 
M >P = 
p<0.001 
Days of cannabis 
use in last 30 days 
12.3(13.4) 
(n=15) 
14.7 (14.2) 
(n=18) 
2.9 (8.0) 
(n=5) 
        n/a p=.75 H>P  = 
p<0.001 
M>P = 
p<0.001 
Age when first used 
alcohol (years) 
12.5(1.3) 
(n=24) 
12.7(1.9) 
(n=29) 
15.2(1.2) 
(n=28) 
14.7 (0.6) 
(n=28) 
p=.89 H>C = 
p<0.001 
M>C = 
p<0.001 
Days of alcohol use 
in last 30 days 
2.2(6.1) 
(n=10)   
4.0(4.9) 
(n=15) 
5.1(8.3)   
(n=17) 
4.0 (6.3) 
(n=17)  
p=.14 p=.06 p=.83 
Sig ¹= significance at p<0.01, *=mean total scores (+/- standard deviation), n/a= not applicable, 
P=Chronic Pain Group, C=Healthy Control Group, H= Heroin Group, M= Methadone Group, n=number in 
group analysed, yrs=years, n= number of individuals analysed, mg=milligrammes, *¹= morphine 
equivalent with heroin purity of 40%. 
 
 
(b) Groups with no history of illicit substance misuse and no opioid dependence 
(CHRONIC PAIN and HEALTHY CONTROLS) where compared. Analysis showed 
significant differences with the CHRONIC PAIN group being older (p<0.001), more 
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unemployed (p<0.001), less educated (p<0.001), and more dependent on nicotine 
(p<0.001) than the HEALTHY CONTROL group. Both groups were similar in SIMD 
(p=.10), accommodation status (p=.12) and NART (p=.07).  
 
(c) The opioid dependent groups (HEROIN and METHADONE) were different from 
either the CHRONIC PAIN or HEALTHY CONTROL groups in most of the 
sociodemographic and substance misuse history domains. The nature and 
consequences of substance misuse was most obvious when one looked at current 
nicotine use and dependence status which showed that all individuals in the HEROIN 
group, and all but one individual in the METHADONE group smoked. This compared 
with only one individual in the HEALTHY CONTROLS who smoked. First initiation to 
alcohol use also showed a tendency for the HEROIN and METHADONE groups starting 
about two years earlier than the CHRONIC PAIN and/or the HEALTHY CONTROL 
groups (Tables 3.3 & 3.4). 
 
In summary NART, age in years, Fagerström total score and past alcohol use have 
been used as co-variates for further analysis of all the four groups. 
 
Comparison of sociodemographic and clinical characteristics of the intra-cohort 
groups 
Further Mann Whitney U test was done with intra-cohort groupings using the above 
demographic variables in order to determine where, if any, differences lie between 
the following groups: 
 HEROIN group: Between participants who experienced lower third (n=8) and 
upper third (n=8) levels of the opioid withdrawal scale (COWS) scores.  
 METHADONE group: Between participants tested at baseline (n=29) and then 
followed up after 6 months (n=18). 
 INJECTING: Between participants with a lifetime subjective history of injecting 
illicit opioids (n=41) and others with no history of injecting (n=11). These 
groups were selected from the HEROIN and METHADONE groups. 
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(a) When the participants from the HEROIN group with a Clinical Opiate Withdrawal 
Scale (COWS) of between 8-14 (lower 8) were compared with the same HEROIN 
cohort with COWS of 18-25 (upper 8) it did not differ significantly with respect to age 
(p=.88), SIMD score (p=.75), years in education (p=.38), years when starting using 
alcohol (p=.07), alcohol amount used in last month (p=.87), current smoking 
dependence (Fagerström scores) (P=.96) and NART (p=.02). 
 
(b) There were no significant differences between the 29 participants of the 
METHADONE group at baseline and the 18 participants from the same METHADONE 
group followed up after six months (Table 3.5 & 3.6).  
 
Table 3.5: Group descriptions of sociodemographic characteristics*.  
 METHADONE 
group at initial 
testing session  
METHADONE 
group  after 6 
months from 
baseline 
Sig.¹ 
 
N 29 18 n/a 
Ethnicity (% white) 100 100 n/a 
SIMD 3.4 (1.4) 3.6 (1.7) p=.22 
Age (yrs) 27.3 (2.3) 27.4 (2.1) p=.82 
R:L 28:1 18:0 n/a 
% unemployed 86.2 83.3 p=.85 
% stable 
accommodation² 
93 88.8 p=.16 
Yrs in education 10.6 (2.2) 10.8 (2.4) p=.87 
Fagerström total 
score 
4.5 (2.7) 5.4 (2.3) p=.03 
NART (IQ) 108.9 (7.6) 106.9 (7.7) p=.07 
Sig ¹= significance at p<0.01, ²Stable accommodation = own house + rented accommodation + living 
with parents (excluded hostel, student and homeless), *=mean total scores (+/- standard deviation), M= 
METHADONE Group, n/a =not applicable, yrs=years; R:L= Right: Left Handedness, SIMD= Scottish Index 
of Multiple Deprivation, NART= National Adult Reading Test, IQ= Intelligence Quotient, %= percentage, 
N=Total number in group. 
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Table 3.6: Comparative drug and alcohol use histories.* 
 METHADONE  
group at initial 
testing session 
(N=29) 
METHADONE 
group after 6 
months from 
baseline (N=18) 
Sig.¹ 
Morphine equivalent 
dose(mg)*¹ 
147.4 (59.3) 
(n=29) 
154.9 (48.7) 
(n=18) 
p=.40 
Age when first used 
heroin (yrs) 
17.9 (2.6) 
(n=29) 
18.3 (2.6) 
(n=18) 
p=.25 
Age when first used 
other opioids (yrs) 
16.8 (2.1) 
(n=29) 
16.7 (2.1) 
(n=18) 
p=.89 
Age when using 
opioids regularly (yrs) 
19.5 (2.8) 
(n=29) 
20.1 (3.1) 
(n=18) 
p=.14 
Age when dependent 
on opioids (yrs) 
19.9 (2.8) 
(n=29) 
20.5 (3.1) 
(n=18) 
p=.49 
Age when injecting 
opioids  
19.1 (6.0) 
(n=11) 
21.0 (3.1) 
(n=8) 
p=.06 
Opioid use (yrs)  8.8 (2.8) 
(n=29) 
9.39 (2.9) 
(n=18) 
p=.18 
Stable methadone use 
(yrs) 
1.3 (0.5) 
(n=29) 
1.2 (4.9) 
(n=18) 
p=.22 
Days of illicit 
methadone in last 30 
days 
    n/a n/a n/a 
Days of heroin use in 
last 30 days 
 0.8 (3.9) 
(n=2) 
0.05 (0.2) 
(n=4) 
p=.31 
Age when first used 
benzodiazepine(yrs) 
16.2 (3.5) 
(n=28) 
15.2 (1.8) 
(n=18) 
p=.66 
Days of 
benzodiazepine use in 
the last 30 days 
 0.2 (0.8) 
(n=2) 
0.1 (0.4) 
(n=4) 
p=.52 
Age when first used 
Cocaine (yrs) 
18.1 (2.5) 
(n=11) 
19.0 (2.5) 
(n=18) 
p=.84 
Days of cocaine use in 
last 30 days 
     n/a n/a n/a 
Age when first used 
cannabis (yrs) 
12.9 (1.4) 
(n=29) 
13.2 (1.5) 
(n=18) 
p=.26 
Days of cannabis use 
in last 30 days 
14.7 (14.2) 
(n=29) 
11.28 (14.1) 
(n=18) 
p=.81 
Age when first used 
alcohol(yrs) 
 12.7 (1.9) 
(n=29) 
12.83 (2.2) 
(n=18) 
p=.82 
Days of alcohol use in 
last 30 days 
4.0 (4.9) 
(n=29) 
4.00 (4.9) 
(n=18) 
p=.62 
Sig ¹= significance at p<0.01, *=mean total scores (+/- standard deviation), n/a= not 
applicable, n=number in group analysed, yrs=years, mg=milligrams, N=total number in study 
group, *¹= morphine equivalent assuming 40% heroin purity. 
 
 
(c) There were no significant differences in most characteristics when the 43 injecting 
opioid dependent participants from both the HEROIN and METHADONE groups were 
compared with the 10 non- injecting participants from the same collapsed grouping. 
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The NART score was the only variable to be significantly in favour to the injecting 
group (p<0.01) (Tables 3.7 & 3.8).Therefore NART has been used as a co-variate for 
further analysis of this grouping 
 
 
Table 3.7: Group descriptions of sociodemographic characteristics* between  
INJECTING and non- injecting groups within the opioid dependent cohorts. 
 Injecting Non-Injecting Sig¹ 
 
N 43 10 n/a 
Ethnicity (% white) 100 100 n/a 
SIMD 3.42 (1.48) 3.90 (2.02) p=.41 
Age (yrs) 26.85(2.79) 26.86(3.51) p=.83 
R:L 20:1 9:1 p=.51 
% unemployed 88.4 80 p=.47 
% stable 
accommodation² 
88.4 90 p=.20 
Yrs in education 10.56 (2.0) 11.10 (1.37) p=.61 
Fagerström total 
score 
4.95 (2.80) 4.20 (2.89) p=.48 
NART (IQ) 109.33(8.93) 100.30(11.20) p<0.01 
Sig ¹= significance at p<0.01, ²stable accommodation = own house + rented accommodation + 
living with parents (excluded hostel, student and homeless), *=mean total scores (+/- 
standard deviation), n/a =not applicable, yrs=years; R:L= Right: Left Handedness, SIMD= 
Scottish Index of Multiple Deprivation, NART= National Adult Reading Test, IQ= Intelligence 
Quotient, %= percentage, N=Total number in group, %= percentage. 
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Table 3.8: Comparative drug and alcohol use histories*. 
 Injecting (N=43) Non- Injecting 
(N=10) 
Sig.¹ 
Morphine equivalent 
dose(mg)*¹ 
174.62(72.89) 119.48(51.61) p=.02 
Age when first used 
heroin (yrs) 
18.16(3.07) 
(n=43) 
20.3 (4.37) 
(n=10) 
p=.28 
Age when first used 
other opioids (yrs) 
18.0 (2.88) 
(n=7) 
n/a  
(n=0) 
n/a 
Age when using 
opioids regularly (yrs) 
19.55 (3.09) 
(n=43) 
21.0 (3.74) 
(n=10) 
p=.26 
 
Age when dependent 
on opioids (yrs) 
20.14 (3.55) 
(n=43) 
21.1 (3.58) 
(n=10) 
p=.41 
Age when injecting 
opioids  
20.58 (3.35) 
(n=43) 
n/a n/a 
Opioid use (yrs) 7.81 (3.03) 
(n=43) 
6.6 (3.56) 
(n=10) 
p=.34 
Age when first used 
methadone use (yrs) 
22.7 (2.77) 
(n=30) 
26.0 (3.83) 
(n=4) 
p=.04 
Days of illicit 
methadone in last 30 
days 
0.37 (0.98) 
(n=17) 
2.7 (5.44) 
(n=7) 
p=21 
Days of heroin use in 
last 30 days 
11.72 (14.59) 
(n=16) 
22.1 (5.44) 
(n=7) 
p=.04 
Age when first used 
benzodiazepine(yrs) 
16.07 (2.97) 
(n=27) 
18.14 (4.48) 
(n=7) 
p=.14 
Days of 
benzodiazepine use in 
the last 30 days 
1.07 (2.84) 
(n=17) 
3.4 (4.99) 
(n=7) 
p=.24 
Age when first used 
Cocaine (yrs) 
17.87 (2.53) 
(n=16) 
18.0 (0.00) 
(n=3) 
p=.42 
Days of cocaine use in 
last 30 days 
n/a n/a n/a 
Age when first used 
cannabis (yrs) 
12.76 (1.47) 
(n=43) 
13.3 (1.42) 
(n=10) 
p=.18 
Days of cannabis use 
in last 30 days 
13.33 (13.66) 
(n=21) 
13.2 (14.71) 
(n=8) 
p=.94 
Age when first used 
alcohol(yrs) 
12.67 (1.79) 
(n=43) 
12.3 (0.83) 
(n=10) 
p=.27 
Days of alcohol use in 
last 30 days 
3.58 (5.77) 
(n=28) 
1.4 (4.09) 
(n=10) 
P=.07 
Sig ¹= significance at p<0.01, *=mean total scores (+/- standard deviation), n/a= not 
applicable, n=number in group analysed, yrs=years, mg=milligrams, N=total number in study 
group, *¹= morphine equivalent assuming 40% heroin purity. 
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Chapter 4: Results-Neuropsychological functioning in men with a 
history of chronic opioid use: Impulsivity  
 
Background 
 
Impulsivity may be defined as ‘a predisposition toward rapid, unplanned reactions to 
internal or external stimuli with diminished regard to the negative consequences of 
these reactions for the impulsive individual or to others’ (Chamberlain & Sahakian, 
2007; Potenza, 2007). Impulsivity encompasses behaviours that are rash, poorly 
planned, or focus on short-term outcomes despite potentially negative consequences 
in the long-term (Ainslie, 1975; Dawe and Loxton, 2004; Dawe et al., 2004). It is a 
multiple component construct (Lane et al., 2003; Reynolds et al., 2006; Reynolds, 
2006) with three broad classes of neuropsychological tests used to measure 
impulsivity. They include cognitive impulsivity, motor impulsivity and non-planning 
impulsivity (Table 4.1 and Chapter 1 &2). 
 
Cognitive impulsivity involves making quick but disadvantageous decisions (Olmstead, 
2006). The decisions of more impulsive individuals are influenced by preferring to 
choose a small reward available immediately (or after a short delay) over a larger 
reward available at some point in the future (Bickel & Marsch, 2001; Reynolds, 2006, 
Kirby et al., 1999). The terms sensation seeking, urgency (Whiteside & Lynam, 2001) 
or delay-discounting (Mischel et al., 1989) are other terms that describe cognitive 
impulsivity.  
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Table 4.1: Impulsivity domains: 
Main 
Domain 
Subtypes Other names Definition Examples of test 
Cognitive 
Impulsivity  
Reflection 
Impulsivity 
Delay Discounting 
or Urgency 
Lack of 
premeditation and 
inability to gather 
and evaluate 
information 
IGT, MFFT, 
BIS,GDT,DDT, CGT, 
RDMT 
 Risk Taking Sensation Seeking  CGT, IGT, RDMT 
Motor 
Impulsivity 
 Inhibitory Control Ability to suppress 
emotional, 
cognitive and 
behavioural 
responses 
 
 Behavioural 
Inhibition 
Motor Response 
Inhibition 
Process requires to 
stop a planned 
movement 
AGN,SS,Go/NoGo  
 Cognitive 
Inhibition 
Focused Attention Process in which 
individuals are 
required to 
suppress a salient 
but conflicting 
stimulus while 
identifying  less 
salient ones 
ST 
Non-
Planning 
Impulsivity 
Reasoning and 
Problem Solving 
Central Executive 
(Working Memory) 
Ability to think 
ahead and actively 
search for an 
appropriate 
solution AND 
ability to opt for 
larger delayed 
rewards over 
smaller more 
immediate 
rewards 
TOL, SOC, ROCFT, 
TOH, PMT,WAIS –III 
(Block Design, Matrix 
Reasoning), SSP, SWM 
AGN= Affective Go-NoGo (CANTAB) , BIS= Barratt Impulsivity Scale , CGT= Cambridge Gambling Task 
(CANTAB), DDT= Delay Discounting Test, GDT= Game and Dice Test, IGT= Iowa Gambling Task, MFFT= 
Matching Familiar Figures, PMT= Proteus Maze Test, RDMT= Rogers Decision Making Task, ROCFT= 
Rey-Osterreith Complex Figure Test, SOC= Stockings of Cambridge (CANTAB), SSP= Spatial Span 
(CANTAB), SS= Stop Signal ,SWM= Spatial Working Memory (CANTAB), ST= Stroop Test , TOH= Tower of 
Hanoi, TOL=Tower of London (CANTAB), WAIS-III= Weschler Adult Intelligence Scale Third Edition. 
 
A series of studies have suggested that both licit and illicit substance using 
populations show significantly higher rates of cognitive impulsivity, compared to non 
substance using controls (Kollins, 2003; Baker et al., 2003; Petry, 2002; Monterosso 
et al., 2001, Mitchell et al., 2002). Impaired cognitive impulsivity was also reported in 
opioid dependent (Clark et al., 2006) and methadone using (Rotheram-Fuller et al., 
2004) populations. However abstinent heroin users were also found to discount 
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significantly higher than non substance using controls (Mintzer et al., 2005).This is 
especially relevant in suggesting that cognitive impulsivity may be conceptualized as 
trait-like and not simply due to direct effect of opioid or other substance dependence 
(de Wit, 2009; Ersche et al, 2010). Impulsive behaviours are closely linked to 
substance use and abuse, both as contributors and as consequences of substance 
use. Trait impulsivity is an important determinant of substance use during 
development, and impulsive behaviour may increase the likelihood of substance use, 
dependence and/or relapse after a period of abstinence (Koob & Volkow, 2010). 
However, these effects depend on the behavioural measure used to assess 
impulsivity (de Wit, 2009; Everitt et al., 2008) and it is remains unclear to what 
extent impulsive behaviour especially cognitive impulsivity is ‘state’ dependent or an 
individual trait (Rose et al., 1996; Davis et al., 2002).  
 
In another study, a buprenorphine treated group performed significantly better than 
those participants maintained on methadone and a non- substance using healthy 
control group in the cognitive impulsivity tasks (Pirastu et al., 2006).This study 
indicated that specific opioids might have differential effects on cognitive impulsivity. 
This observation is limited by the fact that such groups were prescribed different 
opioids due to their differences in their dependence status, perhaps due to different 
substance use careers with one population exposed to less risk than the other, or that 
the different populations experiencing different vulnerability trait factors to sensation 
seeking (Chapter 1). 
 
There are inconsistencies in substance users’ cognitive impulsivity or decision making 
on the Iowa Gambling Task (IGT) across studies. Whilst studies did not find a 
measurable impairment in cognitive impulsivity in opioid and polysubstance users 
(Adinoff et al., 2003; Ernst et al., 2003; Mintzer et al., 2005) others found increased 
cognitive impulsivity (or impaired decision making) outcomes in these groups of 
substance users compared with non- substance using healthy controls (Bechara et al., 
2002b; Rotheram-Fuller et al., 2004; Pirastu et al., 2006). However such impaired 
decision making performance has also been identified in other clinical non- substance 
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dependent groups, for example, in suicide attempters (Jollant et al., 2005) and 
psychopathic individuals (Mitchell et al., 2002; van Honk et al., 2002). In Vassileva et 
al.,(2007) eighteen psychopathic opioid users, based on their scores on the Revised 
Hare Psychopathy Checklist (PCL-R), consistently showed impaired decision making 
outcomes whilst the sixty non-psychopathic opioid users successfully adjusted their 
decision- making outcomes in the course of the task toward the advantageous tasks 
(Hare, 1991).  
 
These findings have also been observed in studies using the Cambridge Gambling 
Task (CGT) when chronic opioid users were compared to chronic amphetamine users 
(Ersche et al., 2005a & 2005b; Rogers et al., 1999a). Chronic amphetamine users, 
overall, selected the small immediate reward option less frequently (i.e., in only 85% 
of trials) than chronic opioid users (92%) and controls (95%) (Rogers et al., 1999a). 
Even though the amphetamine users chose disadvantageously, they neither increased 
their gambles on the less favourable options nor did they significantly choose against 
the odds on the risky conditions. Disadvantageous decision-making outcomes in 
amphetamine users on the CGT appears to be due to impairment in correctly 
estimating outcome probabilities and may not reflect a reward-seeking strategy per 
se (Ersche et al., 2006a). 
 
Impairment in motor impulsivity (Olmstead, 2006; Barratt, 1985) occurs when 
individuals have difficulty in suppressing reward-driven automatic behaviour or pre-
potent responses (Logan et al., 1997). Motor impulsivity is assessed by observing (a) 
behavioural (or motor) response inhibition (e.g. through the Go-NoGo Tasks) 
(Newman et al., 1990) and (b) cognitive inhibition (e.g. through the Stroop Test (ST)) 
(Stroop, 1992) (Table 4.1). 
 
In contrast to the accumulating evidence for behavioural response inhibition 
impairments in populations who use other drugs, such as in chronic psychostimulant 
users, (Hester & Garavan, 2004; Hester et al., 2007; Monterosso et al., 2005), the 
majority of the limited but methodologically sound opioid related studies did not find 
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behavioural inhibition impairments in either the methadone users (Rounsaville et al., 
1982; Passetti et al., 2008) or in the abstinent heroin users (Verdejo-Garcia et al., 
2007b).Consistent with the above opioid related studies the ability to suppress a 
salient but conflicting stimulus while identifying a less salient one (cognitive 
inhibition) was also not compromised in methadone users (Prosser et al., 2006). 
 
Non-planning impulsivity is the ability to ‘think ahead’ and to actively search for an 
appropriate solution. It is considered as an essential part of goal directed behaviour 
(Owen, 1997). This neuropsychological domain also includes the central executive 
component of the working memory (Baddeley, 1986) as assessed with the Spatial 
Working Memory (SWM) task from the CANTAB test battery (Downes et al., 1989). 
 
In a study by Clark et al. (2006) opioid dependent users not only reported higher 
overall levels of impulsivity compared with non-substance using controls, they also 
scored higher on the non-planning impulsivity subscale of the Barratt Impulsiveness 
Scale-11 (BIS) (Patton et al., 1995). Opioid dependent users also significantly solved 
fewer problems correctly on the one-touch Tower of London (TOL) (Owen et al., 
1995), and needed more attempts in order to generate correct answers compared to 
non- substance using controls (Ersche et al., 2006a; Ornstein et al., 2000) even 
though they took as long to answer as did the controls (i.e. no impairment in motor 
impulsivity). Fishbein et al. (2007a) tested abstinent heroin users with the Stockings 
of Cambridge (SOC) task from the CANTAB test battery (Downes et al., 1989), with 
similar results.  In contrast methadone users (Passetti et al., 2008) and abstinent 
heroin users (Brand et al., 2008) tested on the TOL task did not show impairment in 
non-planning impulsivity when compared with non-substance using healthy controls. 
This inconsistency could be related to the clinical characteristics of the opioid cohorts 
tested (e.g. after inpatient opioid detoxification vs initiation of methadone 
community treatment) and the lack of methodological clarity to differentiate 
neuropsychological effects due to either acute or subacute use from those of chronic 
opioid exposure (Chapters 1 &2 and Table 4.2). 
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Table 4.2: Chronic opioid use and impulsivity. Previous research findings.* 
Neuropsychological 
domain 
Illicit chronic 
heroin use  
Abstinent 
ex-heroin 
use 
Methadone 
use 
Other 
opioids ¹ 
Chronic opioid dependence 
Cognitive 
Impulsivity 
(reflection 
impulsivity) 
 Mintzer et 
al (2005)↓ 
Verdejo-
Garcia et al 
(2007 a)↓ 
Pirastu et al 
(2006)↓ 
Rotheram-
Fuller et al 
(2004)↓ 
 
Pirastu et al 
(2006)↑ 
Clark et al (2006)↓ 
Cognitive 
Impulsivity (risk 
taking) 
Ersche et al 
(2005)↔ 
Fishbein et 
al (2007)↓ 
Fishbein et 
al (2005)↓ 
Clark et al 
(2006)↓ 
Passetti et 
al (2008)↓ 
 Rogers et al (1999)↓ 
Ersche et al (2005) ↔ 
Motor 
Impulsivity 
(behavioural or 
motor response 
inhibition) 
McNairy et al 
(1984)↓ 
Verdejo-
Garcia et al 
(2007b)↔ 
Verdejo-
Garcia et al 
(2007a)↓ 
Rounsaville 
et al 
(1982)↔ 
Passetti et 
al (2008)↔ 
Specka et al 
(2000) ↓ 
Sjogren et al 
(2005)↓ 
Vainio et al 
(1995)↔ 
Schindler et 
al (2004)↔ 
 
 
Motor 
Impulsivity  
(cognitive 
Inhibition) 
  Prosser et al 
(2008)↔ 
 
  
Non-Planning 
Impulsivity  
 
 
Fishbein et 
al (2007)↔ 
Brand et al 
(2008)↔ 
Passetti et 
al (2008)↔ 
 
Vainio et al 
(1995)↔ 
Schindler et 
al (2004)↔ 
Ersche et al (2006)↓ 
Ornstein et al (2000)↓ 
Clark et al (2006)↓ 
*= p<0.05; ↔= no difference in neuropsychological (impulsivity) performance; ↓= 
neuropsychological (impulsivity) deficits present; ↑= improvement in neuropsychological 
(impulsivity) performance when compared to healthy controls, other opioids 1 = 
buprenorphine, morphine, oxycodone and/or tramadol. 
 
In summary, the accumulated evidence is inconsistent and limited. Chronic 
consumption of opioids might be worsening an underlying trait for poor quality of 
decision making, especially cognitive impulsivity, with different subgroups of opioid 
dependent populations expressing different quality of risk. However there is limited 
evidence that chronic heroin and methadone use causes deficits in motor or non-
planning impulsivity (Table 4.2). 
 
There are a variety of confounding variables, such as age (Deakin et al., 2004), 
differences in intelligence quotient (Fishbein et al., 2005a, 2005b), co-morbid 
psychiatric illness (Jollant et al., 2005; Jollant et al., 2007), and co-morbid personality 
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disorder (Leland & Paulus, 2005), amongst others, as described in Chapter 1 of this 
thesis, which may exacerbate the presence or absence of impulsivity in individuals 
with chronic opioid dependence. 
 
In light of the previous research in the area of opioid dependent use and 
neuropsychological functioning, the present study set out to expand on the current 
limited knowledge base by comparing the neuropsychological performance of chronic 
heroin dependent users, methadone maintained male participants and others taking 
opioid for chronic pain compared to non-substance using healthy controls as 
explained in Chapter 3 of this thesis. This will help test the hypothesis (1): 
 
(1) Is chronic opioid dependence associated with neuropsychological impairment 
reflected in altered performance on measures of impulsivity and risk taking?  
 
At least three factors have been identified as related to drug taking that may exert an 
important influence over neuropsychological performance;(1) duration of opioid use, 
(2) level of opioid receptor occupancy during behavioural testing (a) during 
intoxication, (b) during withdrawal and (c) during a stable methadone maintenance 
and (3) injecting status.  
 
Clinical studies suggest that with increasing duration of heroin use comes increased 
tolerance, which means that increasing doses are required to reduce or abolish 
physical cravings and to prevent opioid withdrawal symptoms (Jasinski, 1997). 
Therefore, as duration of use increases, the dose required to avoid withdrawal is 
predicted to increase (Martin & Jasinski, 1969). A shift from smoking to injecting 
opioid is a phenomenon that is closely linked to opioid dependence. Similarly, 
individuals who use higher doses of heroin will generally require higher doses of 
methadone to prevent opioid withdrawal symptoms (Olmedo & Hoffman, 2000). This 
means that these three factors; duration of use, state of intoxication or withdrawal 
and injection status are related to each other. However the evidence relating to the 
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influence of any of these factors on neuropsychological functioning is limited and 
inconsistent. Therefore the next two related hypothesis (2 and 3) to test are: 
 
(2) In patients with chronic opioid dependence, is injection status associated with 
neuropsychological impairment as reflected in altered performance on measures of 
impulsivity and risk taking? 
(3) In patients with chronic opioid dependence is the degree of acute opioid 
exposure (acute intoxication, withdrawal or stable initial exposure to methadone), 
or duration of opioid exposure (period of methadone maintenance) associated with 
neuropsychological impairment as reflected in altered performance on measures of 
impulsivity and risk taking?  
 
Statistical considerations 
Basic statistical considerations have been described in Chapter 2. The data from the 
CGT, AGN, SWM and SSP tasks met assumptions of normality and homogeneity of 
variance. The SOC did not meet this assumption and to stabilise variance and diminish 
skewness and kurtosis, SOC data were subjected to square root (SQRT) 
transformation (Fields, 2009).  
 
Testing hypothesis 1 and 2 
Data were initially analysed using univariate or repeated measures ANCOVA with a 
between subjects factor of GROUP (HEROIN vs. METHADONE vs. CHRONIC PAIN vs. 
HEALTHY CONTROL) and NART, age in years, SIMD, total Fagerström score , years in 
education and past alcohol use in years as covariates.  
 
Further a priori subgroup analyses were conducted using (1) a two-group factor 
reflecting DEPENDENCE status (HEROIN and METHADONE groups vs. CHRONIC PAIN 
and HEALTHY CONTROL  groups) and (2) a two-group factor reflecting INJECTING 
status (HEROIN and METHADONE injecting vs. HEROIN and METHADONE never 
injecting groups) separately as between subject factors.  
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Behavioural data on the CGT were further analysed using mixed-model analysis of 
variance (ANCOVA) with GROUP (HEROIN vs METHADONE vs CHRONIC PAIN vs 
HEALTHY CONTROL) as a between-subjects fixed factor, and direction (Ascend, 
Descend) and difficulty (ratio 9:1, 8:2, 7:3, and 6:4) as within-subjects factors. A 
clustering technique utilising repeated measures ANCOVA that allowed comparison 
between all difficulty levels on both condition levels was used. Trials with a 5:5 ratio 
of red-blue boxes were included in the task design to ensure that participants 
perceived the task as a random trial sequence.  
 
Between-group effects in the ANCOVA models were analysed as follows. A planned 
comparison between the HEALTHY CONTROL and three experimental groups 
(HEROIN, METHADONE and CHRONIC PAIN) was used to detect any difference in 
performance. In this four-group model, significant between-group effects were 
investigated using pair-wise comparisons with Bonferroni correction procedure. Effect 
sizes for the group comparisons were calculated using Cohen’s d, i.e. the difference 
between the means divided by the pooled SD (Cohen, 1988).  
 
Testing hypothesis 3 
Repeated measures ANCOVA was used to evaluate CGT, AGN, SWM, SSP and SOC 
performance between the HEROIN group participants at baseline (whilst on illicit 
heroin), in controlled opioid withdrawal and subsequently when stabilised on 
methadone according to the tolerance testing procedure protocol with presumed 
opioid receptor occupancy state as a within subject factor to determine whether 
performance on any of these tasks was modified by different degrees of opioid 
receptor occupancy (heroin, withdrawal and stable on methadone). 
 
Similarly repeated measures ANCOVA was performed for the METHADONE group at 
baseline and at 6 months follow up with duration as a within subject factor to 
determine whether any aspects of performance improved or deteriorated with time 
and continued exposure to chronic, sustained released opioid (methadone). 
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The homogeneity of variance across groups in repeated‐measures design ANCOVAs 
was assessed by the Mauchly Sphericity Test (Mauchly, 1940). Where data sets 
significantly (p<0.05) violated this requirement for a repeated‐measures design 
ANCOVA, the Greenhouse Geisser Epsilon (^ε) correction parameter for degrees of 
freedom (Greenhouse & Geisser, 1959; Winer et al., 1991) was used to calculate a 
more conservative p value for each F ratio. 
 
Results 
All subjects completed all of the tests. Mean performance (not adjusted for 
covariates), statistical comparisons and effect sizes (d) for the HEROIN, METHADONE, 
CHRONIC PAIN and HEALTHY CONTROL groups, are summarised in Table 4.3a, b & c. 
 
 
Table 4.3a : Summary of baseline neuropsychological findings for cognitive impulsivity (not 
adjusted for covariates). 
 
Cognitive 
Impulsivity 
HEROIN 
N= 24 
METHADONE 
N= 29 
CHRONIC PAIN 
N= 28 
HEALTHY 
CONTROL 
N= 28 
  
 Mean (s.d) Mean (s.d) Mean (s.d) Mean (s.d) Sig. d 
CGT       
Quality of 
Decision 
0.83 (0.21) 0.91 (0.09) 0.93 (0.10) 0.96 (0.06) C>H** 0.84 
Deliberation 
Time 
2826.92(1365.51) 3386.89 
(1762.26) 
2676.23(766.70) 2128.49(350.74) C<M*** 0.99 
Risk taking 0.58 (0.18) 0.64 (0.11) 0.52 (0.13) 0.58 (0.08) NS  
Overall 
Proportion 
Bet 
0.55 (0.17) 0.59 (0.10) 0.50 (0.13) 0.53 (0.08) C<H** 
P<H** 
0.14 
0.36 
Delay 
Aversion 
0.43 (0.23) 0.31 (0.19) 0.32 (0.23) 0.25 (0.14) C<H* 0.95 
Risk 
Adjustment 
0.72 (0.71) 1.00 (0.78) 1.08 (0.73) 1.72 (0.76) C>H*** 
C>M** 
1.36 
0.94 
d= effect size, Sig= Significance;*= p<0.01, **= p<0.005, ***= p<0.001, NS=no significant 
impairment in neuropsychological outcomes with p<0.01, H=HEROIN Group, P=CHRONIC PAIN 
Group, M= METHADONE Group, C=HEALTHY CONTROL Group. 
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Table 4.3b : Summary of baseline neuropsychological findings for motor impulsivity (not 
adjusted for covariates). 
 
Motor 
Impulsivity 
HEROIN 
N= 24 
METHADONE 
N= 29 
CHRONIC 
PAIN 
N= 28 
HEALTHY 
CONTROL 
N= 28 
  
 Mean (s.d) Mean (s.d) Mean (s.d) Mean (s.d) Sig. d 
Affective Go-
NoGo (AGN) 
      
Total 
Commission 
Errors 
16.37 
(11.95) 
11.28 (8.32) 6.96 (6.17) 6.36 (4.82) P<H*** 
C<H*** 
1.10 
Commission 
Errors (shift) 
8.25 (6.66) 5.52 (4.52) 3.50 (3.28) 3.18 (2.59) C<H** 1.00 
Commission  
Errors (non-shift) 
8.12 (5.94) 5.24 (4.08) 3.46 (3.50) 3.18 (2.82) C<H*** 1.06 
Commission 
Errors (positive) 
7.87 (6.67) 5.17 (4.15) 4.14 (3.61) 3.64 (3.08) C<H* 0.81 
Commission 
Errors (negative) 
8.50 (6.12) 5.59 (4.29) 2.82 (3.02) 2.71 (2.65) C<H*** 1.23 
Total Omissions 
Errors 
12.75 
(10.30) 
19.90 (25.16) 7.86 
(13.22) 
6.54 
(14.64) 
NS  
Omission Errors 
(shift) 
6.04 (5.02) 9.48 (12.86) 3.71 (6.68) 3.25 (7.15) NS  
Omission 
Errors(non-shift) 
6.71 (5.68) 9.96 (12.53) 4.14 (6.73) 3.29 (7.56) C<H* 0.51 
Omission Errors 
(positive) 
5.79 (5.15) 10.41 (12.64) 4.32 (6.67) 3.57 (7.37) NS  
Omission Errors 
(negative) 
6.96 (5.89) 9.03 (12.83) 3.54 (6.93) 2.96 (7.38) NS  
Mean Correct  
Latency 
524.88 
(77.30) 
533.20 
(92.26) 
530.07 
(62.65) 
495.46 
(65.99) 
NS  
d= effect size, Sig =Significance, *= p<0.01, **= p<0.005, *** =p<0.001, NS= no significant 
impairment in neuropsychological outcomes with p<0.01, H=HEROIN Group, P= CHRONIC 
PAIN Group, M= METHADONE Group, C=HEALTHY CONTROL Group. 
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Table 4.3c : Summary of baseline neuropsychological findings for non-planning impulsivity 
(not adjusted for covariates). 
Non-Planning Impulsivity HEROIN 
N= 24 
METHADONE 
N= 29 
CHRONIC 
PAIN 
N= 28 
HEALTHY 
CONTROL 
N= 28 
  
 Mean (s.d) Mean (s.d) Mean (s.d) Mean (s.d) Sig. d 
Stocking of Cambridge 
(SOC) (SQRT) 
      
Problem solved in 
minimum  number of 
moves (2 moves) 
1.47 (0.14) 1.41 (0.00) 1.43 (0.09) 1.41 (0.00) NS  
Problem solved in 
minimum  number of 
moves (5 moves) 
2.59 (0.22) 2.62 (0.28) 2.65 (0.28) 2.41 (0.19) C<H * 
C<M*** 
0.80 
0.87 
Mean Initial Thinking 
Time (2 moves) 
38.74 (24.45) 51.48 (23.24) 38.82 
(21.49) 
36.94 (25.69) NS  
Subsequent Thinking 
Time (2 moves) 
18.67 (29.65) 5.47 (14.14) 5.04 (13.57) 4.05 (7.99) NS  
Subsequent Thinking 
Time (5 moves) 
30.83 (23.45) 32.39 (20.55) 27.51(20.50) 14.78 (15.21) NS  
       
Spatial Span (SSP)       
Total Errors 12.79 (5.84) 12.65 (5.27) 14.26 (5.99) 11.11 (4.7) NS  
Total usage errors 3.25 (1.39) 1.59 (1.82) 2.64 (1.62) 1.71 (1.30) C<H** 
C>M*** 
1.14 
1.25 
Mean time to 1
st
 response 2983.98 
(478.24) 
3250.23 
(1191.88) 
3027.10 
(663.07) 
3026.97 
(477.44) 
NS  
Mean time to last 
response  
7350.55 
(1499.08) 
7114.18 
(3213.55) 
7776.33 
(2321.40) 
7927 
(1778.39) 
NS  
Number of attempts  8.33 (1.88) 7.69 (2.61) 8.86 (2.21) 9.46 (1.73) C>M* 0.80 
Span length 5.42 (1.02) 4.86 (1.78) 5.89 (1.29) 6.86 (1.41) C>M** 
 
1.17 
 
       
Spatial Working 
Memory (SWM) 
(SQRT) 
      
Between search errors 
(mean) 
4.81 (2.31) 4.84 (1.98) 4.10 (2.47) 3.17 (2.37) NS  
Double search errors 
(mean) 
0.44 (0.73) 0.62 (0.68) 0.38 (0.58) 0.31 (0.73) NS  
Within search errors 
(mean) 
0.56 (0.82) 0.79 (0.82) 0.52 (0.75) 0.45 (0.87) NS  
Total errors (mean) 0.48 (2.32) 4.88 (1.99) 4.13 (2.50) 3.22 (2.37) NS  
Strategy 5.76 (0.61) 5.37 (1.21) 5.27 (1.26) 5.15 (0.63) NS  
Mean time to 1
st
 response 45.30 (7.83) 49.69 (10.85) 46.96 (9.64) 44.58 (8.51) NS  
Mean token search 
preparation time 
33.83 (4.47) 36.99 (4.72) 35.89 (6.31) 32.99 (4.72) NS  
Mean time to last 
response 
158.14 
(15.83) 
165.06 
(15.72) 
162.24 
(21.91) 
152.08 
(14.22) 
NS  
d= effect size, SQRT= Square Root transformation; Sig= Significance, *= p < 0.01, **= p < 
0.005, *** =p < 0.001, NS= no significant impairment in neuropsychological outcomes with 
p<0.01, H=HEROIN Group, P=CHRONIC PAIN Group, M= METHADONE Group, C=HEALTHY 
CONTROL Group. 
156 
 
 
 
 
Cognitive impulsivity 
 Cambridge Gambling Task (CGT) 
(a) Quality of Decision Making. 
Performance on the quality of decision making of the CGT was 87.5 (0.1)% for the 
HEROIN and 91.2 (0.1)% for the METHADONE groups compared to 93.2 (0.19)% for 
the CHRONIC PAIN group and 95.5 (0.1)% for the HEALTHY CONTROL group. 
Participants simply won or lost the amount of points they chose to bet on each trial. 
Consistently choosing the least likely outcome in this task indicates poor quality of 
decision-making. A quality of decision making score of 89.7% for the CGT (Rogers et 
al., 1999) is usually suggested as a cut off score to reflect poor quality of decision 
making in substance misusers. 
 
There was a non-significant trend for performance to be affected by GROUP 
[F(3,102)=3.3,p=.02]. Pairwise post hoc Bonferroni comparison showed a non-
significant trend of HEROIN group (p=.05) and with no difference in quality of decision 
making between HEALTHY CONTROL, METHADONE and CHRONIC PAIN groups 
(p=1.00).  There were no significant interactions [F(9.249.72)=1.0, p=.44] (Figures 4.1a 
& 4.1b). 
 
There were no significant DEPENDENCE effects [F (1,103) =2.8, p=.09] or INJECTING 
effects [F<1] on the quality of decision making. There were also no significant 
interactions [F<1]. 
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Figures 4.1a & 4.1b: CGT-Quality of decision making (descending and ascending orders). 
Across the four difficulty levels, all participants were sensitive to decreasing likelihood of the most 
favourable outcome in either ascending or descending order as suggested by a reduction in quality 
of decision making but there were no significant GROUP [F(3,102)=3.3,p=.02] and interaction effects 
[F(9.249.72)=1.0, p=.44]. SD= Standard Deviation. 
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Overall there was no detectable significant difference in the quality of decision 
making across the four groups with a tendency for all groups to choose the most 
likely outcome.There was also no effect of DEPENDENCE and INJECTING status. When 
the HEROIN group was tested during different opioid receptor occupancy states there 
was no effect of opioid load on the quality of decision making 
[F(2,29.597)=2.0,p=.17]. There was also no effect on decision making quality in the 
METHADONE group following prolonged exposure to stable doses of methadone 
(p=.64). 
 
(b)Deliberation Times. 
There was a significant GROUP [F(3,102)=4.3,p<0.01] effect for deliberation times 
(decision latencies).Post-hoc pair wise Bonferroni comparisions showed that 
participants from the METHADONE group took significantly longer to respond than 
did the HEALTHY CONTROL group (p<0.01, d=0.99) (Figure 4.2). The mean 
deliberation times for the HEROIN and CHRONIC PAIN participants lay between those 
for the METHADONE and HEALTHY CONTROL participants and did not differ 
significantly from these two groups (p=1.00).There were no significant GROUP by task 
difficulty and direction interactions [F(9,206.28)=1.6,p=.16] in deliberation times.  
 
There was a significant effect of DEPENDENCE status [F(1,104)=7.2,p<0.01,d=0.27] on 
deliberation times with increased response time latencies in those with histories of 
opioid dependence. There was no significant interactions with direction 
[F(1,104)=4.94,p=.03] or task difficulty [F(3,211.75)=3.1,p=.05]. 
 
There was no significant effects [F<1] or interactions [F(6,209.55)=1.7,p=.15] with 
INJECTING status. 
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Figure 4.2: All participants were sensitive to decreasing levels of difficulty as suggested by 
the speed of decision making. Overall deliberation times outcomes differed significantly 
across the four groups [F (3,102) =4.3, p<0.01]. Participants from the METHADONE group 
took significantly longer to respond than did the HEALTHY CONTROL group (*p<0.01). There 
were no significant GROUP by task difficulty and direction interactions (p=.16) in 
deliberation times.  
 
Overall the HEROIN group was not significantly slower than any other groups. When 
the HEROIN group was tested during different opioid receptor occupancy states there 
was no effect on deliberation times [F<1]. 
 
Overall, the METHADONE group was significantly slower in making a decision 
compared to the HEALTHY CONTROL group but this was not related to the difficulty 
levels presented or the direction of betting sequence. Since deliberation times 
measured the time taken for the participants to choose a colour to bet on, a longer 
delay is not indicative of impulsive behaviour. There was no additional effect on 
deliberation times in the METHADONE group following prolonged exposure to stable 
doses of methadone (p=.12). 
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(c) Risk Taking (Overall Proportion Bet). 
There was a non-significant GROUP trend on risk taking [F (3,101)=1.5, p=.21]. 
 
However there was a significant GROUP by task difficulty and direction interaction [F 
(9,196.89) =6.4,p<0.01]. Overall GROUP participants placed significantly higher bets at 
the more favourable ratio (less difficulty levels) (i.e. 9:1>8.2>7.3>6:4) as shown by a 
significant GROUP x difficulty interaction [F (9, 196.89) =6.4, p<0.001] (Figure 4.3). 
Post hoc Bonferroni comparision identified the HEROIN group significantly betting 
more at all difficulty levels compared to the CHRONIC PAIN and HEALTHY CONTROL 
groups (p<0.001,d=0.74) and not significantly with the METHADONE (p=.26) group.  
 
Also overall GROUP participants placed significantly higher bets in the descending 
order [F (9,195.19) =7.85, p<0.001] with a non-significant trend in the ascending 
order [F( 9, 215.49)=2.35, p=.03] as shown by a significant GROUP  by direction 
interaction (F(3,101)=3.63, p<0.01]. Post hoc Bonferroni comparison identified the 
HEROIN group performing significantly worse in the descending order than the 
METHADONE, CHRONIC PAIN and HEALTHY CONTROL groups (p<0.001) (Figure 4.3).  
 
There were no significant effects of DEPENDENCE status [F (1,103)= 3.3,p=.07] or 
INJECTING status [F<1] on risk taking. There were also no significant interactions in 
both DEPENDENCE status [F (3,225.53) =1.9, p=.15] and INJECTING status[F<1].  
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Figure 4.3: CGT-Risk Taking. Across the four difficulty levels, all participants were 
significantly placing larger bets at the more favourable ratio (i.e. 9:1>6:4). Overall GROUP 
participants placed significantly higher bets in the descending order [F(9,195.19) =7.85, 
p<0.001]. Post hoc Bonferroni comparision identified the HEROIN group significantly betting 
more at all difficulty (but not significantly at the 9:1 ratio*) levels compared to the 
HEALTHY CONTROL and CHRONIC PAIN (**p<0.001) and not significantly with the 
METHADONE (p=.26) group.  
 
Overall the HEROIN group significantly placed higher and earlier bets on favourable, 
ratios especially in the descending order compared to the HEALTHY CONTROL and 
CHRONIC PAIN groups but not the METHADONE group. When the HEROIN group was 
tested during different opioid receptor occupancy states there was no additional 
effect of opioid load on risk taking [F(2,46)=1.0,p=.37]. The METHADONE group 
placed higher bets on favourable ratios and there was no effect on risk taking in the 
METHADONE group following prolonged exposure to stable doses of methadone 
(p=.42). 
 
(d) Delay Aversion. 
There was a non-significant trend for delay aversion scores by GROUP [F(3,101)=3.3, 
p=0.02].  
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However there was a significant GROUP by task difficulty and direction interaction 
[F(9,222.23)=2.6,p<0.01]. Post hoc Bonferroni comparison showed the HEROIN group 
was significantly unwilling to wait when 8:2, 7:3, and 6:4 ratio of coloured boxes 
where presented compared to the HEALTHY CONTROL (p<0.01), CHRONIC PAIN 
(p=.03) and METHADONE (p<0.01) groups and especially presented in a descending 
order compared to the HEALTHY CONTROL, CHRONIC PAIN and METHADONE groups 
(p<0.001) (Figures 4.4). 
 
There were no significant effects of DEPENDENCE status [F(1,103)= 2.9,p=.09] or 
INJECTING status [F<1] on delay aversion. There were also no significant interactions 
in these two groups. 
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Figure 4.4: CGT-Delay Aversion. There was a significant GROUP by task difficulty and 
direction interaction [F(9,222.23)=2.6,p<0.01] with the HEROIN group exhibited  impaired 
delay aversion compared to the HEALTHY CONTROL, CHRONIC PAIN and METHADONE 
groups (**p<0.001). 
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Overall the HEROIN group was unwilling to wait and resulted in betting larger 
amounts when the possible bet amount was presented in a descending order than 
when the amounts are presented in the ascending order. When the HEROIN group 
was tested during different opioid receptor occupancy states, there was no effect of 
opioid load on delay aversion [F<1].  
 
There was no effect on risk aversion in the METHADONE group following prolonged 
exposure to stable doses of methadone. 
 
(e) Risk Adjustment. 
There was a significant GROUP [F (3,102) =6.2, p<0.001] effect for overall risk 
adjustment. Post-hoc pair wise Bonferroni comparisions showed the HEROIN 
(p<0.001, d=1.36) and METHADONE (p<0.001, d=0.94) groups significantly increasing 
the percentage of available points put at risk in response to more favourable coloured 
box ratios compared to the HEALTHY CONTROL group (Figure 4.5).The CHRONIC PAIN 
group showed a non-significant trend for CHRONIC PAIN (p=0.01) compared to 
HEALTHY CONTROL group.   
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Figure 4.5: CGT -Risk Adjustment.There was a significant GROUP (**p<0.001) effect for 
overall Risk Adjustment. There was also a significant GROUP by task direction interactions 
in both ascending (*p<0.01) and descending (**p<0.001) orders.  
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There was also a significant GROUP by task direction interaction in both ascending  
[F(3,102)=4.4,p<0.01]and descending [F(3,102)=6.4,p<0.001] orders. Post hoc 
Bonferroni comparison showed the METHADONE group significantly increased the 
percentage of available points put at risk in response to more favourable coloured 
box ratios in the ascending order compared to the HEALTHY CONTROL group 
(p<0.005) but not to HEROIN and CHRONIC PAIN groups (p=1.00). Meanwhile the 
HEROIN (p<0.001) and METHADONE  (p<0.01) group significantly increased the 
percentage of available points put at risk in response to more favourable coloured 
box ratios in the descending order compared to the HEALTHY CONTROL  group but 
not to the CHRONIC PAIN groups (p=1.00) 
 
There was a significant effect of DEPENDENCE status [F(1,104)= 9.5,p<0.005] but no 
effect of INJECTING status [F<1] on risk adjustment. 
 
Overall the HEROIN group significantly increased the percentage of available points 
put at risk in response to more favourable coloured box ratios in the descending 
order. When the HEROIN group was tested during different opioid receptor occupancy 
states, there was no effect of opioid load on delay aversion [F<1].  
 
The METHADONE group significantly increased the percentage of available points put 
at risk in response to more favourable coloured box ratios in both ascending and 
descending orders. There was no effect on risk adjustment in the METHADONE group 
following prolonged exposure to stable doses of methadone (p=.42).Table 4.4 
summarisies all results from the Cambridge Gambling Task (CGT). 
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Table 4.4: Summary of results from analysis of CGT outcomes¹. Unless specified significance 
is with HEALTHY CONTROL and/or CHRONIC PAIN groups.* 
 
Cambridge Gambling 
Task (CGT) 
HEROIN vs 
METHADONE vs 
CHRONIC PAIN vs 
HEALTHY CONTROL   
Opioid 
DEPENDENCE (OD) 
vs Non- Opioid 
DEPENDENCE  
(Non OD)  
INJECTING vs non- 
injecting  
Quality of Decision 
Making  
            ↔             ↔               ↔ 
Deliberation time  ↓ METHADONE ↓OD >Non-OD                ↔ 
Risk Taking  ↓ HEROIN             ↔                ↔ 
Delay Aversion ↓ HEROIN             ↔                ↔ 
Risk Adjustment ↓METHADONE  &    
HEROIN  
            ↔                ↔ 
*= significant effects with p<0.01,↓=significant neuropsychological deficits present, ↔= no 
significant neuropsychological deficits present, ¹= ANCOVA ‘between subject factor’ of GROUP, 
DEPENDENCE and INJECTING analysed separately. 
 
 
Motor Impulsivity 
 Affective Go-NoGo (AGN) 
There was a significant effect for commission errors by GROUP [F(3,102)=5.4,p<0.01]. 
Post hoc Bonferroni comparisons revealed that the HEROIN group showed a 
significant effect of making more commission errors compared to the HEALTHY 
CONTROL group (p<0.00,d=1.10) and a non-significant trend to the CHRONIC PAIN 
(p=.06) group. The METHADONE group did not differ significantly from the HEROIN, 
CHRONIC PAIN and HEALTHY CONTROL groups (p=1.0). 
 
Further analysis indicated significant GROUP effects on commission errors when 
responding to happy words during sad word blocks (negative valence) [F(3,102)=6.5, 
p<0.001] with the HEROIN group significantly (p<0.001, d=1.23) and the METHADONE 
group showing a non-significant trend (p=.02) compared to the HEALTHY CONTROL 
group. There was also a significant GROUP effect [F(3,102)=7.6,p<0.01] on commision 
errors in non-shift mode (when the participant’s response orientation remained the 
same between blocks). Post hoc Bonferroni analysis showed the HEROIN group 
significantly (p=0.01, d=1.06) making more commission errors in the non- shift mode 
when compared to HEALTHY CONTROL (Figure 4.6). 
166 
 
 
 
 
 
Interactions
TC TC Non shift TC Shift TC Positive TC Negative TO
A
ff
e
c
ti
v
e
 G
o
-N
o
G
o
 (
A
G
N
) 
E
rr
o
rs
(+
/-
 S
ta
n
d
a
rd
 D
e
v
ia
ti
o
n
)
-20
-10
0
10
20
30
40
50
HEROIN
CHRONIC PAIN
METHADONE
HEALTHY CONTROL
*
*
**
*
  
Figure 4.6: AGN-Total commission and omission errors for HEROIN, METHADONE, CHRONIC 
PAIN and HEALTHY CONTROL groups. There was a significant effect for commission errors 
[F(3,102)=5.4,*p<0.01],especially during negative valence (**p<0.001) and non- shift mode 
(*p<0.01) and omission errors[F(3,102)=4.2,p<0.01*]  to be effected by GROUP.  
 
TC= Total Commission Errors, TO= Total Omission Errors, TC Positive=Total Commission Errors 
in Positive Valence, TC Negative= Total Commission Errors in Negative Valence. 
 
There was also a significant GROUP effect [F(3,102)=4.2,p<0.01] on omission errors 
(Figure 4.6) but post hoc Bonferroni comparisons showed the METHADONE group 
making more omission errors when compared to the HEALTHY CONTROL (p=.02) and 
CHRONIC PAIN (p=.02) groups but not reaching significance.  The METHADONE group 
did not differ significantly from the HEROIN group (p=1.0).There was also a non-
significant GROUP trend in mean correct latency [F<1].  
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There were significant DEPENDENCE status effects on commission errors [F 
(1,104)=8.9, p<0.005], negative valence [F (1,104) =9.4, p<0.005] non- shift mode 
F(1,104)=6.9, p<0.01] and omission errors [F(1,104)=11.3, p<0.005] but not significant 
to mean correct latency [F<1](Figure 4.7). 
 
There were no significant INJECTING status effects on commission errors [F(1,48)=2.2, 
p=.14], omissions errors [F<1] and mean correct latency [F(1,40)=2.8,p=.11]. 
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Figure 4.7: AGN-Total commission and omission errors of DEPENDENCE group compared 
with PAIN and HEALTHY CONTROL (non-opioid dependent) groups .There were significant 
DEPENDENCE status effects on commission errors [F (1,104)=8.9, **p<0.005] especially  
during negative valence [**p<0.005] and non- shift mode [*p<0.01] and on omission errors 
[**p<0.005] to be effected by GROUP.TC= Total Commission Errors, TO= Total Omission 
Errors, TC Positive=Total Commission Errors in Positive Valence, TC Negative= Total 
Commission Errors in Negative Valence. 
 
 
Overall there were detectable differences in commission errors in the HEROIN group 
at baseline testing indicating behavioural inhibition. When the HEROIN group was 
tested during different opioid receptor occupancy states there was a significant effect 
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of opioid load on commission errors [F(2,46)=6.1,p<0.001] with post hoc Bonferroni 
analysis showing the stable methadone stage for the HEROIN group performing 
significantly better than the  illicit (baseline)heroin stage of the same group (p<0.01). 
There was also a non-significant trend for the methadone stage of the HEROIN group 
to do better compared to the withdrawal stage of the same group (p=.04). The above 
significant effect was further observed in the non- shift mode of commission error 
scores [F(2,44)=7.8,p<0.001] with a non-significant trend in the shift mode 
[F(2,44)=3.6,p=.03]. 
 
The HEROIN group as well showed similarity in outcome scores with the METHADONE 
group in omission error scores but showing no significant effects when compared 
with both PAIN and HEALTHY CONTROL groups. Neverthless inattention resulting in 
omission errors was present in the HEROIN group at baseline testing which did not 
change with different opioid receptor occupancy states [F(2,29.869)=1.9,p=.17].  
 
The METHADONE group, however, showed non-significant inattention during 
baseline testing. There was no effect on commission (p=.02) and omission errors 
(p=.12).  
 
Table 4.5: Summary of results from analysis of AGN outcomes¹. Unless specified significance 
is with HEALTHY CONTROL and/or CHRONIC PAIN groups*. 
 
Affective Go-NoGo 
(AGN) 
HEROIN vs 
METHADONE vs 
CHRONIC PAIN vs 
HEALTHY CONTROL   
Opioid 
DEPENDENCE (OD) 
vs Non- Opioid 
DEPENDENCE 
(Non- OD) 
INJECTING vs non- 
injecting  
Total Commissions ↓ HEROIN ↓OD > Non- OD ↔ 
Total Omissions ↔ ↓OD > Non-OD  ↔ 
Mean Correct 
latency 
↔  ↔ ↔ 
*= significant effects with p<0.01,↓=significant neuropsychological deficits present, ↔= no 
significant neuropsychological deficits present, ¹= ANCOVA ‘between subject factor’ of GROUP, 
DEPENDENCE and INJECTING analysed separately. 
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Non-planning impulsivity 
 Stocking of Cambridge (SOC)  
There was a non-significant GROUP [F (3,101) =2.2, p=.09] trend for the problems 
solved on minimum number of moves, subsequent thinking time [F (3,101) 
=2.2,p=.09] and mean initial thinking time [F (3,101)=2.7,p=.06]. 
 
There was a non-significant trend of GROUP by difficulty [F (9,250.8)=2.3,p=.03] 
interaction for the  problems solved in minimum number of moves. ANCOVA at each 
of the 2,3,4 and 5 move problem stages showed a significant GROUP effect at the 5-
move stage [F (3,107)=6.0, p <0.001]. Post hoc Bonferroni comparison at the 5-move 
stage problem showed that participants from the HEROIN (p< 0.01, d=0.80) and 
METHADONE (p<0.001, d=0.87) groups significantly making more moves when 
compared to the HEALTHY CONTROL group. Participants from the CHRONIC PAIN 
(p=0.02) group showed a non-significant trend in making more moves when 
compared to the HEALTHY CONTROL group (Figure 4.8).  
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Figure 4.8: SOC and problems solved in minimum number of moves. Post hoc Bonferroni comparison 
at the 5-move stage problem showed that participants from the HEROIN (*p< 0.01) and 
METHADONE (**p<0.001) groups significantly making more moves when compared to the HEALTHY 
CONTROL group. Participants from the CHRONIC PAIN (p=0.02) group showed a non-significant 
trend. 
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There was no significant GROUP by difficulty interaction for: mean initial thinking 
time [F(9,273.8)=2.1,p=.04] and subsequent thinking time [F (9,253.7)=2.4,p=.02]. 
Specifically an ANCOVA at each of the 2,3,4 and 5 move problem stages revealed non-
significant trends at the 2 move [F (3,107) =3.9, p=0.01], and 3-move [F (3,107) 
=3.9,p=.01] stages, and a significant effect at the 5-move problem[F(3, 107) 
=4.4,p<0.01] stage in subsequent thinking time. Post hoc Bonferroni comparison 
showed the HEROIN group had a significant longer subsequent thinking time at the 5 
move stage problem (p<0.005) when compared to the HEALTHY CONTROL group. 
 
There were no significant effect of DEPENDENCE status for: problems solved in 
minimum number of moves [F (1,103) =1.6,p=.21], mean initial thinking time 
[F(1,103)=2.3,p=.14] and subsequent thinking time [F<1]. There were no significant 
interaction for: problems solved in minimum number of moves [F<1], mean initial 
thinking time [F (3,277.22) =3.1, p=.03] and on subsequent thinking time [F 
(3,256.43)=2.8,p=.05].  
 
There was no significant INJECTING status effects for: problems solved in minimum 
number of moves [F (1,48)=1.9, p=.17], mean initial thinking time [F<1] and 
subsequent thinking time [F<1]. However there was a significant interaction with 
INJECTING status and difficulty [F(6,260.49)=4.8,p<0.001] for subsequent thinking 
time. Post hoc Bonferronic comparisons show that INJECTING status was significant 
(p<0.01) at the 2 stage move problem compared to the non- injecting group. There 
were no significant interactions with INJECTING status for: problems solved in 
minimum number of moves [F<1] and mean initial thinking time [F (6,270.64) =1.7, 
p=.13].  
 
Overall the HEROIN group at baseline significantly struggled to solve complex 
problems in the minimun number of moves and took longer to solve it. Therefore the 
deficit is not due to motor impulsivity. When the HEROIN group was tested during 
different opioid receptor occupancy states there was no effect of opioid load on the 
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minimum number of moves [F<1], mean initial thinking time [F (2,27.206) =3.6, 
p=.06], and subsequent thinking time [F(2,40)=1.9,p=.16]. 
 
The METHADONE group also had significantly less occasions upon which the 
participants had successfully solve a 5 move problem in the minimun number of 
moves. This was not complemented with more time needed to initiate or continue 
the task. There was no effect on the minimum number of moves needed to solve the 
problem task in the METHADONE group following prolonged exposure to stable doses 
of methadone.  
 
Table 4.6: Summary of results from analysis of SOC outcomes¹. Unless specified significance 
is with HEALTHY CONTROL and/or CHRONIC PAIN groups*. 
 
Stockings of 
Cambridge (SOC) 
HEROIN vs 
METHADONE vs 
CHRONIC PAIN vs 
HEALTHY 
CONTROL   
Opioid DEPENDENCE (OD) 
vs Non- Opioid 
DEPENDENCE (Non- OD)  
INJECTING vs 
non- injecting  
Number of 
problems solved in 
minimal number of 
moves. 
↓ HEROIN & 
METHADONE at 5 
move stage 
problem. 
↔ ↔ 
Initial thinking time ↔ ↔ ↔ 
Subsequent 
thinking time 
↓ HEROIN at 5 
move stage 
problem 
↔ ↔ 
*= significant effects with p<0.01,↓=significant neuropsychological deficits present, ↔= no 
significant neuropsychological deficits present, ¹= ANCOVA ‘between subject factor’ of GROUP, 
DEPENDENCE and INJECTING analysed separately. 
 
 
 Spatial Span Task 
There was a significant GROUP [F (3,102)=16.8,p<0.001] effect for total usage error. 
Post hoc Bonferroni comparison showed that the participants from the HEROIN group 
significantly made more errors compared to the METHADONE (p<0.001,d=1.25) and 
HEALTHY CONTROL (p<0.005, d=1.14) groups (Figure 4.9). The total usage errors for 
the CHRONIC PAIN particpants lay between those of the HEROIN, METHADONE and 
HEALTHY CONTROL particpants and did not differ significantly from these three 
groups (p=1.0).   
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Figure 4:9: Total usage errors in Spatial Span (SSP) Task. There was a significant GROUP [F 
(3,102) =16.8, p<0.001] effect for Total Usage Error. HEROIN group participants significantly 
made more errors compared to the METHADONE (p<0.001) and HEALTHY CONTROL 
(p<0.005) groups. 
 
There was also a significant GROUP [F(3,101)=3.7,p<0.01] effect for span length with 
post hoc Bonferroni comparison showing the METHADONE group significantly unable 
to recall successfully the longest sequence compared to HEALTHY CONTROL group 
(p<0.01, d-1.17).The span length for the HEROIN (p=.41) and the CHRONIC PAIN 
(p=.21) groups lay between those of the METHADONE and HEALTHY CONTROL groups 
and did not differ significantly from any of the other groups (Figure 4.10). 
 
There were no significant GROUP effects for: the number of attempts [F (3,102)=1.6, 
p=.18], mean time to first response [F<1] and mean time to last response [F<1].  
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Figure 4.10: Span length in the SSP Task. There was significant GROUP [F(3,101)=3.7,p<0.01] 
effect for span length with the METHADONE group significantly unable to recall successfully 
the longest sequence compared to HEALTHY CONTROL group (p<0.01). 
 
There was a significant effect of DEPENDENCE status [F (1,103) = 7.1, p<0.01] for span 
length (Figure 4.11) but no significant effect of DEPENDENCE status for: mean time to 
first response [F<1], mean time to last response [F<1], number of attempts [F 
(1,104)=3.7,p=.06] and total usage errors [F (1,104)=1.1,p=.29] of the SSP task. 
 
There was no significant effect of INJECTING status for: span length 
[F(1,47)=1.1,p=.29], total usage errors [F(1,48)=12.7,p=.06], mean time to first 
response [F(1,48)=8.7,p=.35] mean time to last response[F<1] and number of 
attempts [F< 1]. 
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Figure 4.11: Span Length for DEPENDENCE status compared with CHRONIC PAIN and 
HEALTHY CONTROL groups. There was a significant effect of DEPENDENCE status [F (1,103) 
= 7.1, p<0.01] for span length. 
 
Overall the participants in the HEROIN group significantly selected a box not in the 
sequence being recalled (total usage error) when compared with the HEALTHY 
CONTROL participants. When the HEROIN group was tested during different opioid 
receptor occupancy states there was no effect of opioid load on all SSP outcomes 
(total errors [F<1], total usage errors [F (2,40)=3.4,p=.05], number of attempts [F<1], 
mean time to first response [F<1], mean time to last response [F(2,40)=2.8,p=.07] and 
span length [F<1]). 
 
Overall participants in the METHADONE group significantly struggled to recall the 
longest sequence presented compared with the HEALTHY CONTROL participants. 
There was no effect on all spatial span outcomes in the METHADONE group following 
prolonged exposure to stable doses of methadone.  
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Table 4.7: Summary of results from analysis of SSP outcomes¹. Unless specified significance is with 
HEALTHY CONTROL and/or CHRONIC PAIN groups.* 
 
Spatial Span (SSP) HEROIN vs 
METHADONE vs 
CHRONIC PAIN vs 
HEALTHY CONTROL   
Opioid DEPENDENCE 
(OD) vs Non- Opioid 
DEPENDENCE  (Non- OD) 
INJECTING vs 
non- injecting  
Total Errors                 ↔ ↔ ↔ 
Total Usage Errors ↓HEROIN (also 
H>M)  
↔ ↔ 
Number of 
Attempts 
                ↔ ↔ ↔ 
Span Length  ↓METHADONE 
                
↓OD > Non- OD ↔ 
Mean Time to 1st 
Response 
                ↔ ↔ ↔ 
Mean Time to Last 
Response 
                ↔ ↔ ↔ 
*= significant effects with p<0.01, ↓=significant neuropsychological deficits present, ↔= no 
significant neuropsychological deficits present, ¹= ANCOVA ‘between subject factor’ of GROUP, 
DEPENDENCE and INJECTING analysed separately. H= HEROIN group, M= METHADONE group, 
C= HEALTHY CONTROL group. 
 
 
 Spatial Working Memory  
There was a no significant GROUP effect for: total errors [F(3,102)=3.2,p=.03], 
between search errors [F(3,100)=2.92,p=.04], mean token-search preparation time 
[F(3,100)=3.8,p=.01],strategy score [F(3,102)=2.9,p=.04] and mean time to last 
response [F(3,100)=3.5,p=.02], double search errors [F(3,102)=1.3,p=.29], within 
search errors [F(3,102)=1.5,p=.22], and mean time to first response [F 
(3,100)=2.3,p=.08]. 
 
There was no significant GROUP and task difficulty interaction for the number of total 
errors [F (9,130.45) =2.6,p=.04].  
 
There were significant DEPENDENCE effects for between search errors [F(1,102)=6.7, 
p<0.01] and total errors [F(3,104)=6.5,p<0.01], but there were no significant 
DEPENDENCE  effects for: mean token-search preparation time [F(1,102)=4.0,p=.05], 
strategy score [F(1,104)=4.8,p=.03], mean time to first response [F(1,102)=5.0,p=.03] 
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and mean time to last response[F(1,102)=3.9,p=.05], double search errors [F<1] and 
within search errors [F<1]. 
 
There was a significant DEPENDENCE status and task difficulty interaction for total 
errors [F(3,133.75)=6.2,p<0.01] and a non-significant trend for between search errors 
[F(3,181.14)=4.3,p=.02].  
 
There was no significant effects of INJECTING status for: between search errors [F<1)], 
total errors [F<1], mean token-search preparation time [F(1,47)=2.9,p=.10], strategy 
score [F<1], mean time to first response [F(1,47)=1.0,p=.31] and mean time to last 
response[F (1,47)=3.6,p=.07], double search errors [F<1] and within search errors[F 
(1,48)=1.3,p =.26].There was also no significant interactions [F<1] on all outcomes. 
 
Overall the HEROIN group showed a non-significant trend of making more between 
search and total errors due to a poor strategy score compared to the METHADONE, 
CHRONIC PAIN and HEALTHY CONTROL groups. When the HEROIN group was tested 
during different opioid receptor occupancy states there was no effect of opioid load 
on all outcomes. 
 
The METHADONE group again showed a non-significant trend of making more 
between search and total errors, longer latency measures [which includes mean time 
to last response (p=.02) and mean token-search preparation time (p=.02)] compared 
to the CHRONIC PAIN and HEALTHY CONTROL groups. There was a  trend on all 
outcomes in the METHADONE group following prolonged exposure to stable doses of 
methadone.  
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Table 4.8: Summary of results from analysis of SWM outcomes¹. Unless specified significance is with 
HEALTHY CONTROL and/or CHRONIC PAIN groups.* 
 
Spatial Working 
Memory (SWM) 
HEROIN vs 
METHADONE vs 
CHRONIC PAIN vs 
HEALTHYCONTROL  
Opioid DEPENDENCE (OD) 
vs Non- Opioid 
DEPENDENCE (Non- OD) 
INJECTING vs non- 
injecting  
Total Errors ↔ ↓OD > Non- OD ↔ 
Between Search 
Errors 
↔ ↓OD > Non- OD ↔ 
Double  Search 
Errors 
↔ ↔ ↔ 
Within Search 
Errors 
↔ ↔ ↔ 
Strategy Score ↔ ↔ ↔ 
Mean Time to 
First Response 
↔ ↔ ↔ 
Mean Time to Last 
Response 
↔ ↔ ↔ 
Mean Token 
Search 
Preparation Time 
↔ ↔ ↔ 
*= significant effects with p<0.01, ↓=significant neuropsychological deficits present, ↔= no significant 
neuropsychological deficits present, ¹= ANCOVA ‘between subject factor’ of GROUP, DEPENDENCE and 
INJECTING analysed separately. 
 
Discussion 
Table 4.9 summarises the association between chronic opioid dependence and 
neuropsychological impairment in the cohorts studied. It describes specific significant 
deficits in cognitive and motor impulsivity and strategic planning in the opioid 
dependent population (HEROIN and/or METHADONE groups) when compared to the 
CHRONIC PAIN and HEALTHY CONTROL groups. Some of the deficits were significantly 
associated to the dependence status whilst others were not. 
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Table 4.9: Summary of outcomes of opioid using groups and neuropsychological functioning in 
impulsivity when compared with HEALTHY CONTROL group.*  
 
Neuropsychological 
domain 
Tests HEROIN  METHADONE  CHRONIC 
PAIN  
Opioid DEPENDENCE 
cohort 
INJECTING 
cohort 
IMPULSIVITY       
Cognitive 
 Impulsivity  
CGT Risk 
Taking, 
Risk 
Adjustment, 
Delay 
Aversion 
Deliberation  
Time,  Risk 
Adjustment  
 
 
 
No 
impairment 
 
 
 
 
 
Deliberation Time    No 
impairment 
Motor 
 Impulsivity  
              
 
AGN 
Total 
Commission 
Errors 
No 
impairment 
No 
impairment 
Total Commissions 
(negative valence 
and non- shift 
modes) Errors, 
Omission Errors 
No 
impairment 
Non-Planning 
Impulsivity 
      
  
SOC 
Number of 
Minimum 
Moves , 
Subsequent 
Thinking 
Time (5 
move 
problem) 
Number of 
Minimum 
Moves (5 
move 
problem) 
No 
impairment 
No impairment No 
impairment 
 SSP Total 
Usage 
Errors 
Span Length No 
impairment 
Span Length 
 
No 
impairment 
 SWM No 
Impairment 
No 
impairment 
No 
impairment 
Between Search 
Errors and Total 
Errors 
No 
impairment 
*= p<0.01, no impairment= no difference in neuropsychological performance when compared 
to healthy controls, AGN= Affective Go-NoGo Task, CGT=Cambridge Gambling Task, 
SOC=Stockings of Cambridge, SSP= Spatial Span, SWM= Spatial Working Memory.  
 
The ability to make decisions is a key element in human behaviour because this will 
influence how people behave in wider society (Hastie, 2001; Mellers et al., 1998). 
Because decisions are usually made with a view to a favourable outcome, rewards 
provide the motivation to make decisions. Cognition is necessary to appraise the 
options and alternatives, assessing the means to achieve them and evaluate 
consequences involved with each choice (Ernst, 2005; Hastie, 2001).The results show 
that the chronic HEROIN dependent individuals tended to significantly place higher 
and earlier bets on favourable ratios (especially in the descending order) and bet 
more at all difficulty levels (favourable or not) reflecting a disadvantageous decision 
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making strategy and impulsive behaviour. The chronic and stable METHADONE 
participants were significantly slower in making a decision compared to the other 
groups which was independent of difficulty levels present (ratio of coloured boxes) or 
direction of betting sequence (ascending or descending order). The METHADONE 
group also had a tendency to place higher and earlier bets but, in this instance, on 
favourable ratios indicating unimpaired risk adjustment. This result is comparable to 
results obtained from studies conducted by Ersche et al., (2005a & 2006a); Rogers et 
al., (1999) and Ornstein et al., (2000). Since confounding variables such as young age 
(Deakin et al., 2004), low intelligence quotient (Fishbein et al., 2005a), and 
psychiatric mood states (Jollant et al., 2007) and psychopathic personality disorder 
(Vassileva et al.,2007) were all controlled in this study amongst others this 
observation could be said to be a result of (1) the chronic intake of either heroin 
and/or methadone, (2) the opioid dependence status, (3) past history of substance 
abuse and associated lifestyle and/or (4) vulnerability to trait impulsivity (de Wit, 
2009; Ersche et al., 2010) and its involvement in drug use experimentation, abuse 
and dependence and/or relapse after a period especially of abstinence (Koob & 
Volkow, 2010). In this study, no such deficits were observed in the CHRONIC PAIN 
population tested and the dependence and injecting status of the HEROIN and 
METHADONE groups did not indicate specific deficits in impulsivity excluding the 
possibility of (1) & (2) from the above. The deficits observed also did not change with 
either different opioid receptor occupancy or duration of methadone used. It is 
difficult from this study to determine if this is predominately due to statements (3) or 
(4) from the above or a combination of both These statements should still be 
interpreted with caution until similar results are seen to be repeated in other 
independent studies. 
 
The index of motor impulsivity or the inability to stop a planned movement is the 
number of false responses or commission errors on the Affective Go-NoGo task 
(Chikazoa et al., 2007, Konishi et al., 1998). This study clearly observed significant 
impairment in this outcome with the HEROIN participants who improved when 
stabilised on methadone after a month. There was a trend for the METHADONE 
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group to have the same inability to stop a planned movement but did not reach 
significance. Significantly the METHADONE group but not the HEROIN group (possibly 
due to a low statistical power) showed lack of attention as well as behavioural 
inhibition reflected by a higher rate of false misses (omissions). 
 
These results are in contrast to the majority of studies which did not find behavioural 
inhibition deficits in opioid users (Fishbein et al., 2007; Rounsaville et al., 1982; 
Passetti et al., 2008; Verdejo-Garcia et al., 2007a; Vainio et al., 1995) but in 
agreement with Fillmore & Vogel-Sprott (1999); McNairy et al., 1984 and Forman et 
al. (2004) who compared opioid-dependent individuals with healthy controls on the 
Go-NoGo task. Their findings significantly showed poorer performance in opioid 
dependent individuals.  
 
Again there were no significant impairments recorded from the CHRONIC PAIN group 
in our study. The deficits seen in the HEROIN and less so in the METHADONE group 
could again be indicative of vulnerability traits but equally the HEROIN group showed 
signs of improvement when the cohort was stabilised on methadone. This 
improvement was not observed in the METHADONE group after the extended 
stabilisation period. Opioid dependence was a significant variable but injecting status 
was not. The results indicate a deficit in motor impulsivity in the HEROIN dependent 
participants independent of the amount of opioid used or method of administration 
as observed in Rogers et al. (1999a) and Clark et al. (2006). 
 
The ability to think ahead and actively search for an appropriate solution (non-
planning impulsivity) is essential in many daily activities (Owen, 1997). There were 
significant differences between groups in performance to either first or subsequent 
and more complex stages of the Stocking of Cambridge (SOC) which required 
differential planning ability. Similar to the results in this cohort, the SOC or equivalent 
task in previous studies showed impairment in opioid dependent individuals 
(Ornstein et al., 2000; Ersche et al., 2006a). 
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In addition  performance on tasks requiring complex spatial executive memory 
function and visuo-spatial strategy generation were impaired in this cohort as 
described in previous studies by Ornstein et al. (2000) and Ersche et al. (2006a).The 
METHADONE group struggled most to recall longer sequences presented (span 
length) in the SSP task indicating memory deficits. HEROIN participants had significant 
impaired planning problems especially when a high level of difficulty was presented. 
This is comparable with previous studies (Ersche et al., 2006a; Shallice, 1982; Owen 
et al., 1990).  
 
Opioid addiction involved neuroadaptive changes within large-scale striato-thalamo-
orbitofrontal networks implicated in the processing of natural rewards and the 
regulation of behaviour (Everitt & Robbins, 2005).  These changes cause the 
overvaluing of drug reinforcers at the expense of the undervaluing of natural 
reinforcers with deficits in inhibitory control of drug responses (Goldstein & Volkow, 
2002). As a result, impaired behavioural control at the level of the prefrontal cortex is 
widely believed to be crucial to the addiction process (Koob & Volkow, 2010; Everitt 
& Robbins, 2005; Dawe et al., 2004). More specifically neuroanatomical models 
suggest the existence of separate but interconnecting ‘impulsive’ and ‘compulsive’ 
cortico-straital circuits (Brewer & Potenza, 2008). In the impulsive circuit, a striatal 
component (ventral striatum/nucleus accumbens shell) driving impulsive behaviours 
and a prefrontal component (anterior cingulate cortex, ventromedial prefrontal 
cortex (VMPFC) and orbitofrontal cortex (OFC)) exerting the inhibitory control 
(Fineberg et al., 2009). Models of vulnerability to opioid dependence are suggestive 
and most studies originate from what are essentially predominantly alcohol and /or 
cocaine dependent studies. Verdejo-Garcia et al., (2008b) suggest that genetic 
associations, especially DRD2 polymorphism, with addiction vulnerability cannot 
conclusively implicate trait impulsivity (Perez de Los Cobos et al., 2007; Xu et al., 
2004). However  there seems to be a more persuasive evidence of increased 
vulnerability to impulsivity in high risk children of substance use disorders parents 
prior to onset of their drug use (Kendler et al., 2003) and in siblings of drug users  
(Ersche et al., 2010). 
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Overall this study has tested the hypothesis that chronic opioid dependence was 
associated with neuropsychological impairment reflected in altered performance on 
measures of impulsivity. The HEROIN group exhibited increased cognitive and motor 
impulsive behaviours and associated poor strategic planning (non-planning 
impulsivity). The METHADONE group were slow to react, inattentive and experienced 
associated memory problems. The hypothesis that injecting status, the degree of 
acute opioid exposure (acute intoxication, withdrawal or stable initial exposure to 
methadone) and/or duration of opioid exposure (period of methadone maintenance) 
in an opioid dependent population would experience altered performance on 
measures of impulsivity has not been confirmed in this study.  The CHRONIC PAIN 
group did not experience deficits in impulsivity and so the above results posit the 
notion that these impairments were related to trait vulnerabilities in impulsivity with 
a relative shift in the types of deficits from global executive dysfunction in the 
HEROIN group to inattention in the METHADONE group indicating neuropsychological 
improvement in impulsivity outcomes with methadone treatment.  
 
 
Conclusion 
Heroin dependence produced difficulties in strategic planning and risk taking.Motor 
impulsivity in HEROIN users improved once stabilised on methadone which could 
possibly be explained by the level of acute intoxication which might have affected the 
result or the actual effect of the methadone after three weeks of stabilisation. 
Dependence and injecting status do not contribute to the causation or deterioration 
of any of the identified deficits. 
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Chapter 5: Results-Neuropsychological functioning in men with a 
history of chronic opioid use: Cognitive flexibility 
 
Background 
Cognitive flexibility has been described as the ability to shift avenues of thought and 
action in order to perceive, process, and respond to situations in different ways 
(Eslinger & Grattan, 1993; Ersche et al., 2010; Fineberg et al., 2009.The Wisconsin 
Cart Sorting Test (WCST) (Grant and Berg, 1948) and the Intra/Extra-Dimensional 
(IED) Set Shifting task of the CANTAB test battery (Downes et al., 1989; Rogers et al., 
2000b) have been widely used to assess cognitive flexibility in opioid dependence in 
laboratory settings (Chapters 1 & 2 and Table 5.1).  
 
Table 5.1: Cognitive flexibility domains. 
Main 
Domain 
Subtypes Other names Definition Examples of 
test 
Cognitive 
Flexibility 
 Cognitive Rigidity Ability to shift 
avenues of thought 
and action in order to 
perceive process and 
respond to situations 
in different ways 
(concrete approaches 
to problem solving) 
 
 Reactive 
Flexibility  
Perseveration or 
shifting of 
perceptual set 
Ability to realign a 
behavioural 
predisposition to 
altered contingencies 
WCST, ST, IED,  
TMT, SCT, MCST 
 Spontaneous 
Flexibility or 
fluency 
Verbal and non- 
verbal fluency 
Requires the intrinsic 
generation of 
responses or 
alternatives 
COWAT, FAS, 
VFT, RFFT, WAIS 
III (Similarities), 
RWT 
COWAT= Controlled Oral Word Association Test, FAS= Phonological Fluency Test, IED= Intra/Extra-
Dimensional Test (CANTAB), MCST= Maudsley Card Sorting Test, RWT= Regensburger Word Fluency 
Test, SCT= Logan Stop Change Task, ST= Stroop Test, TMT= Trail Making Test, VFT= Benton Verbal 
Fluency Test, WCST= Wisconsin Card Sorting Test, WAIS-III= Weschler Adult Intelligence Scale Third 
Edition. 
 
Studies in current and former opioid users have reported contradictory findings. 
Studies either did not identify impairments in cognitive flexibility, suggesting that 
chronic opioid consumption does not have an impact on, for example, attentional set-
shifting (Ersche et al., 2006a; Pau et al., 2002; Rotheram-Fuller et al., 2004; Verdejo- 
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Garcia et al., 2005a, 2005b; Verdejo-Garcia & Perez-Garcia, 2006); or, identified 
impairment in dependent heroin users (Stevens et al., 2007; McNairy et al., 1984), in 
abstinent heroin cohorts (Verdejo-Garcia et al., 2007a, Brand et al., 2008) and/or  
methadone users (Darke et al., 2000; Mintzer et al., 2005; Pirastu et al., 2006) (Table 
5.2). 
Table 5.2: Chronic opioid use and cognitive flexibility. Previous research findings.* 
 
Neuropsychological 
domain 
Illicit chronic 
heroin use  
Abstinent 
ex-heroin 
use 
Methadone 
use 
Other opioid 
use¹ 
Chronic 
opioid 
dependence 
Cognitive 
Flexibility 
(ability to shift 
attentional set) 
Hill et al 
(1979)↓ 
Stevens et al 
(2007)↓ 
McNairy et al 
(1984)↔ 
Verdejo-
Garcia et al 
(2007a)↓ 
Fishbein et 
al (2007)↓ 
Brand et al 
(2008)↓ 
Darke et al 
(2000)↓ 
Mintzer et al 
(2005)↓ 
Rotheram-
Fuller et al 
(2004)↔ 
Pirastu et al 
(2006)↓ 
Prosser et al 
(2006)↓ 
Rounsaville et 
al (1982)↔ 
Soyka et al 
(2008)↓ 
Pirastu et al 
(2006)↓ 
Soyka et al 
(2008)↓ 
Jamieson et 
al (2003)↑ 
Tassain et al 
(2003)↔ 
Schindler et 
al (2004)↔ 
Ersche et al 
(2006)↓ 
Ornstein et al 
(2000)↓ 
Cognitive 
Flexibility 
(verbal fluency) 
 
 
Prosser et 
al 
(2006)↔ 
Verdejo-
Garcia et al 
(2007a)↓ 
Brand et al 
(2008)↔ 
Darke et al 
(2000)↓ 
Soyka et al 
(2008)↓ 
Prosser et al 
(2006)↔ 
Soyka et al 
(2008)↓ 
Ornstein et al 
(2000)↓ 
*=p<0.05; ↔= no difference in neuropsychological (compulsivity) performance; ↓= 
neuropsychological (compulsivity) deficits present; ↑= improvement in neuropsychological 
(compulsivity) performance when compared to healthy controls, other opioid use1= 
buprenorphine, morphine, oxycodone and tramadol. 
 
The WCST and IED tasks both assess the capacity to relearn a stimulus-reward 
association by inhibition of the previously reinforced dimension (i.e. reversal shift) as 
observed in both animal (Dias et al., 1996) and human (Rogers et al., 2000a) studies. 
No impairments were observed in chronic opioid users on the reversal shift in the IED 
task (Ersche et al., 2006a; Ornstein et al., 2000). However impairment in reversal 
shift on the WCST has been described with early methadone withdrawal (Lyvers 
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&Yakimoff, 2003), co-morbid alcohol dependence and history of previous heroin 
overdoses (Darke et al., 2000) but does not seem to be a consistent, or characteristic, 
behavioural correlate of opioid dependence. 
 
In light of the previous research in the area of opioid dependent use and 
neuropsychological functioning, the present study set out to expand on the current 
limited knowledge base by comparing the neuropsychological performance of chronic 
heroin dependent users, methadone maintained male participants and others taking 
opioids for chronic pain compared to non- substance using healthy controls as 
explained in Chapter 3 of this thesis. This will help test the hypothesis (1): 
 
(1) Is chronic opioid dependence associated with neuropsychological impairment 
reflected in altered performance on measures of compulsivity?  
 
As previously described in Chapter 4, at least three factors were considered to be 
related to drug taking which may exert an important influence over 
neuropsychological performance. These include: (1) duration of opioid use, (2) level 
of opioid receptor occupancy during behavioural testing-(a) during intoxication, (b) 
during withdrawal and (c) during stable methadone maintenance and (3) injecting 
status. Therefore the next two related hypotheses (2 and 3) to be tested were: 
 
(2) In patients with chronic opioid dependence, is injection status associated with 
neuropsychological impairment as reflected in altered performance on measures of 
compulsivity?  
(3) In patients with chronic opioid dependence is the degree of acute opioid 
exposure (acute intoxication, withdrawal or stable initial exposure to methadone), 
or duration of opioid exposure (period of methadone maintenance) associated with 
neuropsychological impairment as reflected in altered performance on measures of 
compulsivity?  
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Statistical considerations 
Basic statistical considerations have been described in Chapter 2. The data from the 
IED tasks violated assumptions of normality and homogeneity of variance. To stabilise 
variance and diminish skewness and kurtosis, IED data were subjected to square root 
(SQRT) transformation (Fields, 2009).  
 
Testing hypotheses 1 and 2 
Data from the IED were initially analysed using univariate or repeated measures 
ANCOVA with a between subject factor of GROUP (HEROIN vs. METHADONE vs. 
CHRONIC PAIN vs. HEALTHY CONTROL) and difficulty as expressed by the nine IED 
stages as a within-subjects factor. NART, age in years, SIMD, total Fagerström score, 
years in education and past alcohol use in years were considered as covariates.  
 
Further a priori subgroup analysis for the IED was conducted using (1) a two-group 
factor reflecting DEPENDENCE  (HEROIN and METHADONE groups vs. CHRONIC PAIN 
and HEALTHY CONTROL groups) and (2) a two-group factor reflecting lifetime 
INJECTING  (HEROIN and METHADONE injecting vs. HEROIN and METHADONE never 
injecting groups) separately as the between subject factors.  
 
Between-group effects in ANCOVA were analysed as follows. A planned post hoc 
comparison between the HEALTHY CONTROL and the three experimental groups 
(HEROIN, METHADONE and CHRONIC PAIN) was used to detect any difference in 
performance. In this four-group model, significant between-group effects were 
investigated using pair-wise comparisons with Bonferroni correction procedure. Effect 
sizes for the group comparisons were calculated using Cohen’s d, (i.e. the difference 
between the means divided by the pooled standard deviation) (Cohen, 1988).  
 
Testing hypothesis 3 
Repeated measures ANCOVA was used to evaluate IED task performance between 
the HEROIN group participants at baseline (whilst on illicit heroin), in controlled 
opioid withdrawal and subsequently when stabilised on methadone according to the 
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tolerance testing procedure protocol with presumed opioid receptor occupancy state 
as a within subject factor to determine whether performance on the IED task was 
modified by different degrees of opioid receptor occupancy (heroin, withdrawal and 
stable on methadone).  
 
Similarly repeated measures ANCOVA was also performed to follow up IED 
performance for the METHADONE group at baseline and at 6 months follow up with 
duration as a within subject factor to determine whether any aspects of performance 
improved or deteriorated with time and continued exposure to chronic, sustained 
released opioid (methadone). . 
 
The homogeneity of variance across groups in repeated‐measures design ANCOVAs 
was assessed by the Mauchly Sphericity Test (Mauchly, 1940). Where data sets 
significantly (p<0.05) violated this requirement for a repeated‐measures design 
ANCOVA, the Greenhouse Geisser Epsilon (^ε) correction parameter for degrees of 
freedom (Greenhouse & Geisser, 1959; Winer et al., 1991) was used to calculate a 
more conservative p value for each F ratio. 
 
Results 
All subjects completed all of the tests. Mean performance (not adjusted for 
covariates), statistical comparisons and effect sizes (d) for each task, for the HEROIN, 
METHADONE, CHRONIC PAIN and HEALTHY CONTROL groups, are summarised in 
Table 5.3. 
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Table 5.3: Summary of baseline neuropsychological findings in cognitive flexibility (not 
adjusted for covariates). 
 
Compulsivity or 
lack of cognitive 
flexibility 
HEROIN 
N= 24 
METHADONE 
N= 29 
CHRONIC 
PAIN 
N= 28 
HEALTHY 
CONTROL  
N= 28 
  
IED (SQRT)       
Stages 
Completed 
8.19 (1.91) 8.64 (1.05) 8.50 (1.20) 8.56 (0.99) NS  
Total Errors  5.07 (1.31) 4.34 (1.41) 4.57 (1.23) 3.10 (1.12) C<H * 1.62 
Pre ED Shift 
Errors 
2.73 (1.07) 2.48 (0.65) 2.35 (0.63) 2.32 (0.49) NS  
ED Shift Errors 3.20 (1.76) 2.70 (1.46) 3.27 (1.51) 2.77 (1.41) NS  
d= effect size, SQRT= Square Root transformation; Sig= Significance, *= p < 0.01, **= p < 
0.005, *** =p < 0.001, NS= no significant impairment in neuropsychological outcomes with 
p<0.01, H=HEROIN Group, P=CHRONIC PAIN Group, M= METHADONE Group, C=HEALTHY 
CONTROL Group. 
 
Cognitive flexibility 
 Intra/Extra-Dimensional Set Shifting (IED) Task 
All participants from the four groups succeeded in completing all nine stages of the 
IED task.  
 
There was a non-significant GROUP [F (3,102) =3.9, p=.01] trend for total mean 
errors. Post hoc Bonferroni comparisons showed that participants from the HEROIN 
group had significantly made more errors on the IED tasks compared to the HEALTHY 
CONTROL group (p<0.01, d=1.62) (Figure 5.1). The total mean errors for the CHRONIC 
PAIN (p=.70) or METHADONE (p=.16) groups lay between those for the METHADONE 
and HEALTHY CONTROL groups and did not differ significantly from any of the other 
two groups. 
 
However there were no significant GROUP effects for pre-EDS errors [F (3,102) =0.4, 
p=.76] and EDS error scores [F (3,102) =2.2, p=.09] There were no significant GROUP 
by task difficulty interactions for all IED outcomes. 
  
There was no effect of DEPENDENCE status effects for: total errors [F (1,104) =3.4, 
p=.07], pre-EDS errors and EDS errors [F<1]. There was also no effect of INJECTING 
189 
 
 
 
status for: total errors and pre-EDS errors [F<1] and EDS errors [F (1, 48) =4.5, p=.04]. 
There was no significant DEPENDENCE or INJECTING interaction for all IED outcomes. 
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Figure 5.1: IED- Total mean errors of the HEROIN and HEALTHY CONTROL groups with the  HEROIN 
group making significantly more errors on the total IED tasks compared to the HEALTHY CONTROL 
group (*p<0.01). SD= Simple Discrimination, SDR=Simple Reversal, C_D= Compound Discrimination, 
CD=Compound Discrimination, CDR= Compound Reversal, IDS=Intra-Dimensional Shift, IDR= Intra-
Dimensional Reversal, EDS= Extra-Dimensional Shift, EDR= Extra-Dimensional Reversal, pre-EDS= 
Pre- Extra-Dimensional Shift. 
 
Overall participants from the HEROIN group significantly made more total errors in 
the IED tasks compared to the HEALTHY CONTROL group (p<0.01) but not to the 
CHRONIC PAIN or METHADONE groups. When the HEROIN group was tested during 
different opioid receptor occupancy states there was no effect of opioid load on all 
the IED outcomes. There was also no effect on all IED outcomes in the METHADONE 
group following prolonged exposure to stable doses of methadone (Table 5.4). 
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Table 5.4: Summary of results from analysis of IED¹ outcomes. Unless specified significance 
is with HEALTHY CONTROL and/or CHRONIC PAIN groups*. 
 
Intra-Extra 
Dimensional Shift 
Test (IED) 
HEROIN vs 
METHADONE vs 
CHRONIC PAIN vs 
HEALTHY CONTROL   
Opioid 
DEPENDENCE (OD) 
vs Non- Opioid 
DEPENDENCE (Non- 
OD) 
INJECTING vs 
non- injecting  
IED 
StagesCompleted 
↔ ↔ ↔ 
Total Mean Errors ↓HEROIN ↔ ↔ 
ID (Pred EDS) 
Errors 
↔ ↔ ↔ 
EDS Errors ↔ ↔ ↔ 
*= significant effects with p<0.01, ↓=significant neuropsychological deficits present, ↔= no 
significant neuropsychological deficits present, ¹= ANCOVA ‘between subject factor’ of GROUP, 
DEPENDENCE and INJECTING analysed separately. 
 
Discussion 
Table 5.5 summarises the neuropsychological outcomes of the opioid using groups 
with respect to cognitive flexibility. Set-shifting represents the ability to switch 
attention from one aspect of a stimulus to another in an ongoing task, as a result of 
changing reinforcement contingencies (Chapter 2).  
 
Table 5.5: Summary of outcomes of opioid using groups and  neuropsychological 
functioning in cognitive flexibility when compared with the HEALTHY CONTROL group*.  
 
Neuropsychological 
domain 
Tests HEROIN  METHADONE  CHRONIC 
PAIN  
Opioid 
DEPENDENCE   
INJECTING  
Cognitive  
Flexibility 
IED Total 
mean 
errors  
No 
 impairment 
No 
impairment 
No  
impairment 
No 
impairment 
*= p<0.01, no impairment= no difference in neuropsychological performance when compared 
to healthy controls, IED= Intra/Extra-Dimensional Set Shifting Task. 
 
The HEROIN group made significantly more errors than participants in the HEALTHY 
CONTROL group throughout the multiple stages of the IED task. At the pre EDS stage 
participants needed to maintain attention to the same dimension for correct 
responding, thus testing their ability to generalise the rule they had just learned 
(Roberts et al., 1988). In normal psychologically unimpaired individuals, choice 
behaviour in a sensorimotor association task requires structure learning processes 
191 
 
 
 
and cannot be just accounted for by forming specific associations between sensory 
stimuli and motor responses (Braun et al., 2010). It is suggested that normal and 
unimpaired individuals learn much more than specific stimulus-response associations, 
namely that they also learn to extract abstract invariants that are applicable to a 
broad class of tasks (Trobalon et al., 2003). The HEROIN group showed generalsation 
errors with a cognitive inability to move from a learned specific rule to another 
possibly due to lack of attention and associated impairment in applied learning 
processes (Ornstein et al, 2000).  
 
Set shifting impairments were not observed in any of the other experimental groups 
suggesting no significant impairment in cognitive flexibility. Therefore the hypothesis 
that chronic opioid dependence was associated with neuropsychological impairment 
reflected in altered performance on measures of cognitive flexibility (cognitive 
rigidity) has not been confirmed. 
 
The degree of acute opioid exposure, injecting status and duration of opioid exposure 
did not significantly alter performance on measures of cognitive flexibility in this 
study. Compared to previous studies discussed earlier (Chapter 1) cognitive rigidity 
was evidently present during most opioid related states (heroin, methadone and/or 
other opioid use/abuse and abstinence from any opioids) but in most studies one 
could not clearly define the contribution of confounding variables present in the 
population studied. 
 
In McNairy et al., 1984, the heroin group tested, showed significant deficits in 
cognitive flexibility amongst other outcomes, but this cohort were also experiencing 
chronic pain. The authors suggested that the neuropsychological impairment could 
have been caused by the chronic use of opioids and compounded by the ‘slowed, 
disorganised or inappropriate responses to environmental demands for adaptive and 
stressful behaviour such as chronic pain and iatrogenic prescription of opioids’. 
Participants from the CHRONIC PAIN group in my study did not experience significant 
extra-dimensional task errors when compared to participants in the HEALTHY 
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CONTROL group.  However the participants from the METHADONE and HEROIN 
groups were assessed for presence of past and current pain syndromes when 
screened with the M.I.N.I questionnaire during the recruitment phase. The notion 
that chronic pain is exacerbating cognitive rigidity could not be observed in this study.  
 
However one needs to take these results with caution as only one neuropsychological 
task sensitive to one aspect of cognitive flexibility was used. The IED task is sensitive 
to identify impairment in reactive flexibility which is defined as the inability to realign 
a behavioural predisposition to altered contingencies (Grattan & Eslinger, 1989). No 
neuropsychological tasks were used to determine other aspects of cognitive flexibility 
such as spontaneous flexibility using verbal and non-verbal fluency tasks (Demakis & 
Harrison, 1997; Zinn et al., 2004). Switching tasks, in which participants undertaking 
two or more tasks that run alternately in a rapid fashion, may help to clarify the 
nature of deficits, if any, in cognitive flexibility in opioid dependent individuals. As a 
behavioural addiction with  clinical and phenomenological similarities to substance 
addiction, recreational and pathological gambling represent models for studying the 
neurobiology of addiction especially cognitive flexibility, without the confounding 
deleterious brain effects which may occur from chronic substance abuse (Odlaug et 
al., 2011) (Chapter 7). 
 
Conclusion 
Chronic opioid use or opioid dependence is not associated with deficits in cognitive 
flexibility or cognitive rigidity. In this study cognitive flexibility did not improve or 
deteriorate following periods of stability with the dependence and injecting status 
not contributing to the causation or deterioration of the condition. 
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Chapter 6: Results-Neuropsychological functioning in men with a 
history of chronic opioid use: Memory and Learning 
 
Background 
This chapter aims to incorporate three interrelated memory and learning 
neuropsychological domains. They include attentional bias and/or sustained 
attention, short term memory (STM) and long term memory (LTM) (Table 6.1 and 
Chapter 1). 
Table 6.1: Memory domains. 
Main Domain Subtypes Other names Definition Examples of test 
Directed 
Attention/ 
Registration   
Sensory 
Peripheral Store 
or Sensory 
Memory 
Visual or Iconic  
Memory 
Retains large amount 
of information  
 
Auditory or Echoic 
Memory 
 
 
 
Short Term 
Memory 
 
 
 
Immediate 
Memory 
 
Verbal Memory 
 
 
 
 
 
Visuospatial  
Memory 
Reproduction, 
recognition or recall 
of information 
directly or some time 
after presentation 
 
 
Allow information to 
be evaluated and 
perhaps stored longer 
through rehearsal 
and coding 
LMT, RAVLT, 
CVLT,WAIS-III , 
VRM, WMSR , 
WRM, GNT, DFDBT, 
TBT 
 
SWM, SSP. DMS, 
PRM, PAL, BVRT, 
PAL, SRM,.WMSR, 
RCFT, PASAT, WAIS-
III 
 
 
 
 
 
 
 
Long Term 
Memory 
 
 
 
Explicit 
(Declarative) 
Memory 
Autobiographical, 
Episodic or Event 
Memory 
 
Records details 
salient to individual’s 
life.Needs conscious 
thinking. ‘Knowing 
that’ 
Meaning of words 
and concepts or facts 
PRM,SRM,CVLT, 
RAVLT, PAL 
RCFT,  WMSR 
WAIS-III 
(Vocabulary) 
Semantic Memory 
 
 
RCFT, 
COWAT, GNT , 
WMSR, RBMT 
 
Implicit (Non- 
Declarative) or 
Procedural 
Memory 
(1)  Motor skill 
training 
 
Does not need 
conscious thinking. 
’Knowing how’ 
 
(2) Priming or 
classical conditioning  
 
BVRT=Benton Visual Retention Test, COWAT= Controlled Oral Word Association Test, CVLT= California Verbal 
Learning Test, DFDBT= Digit Forward and Digit Backwards Test, DMS=Delayed Matching to Sample (CANTAB), 
GNT=Graded Name Test (CANTAB), LMT= Logical memory Test, SRM=Spatial Recognition Memory (CANTAB), PAL= 
Paired Associate Learning (CANTAB), PASAT= Paced Auditory Seriel Addition Task, PRM= Pattern Recognition 
Memory (CANTAB), RAVLT= Rey Auditory Verbal Learning Test, RBMT= Rivermead  Behavioural Memory Test, 
RCFT= Rey Complex Figure Test, SWM=Spatial Working Memory (CANTAB), SSP=Spatial Span (CANTAB), TBT= Two 
Back Test ,VRM= Verbal Recognition Memory (CANTAB), WAIS-III= Weschler Adult Intelligence Scale Third 
Edition, WMSR= Weschler Memory Scale Revised, WRM= Word Recognition Memory. 
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Baddeley (1999; 2000) used the term ‘working memory’ rather than STM to describe 
the memory system that allows us to hold and manipulate stored information ‘on-
line’. Working memory allows relevant information from our long term store to be 
brought in and used with current mental processing. It is not unitary, rather it is 
divided into three subsystems – the central executive and its’ two slave systems, the 
phonological loop and the visuospatial sketch-pad. The central executive is like the 
‘supervisory attentional system’ proposed by Norman & Shallice (1986) .This 
‘supervisory attentional system’ and/or ‘buffer zone’  is involved in planning and 
attentional control, linking the ‘slave systems to LTM. The phonological loop serves to 
hold and refresh an articulation (e.g., mentally rehearsing a phone number) while the 
visuo-spatial sketch-pad allows location and visual information to be held (Baddeley, 
1986; 1998) (Table 1.2).  
 
The neural substrates of memory and learning are among the major circuits 
undergoing aberrant neuro-adaptations in response to chronic drug exposure 
(Volkow et al., 2004). Different memory systems have been proposed to be involved 
in drug addiction. The frontal lobes have been suggested as important in working 
memory with the Broca’s area related to the phonological loop (Gazzaniga et al., 
2002). The declarative memory system (knowing what, where, and when) is generally 
associated with circuits that encompass the medial temporal lobe (e.g. the 
hippocampus and perirhinal and entorhinal cortices), anterior thalamic nuclei, regions 
of the association cortex, and prefrontal cortex (PFC) (Mayes et al., 2007).The 
procedural memory (knowing how) has been linked with structures implicated in 
sensorimotor function, including sensory neocortex, motor cortex, striatum (caudate–
putamen), and cerebellum (Squire et al. 1993; White, 1996). Classical conditioning 
and/or emotional memory may depend on other structures in the limbic system, 
including the amygdala and perhaps the nucleus accumbens (Robbins et al., 2008). 
 
Learning and memory impairments have been identified in chronic amphetamine, 
methamphetamine users (Ersche et al., 2006a; Gonzalez et al., 2004; Hoffman et al., 
2006; Kalechstein et al., 2003; Moon et al., 2007; Ornstein et al., 2000; Rippeth et 
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al., 2004; Simon et al., 2002; Woods et al., 2005), alcohol, opioids, ecstacy (MDMA) 
and cannabis users (Fernandez-Serrano et al., 2010a) with mixed evidence that 
performance improves following long term abstinence (Fernandez-Serrano et al., 
2010a; Wang et al., 2004). 
 
In addition impairment in attention (attentional bias) has been observed in opioid 
dependent individuals (Lubman et al., 2000; Mariseen et al., 2006).Impairment in 
short and long term memory  associated with chronic opioid use was considered as 
either related to generalised or specific effects of substance misuse (Fernandez-
Serrano et al., 2010b). While a number of studies identified various aspects of 
memory impairment (Amir & Bahri, 1994; Darke et al., 2000; Ornstein et al., 2000; 
Ersche et al., 2006a; Papageorgiou et al., 2004; Pirastu et al., 2006; Soyka et al., 
2008; Prosser et al., 2006), others did not find memory deficits in chronic opioid 
users (Fishbein et al., 2007; Rapeli et al., 2006; Rounsaville et al,. 1982) (Table 6.2). 
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Table 6.2: Chronic opioid use and memory. Previous research findings*.  
Neuropsychological 
domain 
Illicit chronic 
heroin use  
Abstinent ex-
heroin use 
Methadone use Other opioid 
use¹ 
Chronic 
opioid 
dependence 
Sustained Attention McNairy et al 
(1984)↔ 
Stevens et al 
(2007)↓ 
Verdejo-Garcia et 
al (2007a)↓ 
Mintzer et al 
(2005)↓ 
Darke et al 
(2000)↓ 
Specka et al 
(2000)↓ 
Mintzer et al 
(2005)↓ 
Rounsaville et al 
(1982)↔ 
Soyka et al 
(2008)↓ 
Soyka et al 
(2008)↓ 
Sjogren et al 
(2005)↓ 
Jamieson et al 
(2003)↔ 
Tassain et al 
(2003)↔ 
Vainio et al 
(1995)↔ 
Schindler et al 
(2004)↓ 
 
Short term  
memory 
 
McNairy et al 
(1984)↓ 
Stevens et al 
(2007)↓ 
 
Verdejo-Garcia et 
al (2007a)↓ 
Fishbein et al 
(2007a)↔ 
Darke et al 
(2000)↓ 
Mintzer et al 
(2005)↔ 
Prosser et al 
(2006)↓ 
Pirastu et al 
(2006)↓ 
Soyka et al 
(2008)↓ 
Pirastu et al 
(2006)↓ 
Soyka et al 
(2008)↓ 
Tassain et al 
(2003)↔ 
Ersche et al 
(2006a)↓ 
Ornstein et 
al (2000)↓ 
Long term memory Stevens et al 
(2007)↓ 
 
 Darke et al 
(2000)↓ 
 
Tassain et al 
(2003)↔ 
Ersche et al 
(2006a)↓ 
Ornstein et 
al (2000)↓ 
*= p<0.05, ↔= no difference in memory performance; ↓= neuropsychological (memory) 
deficits present, ↑= improvement in memory performance when compared to healthy 
controls, Other opioid use1= buprenorphine, morphine, oxycodone and/or tramadol. 
 
Most studies did not find associations of memory deficits with the amount of opioids 
consumed or the duration of opioid use (Ersche et al., 2006a; Prosser et al., 2006; 
Rounsaville et al., 1982). By contrast, improved memory function has been reported 
following two months of methadone-maintenance treatment (Gruber et al., 2006). 
 
In light of the previous research in the area of opioid dependent use and 
neuropsychology, the present study set out to expand on the current limited 
knowledge base by comparing the level of neuropsychological function in memory 
and learning on chronic heroin, methadone and other opioids in a male population 
compared to non- substance using healthy controls as explained in Chapter 3 of this 
thesis. This will help test the hypothesis (1):  
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(1) Is chronic opioid dependence associated with neuropsychological impairment 
reflected in altered performance on measures of memory and learning?  
 
As previously described in Chapter 4 and 5 at least three factors were considered to 
be related to drug taking which may exert an important influence over 
neuropsychological performance. These include: (1) duration of opioid use, (2) level 
of opioid receptor occupancy during behavioural testing-(a) during intoxication, (b) 
during withdrawal and (c) during stable methadone maintenance and (3) injecting 
status. Therefore the next two related hypothesis (2 & 3) to test are: 
 
(2) In patients with chronic opioid dependence, is injection status associated with 
neuropsychological impairment as reflected in altered performance on measures of 
memory and learning?  
(3) In patients with chronic opioid dependence is the degree of acute opioid 
exposure (acute intoxication, withdrawal or stable initial exposure to methadone), 
or duration of opioid exposure (period of methadone maintenance) associated with 
neuropsychological impairment as reflected in altered performance on measures of 
memory and learning?  
 
Statistical considerations 
Basic statistical considerations have been described in Chapter 2. The data from the 
DMS and SRM tests met assumptions of normality and homogeneity of variance.  
However the PAL and PRM tests did not meet assumptions and to stabilise variance 
and diminish skewness and kurtosis, the PRM data was subjected to square root 
(SQRT) transformation and the PAL data was subjected to logarithmic (log10) 
transformation (Fields, 2009).  
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(1) Testing hypothesis 1 and 2 
Data were initially analyzed using univariate or repeated measures ANCOVA with a 
between subject factor of GROUP (HEROIN vs. CHRONIC PAIN vs. METHADONE vs. 
HEALTHY CONTROL) and NART, age in years, SIMD, total Fagerström score, years in 
education and past alcohol use in years as covariates.  
 
Further a priori subgroup analyses for the DMS, PAL, PRM, and SRM tests were 
conducted using (1) a two-group factor reflecting DEPENDENCE (HEROIN and 
METHADONE groups vs. CHRONIC PAIN and HEALTHY CONTROL groups) and (2) a 
two-group factor reflecting lifetime INJECTING (HEROIN and METHADONE injecting 
vs. HEROIN and METHADONE never injecting groups) separately as between subject 
factors.  
 
Behavioural data from the DMS and PAL were further analysed using a mixed-model 
analysis of variance (ANCOVA) with GROUP (HEROIN vs. METHADONE vs. CHRONIC 
PAIN vs. HEALTHY CONTROL) as a between- subjects fixed factor, and difficulty 
(expressed by the 0.4 and 12 second delay stages in the DMS test and the 1-3, 6 or 8 
shape stages in the PAL test) as within-subjects factors.  
 
Between-group effects in the ANCOVA models were analysed as follows. A planned 
comparison between the HEALTHY CONTROL and three experimental groups 
(HEROIN, METHADONE and CHRONIC PAIN) was used to detect any difference in 
performance. In this four-group model, significant between-group effects were 
investigated using pair-wise comparisons with Bonferroni correction procedure. Effect 
sizes for the group comparisons were calculated using Cohen’s d (Cohen, 1988).  
 
(2) Testing hypothesis 3 
Repeated measures ANCOVA was used to evaluate DMS, PAL, PRM and SRM 
performance between the HEROIN group participants at baseline (whilst on illicit 
heroin), in controlled opioid withdrawal and subsequently when stabilised on 
methadone according to the tolerance testing procedure protocol with presumed 
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opioid receptor occupancy state as a within subject factor to determine whether 
performance on any of these tasks was modified by different degrees of opioid 
receptor occupancy (heroin, withdrawal and stable on methadone). 
 
Similarly repeated measures ANCOVA was performed for the METHADONE group at 
baseline and at 6 months follow up with DURATION as a within subject factor to 
determine wether any aspects of performance improved or deteriorated with time 
and continued exposure to chronic, sustained released opioid (methadone). . 
 
The homogeneity of variance across groups in repeated‐measures design ANCOVAs 
was assessed by the Mauchly Sphericity Test (Mauchly, 1940). Where data sets 
significantly (p<0.05) violated this requirement for a repeated‐measures design 
ANCOVA, the Greenhouse Geisser Epsilon (^ε) correction parameter for degrees of 
freedom (Greenhouse & Geisser, 1959; Winer et al., 1991) was used to calculate a 
more conservative p value for each F ratio. 
 
Results 
All subjects completed all of the tests. Mean performance (not adjusted for 
covariates), statistical comparisons and effect sizes (d) for each task, for the HEROIN, 
METHADONE, CHRONIC PAIN and HEALTHY CONTROL groups, are summarised in 
Tables 6.3. 
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Table 6.3: Summary of baseline neuropsychological findings for memory and learning (not adjusted 
for covariates). 
 HEROIN 
N=24 
METHADONE 
N=29 
CHRONIC PAIN 
N=28 
HEALTHY 
CONTROL 
N=28 
  
Memory and 
Learning 
Mean (s.d) Mean (s.d) Mean (s.d) Mean (s.d) Sig. d 
Delayed 
Matching to 
Sample (DMS)  
      
Total Number of 
Correct 
Responses (all 
delays) 
22.04 (3.59) 25.76 (2.87) 25.39 (3.04) 27.43 (1.89) P>H*** 
C>H*** 
1.00 
1.87 
Mean Correct 
Latency (all 
delays) 
3630.61(922.64) 4372.35 
(1579.98) 
3310.22(1049.63) 3536.67(745.99) M>P** 0.79 
       
Paired Associate 
Learning (PAL) 
(log10) 
      
Total Errors 
(Adjusted) 
0.22 (0.45) 0.46 (0.64) 0.01 (0.06) 0.00 (0.00) NS  
Mean Errors to 
Success 
0.51 (0.26) 0.42 (0.19) 0.45 (0.27) 0.29 (0.19) C<H* 0.97 
Mean Trials to 
Success 
0.45 (0.09) 0.41 (0.06) 0.43 (0.09) 0.37 (0.05) C<H* 1.10 
Memory Score 1.23 (0.11) 1.30 (0.06) 1.27 (0.08) 1.33 (0.06) C>H*** 1.13 
Stages 
Completed 
0.94 (0.03) 0.95 (0.02) 0.95 (0.02) 0.95 (0.00) NS  
Stages complete 
1
st
 trial 
0.79 (0.08) 0.84 (0.05) 0.82 (0.07) 0.87 (0.04) C>H*** 1.26 
       
Pattern 
Recognition 
Memory (PRM) 
(SQRT) 
      
Percentage Trials       
Correct 9.18 (0.69) 9.27 (0.51) 9.26 (0.49) 9.64 (0.46) C>H* 0.78 
Incorrect 3.37 (1.97) 3.46 (1.46) 3.43 (1.52) 1.97 (1.74) C<H* 
C<M* 
0.75 
0.92 
Correct Response 
Latency 
      
Correct 45.82 (5.36) 47.88 (5.98) 46.37 (6.74) 46.60 (5.56) NS  
Incorrect 49.80 (11.99) 54.48 (11.74) 50.22 (10.76) 50.15 (8.96) NS  
       
Spatial 
Recognition 
Memory (SRM) 
      
Number of Trials       
Correct 15.58 (2.21) 16.48 (1.94) 15.89 (1.77) 17.75 (1.51) C>H*** 1.15 
Incorrect 4.42 (2.21) 3.52 (1.94) 4.11 (1.77) 2.25 (1.51) C<M*** 1.15 
Mean Latency       
Correct 1979.04 
(432.81) 
2358.89 (810.68) 2035.71 (505.51) 2040.19 (469.3) NS  
Incorrect 2172 (878.02) 2520.36 (966.13) 2199.65 (737.71) 2456.38 (122.41) NS  
d= effect size, SQRT= square root transformation; log10 = logarithmic 10 transformation, Sig= significance,  
*= p<0.01, **= p< 0.005, ***=p<0.001, NS= no significant impairment in neuropsychological outcomes with 
p<0.01, H=HEROIN Group, P=CHRONIC PAIN Group, M= METHADONE Group, C=HEALTHY CONTROL Group. 
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 Delayed Matching to Sample (DMS) 
There was a significant GROUP [F (3,100) =10.3, p<0.001] effect on the percentage of 
correct responses but a non-significant GROUP [F(3,100)=2.6, p=.06] trend on mean 
correct latency response. Post hoc Bonferroni comparison showed participants from 
the HEROIN group significantly made more errors than did the HEALTHY CONTROL 
group in the 0 (p<0.005), 4 (p<0.001) and 12 second (p<0.001) delay stages, from the 
CHRONIC PAIN group for the 4 (p<0.01) and 12 (p<0.005) second delay stages and 
from the METHADONE group for 0 (p<0.005), 4 (p<0.005) and 12 (p<0.001) second 
delay stages (Figure 6.1).  
 
There were no significant DEPENDENCE status effects (average speed of responses [F 
(1,102) =3.8, p=.05] and percentage of correct responses [F (1,102) =1.1,p=.30] or 
INJECTING [F<1] on DMS outcomes. There were also no significant interactions [F<1].  
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Figure 6.1: DMS-Percentage of correct responses at different delay conditions. There was a 
significant GROUP [F (3,100) =10.3,p<0.001] Post-hoc Bonferroni comparison showed participants 
from the HEROIN group significantly made more errors than did the HEALTHY CONTROL group in the 
0 (**p<0.005), 4 (***p<0.001) and 12 second (***p<0.001) delay stages, from the CHRONIC PAIN 
group for the 4 (*p<0.01) and 12 (**p<0.005) second delay stages and from the METHADONE group 
for 0 (**p<0.005), 4 (**p<0.005) and 12 (***p<0.001) second delay stages. Sim= Simultaneous 
condition, SD= Standard Deviation. 
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Overall the HEROIN group significantly made more errors at all three difficulty levels 
but spend the same time as any of the other three groups in the length taken to make 
a decision. When the HEROIN group was tested during different opioid receptor 
occupancy states there was a significant effect of opioid load on mean correct latency 
[F (2,34.22)=10.5,p<0.001]. Post hoc Bonferroni comparison showed a significant 
improvement at the 12 second delay stage (p<0.001) and a non-significant trend at 
the 0 second (p=.05) and 4 second (p=.07) delay condition stages. The pattern of 
improvement was significantly shifting towards the stable methadone stage when 
compared to the withdrawal stage (p<0.005) and illicit heroin stage (p<0.001). 
 
Overall the METHADONE group was significantly selecting the right stimulus when 
compared to the HEROIN group at baseline. There was a non-significant trend 
(p<0.05) for the METHADONE group to improve in selecting the right stimulus 
following prolonged exposure to a stable dose of methadone. 
 
Table 6.4: Summary of results from analysis of DMS outcomes¹.Unless specified significance is 
with HEALTHY CONTROL and/or CHRONIC PAIN groups*. 
 
Delayed Matching to 
Sample (DMS) 
HEROIN vs 
METHADONE vs 
CHRONIC PAIN vs 
HEALTHY CONTROL  
Opioid DEPENDENCE 
(OD) vs Non- Opioid 
DEPENDENCE  (Non- 
OD)  
INJECTING (INJ) vs non- 
injecting 
Correct Responses 
(Simultaneous, 0, 4 
and 12 sec. delays) 
↓HEROIN (also H>M) 
at 0, 4 and 12 sec. 
delays 
 
            ↔ 
 
            ↔ 
Speed of responses 
(mean correct 
latencies at 0,4 and 
12 sec. delays 
                  
               ↔ 
            ↔             ↔   
*= significant effects with p<0.01, ↓=significant neuropsychological deficits present, ↔= no significant 
neuropsychological deficits present, ¹= ANCOVA ‘between subject factor’ of GROUP, DEPENDENCE and 
INJECTING analysed separately, H= HEROIN, M= METHADONE. 
 
 Paired Associate Learning (PAL) 
There was a no GROUP effect for: total number of errors [F<1], total trials to locate 
the pattern correctly [F(3,102)=1.5,p=.23], stages completed on first trial 
[F(3,102)=3.2,p=.03] and memory score [F(3,102)=3.4,p=.02] (Figure 6.2).  
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There were no significant DEPENDENCE effects or INJECTING effects [F<1] on all 
outcome measures of the PAL task. There were also no significant interactions in the 
DEPENDENCE [F (4,326.81) =3.1,p=.03] and INJECTING [F<1] status.  
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Figure 6.2: PAL outcomes in HEROIN, METHADONE, CHRONIC PAIN and HEALTHY CONTROL groups. 
There was a non-significant GROUP trend for: Total trials to locate the pattern correctly 
[F(3,102)=1.5,p=.23], Stages completed on first trial [F(3,102)=3.2,p=.03] and Memory score 
[F(3,102)=3.4,p=.02]. 
 
Overall the HEROIN group did not significantly experience memory problems.When 
the HEROIN group was tested during different opioid receptor occupancy states there 
was no effect of opioid load on PAL outcomes. 
 
Overall the METHADONE group did not significantly experience memory problems. 
There was no significant additional effect on all PAL outcomes in the METHADONE 
group following prolonged exposure to a stable dose of methadone. 
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Table 6.5: Summary of results from analysis of PAL outcomes¹.Unless specified significance is with 
HEALTHY CONTROL and/or CHRONIC PAIN groups*. 
 
Paired Associate 
Learning (PAL) 
HEROIN vs METHADONE 
vs CHRONIC PAIN vs 
HEALTHY CONTROL   
Opioid DEPENDENCE (OD) 
vs Non- Opioid 
DEPENDENCE 
INJECTING (INJ) vs 
non- injecting 
Total Errors ↔ ↔ ↔ 
Total Trials to Locate 
Patterns Correctly 
↔ ↔ ↔ 
Stages Completed on 
First Trial 
↔ ↔ ↔ 
Memory Score ↔ ↔ ↔ 
*= significant effects with p<0.01, ↓=significant neuropsychological deficits present, ↔= no significant 
neuropsychological deficits present, ¹ = ANCOVA ‘between subject factor’ of GROUP, DEPENDENCE and 
INJECTING analysed separately. 
 
 
 
 Pattern Recognition Memory (PRM) 
There were no significant GROUP effects on the number of correct trials [F<1] and 
mean response latency [F<1]. There were also no significant DEPENDENCE effect 
[F<1] and INJECTING effects [F<1] on the number of correct trials and mean response 
latency.  
 
When the participants from the  HEROIN group were tested during different opioid 
receptor occupancy states there was no effect of opioid load. There was also no 
additional effect on all PRM outcomes in the METHADONE group following prolonged 
exposure to a stable dose of methadone. 
 
Table 6.6: Summary of results from analysis of PRM outcomes¹. Unless specified significance is with 
HEALTHY CONTROL and/or CHRONIC PAIN groups*. 
 
Pattern Recognition 
Memory (PRM) 
HEROIN vs 
METHADONE vs 
CHRONIC PAIN vs 
HEALTHY CONTROL  
Opioid DEPENDENCE 
(OD) vs Non- Opioid 
DEPENDENCE 
INJECTING (INJ) vs 
non- injecting  
Number of Correct Trials ↔ ↔ ↔ 
Mean Response Latency ↔ ↔ ↔ 
*= significant effects with p<0.01, ↔= no significant neuropsychological deficits present, ¹ = ANCOVA 
‘between subject factor’ of GROUP, DEPENDENCE and INJECTING analysed separately. 
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 Spatial Recognition Memory (SRM) 
There were no significant GROUP effects on the number of correct trials 
[F(3,102)=3.6,p=.02] and mean response latency [F(3,102)=2.8,p=.04].There were also 
no significant DEPENDENCE and INJECTING status [F<1] effects on all the SRM 
outcomes.  
 
When the HEROIN group was tested during different opioid receptor occupancy states 
there was no effect of opioid load. There was also no additional effect on all SRM 
outcomes in the METHADONE group following prolonged exposure to a stable dose of 
methadone. 
 
Table 6.7: Summary of results from analysis of SRM outcomes¹. Unless specified significance is with 
HEALTHY CONTROL and/or CHRONIC PAIN groups*. 
 
Spatial Recognition 
Memory (SRM) 
HEROIN vs 
METHADONE vs 
CHRONIC PAIN vs 
HEALTHYCONTROL  
Opioid DEPENDENCE 
(OD) vs Non- Opioid 
DEPENDENCE 
INJECTING (INJ) vs 
non- injecting  
Number of Correct Trials               ↔             ↔              ↔ 
Mean Response Latency               ↔             ↔              ↔ 
*= significant effects with p<0.01, ↔= no significant neuropsychological deficits present, ¹ ANCOVA 
‘between subject factor’ of GROUP, DEPENDENCE and INJECTING analysed separately. 
 
Discussion 
Overall this study observed opioid taking groups performing on tasks which were 
visual and/or non- verbal in function and sensitive to working memory that included 
components of short and long term memory. Using Baddeley’s model of working 
memory the cognitive tests sensitive to the spatial executive memory function and 
visuospatial strategy were tested using the SSP and SWM (Chapter 4) (Baddeley, 
1999). The analysis showed that the HEROIN groups made significantly more errors 
impaired planning problems especially when a high level of difficulty was presented. 
The METHADONE group struggled to recall longer sequences presented (span length) 
indicating short and long term memory deficits. 
 
Using Braddeley’s working memory model this chapter analysed the DMS, PAL, PRM 
and SRM tasks testing opioid dependent and opioid using individuals. These cognitive 
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tasks are sensitive to both phonological loop and visuospatial sketch pad slave system 
(Baddeley, 1999). 
 
Table 6.8 summarises the outcomes of opioid using groups and associated, if any, 
memory deficits. Overall it was only the HEROIN group that showed significant 
deficits in visuospatial working memory ability at the p<0.01 significance level. There 
were other deficits observed in both HEROIN and METHADONE groups but the 
outcomes only reached the 95% level of confidence. The DEPENDENCE and INJECTING 
status showed latency problems in the DMS task but again did not reach p<0.01 
significance level. 
Table 6.8 : Summary of outcomes of opioid using groups and neuropsychological functioning in 
memory compared with HEALTHY CONTROL group.*  
 
Neuropsychological 
domain 
Tests HEROIN  METHADONE  CHRONIC 
PAIN  
Opioid 
DEPENDENCE  
INJECTING 
group 
MEMORY and 
LEARNING 
      
Visual immediate 
and working 
memory (1) 
DMS Number of 
Correct 
Responses  
 
No 
impairment 
No 
impairment 
No impairment No 
impairment 
Visual immediate 
and working 
memory (2) 
PAL, 
PRM,       
SRM 
No 
Impairment 
No 
Impairment 
No 
impairment 
No impairment No 
impairment 
*= p<0.01, no impairment= no difference in neuropsychological performance when compared to 
healthy controls, d= effect size, DMS= Delayed Matching to Sample, PAL=Paired Associate Learning, 
PRM= Pattern Recognition Memory, SRM= Spatial Recognition Memory. 
 
The simultaneous condition of the DMS may be conceptualised as a control task for 
the delayed matching conditions. The simultaneous and delay conditions have the 
same neurocognitive requirements except that the ability to internally represent the 
stimuli is required in the delay conditions (Pantelis et al., 2001). In this study the 
HEROIN group did not perform significantly different between the simultaneous and 
delayed matched conditions. The participants in the HEROIN group significantly 
performed poorly compared to the other three groups at the 0, 4 and 12 second 
delay stages indicating poor memory ability but improved when stabilised on 
methadone. 
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The PAL assesses visual working memory and visuospatial associative learning 
(explicit or declarative memory).The METHADONE group experienced long term 
memory problems on the PAL but did not reach significance of p<0.01 level (Table 
6.8). The PRM and SRM are often used before the PAL test in order to help to train 
the participant for the PAL tasks. The PRM has been shown to be sensitive to 
temporal lobe and hippocampus and not the frontal lobe, whereas the SRM showed 
the opposite pattern of morphological sensitivity (Owen et al, 1995). In this study the 
HEROIN group but not the METHADONE group experienced memory deficits but 
again did not reach the p<0.01 significance levels (Table 6.8). 
 
Overall both the HEROIN and the METHADONE groups experienced memory deficits 
but most did not reach significance (p<0.01). Therefore the hypothesis that chronic 
opioid dependence is associated with neuropsychological impairment reflected in 
altered performance on measures of memory and learning has only been partially 
confirmed  with participants in the HEROIN group experiencing significant (p<0.01) 
non verbal memory problems on the DMS task. Injecting status, the degree of acute 
opioid exposure, and duration of opioid exposure did not significantly alter 
performance on measures of memory.  
 
Ersche et al. (2006 & 2005) compared a group of opioid dependent individuals with a 
group of amphetamine dependent individuals across a number of neuropsychological 
domains. The opioid dependent group consisted largely of methadone maintenance 
patients and current illicit heroin users, as well as participants receiving prescribed 
buprenorphine, dihydrocodeine, diamorphine and morphine sulphate. Control groups 
included drug free controls, drug free ex-opioid users and drug-free ex-amphetamine 
users. The study utilised the PAL and the PRM to test working visuospatial memory. 
On both these tests on memory, current and former opioid users performed at a level 
that was significantly (p<0.05) poorer than controls supporting the notion that the 
neuropsychological deficits observed in chronic opioid users were not a direct result 
of the opioid itself, but rather were a consequence of the factors associated with 
long-term drug abuse. 
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However Ornstein et al. (2000) conducted a study which aimed to clarify the notion 
that there exists a distinct profile of neuropsychological impairment which is common 
to heroin dependent individuals. In this study, a group of participants whose primary 
drug of abuse was heroin and most also treated with methadone were compared to a 
group who primarily used amphetamine. A third group of drug-free control 
participants was matched to the other two groups for age and pre-morbid intellectual 
functioning. The assessment consisted of a number of subtests chosen from the 
CANTAB computerised test battery including SRM, SWM and PRM tasks. This study 
found that, relative to controls, the heroin group were found to be significantly 
impaired in visuospatial recognition memory. These results pointed to the existence 
of a diverse pattern of neuropsychological impairment in heroin dependent 
individuals who were still using heroin. 
 
Memory and learning was tested using the DMS to twenty five male heroin 
dependent individuals and compared to twenty six polydrug abusers abstinent for 
more than 3 months and another twenty six non- drug using healthy male controls. 
There was a moderate but significant impairment in working memory and sustained 
attention in the heroin group (Stevens et al., 2007).  
 
Compared to these previous studies, which utilised the same neuropsychological task 
as this study, impairment in memory is a significant problem during most opioid 
related states but most distinctively in the heroin group. This was partially observed 
in the current study. The notion that memory improves with stability or cessation of 
opioid use needs further investigation. 
 
Conclusion 
Participants from the HEROIN and METHADONE but not the CHRONIC PAIN groups 
experienced visuo-spatial memory problems especially at a 12 second delay stage of 
difficulty of the DMS task indicative of long term memory problems. These 
observations do not indicate deficits as a result of chronic opioid use but rather due 
to the use of heroin with potential improvement after 3 weeks stability with 
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methadone use. Dependence and injecting status do not contribute to the causation 
or deterioration of any of the identified deficits. 
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Chapter 7: Summary and general discussion, limitations and future 
directions. 
 
Summary and general discussion 
The work presented in this thesis describes the neuropsychological heterogeneity 
defined within a group of rigorously diagnosed opioid dependent and non-opioid 
dependent populations. Specific experimental findings were discussed in some detail 
at the end of Chapters 4, 5 and 6.The purpose of this chapter, therefore, is to bring 
these findings together into a more general discussion, to consider the limitations of 
the study and to suggest potential avenues for further investigation.The main 
hypotheses and findings from each chapter are summarised in Tables 7.1-7.3. 
 
Overall chronic opioid dependence is associated with neuropsychological impairment 
reflected in altered performance on measures of risk taking and strategic planning. 
This is indicative of trait vulnerability for drug taking and/or dependence rather than 
due to chronic opioid use as no neuropsychological impairments were recorded with 
participants from the CHRONIC PAIN group. These impairments were more evident 
with the HEROIN participants. Motor impulsivity and visuo-spatial memory 
impairments in HEROIN group improved after three weeks stability with methadone. 
There was no reduced intellectual function or impairment with cognitive flexibility in 
participants with a history of chronic opioid dependence. Dependence and injecting 
status did not contribute to the causation or deterioration of any of the identified 
impairments. 
 
This study complement evidence from previous studies as highlighted in the 
systematic review in Chapter 1 of this thesis. Studies of current and abstinent chronic 
opioid users (illicit heroin users, patients prescribed methadone for illicit opioid 
dependence and patients taking opioids as part of the management of chronic pain) 
have identified performance deficits in measures of executive functioning and 
memory. These have included impairments in cognitive and motor impulsivity, 
strategic planning, cognitive flexibility and memory. Similar to results from this study 
the systematic review highlighted that impulsivity problems seem to be the ‘core’ or 
211 
 
 
 
residual deficit of the dependence phenotype. The literature also suggested that 
these neuropsychological deficits may be subject to at least partial recovery following 
initiation of methadone or total withdrawal from any opioids. 
 
Table 7.1: Hypothesis and main findings from Chapter 4: Neuropsychological impairments  
on performance in cognitive impulsivity. 
 
Chapter 4   
Hypothesis Outcome Comments 
Is chronic opioid dependence associated with 
neuropsychological impairment reflected in 
altered performance on measures of 
impulsivity and risk taking?  
 
Partially 
Supported 
HEROIN users placed higher bets earlier 
and risked more. HEROIN users also 
showed motor impulsivity shown by 
deficits in commission errors of the AGN 
task. HEROIN users also showed poor 
strategic planning as reflected by 
number of errors at highest level of 
difficulty (5 move stage problem) on the 
SOC and on the SSP (but not the SWM) 
task.  
 
METHADONE users deliberated longer 
and placed higher bets earlier. 
METHADONE users were more 
inattentive and showed poor strategic 
planning as reflected by number of 
errors at highest level of difficulty (5 
move stage problem) on the SOC. 
 
The participants in the CHRONIC PAIN 
group showed a non-significant trend in 
poor strategic planning as reflected by 
number of errors at highest level of 
difficulty (5 move stage problem) on the 
SOC but not in other tasks.This was not 
observed when tested with the SSP and 
SWM task. 
In patients with chronic opioid dependence, is 
injection status associated with 
neuropsychological impairment as reflected 
in altered performance on measures of 
impulsivity and risk taking?  
Not 
Supported 
 
In patients with chronic opioid dependence is 
the degree of acute opioid exposure (acute 
intoxication, withdrawal or stable initial 
exposure to methadone), or duration of 
opioid exposure (period of methadone 
maintenance) associated with 
neuropsychological impairment as reflected 
in altered performance on measures of 
impulsivity and risk taking? 
Partially 
Supported 
Motor impulsivity in HEROIN improved 
when stabilised with methadone. 
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Table 7.2: Hypothesis and main findings from Chapter 5: Neuropsychological impairments 
on performance in cognitive flexibility . 
 
Chapter 5   
Hypothesis Outcome Comments 
Is chronic opioid dependence associated with 
neuropsychological impairment reflected in 
altered performance on measures of cognitive 
flexibility?  
 
Not 
Supported 
HEROIN users made more 
errors compared to other 
groups on the overall IED 
task but both HEROIN and 
METHADONE users did not 
experience deficits in 
cognitive flexibility  
In patients with chronic opioid dependent, is 
injection status associated with 
neuropsychological impairment as reflected in 
altered performance on measures of cognitive 
flexibility?  
 
Not 
Supported 
 
In patients with chronic opioid dependent is the 
degree of acute opioid exposure (acute 
intoxication, withdrawal or stable initial exposure 
to methadone), or duration of opioid exposure 
(period of methadone maintenance) associated 
with neuropsychological impairment as reflected 
in altered performance on measures of cognitive 
flexibility? 
Not 
Supported 
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Table 7.2: Hypothesis and main findings from Chapter 6: Neuropsychological impairments 
on performance in learning and memory. 
 
Chapter 6   
Hypothesis Outcome Comments 
Is chronic opioid dependence associated 
with neuropsychological impairment 
reflected in altered performance on 
measures of learning and memory?  
 
Partially 
supported 
HEROIN users experienced 
deficits in visuo-spatial memory 
at the 0,4,12 second delay 
stages of the DMS. This was not 
complemented with the PAL, 
PRM and SRM tasks which 
showed no memory deficits in 
HEROIN users 
 
METHADONE users did not 
recall longer sequences 
presented on the SSP tasks 
indicative of memory problems. 
This was not complemented 
with the DMS, PAL, PRM and 
SRM tasks which showed no 
memory deficits in the 
METHADONE users 
In patients with chronic opioid dependent, is 
injection status associated with 
neuropsychological impairment as reflected 
in altered performance on measures of 
learning and memory?  
 
Not 
Supported 
 
In patients with chronic opioid dependent is 
the degree of acute opioid exposure (acute 
intoxication, withdrawal or stable initial 
exposure to methadone), or duration of 
opioid exposure (period of methadone 
maintenance) associated with 
neuropsychological impairment as reflected 
in altered performance on measures of 
learning and memory? 
Partially 
Supported 
The HEROIN users showed 
improvement at the 12 second 
delay stage of the DMS when 
stabilised with methadone 
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Impulsivity, cognitive flexibility and memory 
The ability to adapt to the constantly changing environment needs not only the 
suppression of inappropriate behaviour associated with punsihment but also the 
selection and maintenance of appropriate behaviour associated with reward (Cools, 
2008). This can only be achieved through a motivated and goal directed mind that is 
both cognitively stable and flexible. Such processes are known to be modulated by 
dopamine driven circuits in the frontostriatal and limbic-striatal areas (Alexander et 
al., 1986). 
 
Healthy but highly impulsive individuals respond faster in anticipation of reward 
(Wallace & Newman, 1990; Cools et al., 2005). Highly impulsive individuals also have 
greater difficulty with reversal based on unexpected punishment than with reversal 
based on unexpected reward (Hyman, 2007; Roshan, 2008).  Koob et al. (1978) 
followed by Baldo & Kelley (2007) deconstructed ‘reward’ as an activating, 
preparatory and energising effect or ‘wanting’ and a consummatory and hedonic 
effect or ‘liking’ (Robinson & Berridge, 2003). Preparatory reward-directed behaviour 
is characterised by increased cognitive flexibility and exploration that could be 
activated by drug related cues. Meantime consummatory reward-maintaining 
behaviour is characterised by cognitive inflexibility, rigidity and repetitive behaviour 
(Baldo & Kelley (2007). Together with impulsivity and cognitive flexibility, working 
memory is also considered as vital in the active maintenance and stabilisation of goal 
representations that is critical for the active suppression and selection of irrelevant 
and relevant behaviours (Hyman, 2007; Roshan, 2008, Baddeley et al., 1998).  
 
Although prior models of cognitive control and working memory have considered 
almost exclusively the role of the PFC, more recent theorising highlights a critical role 
in cognitive control for an additional brain region, the striatum (Frank et al., 2001; 
Zhang et al., 2007; McNab & Klingberg, 2008). A large body of work has established 
that the rewarding properties of addictive drugs depend on their ability to increase 
dopamine in synapses made by ventral tegemental area neurons on the nucleus 
accumbens which occupy the ventral straitum especially within the nucleus 
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accumbens shell region (Wise & Bozarth, 1987; Di Chiara, 1998; Koob & Bloom, 
1988; Pontieri et al., 1995). 
 
Specifically, whereas dopamine (D1) receptor stimulation in the PFC is thought to 
promote cognitive stability (Durstewitz et al., 2000), dopamine receptor stimulation 
in the striatum has been hypothesized to promote cognitive flexibility (and set 
shifting), by allowing the flexible updating of newly relevant goal representations 
(Frank, 2005). Increases and decreases in PFC dopamine lead to decreases and 
increases in striatal dopamine respectively, possibly reflecting compensatory 
regulation at the systems level (Meyer-Lindenberg et al., 2005). Thus, ‘high levels of 
striatal dopamine that are good for cognitive flexibility might be bad for cognitive 
stability. Similarly, high levels of PFC dopamine that is good for cognitive stability 
might be bad for flexibility. One implication of this model is that cognitive stability and 
flexibility, mediated by prefrontal and striatal dopamine respectively, trade off in the 
healthy brain, where dopamine levels interact dynamically’ (Cools, 2008).  
 
In the diseased brain, dopamine dysregulation in both the PFC and the striatum may 
independently disrupt subcomponent processes, sometimes causing the apparently 
paradoxical combination of instability (or impulsivity) and inflexibility (or rigidity) 
(Cools, 2008). 
 
HEROIN participants in the study exhibited significant cognitive impulsivity and motor 
impulsivity together with significant impairment in executive working memory 
function. However the same HEROIN users did not experience significant cognitive 
rigidity. The presentation in the HEROIN users might indicate:  
(1) A diseased brain with striatal dopamine levels overriding PFPFC dopamine 
receptor stimulation. 
(2) A diseased brain with significant decreases in PFC dopamine levels.  
(3) A diseased brain with the dopamine regulation in both PFC and straitum 
independently disrupted.  
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Meantime METHADONE participants in the study did not significantly exhibit either 
cognitive impulsivity or cognitive rigidity. One can postulate that this might indicate a 
protective and ‘healing’ influence of methadone treatment with possible (partial or 
complete) reversal towards cognitive stability in the opioid dependent individuals as a 
result of long term methadone treatment. 
 
Impulsivity as a cognitive endophenotype   
Robbins et al. (2012) proposed a biological approach to substance misuse and 
dependence based on ‘neurocognitive endophenotypes’.An endophenotype is 
operationally defined as a biomarker that is associated with illness in the population, 
is heritable, found in nonaffected family members especially first degree relatives at a 
higher rate than in the general population and primarily state-independent (manifests 
in an individual whether or not illness is active) (Gershon & Goldin, 1986; Gottesman 
& Gould, 2003; Lebover et al., 1998).  
The characterisation of neurobiological traits associated with vulnerability for 
substance misuse and subsequent dependence has extended to the cognitive 
domain. Advocates for neurocognitive endophenotypes note that these 
neuropsychological features appear before the disorder becomes clinically apparent, 
stay stable throughout its course, and do well in predicting functional outcomes 
(Robbins et al., 2012; Everitt et al., 2008). Eventually the scope of identifying these 
endophenotypes is to describe and explain substance use, abuse and dependence. 
 
Current research has highlighted that impulsivity could be a proposed cognitive 
endophenotype for substance dependence, servicing as a predisposing risk factor, as 
well as a possible consequences of chronic substance use (Robbins et al., 2012). High 
levels of impulsivity were proposed as a biomarker to the development of compulsive 
drug taking (Robbins et al., 2012; Ersche et al., 2011a). Such observations were based 
on neuropsychological and neuroimaging studies of psychostimulant dependent 
individuals predominantly cocaine and/or amphetamine users (Ersche et al., 2011b) 
Given the complexities and heterogenous nature of this domain, cognitive 
endophenotyping allows further exploration to ask if such a domain is a unitary 
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contruct (Dalley et al., 2011). In this thesis we subdivided impulsivity into cognitive 
impulsivity (reflection impulsivity and risk taking); motor impulsivity (behavioural and 
cognitive inhibitions); and non-planning impulsivity (reasoning and problem solving) 
(Ersche et al., 2006a). These different aspects of impulsivity were assessed by specific 
neuropsychological measures such as Cambridge Gambling Task for cognitive 
impulsivity, Affective Go NoGo for motor impulsivity and the Stockings of Cambridge 
for non-planning impulsivity. Whether these different measures relate to a unitary 
construct of impulsivity is still controversial (Dalley et al., 2011). . 
 
 
This thesis will be the first to help start unravelling if the concept of cognitive 
endophentypes identified as a result of psychostimulant based human models are in 
fact still valid in opioid research. This study has identified impairments in cognitive 
impulsivity (risk taking) and non–planning impulsivity (strategic planning). It is not 
correct to assume that these deficits are core addiction phenotype markers for heroin 
dependent individuals as this was not the intention of this study. If such markers are 
indeed endophenotypes than one would assume that individuals treated with 
methadone with a past history of heroin dependence will be experiencing the same 
neuropsychological impairments. This was not observed in this study.  
 
This study therefore highlights that not only should such studies be replicated but 
that possibly the route to opioid dependence might necessitate different vulnerability 
markers than those observed in psychostimulant dependence (Dilleen et al., 2012). 
Further specific studies need to be conducted to explore further such assumptions. 
 
Limitations 
Although this study was designed to avoid many of the limitations of previous work in 
this field as described in Chapter 1, it is inevitable that there were still several 
significant limitations. These include the type of population studied; the objective 
measurement of substance use; acute and chronic effects of polysubstance use; and 
data gathering.  
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The population studied 
Recruitment 
As the study focused on recruiting males the results cannot be generalised to 
females. It is equally not known what the impact of ethnicity, social deprivation and 
age have on the neuropsychological performance in opioid dependence (Hackman et 
al., 2010; Hackman & Farah, 2009; Noble et al., 2007; Turner & Avison, 2003; van 
Praag et al., 2000).The study sample, although larger than that of comparable studies 
and rigorously defined, included only referred and treatment seeking male 
population which might have introduced a Berkson (recruitment) bias (Berkson, 
1946). This study did not attempt to seek other community opioid dependent or 
abusing populations sometimes categorised as ‘hidden’ or ‘hard to reach’ which 
would have made this study difficult and unsafe to conduct primarily due to the 
nature of the ‘drug fuelled lifestyle’.  
 
All opioid dependent participants had a mean duration of 7.5 years heroin use and a 
daily dose of 165mg morphine equivalent. Recruiting a CHRONIC PAIN group with no 
history of opioid dependence or illicit drug use would inevitably bias the type of 
population and opioid dosage used. The CHRONIC PAIN group were significantly 
older, more educated and employed than the HEROIN and METHADONE cohorts with 
a much lower mean daily dose of 59.1 mg of morphine equivalence than that of the 
opioid dependent participants 
 
Sample size 
While this sample was of adequate size for most of the statistical analyses, it is 
possible that several of the subgroup analyses, in particular those investigating the 
impact of injecting and opioid dependence might have been underpowered. This may 
have resulted in Type II errors whereby actual group differences were not recognised 
due to a lack of study power. 
 
The opioid dependent cohorts (HEROIN and METHADONE groups) were matched on a 
series of variables such as chronicity and severity of opioid use, injecting status and 
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severity of the opioid dependence syndrome. The HEROIN and METHADONE cohorts 
recruited were representative of the treatment seeking population (non-participants 
and non-completers) attending services in the South East Scotland region, Scotland 
and UK wide. The difficulty was matching the METHADONE and HEROIN users with 
the CHRONIC PAIN and/or HEALTHY CONTROL groups. Therefore attempts to 
compensate this inevitable mismatching were minimised by using NART, age in years, 
Fagerström status, past alcohol use and dosage of opioid used as covariates 
throughout the statistical analysis. 
 
Substance use and dependence 
This study lacked objective measurements to the use of drug and alcohol use. 
Information on lifetime and recent use was recorded verbatim from the participants 
with an assumption that they are able to remember such detail and to be totally 
honest about their illicit behaviour. The opioid dependent population tend to 
underestimate their own levels of use (Mensch & Kandel, 1988). A more objective 
measurement could only have been possible if all participants had a hair analysis 
every six months or a serial analysis of drug and alcohol serum metabolite levels 
(Fraser et al., 2002). These techniques would still not have been able to determine 
lifetime use which can only be achieved if prospective longitudinal studies are 
conducted recruiting individuals at their early teens and followed up for 10-15 years. 
 
Neuropsychological research has shown that consumption of alcohol, 
benzodiazepines and psychostimulants including nicotine are important confounding 
variables (Ersche et al., 2007; Robbins et al., 2007; Koobs & Volkow, 2010).This study 
tried to use stringent criteria to exclude regular and dependent users of other 
psychoactive substances but this was only objectively confirmed by using drug urine 
analysis for pragmatic reasons aware of its limitations as discussed. Such analysis can 
be inappropriate as a large quantity of information is lost about the frequency of use, 
the amount consumed, how recent the use was or the pattern of use over a long 
period of time. Due to the psychoactive nature of the adulterants present in heroin 
seizures in Fife one is not certain what neuropsychological effects caffeine and 
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paracetamol have on the results of this study. It was also very difficult to recruit 
normal HEALTHY CONTROL participants who were also nicotine dependent. 
 
This study also tried to operationally define acute, subacute and chronic use. It 
attempted to standardise the time when the participants were tested which was 
between 2-4 hours after the intake of either the illicit heroin, prescribed methadone 
or other opioids. Heroin has a different time to peak concentrations (tmax) than that of 
methadone. The bioavailability of heroin largely depends on the route of 
administration. The tmax of smoking heroin is 2-4 minutes with heroin’s blood levels 
becoming undetectable after 10-70 minutes and with a bioavailability estimated 
between 38-53% (Rook et al., 2006). Methadone’s tmax is 2.5 – 5 hours with a 
bioavailability ranging from 36 – 100% (Eap et al., 2002). 
 
There were no attempts to test heroin, methadone and other opioid users at any 
stage before or after the cognitive tests to determine the tmax serum levels of every 
participant. This would have been logistically difficult due to the population recruited 
and the drug related lifestyle of the heroin users which would have made recruitment 
or even obtaining a blood specimen very difficult. It would also have been unethical 
and perhaps illegal to determine how much and what quality of the heroin the 
participants in that group needed to take prior to cognitive testing. Interpretation of 
the data collected is further hindered by the absence of reliable and valid measures of 
treatment adherence. Although assigned to methadone treatment for opioid 
dependence or opioid analgesics for chronic pain, it was not possible to be absolutely 
certain that the participants actually took their medication as prescribed, nor that 
other illicit drugs or alcohol were avoided throughout the treatment period. 
 
Tolerance testing procedure provided a unique opportunity to create an equitable 
platform to test three different periods of opioid receptor occupancy in the HEROIN 
group. Timing to test the HEROIN group two weeks or more after stabilising with 
methadone was arbitrary with no biological foundation to it. There was also no 
relevant literature that could confidently show cognitive improvement or 
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deterioration in neuropsychological function in methadone users after six months to 
one year stability. This study showed neuropsychological deficits at baseline in 
decision making in the METHADONE group with no change when followed up after six 
months. One is still unable to determine if these impairments were still irreversible 
with a longer treatment period on methadone. A longer longitudinal study will help 
determine: 
 
(a) If methadone does help improve (all or partial) neuropsychological performance 
with time. 
(b) If heroin related impairments improve or not with longer periods of methadone 
treatment. 
(c) Determine if neuropsychological impairments present are reversible or, if some 
are, others are not. 
 
Data gathering 
The battery of neuropsychological tasks used was more extensive than that used in 
previous studies. By utilising the CANTAB tasks, it was possible to include a cohesive 
and comprehensive battery of tasks that are rooted in experimental and laboratory 
neuroscience and which included a range of built in control tasks that are usually 
missing from clinical neuropsychological batteries (Robbins et al., 1994; Lowe & 
Rabbit, 1998). There are, however, additional tasks which tap into other aspects of 
neuropsychological functioning thought to be important in opioid dependence and 
which CANTAB does not test for. This includes tasks measuring verbal memory 
(Luciana, 2003). It is also unfortunate that this study did not utilise the CANTAB tasks 
specifically measuring reaction time. For pragmatic reasons it was decided not to 
conduct the Reaction Time task as its inclusion would have increased the session by 
another 30 minutes. In addition the ecological validity of CANTAB needs further 
investigation in order to establish the value of CANTAB tests outcomes as predictors 
of community functioning and levels of morbidities within the population studied 
(Levaux et al., 2007). 
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Future directions 
Seven main avenues for future studies are presented below: the use of latent variable 
analysis; improved and alternative sampling techniques, the issue of specificity, the 
use of a broader range of neuropsychological tasks; measurement across the various 
levels of analysis; the use of other medications; the use of broader measures of 
clinical outcome. 
 
The use of latent variable analyses 
Latent variable analyses are designed to examine average effects and individual 
differences in tandem and are therefore ideal tools to investigate the impact of these 
differences on neuropsychological functioning. Because they account for 
measurement error the latent variables generated by these techniques allow the 
researcher to compare groups using 'true', rather than the overall, scores. Although 
still relatively complex, such analyses have become much more accessible in recent 
years with the development of statistical packages such as Mplus and AMOS 
(Muth n, 2002).  
 
The use of a latent variable approach with confirmatory factor analyses with the 
opioid using groups and healthy control baseline data from this study would allow 
one to test whether: 
 
(1) The tasks presumed to have either high or low executive demands did indeed 
separate as predicted. 
(2) Measurement invariance (i.e. did the various tasks used in the study tap the same 
underlying constructs for both the opioid and the healthy control groups?). If this is 
not true for all tasks used in the study can a subset of tasks be identified that does 
allow a meaningful comparison between the four groups? 
(3) There are group differences when the true (as opposed to overall) scores are used. 
(4) There is heterogeneity in neuropsychological function within the HEROIN and 
METHADONE groups even when ‘true’ scores are used. 
(5) Factors such as age, SIMD and others might be contributing to this heterogeneity. 
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A second set of confirmatory factor analyses could then be used to assess the 
heterogeneity in methadone treatment response when ‘true’ scores are used. 
 
Improved and alternative sampling techniques 
In order to ensure that the results of studies are generalisable, it will be important for 
future studies to be conducted using community samples and across cultures. It will 
also be important to utilise both developmental and genetically sensitive designs and 
sampling techniques. Whilst much more expensive to conduct, longitudinal studies 
clearly provide the strongest developmental design and should be implemented if at 
all possible. Genetically sensitive designs should also be considered and future studies 
should seek to include unaffected siblings and parents in samples.  
 
Attempting to objectively quantify and qualify drug and alcohol use by serum and hair 
analysis should be further explored. Other methodological issues to be considered in 
future studies include: 
(a) To narrow the age, SIMD and drug history and dosage range of the recruited 
cohort. 
(b) Exposure to adulterants could be eliminated by recruiting individuals who are 
prescribed diamorphine (heroin). 
(c) Impact of the heterogenous populations with different drug and alcohol histories 
(e.g. injecting behaviour) could be eliminated by using the same cohort throughout all 
stages of neuropsychological testing including the final stage when the same cohort 
are abstinent from any medication or other opioids. 
(d) Understand further the biological relationship between dependence and 
neuropsychological constructs used. 
 
Issues of specificity 
Whilst the current analyses have taken into account the impact of coexisting 
polysubstance use, dysthymia, personality traits and the effects of adulterants on 
neuropsychological functions, further studies are required to describe the impact of 
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these other disorders on neuropsychological performance both in the presence and 
absence of coexisting opioid dependence.  
 
Whilst many other disorders have been associated with various deficits in 
neuropsychological functioning, few studies have looked at the issue of specificity i.e. 
which aspects of neuropsychological functioning are specific to a particular disorder 
and which are more general markers of psychopathology, developmental delay or 
vulnerability to initiation of drug use, susceptibility to dependence and ability to 
remain abstinent and stable on methadone treatment? Particular disorders of 
relevance to the current discussion include, but are not limited to, anorexia, 
Aspergers syndrome, ADHD, pathological gambling, OCD and other compulsive 
disorders, depression, schizophrenia and bipolar disorder. An alternative approach is 
to investigate neuropsychological functioning in an epidemiological sample and to 
then map poor neuropsychological function (e.g. the bottom 10%) forwards onto 
psychopathology and impairment. Another approach is to profile all treatment 
seeking individuals at a neuropsychological level and follow up their outcomes. 
 
The use of a broader range of neuropsychological tasks 
Whilst the battery of tasks used in this study covered a broader range of 
neuropsychological functions than those used in most other similar studies. It also 
included both control tasks and included more than one task to address each area of 
functioning. It is still the case that these did not cover all of the potential 
neuropsychological associations with chronic opioid use. Of particular interest would 
be measures of reaction time such as Continuous Reaction Time (CRT) (Bruhn, 1971) 
and Seriel Reaction Time (SRTT) (Cleeremans, 1991), verbal memory tasks such as 
Auditory Verbal Learning Test (AVLT) (Van der Elst et al., 2005) and  Digit Forward 
and Digits Backward Test (DFDBT) (Lezak, 1994), and verbal fluency tasks such as the 
Verbal Fluency Test (VFT) (Benton, 1978) and Controlled Oral Word Association Test 
(COWAT) (Loonstra et al., 2001). 
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Wherever possible studies should use tasks, like those in the CANTAB, that are rooted 
in laboratory neuroscience and for which aspects of the neuroanatomical and 
pathophysiological substrates are understood. This could be improved by making 
neuropsychological tasks more ecologically valid (Verdejo-Garcia et al., 2007a). 
 
Measurement across the various levels of analysis 
Future studies should include measures across the various levels of analysis. Thus it 
will be important to integrate genetic, environmental, imaging and 
electrophysiological measures into neuropsychopharmacological study designs and 
vice versa.  
 
Such studies are essential if we are to directly test proposed causal models and 
develop new ones. The neuropsychological deficits described here are generally 
thought of as endophenotypes, intermediate factors that bridge the gaps between 
genetic and environmental causative agents and their effects on pathophysiology and 
brain structure and functioning on the one hand, and the behavioural phenotype on 
the other. Whilst indirect evidence can sometimes be used to hypothesise the bridges 
between these different levels of analysis, only direct evidence from well designed 
studies can really provide an adequate level of proof. Clearly such studies will be 
costly and will require close collaboration between groups with complementary skills, 
however, the payoff from a comprehensive, well designed and well powered study 
would be immense. 
 
The use of other opioid medications 
Whilst methadone is both the best understood and most commonly used medication 
to treat opioid dependence, there are other treatments available. These include 
licensed medications such as buprenorphine (Subutex®) and buprenorphine/naloxone 
combination (Suboxone®), and unlicensed but relatively well established medications 
such as diamorphine, and dihydrocodeine. Each of these has different mechanisms of 
action and therefore may also impact differently on neuropsychological functioning. 
Further studies are required to understand how each of these drugs impact on 
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symptoms and neuropsychology. Clearly the hope for the future is that we can move 
to a situation whereby once one understands an individual’s neuropsychological 
profile, it will be possible to predict which medication, combination of medications 
and appropriate treatment package will be the most likely to improve performance 
and symptoms and reduce impairment. It will also be informative to measure the 
associations between the clinical and neuropsychological impact of 
non‐pharmacological treatments, including cognitive behavioural, relapse prevention 
techniques and motivational enhancement therapies together with the effects of 
social stability. 
 
The use of broader measures of clinical outcome 
Lastly it will important that future studies include a broad range of outcome 
measures that access multiple viewpoints by either using cross linkage electronic 
databases, both subjective (e.g. rating scales) and objective (e.g. academic 
productivity, neuropsychological testing and functional imaging), and measures of 
symptoms, impairments and quality of life. By doing so we may be able to develop a 
better understanding of the impact of chronic opioid use, which would not only help 
us understand their mechanisms of action and potential benefits, but also their 
limitations and potential adverse effects in order that, in the future, treatments can 
be targeted more efficiently, effectively and safely. It will also allow new 
biopsychosocial treatments to be developed which allows personalised care planning 
to occur (DH, 2009).  
 
Such future studies have the potential to further improve our understanding of the 
causes and impact of chronic opioid use and aid in improving our management of this 
chronic and relapsing condition that currently blights the lives of many individuals as 
well as those of their families and communities. 
 
 
 
 
227 
 
 
 
Suggested future research projects 
(1) Both the systematic review and cohort study identified neuropsychological 
impairment possibly due to ‘core’ addiction phenotype and/or chronic use of opioids. 
One way to differentaite between these two is to study a population born from 
opioid using pregnant mothers. Previous studies suggest that exposure to opioids in 
utero adversely affect neurodevelopment including decision-making (Ornoy, 2002; 
Prandi et al, 2004; Bunikowski, 1998). However, the nature and the magnitude of 
this effect remain unknown. Some of the possible ways in which decision making may 
be affected by opioid exposure, as suggested by these studies, are: less adaptive 
decision-making with impaired option selection; decreased use of previously learnt 
information; impaired group and social decision-making; impulsive decision making 
and impaired perception of relevant stimuli; inability to sustain attention; and 
increased in risk taking and greater reward-weighted decision-making (Rosen, 1982; 
Ornoy, 1992; Guo et al., 2002; Hunt et al., 2008; Suess et al.,1997). 
 
This longitudinal study will follow up children with maternal methadone use during 
pregnancy; children with maternal methadone and or other drug use during 
pregnancy; children born to mothers with previous history of drug use but no use 
during pregnancy and deprivation matched children with no known maternal drug 
history.They will monitor the neurodevelopmental and neuropsychological 
progression through data linked access to school, health and other records and also 
utilising successive neuropsychological assessments throughout the childhood and 
adolescence period. 
 
 (2) The consequences of chronic opioid use in old age take a greater toll than in 
younger adults (Ersche & Nutt, 2009). With increasing age, older people metabolise 
the opioids slower, which may prolong or intensify the effects of the drug. 
Interactions between illicit substances and prescribed medication are more common 
in the older generation than in younger people (Rosenberg, 1995). Moreover, the 
social situation of long-term substance users is often much more unstable than in 
young susbtance users due to long-term unemployment, depleted financial 
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resources, lack of family support, isolation and social stigma (Patterson & 
Jeste,1999). Older substance users are particularly vulnerable and accelerated 
cognitive decline further worsens their already poor state of psychosocial functioning 
(Roe et al., 2010; Deakin et al., 2004). The study has identified neuropsychological 
sequelae as a result of chronic opioid use in a population aged between 18 and 40 
years. A similar ambispective cohort designed study will need to be replicated within 
the 40 and 60 year range in order to determine if similar or different impairments in 
cognitive impulsivity and memory are present. 
 
 (3) The neuropsychological impairment identified as putative markers of chronic 
heroin use need to be further explored by comparing these results with that of other 
specific opioids which either present as agonist (e.g. morphine and methadone) or 
partial agonists (e.g.burpenorphine). An ambispective multiphasic cohort designed 
study will be planned. The cohorts will be tested during induction to these opioids 
and then subsequently followed up 3, 6 and 12 months following stabilisation. If 
possible the same cohort will be tested again when such opioids have been stopped 
as part of the treatment plan and again retested 6, 12 and 18 months during this 
period of abstinence. 
 
(4) It has been proposed that a progressive dysregulation of reward function could 
explain key features of the human addiction syndrome (Redish et al., 2004; Redish et 
al., 2008).  One popular interpretation is that repeated use of addictive substances 
‘hijacks’ the normal cognitive -neural systems for learning about rewards and 
punishments, such that substance-related stimuli become overvalued and non-
substance stimuli become correspondingly undervalued. This work requires 
measurement of fast time scale (‘phasic’) neurophysiological signals reflecting 
learning the salience of changing predictors of rewards in the environment (Hyman, 
2007).  
 
It has also been suggested that opioid dependence is associated with other 
longstanding neurobiological changes (Martin et al., 2007).  For example, grey matter 
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reductions in prefrontal, insular and temporal cortices in patients on methadone 
maintenance have been reported (Lyoo et al., 2006).  However, the effects of opioid 
dose and duration on brain structure was not specifically explored (Martin et al., 
2007) and the putative mechanisms of atrophic change remain unclear in the field of 
opioid dependence.  Abnormalities of white matter tracts occur more commonly 
(Lyoo et al., 2004) but have been little investigated.  Therefore, in addition to fMRI, 
the use of diffusion tensor imaging (DTI) in conjunction with stereotactic tractography 
that investigates white matter tracts, and optimised voxel based morphometry using 
T1 imaging, will assist in studying the effects of opioids on hypothesised abnormal 
white and grey matter structure in patients exposed to chronic opioids – for example 
those on methadone maintenance. Structural and functional brain abnormalities are 
important to identify, as these may help to explain emerging evidence for 
neurophysiological abnormalities.  Importantly, if group differences are identified, the 
neuroimaging data will be explored for correlations with opioid dosing and duration 
of use. 
   
In this study, we propose to use an ambispective two phase cohort design to conduct 
neuropsychological and neuroimaging tests in chronically opioid-exposed subjects 
prescribed methadone and buprenorphine matched with equal numbers of healthy 
non-substance using controls.  
 
 
 
 
 
 
 
 
 
 
230 
 
 
 
Neuropsychological profiling of a male chronic opioid using and/or dependent 
individual described as three case scenarios 
 
Case 1: A 26 year old male unemployed chronic heroin user who lived in his own 
accomodation in Fife between 2007 and 2009 consented to participate in this study. 
He had 10.75 years of education and a pre-morbid IQ of 106.12. His daily intake of 
opioids was 184.52 mg morphine equivalent daily and presented with an ICD-10 
diagnosis of opioid and nicotine dependence. He presented with a subjective history 
of 6 years of regular and daily heroin use and 14 years of infrequent use of 
benzodiazepine, cocaine, cannabis and/or alcohol. He has never been treated in the 
past with methadone or had been using methadone and other opioids illicitly. He had 
no history of head injury, non- fatal overdoses, severe and/or acute psychiatric and 
medical problems or was prescribed psychotropic drugs. 
 
During the period of drug experimentation he was liable to make risky decisions even 
though the quality of these decisions was not evidently poor. He was keen to act 
quickly on his decisions. Strategic planning deteriorated as he continued with his 
chronic heroin use compounded by long term visuo-spatial memory problems. After 
three weeks of initiating methadone his motor impulsivity and visuo-spatial memory 
improved. There were no problems with cognitive flexibility. 
 
Case 2: A 27 year old male unemployed chronic methadone user who lived in his own 
accomodation in Fife between 2007 and 2009 consented to participate in this study. 
He had 10.58 years of education and a pre-morbid IQ of 108.86. His daily intake of 
opioids was 147.41 mg morphine equivalent daily and presented with an ICD-10 
diagnosis of opioid and nicotine dependence. He presented with a subjective history 
of 9 years of regular and daily heroin use and 15 years of infrequent use of 
benzodiazepine, cocaine, cannabis and/or alcohol. He was prescribed methadone for 
treatment of his opioid dependence with objective evidence that he had not relapsed 
into illicit regular heroin or other drug use during the 6-12 month period in 
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treatment. He had no history of head injury, non- fatal overdoses, severe and/or 
acute psychiatric and medical problems or was prescribed other psychotropic drugs. 
During this treatment period of methadone stabilisation, he exhibited poor attention 
taking longer period of time to make a decision in the context of poor strategic 
planning and associated visuo-spatial memory problems.There were no problems 
with cognitive flexibility and set shifting. Length of time stable on the methadone 
precribed did not help change this neuropsychological profile.  
 
Case 3: A 34 year old male unemployed chronic opioid user who lived in his own 
accomodation in Fife or Tayside between 2007 and 2009 consented to participate in 
this study. He had 11.18 years of education and a pre-morbid IQ of 115.86. His daily 
intake of opioids was 59.11 mg morphine equivalent daily and did not present with an 
ICD-10 diagnosis of opioid and nicotine dependence. He presented with a subjective 
history of 5 years of regular and daily opioid use precribed for persistent and chronic 
non- malignant pain of either neuropathic and/or muscular origin. He subjectively 
described an 18 year history of infrequent use of cannabis and/or alcohol. He had no 
history of head injury, non- fatal overdoses, severe and/or acute psychiatric and 
medical problems or was prescribed other psychotropic drugs. During the study 
period, he exhibited a trend towards poor strategic planning and associated visuo-
spatial memory problems but did not reach significance.There were no problems with 
risk taking, motor impulsivity, cognitive flexibility or visuo-spatial memory.  
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